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Approach to primary immunodeﬁciency in
children and adults
S1 Classiﬁcation of primary immunodeﬁciencies
C. Picard ° (Paris, FR)
Human primary immunodeﬁciencies (PIDs) comprise a broad group
of inherited disorders characterised by developmental or functional
defects of myeloid or lymphoid haemapoietic-derived cells, as well
as non-haemapoietic cells involved in protective immunity. More
than 150 different forms of PIDs affecting distinct components
of the innate and adaptive immune system, such as neutrophils,
macrophages, dendritic cells, complement proteins, natural killer cells,
and T and B lymphocytes have been described [1]. Clinically, PIDs
can be associated with any combination of infectious disease, auto-
immunity, auto-inﬂammatory, allergy and malignancy. The best known
PIDs show Mendelian inheritance and ﬁrst become symptomatic during
childhood. However, the ﬁeld of PIDs is rapidly expanding and
PIDs showing non-Mendelian inheritance and/or affecting primarily
adult patients is being increasingly recognized. Conventional PIDs are
typically seen as rare monogenic conditions associated with detectable
immunologic abnormalities, resulting in a broad susceptibility to multiple
and recurrent infections caused by weakly pathogenic and more
virulent microorganisms. By opposition to these conventional PIDs,
nonconventional primary immunodeﬁciencies as Mendelian conditions
manifesting in otherwise healthy patients as a narrow susceptibility to
infections, recurrent or otherwise, caused by weakly pathogenic or more
virulent microbes are now reported [2]. By now, up to 120 disease-
causing genes have been identiﬁed. This molecular characterisation of
PIDs has helped to increase our understanding of their physiopathology.
The study of these diseases has provided essential insights into the
functioning of the immune system with the ultimate goal of facilitating
diagnosis and treatment.
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S2 Clinical manifestations
N. Rezaei ° (Tehran, IR)
Primary immunodeﬁciency diseases are a heterogeneous group of
disorders, caused by inherited defects in the immune system, and
characterised by wide spectrum of clinical manifestations, particularly an
increased susceptibility to infections and a predisposition to autoimmune
diseases and malignancies.
Recurrent infections or infection with unusual organisms are the most
commonly presentation of primary immunodeﬁciency diseases. Although
recurrent respiratory tract infections and gastrointestinal manifestations
are the most common features of these diseases, especially in
predominantly antibody deﬁciencies and combined immunodeﬁciencies,
other organs can be involved as well. Recurrent cutaneous abscesses with
unusual organisms or deep abscesses may represent infections with an
association with immunodeﬁciencies, particularly in phagocytes defects.
Meningococcal infections could have an association with complement
deﬁciencies. Meanwhile other bacterial infections, mainly Streptococcus
pneumoniae and Staphylococcus aureus, as well as infections with
viruses, fungi and parasites are also common in several primary
immunodeﬁciency diseases.
Autoimmune diseases such as idiopathic thrombocytopenic purpura, au-
toimmune haemolytic anaemia, systemic lupus erythematosus, juvenile
arthritis, sclerosing cholangitis, and vasculitis are common in primary
immunodeﬁciency diseases. Whilst some syndromic immunodeﬁciencies
(e.g., Wiskott Aldrich syndrome, Di George syndrome) have a strong
association with autoimmunity, there are a group of disorders (e.g.,
ALPS, APECED, IPEX) that the autoimmune manifestations are
typically the ﬁrst and most signiﬁcant ﬁndings.
Malignancies are also common in some primary immunodeﬁciency
diseases (e.g., CVID, ALPS, XLP, and DNA repair defects). Other
manifestations such as dysmorphic features, associated anomalies,
skeletal dysplasia, and oculocutaneous hypopigmentation can be unique
characteristics of some cases with primary immunodeﬁciency diseases.
The clinical manifestations of these diseases are often helpful in guiding
the appropriate evaluation of the patients. Prompt and precise diagnostic
laboratory evaluation should be performed in the patients with such
features, whereas early diagnosis and successful management of these
patients prevent irreparable organ system damage and improve the
prognosis.
S3 Diagnosis
E. de Vries ° (’s-Hertogenbosch, NL)
Immunodeﬁciency specialists from all over Europe have composed a
multistage diagnostic protocol that is based on their expert opinion,
in order to increase the awareness of PID among doctors working in
different ﬁelds. The protocol starts from the clinical presentation of
the patient; immunological skills are not needed for its use. A list of
relevant symptoms and signs from the history and physical examination
that should alert any physician to potential PID is given. These are
grouped together to form eight typical clinical presentations of PID:
recurrent ENT and airway infections; failure to thrive from early infancy;
recurrent pyogenic infections; unusual infections or unusually severe
course of infections; recurrent infections with the same type of pathogen;
autoimmune or chronic inﬂammatory disease, or lymphoproliferation;
characteristic combinations of clinical features in eponymous syndromes;
and angioneurotic edema. These presentations lead the user towards
different algorithms, which in fact represent the traditional division
into antibody, complement, lymphocyte, and phagocyte deﬁciencies,
respectively. The algorithms each are comprised of several steps. This
multistage design allows cost-effective screening for PID within the large
pool of potential cases in all hospitals in the early phases, while more
expensive tests are reserved for deﬁnitive classiﬁcation in collaboration
with an immunologist at a later stage.
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Update on HIV for the non-HIV expert
S5 Male circumcision − only for Sub-Saharan Africa?
G. Schmid ° (Geneva, CH)
In 1986, articles suggesting that male circumcision (MC) decreased the
risk of HIV infection appeared. Over the next 15 years, studies of
two epidemiologic types − ecologic and observational − increasingly
supported this contention. Ecologic studies showed strong correlations
between prevalences of MC and HIV, e.g., tribes with low prevalences of
MC had high prevalences of HIV infection. Observational cross-sectional
studies showed that uncircumcised men had higher rates of HIV than
circumcised men. Observational cohort studies conﬁrmed these weaker
study design ﬁndings. A systematic review of observational studies in
2000 found a relative risk (RR) of 0.42 (95% CI, 0.34−0.54), a 58%
protective effect.
In 2005 and 2007, results from three randomised controlled trials, all
from sub-Saharan Africa, were reported. Results were consistent, and
the pooled RR of 0.42 (95% CI, 0.31−0.57) was identical to that of
the observational studies. The protective effect in the three trials, found
at about 21−24 months’ follow-up, has been extended in one trial to a
protective effect of 64% at 42 months of follow-up. WHO and UNAIDS
have strongly endorsed MC as an effective HIV prevention strategy in
generalised HIV epidemics where MC is uncommon.
What about Europe? MC is uncommon with an adult male prevalence
of <20%. HIV incidence is low enough that MC for HIV prevention
purposes is unlikely to have much impact. No public health authority
recommends routine neonatal circumcision.
Increasingly, however, data are showing beneﬁts of MC in addition
to HIV prevention. Lessened risk of urinary tract infection in infants
(RR 0.13, 95% CI 0.08−0.20) and lifetime avoidance of phimosis and
associated conditions occur when MC is performed neonatally.
Other beneﬁts occur in males circumcised at any age. MC protects
against acquiring sexually transmitted infections characterised by genital
ulcers–syphilis, chancroid and herpes–and possibly trichomoniasis.
Circumcised men may be less likely to acquire HPV and are more likely
to clear the infection. Through the protective effect against HPV, MC
halves risk of penile cancer (RR 0.52, 95% CI 0.33−0.82) and partners
of circumcised men are at lessened risk of cervical cancer.
Other issues must be considered in making public health decisions about
MC. Cultural objections may occur, but MC in the developing world is
readily accepted in non-circumcising societies. Studies of sexual pleasure
and function have found no relationship to circumcision status. MC may
be advised for subgroups, even if not for the entire population. And,
surgical risk and cost must be considered.
While many sub-Saharan African countries are scaling up MC services
to prevent HIV infection, public health agencies in many industrialised
countries are reconsidering MC policies–the outcomes of both efforts
are being followed with interest.
Prevention and management of acute otitis
media: a case for the prudent use of
antibiotics
S9 Bacteria and viruses in acute otitis media
T. Heikkinen ° (Turku, FI)
Acute otitis media (AOM) is generally considered a bacterial infection
that is treated with antibiotics. However, despite extensive use of broad-
spectrum antibiotics for this condition, the clinical response to the
treatment is often poor. This fact, together with vast clinical experience
connecting AOM with viral respiratory infections, has prompted research
into the role of viruses in AOM. To date, ample evidence from studies
ranging from animal experiments to large clinical trials supports a crucial
role for respiratory viruses in the aetiology and pathogenesis of AOM.
In most cases, viral infection of the upper respiratory mucosa initiates
the whole cascade of events that ﬁnally leads to the development of
AOM as a complication. The pathogenesis of AOM involves a complex
interplay between viruses, bacteria, and the host’s inﬂammatory response.
Recent studies indicate that with sensitive techniques viruses can be
found in the middle-ear ﬂuid in most children with AOM, either alone
or together with bacteria. Viruses appear to enhance the inﬂammatory
process in the middle ear, and they may profoundly impair the resolution
of otitis media. It is important to understand, however, that our increasing
knowledge of the importance of viruses in the etiopathogenesis of AOM
does not diminish the central role of bacteria in AOM. Therefore, while
viruses may explain many of the problems encountered in treating AOM,
the ultimate decision on whether or not to treat AOM with antibiotics
cannot be based solely on the degree of viral involvement in AOM.
S11 The role of guidelines
D. Spiro ° (Portland, US)
The non-judicious use of antibiotics has lead to an epidemic in
antimicrobial resistance. Acute otitis media (AOM) is the most common
indication for use of antibiotics in children in the United States (US).
Despite available evidence that supports a wait and see approach, most
US physicians immediately prescribe antibiotics for the treatment of
AOM.
The American Academy of Pediatrics published a guideline in 2004
that addressed the diagnosis and treatment of AOM. This guideline
recommends the use of observation as a potential strategy for the
treatment of AOM. The key components of this published guideline
will be discussed, as well as the evidence and rationale that supports the
use of observation as an initial strategy to treat AOM.
S12 The role of vaccination in the prevention of otitis media
R. Dagan ° (Beer-Sheva, IL)
Otitis media (OM) is the most common bacterial infection in children
aged <5 years for which antibiotic treatment is prescribed worldwide.
Although most of the time this entity resolves spontaneously it is
associated with morbidity, family dysfunction, antibiotic use and burden
on the medical system. Efforts to reduce the burden of OM by
vaccination have not been extremely rewarding, but some progress has
been made. The ﬁrst obvious step would be to reduce viral infections
leading secondarily to OM. In the modern era, the only viral vaccine
with proven effect on AOM is the inﬂuenza virus vaccine. Both the
inactivated and the live virus showed some effect, but since inﬂuenza
virus has only a limited season yearly the effect on the overall OM rate
is far from being remarkable.
Haemophilus inﬂuenzae (Hi) b vaccine did not reduce OM since most Hi
causing OM are nontypable (NTHi) and not Hib. The newly developed
pneumococcal conjugate vaccines (PCVs) have all been shown to reduce
>50% of the OM caused by the serotypes included in the vaccines, but
some replacement with serotypes not included in the vaccines and non
pneumococcal organisms was demonstrated to reduce the overall effect of
pneumococcal vaccines. The effect of PCV on the reduction of recurrent
OM, OM with effusion, the need for ventilation tubes and frequent visits
for AOM has been suggested, and the real impact is still being studied.
Aiming with PCV at those with established recurrent OM has proved
disappointing. PCVs can reduce OM caused by antibiotic-resistant
S. pneumoniae but the continued overuse of antibiotics is responsible
for the increase in antibiotic resistance in non-vaccine serotypes. A
newly developed PCV with an outer membrane protein for Hi (PnPD)
is suggested to reduce also OM caused by Hi, but conﬁrmation studies
are needed. The expansion of the 7 serotypes included in the current
licensed PCV to 10 or more serotypes may add to the prevention of OM
in the near future.
In the next decade, OM will continue to be an important disease
in children. However, we can expect it to be modiﬁed in terms of
bacteriologic aetiologies, antibiotic resistance and hopefully short and
long term consequences.
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War, famine and beyond . . . infections in
disaster settings
S14 Earthquakes
V. Korten ° (Istanbul, TR)
Infectious consequences of an earthquake mainly involve several types
of communicable diseases and crush related infections. Water-borne
and food-borne illnesses often result from the disruption of the
public water and sewage systems and contamination of water supply.
Overcrowding, poor hygiene and sanitation in temporary shelters also
may be factors. The type of infectious diseases are associated with the
epidemiology of communicable diseases in the area where the earthquake
occurred. The most common outbreaks associated with earthquakes
are gastroenteritis, infectious hepatitis and pulmonary infections. In
unvaccinated populations, there are reports of increased measles. Tetanus
can be seen in populations where vaccination coverage levels are low.
The risk for diarrhoeal disease outbreaks following earthquakes is higher
in developing countries than in industrialised countries. An outbreak of
acute watery diarrhoea involved >750 cases occurred in a camp after
the 2005 earthquake in Pakistan. Acute respiratory infections, hepatitis E
clusters and measles (>400 clinical cases in the 6 months) also occurred
among the displaced victims after the same earthquake. Contamination of
drinking water led to an outbreak of rotavirus after the 2005 earthquake
in Kashmir, India. An unusual outbreak of coccidiomycosis associated
with exposure to increased levels of airborne dust occurred after the
1994 Southern California earthquake.
Persons who have been trapped by rubble for several hours or days may
develop compartment syndromes requiring fasciotomy or amputation.
Infectious complications were common in renal victims of the1999
Marmara Earthquake in Turkey and were associated with increased
mortality when complicated by sepsis. Of 639 renal victims, 223 (34.9%)
had infectious complications, mainly sepsis and wound infections. Most
of the infections were nosocomial in origin and caused by Gram-negative
aerobic bacteria and Staphylococcus spp. Multivariate analysis of the
risk-factors for nosocomial infections revealed a signiﬁcant association
with fasciotomy and length of hospital stay in a back up university
hospital. The most frequent pathogens isolated from pus and/or wounds
culture in 2008 Wenchuan earthquake survivors were S. aureus, E. coli,
A. baumannii, E. cloacae, and P. aeruginosa.
Disaster-preparedness plans, focused on trauma and mass casualty
management and also on health needs of the surviving affected
populations may decrease the health impact of earthquakes.
S16 Infections in the disaster setting: famine. Experience from
Darfour, Sudan
V. Krcmery ° (Bratislava, SK)
Clinic malnutrition is a known risk factor for ID worldwide. Subsaharan
Africa and India is at higher risk due to vegetarian habits on absolute ab-
sence of animal meat proteins, resulting to depletion of micronutritients
(Zinc, Iron, Selenium), responsible for recovery of postmalarial anaemia.
In addition, depletion of proteins results to immunoglobulinaemia and
to delayed response to many bacterial pathogens causing ID in topics
(pneumococci, Salmonella, etc.). Third problem is absence of vitamins
dissolved in oil and fat, resulting to delayed phagocytic activity.
Therefore proteinocaloric malnutrition results to signiﬁcant adverse
outcome in HIV, TB (diarrhoea, pneumonia), the major killers of
children under ﬁve. St. Elizabeth University Tropical programme runs
4 antimalnutrition centres: 1 in Sudan, Darfour and 2 in Kenya Amaong
upcountry refugees from major conﬂict areas (Sudan − Turrana Border)
and 1 in Uganda trying to rehabilitate malnourished children under 5
and helping them to combat disease, responsible for 12.5 million deaths
in children mean 5 a year − malaria (1.2 mil), TB (1.1 mil), HIV
(2.0 mil), pneumonia (7.5 mil) and diarrhoea (0.5 mil. children deaths
approximately a year).
Use and abuse of antimicrobials: are we
getting what we deserve?
S17 The Greek experience with carbapenem resistance in
Enterobacteriaceae
H. Giamarellou ° (Athens, GR)
For the last six years Greece has faced a large number of infections,
mainly in the intensive care units (ICU), due to carbapenems-
resistant Klebsiella pneumoniae. The proportion of imipenem-resistant
K. pneumoniae has increased from less than 1% in 2001, to 23% in
isolates from hospital wards and to 53% in isolates from ICUs in
2008. Likewise, in 2002, these strains were identiﬁed in only three
hospitals, whereas now they are isolated in at least 32 of the 40 hospitals
participating in the Greek Surveillance System. Until 2007 this situation
was due to the spread of the blaVIM-1 cassette among the rapidly
evolving multiresistant plasmids and multiresistant or even panresistant
strains of mainly K. pneumoniae and also other enterobacterial species.
However, the fact that most strains display MIC values below or near the
CLSI resistance breakpoint create diagnostic and therapeutic problems,
and possibly obstruct the assessment of the real incidence of these
strains. As of 2007, the emergence of KPC-producing K. pneumoniae
has been noted in ICUs of some Greek hospitals and has now spread to
most hospitals throughout the country creating a countywide outbreak
in 2008. In Attikon University Hospital we recently described the
ICU outbreak of KPC-producing K. pneumoniae. Twenty-nine patients
(admitted from February to December 2008) were colonised mainly in GI
tract. Fifteen patients were male (52%) and the median APACHE II was
19. Patients had already long hospital stays preceding ICU admission
with a median of 25 (17−40) days. In twenty-two of these patients
(76%) KPC-producing K. pneumoniae colonisation was deﬁnitely ICU-
acquired while in 7 (24%) acquisition in other wards or other hospitals
was hypothesized. Five of these patients are still hospitalised in the ICU
and, of the remaining 24, 11 died (ICU mortality 46%). Ten of the
29 colonised patients were clinically infected. Fifteen infections were
documented, mostly BSI (11/15), followed by VAP (2/15) and SSI (2/15).
Only 1 patient died from this infection (1/15, 6.7%).
An evidence-based consensus on the therapeutic strategy for these
infections has been reached by KEELPNO and the Greek Ministry of
Health which proposed the use of high dose meropenem (6−8 g/day)
combined with an active aminoglycoside or colistin for strains with
an MIC  4mg/ml whereas for strains with a higher MIC the use of
carbapenems is contraindicated and active alternatives (monotherapy
with tigecycline, colistin, or an aminoglycoside or aztreonam-based
combinations) could be used.
Antibiotic stewardship is of great importance in such a dismal situation
but stringent adherence to infection control measures is probably of
even greater importance for the effective containment of these pandrug-
resistant strains.
S18 ESBL-producing Escherichia coli in the UK
N. Woodford ° (London, UK)
The ﬁrst E. coli with CTX-M-type ESBLs to cause infections in the
UK were detected in 2001, and CTX-Ms were the dominant ESBLs
by 2004. Currently >12% of E. coli from bacteraemias are resistant to
third-generation cephalosporins. Most (>90%) ESBL-producing E. coli
produce CTX-M group 1 enzymes (CTX-M-15 or -3); less common
are group 9, 9%, and other groups, 1%. Producers have diverse PFGE
patterns, but 5 major strains (A-E), and those clustering with them
at >65% similarity, belong to the international O25:H4-ST131 clone.
This belongs to phylogroup B2 and is uropathogenic, although the
complement of virulence genes varies. Strain A is the most widespread
UK ST131 variant (isolates referred from >50 laboratories); D is local to
one centre; B, C and E are nationally scattered. Strain A produces CTX-
M-15 ESBL encoded on a 118-kb IncFII-FIA plasmid, which encodes
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resistance to 8 antibacterial classes and is related to internationally-
disseminated blaCTX-M plasmids. ST131 E. coli producing CTX-M
ESBLs also occur outside the hospital. In a Belfast study, 74/135
nursing home residents carried strain A (CTX-M-15) in their gut ﬂora;
60 others had ST131 variants with IncI1 plasmids encoding CTX-
M-3 enzyme. The means of spread in Belfast and nationally is not
clear. CTX-M ESBL-producing E. coli are isolated from raw meat,
but most produce group 2 or 8 enzymes, which account for <1% of
ESBLs from E. coli causing infections. Associations with foreign travel
have not yet been fully explored. Are we getting what we deserve?
Cephalosporin use drives accumulation of resistance mechanisms, but
the rise of CTX-M ESBLs in E. coli could not have be predicted.
Their dominance reﬂects expansion of uropathogenic clones and spread
of plasmids. The success of these clone/plasmid combinations implies
intrinsic/acquired advantages compared with diverse E. coli strains with
CTX-M enzymes. However, not all ST131 E. coli are equal, as illustrated
by the national vs. local distribution of UK strains A and D, respectively.
As prevalence increases, therapeutic options for ESBL producers are
increasingly pushed towards carbapenems. On rare occasions, E. coli
strain A has developed carbapenem resistance through OmpC loss
combined with non-carbapenemase b-lactamases. The UK sees a few
Enterobacteriaceae with carbapenemases (KPC, OXA-48, VIM or IMP
enzymes), though rarely in E. coli. Acquisition of a carbapenemase by a
pandemic E. coli clone would have immense public health implications.
S19 Antimicrobials and Clostridium difﬁcile infection in the
Netherlands and Europe
E. Kuijper °, B. Goorhuis, T. van der Kooi, P. Filius (Leiden, Bilthoven,
Rotterdam, NL)
The presentation of Clostridium difﬁcile infection (CDI) varies from mild
diarrhoea to a potentially fatal pseudomembranous colitis. The recent
emergence of types 027 and 078 of C. difﬁcile has been associated
with increased virulence. C. difﬁcile takes advantage of disruption
of the normal intestinal ﬂora as caused by antibiotic therapy. The
antibiotical class and the antimicrobial resistance pattern of C. difﬁcile
inﬂuence the development of disease. In The Netherlands, signiﬁcantly
more patients with CDI due to Type 027 used ﬂuoroquinolones (OR,
2.88; 95% CI, 1.01−8.20) compared with those who were infected
with other PCR ribotypes. Similar as Type 027 CDI, patients infected
with Type 078 also more frequently received ﬂuoroquinolones therapy
(OR, 2.17; 95% CI 1.06−4.44). The risk to develop CDI due to
Type 027 was particularly high in persons receiving a combination
of cephalosporin and ﬂuoroquinolone (OR 57.5, 95% CI 6.8–483.6).
This association was also strongly dependent on the duration of therapy.
The use of clindamycin was found as a protective factor. However, the
recent detection of clindamycin-resistant C. difﬁcile Type 027 strains in
other European countries is an important and worrying development.
Since the association of CDI with ﬂuoroquinolones has only been
investigated at patient level, a study was performed to investigate the
relationship between CDI incidence and the preceding use of different
antibiotic classes at hospital level in The Netherlands. Comparisons
were made between hospitals where type 027 caused an epidemic,
hospitals where only isolated cases of type 027 were observed and
hospitals where no outbreak of CDI or type 027 were encountered.
In the pre-epidemic period, the total use antibiotics was comparable
between affected and unaffected hospitals. Higher use of second-
generation cephalosporins, macrolides and all other studied antibiotics
were independently associated with a small increase in CDI incidence,
but the effect was too small to predict which hospitals might be more
prone to 027-associated outbreaks.
Despite the fact that The Netherlands is known by its restrictive and
conservative use of antibiotics, outbreaks of CDI due to new emerging
types have been recognized. This is probably associated with the use of
antibiotics at patient level and hospital department level rather than the
use of antibiotics at the level of the healthcare institute.
Pharmacokinetics/pharmacodynamics:
clinical relevance
O21 PK-PD of posaconazole in a murine model of disseminated
aspergillosis
R.J.M. Bru¨ggemann °, E. Mavridou, D.M. Burger, W.J.G. Melchers,
P.E. Verweij, J.W. Mouton (Nijmegen, NL)
Objectives: Recently, Aspergillus fumigatus (Af) strains with reduced
azole susceptibility have been discovered. A non-neutropenic murine
model of invasive aspergillosis was used to determine the pharmacoki-
netics and pharmacodynamics (PK-PD) of posaconazole (POS) against
various Af strains.
Methods: Groups of 11 female CD1 mice were inoculated in the tail vein
with Af strains having MICs of 0.031, 0.5, 0.5 and 16mg/l, reﬂecting
1 wildtype and 3 mutations in CYP51a, respectively. Antifungal therapy
with POS was administered through oral gavages for 14 days as once-
daily dosages of 1, 4, 16 and 64mg/kg or placebo starting 24 hours
after inoculation. PK were determined in infected animals by collecting
plasma at day 2 of POS treatment through the orbital vein at: 0, 0.5,
1, 2, 4, 8, 12 and 24 h after POS administration, n = 3 per time point.
The arithmetic mean plasma concentrations were calculated per time
point. A non-compartmental analysis (WinNonLin 5.2) was then used
to determine PK parameters of POS. Survival (previously determined)
was determined daily until day 14. Results were analyzed by survival
curve analysis and plotting PD indices against survival and ﬁtting the
Hill equation with variable slope (HEVS) using Prism 5.0.
Results: PK: 96 mice were assessable. The AUC normalised to a dose
of 1mg/kg was 10.19, 11.27, 9.96 and 4.64mg/L·h for dosages of 1, 4,
16 and 64mg/kg, respectively. The AUC was strongly correlated with
dose in a linear fashion from 1 to 16mg/kg (r2=0.99). Higher dosages
of 64mg/kg however resulted in a slightly less linear relation (r2=0.92).
The apparent oral clearance (CL/F) was 0.10, 0.09, 0.10 and 0.22 L/h/kg
for dosages of 1, 4, 16 and 64mg/kg respectively. PD: 176 mice were
available for PD assessment. Survival curves indicated that exposure
responses were obtained for all 4 strains, with increasing exposure
needed to obtain the same result if the MIC was higher. Survival best
correlated with AUC/MIC ratio; an AUC/MIC − survival plot of all four
strains indicated a clear sigmoid exposure-response. The HEVS ﬁtted the
data well with a R2 of 0.93. The EI50 was 357 (95% CI 222.1–573.8).
Conclusion: The AUC–dose correlation of POS is linear for dosages up
to 16mg/kg. The higher apparent oral clearance in the 64mg/kg group
is most probably caused by a lower bioavailability possibly related to
saturation of uptake. The concentration effect relationships indicate that
AUC/MIC of POS best correlates with outcome.
O22 Pharmacological interaction between benzodiazepines and
voriconazole in patients with haematological malignancies
W.J. Heinz °, C. Kloeser, A. Kuhn, K. Kahle, D. Keller, H. Einsele,
H. Klinker (Wurzburg, DE)
Objective: Voriconazole is recommended as ﬁrst line antifungal therapy
for invasive aspergillosis and is often used in patients suffering from
haematological malignancies. Metabolised by cytochrome P450 (mainly
isoenzymes 2C9, 2C19 and 3A4), voriconazole is also a potent inducer
and inhibitor of this important enzyme system. Otherwise, voriconazole
metabolism may be inﬂuenced by different comedication. Thus, drug-
drug interactions are frequent in patients on voriconazole and may lead
to treatment failure in case of enzyme induction or increased side effects
in case of enzyme inhibition.
Especially, patients of older age and/or those undergoing chemotherapy
receive sedatives also interacting with cytochrome P450. In the present
study we investigated the impact of this often unintended combination
on voriconazole pharmacokinetic.
Methods: Serum samples from hospitalised patients receiving voricona-
zole have been collected routinely since 2005. Comedication and patient
characteristics were recorded. Trough levels of serum concentrations
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were determined by a high performance liquid chromatographic method
(HPLC). Statistic analyses were performed by t-test.
Results: 259 voriconazole concentrations from 91 patients were
determined including 17 samples from 14 patients receiving temazepam
(group I), 20 samples from 9 patients with lorazepam (group II) and 222
samples from 68 patients without benzodiazepines (group III). Mean
voriconazole concentration was 726 ng/ml in group I (p for I versus
III: 0.0167), 1153 ng/ml in group II (p for II versus III: 0.17), and
1701 ng/ml in group III, the median levels were 302 ng/ml, 764 ng/ml
and1159 ng/ml, respectively. Comparing all samples with (n = 35) and
without comedication of benzodiazepines, mean voriconazole levels were
1007 ng/ml and 1579 ng/ml with a statistical power of p = 0.0123.
Conclusion: Benzodiazepines have a signiﬁcant inﬂuence on the serum
concentration of voriconazole. This pharmacological interaction should
be taken into account during antifungal therapy. Therapeutic drug
monitoring of voriconazole is helpful to identify patients who are at
risk for treatment failure or increased side effects.
O23 Competition between ciproﬂoxacin and antiviral agents
(adefovir, saquinavir, ritonavir) for efﬂux transporters in J774
macrophages
L. Garcia °, B. Marquez, S. Carryn, M.P. Mingeot-Leclercq,
P.M. Tulkens, F. Van Bambeke (Brussels, BE)
Background: Ciproﬂoxacin (CIP) is substrate for a multidrug efﬂux
transporter that reduces its accumulation and intracellular activity in
J774 macrophages (AAC 2004, 48:2673) and was recently identiﬁed
as MRP4 (ICAAC 2008, A-045). Adefovir (PMEA) is described as a
substrate for MRP4 and MRP5 (Mol Pharmacol. 2003, 63:1094), and
saquinavir (SQV) and ritonavir (RTV) for MRP1 and MRP2 (JAC, 2002,
50:583; AIDS 2002, 16:2295). This study examines the possibility of
cross-competition between CIP and antiviral agents for efﬂux.
Methods:We used wild-type (WT) and CIP-resistant (overexpressing the
CIP transporter [AAC 2006, 50:1689]) macrophages. PMEA was used as
its prodrug Bis(POM)PMEA. Cells were incubated for 2 h with CIP, the
antiviral agent alone, or together (competition). Cellular concentration
was measured by ﬂuorimetry for CIP and HPLC for antiviral agents.
Results: As shown in the Table, CIP and PMEA accumulations
were markedly reduced in CIP-resistant cells. High concentrations of
BIS(POM)PMEA and SQV increased CIP accumulation in both cell
types, while RTV was ineffective. High concentrations of CIP increased
PMEA accumulation in both cell types.
Conclusions: CIP and PMEA are both substrates and inhibitors, and
SQV inhibitor of the CIP transporter (MRP4 overexpressed in CIP-
resistant cells). These data (a) illustrate that MRP4 is truly a multidrug
transporter and (b) call for caution about potential drug interactions
between CIP and some of the antiviral agents studied due to competition
for transport.
Condition Cellular accumulation (% drug alone in
WT cells)
WT cells CIP-resistant cells
CIP PMEA CIP PMEA
Drug alone (50mM) 100±9 100±7 15±10 37±3
+ CIP 540mM – 146±4 – 187±34
+ Bis(POM)PMEA 1000mM 170±21 – 141±28 –
+ SQV 300mM 414±32 ND 278±13 ND
+ RTV 300mM 112±13 ND 25±9 ND
Values in bold characters highlight values that are signiﬁcantly different
from those measured for the drug alone.
O24 Pharmacokinetics/-dynamics of piperacillin-tazobactam in
plasma and alveolar epithelial lining ﬂuid when administered
as continuous infusion in severely ill patients
M. Peiffer, J. Bulitta, H.A. Haeberle, M. Kinzig-Schippers, M. Rodamer,
V. Jakob, B. Nohe´, F. So¨rgel, W.A. Krueger ° (Trier, DE; Albany, US;
Tubingen, Nuremberg, Constance, DE)
Piperacillin-tazobactam (pip-tazo) is a broad spectrum antibiotic,
used for treatment of severe infections such as ventilator-associated
pneumonia (VAP). The effectiveness of betalactams is best predicted
by the duration of free drug concentrations above the minimal inhibitory
concentration
(t>MIC) of infecting pathogens [1]. Animal experiments suggest that
more than 50% of t>MIC should be reached. Continuous infusion (CI)
of pip-tazo may enhance the therapeutic performance, but there is little
data on pharmacokinetic/-dynamic (PK/PD) parameters, when CI is used
in critically ill patients.
Objectives: The aim of our study was to determine concentrations of
pip-tazo in plasma and broncho-alveolar epithelial lining ﬂuid (ELF)
at steady state during CI. Based on these results, the penetration ratio
(plasma/ELF) and PK/PD parameters for pip-tazo are derived.
Methods: After approval by the Ethics Committee, 16 mechanically
ventilated critically ill patients were enrolled during treatment in 3
intensive care units. Each patient received a loading dose of 4 g/0.5 g
of pip-tazo, followed by CI of 12 g/1.5 g over 24 h. At steady state (67.8
+ 39.5 h after loading dose), a total of 30 blood samples were drawn and
bronchoalveolar lavage (BAL) was simultaneously performed in 8 cases
(1 sample discarded for technical reasons). Samples were stored at −80ºC
until analysis by liquid chromatography coupled with mass-spectrometry
(LC-MS). ELF-concentrations were calculated from BAL-samples using
the relation of ureaplasma:ureaBAL as dilution factor.
Results: Plasma concentrations of pip and tazo (n = 30 in 16 pts.)
amounted to 15.38+8.89mg/ml, and 1.31+0.95mg/ml, respectively. ELF-
levels (n = 7) were 56.63+27.24mg/ml, and 5.95+3.74mg/ml. ELF-levels
were 368+236%, and 587+584% of corresponding plasma levels (n = 7)
for pip and tazo, respectively. The ratio pip:tazo was 11.74:1 in plasma,
and 9.52:1 in ELF.
Conclusions: Using advanced analytical techniques, ELF concentrations
were higher compared to traditional bolus administration [2]. CI yielded
steady state plasma concentrations in excess of MICs of susceptible
bacteria (<8mg/ml, according to EUCAST) in 76.6% of measurements,
respectively, but ELF levels exceeded 8mg/ml in all cases. Taken
together, our data provide further arguments for CI being the preferred
mode of administration for pip-tazo in critically ill patients with
suspected VAP.
Reference(s)
[1] WA Krueger et al., AAC 2005.
[2] E Boselli et al., ICM 2004.
O25 Serum bactericidal activity of three different dosing regimens
of colistin against Pseudomonas aeruginosa
A. Skiada °, J. Pavleas, C. Vaﬁadi, K. Salatas, A. Markoyannakis,
P. Tofas, K. Tzanetou, G. Thomopoulos, A. Rigas, E. Vaﬁadi, K. Rigas,
G. Petrikkos, G.L. Daikos (Athens, GR)
Objectives: Although colistin has been used extensively in critically ill
patients, the optimum dosing regimen has not been deﬁned. The aim
of this study was to evaluate the serum bactericidal activity of three
different dosing regimens of colistin methanesulphonate (CMS) against
P. aeruginosa.
Methods: Adult patients with purulent bronchitis who had not received
any antibiotic over the last 72 hours and had normal renal function were
administered CMS in three different dosing regimens; 3 million units
(MU) q8 h (regimen A), 4.5 MU q12 h (regimen B), and 9 MU q 24 h
(regimen C) intravenously. Blood samples were collected on the third
day of treatment at 0, 1, 2, 4, 8, 12 and 24 h following drug infusion.
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CMS and colistin (CS) levels were determined by HPLC. The serum
bactericidal activity containing various concentrations of colistin against
P. aeruginosa ATCC 27853 (MIC 2mg/L) was measured at 0, 1, 3, 5
and 24 hours.
Results: Thirteen patients were included in the study, 7 males and
6 females, their mean age was 63.4 years. Four received regimen
A, 4 regimen B, and 5 regimen C. Mean serum concentrations
of CMS+CS/CS were ranging from 4.65/2.00, 5.05/1.63, 5.28/2.60
to 7.71/3.33, 7.72/2.97, 13.86/5.62 mg/ml for regimens A, B and C
respectively. The mean serum concentrations of CS in the samples which
achieved killing at 24 hours were 4.12±1.80mg/L and for the samples
with no killing 2.55±0.76mg/L (P = 0.001). Serum concentrations of
CS >3mg/L achieved killing in 70.8% (17/24) of the samples whereas
concentrations  3mg/L achieved killing in 36.8% (7/19) of the samples
tested and serum concentrations of CS >4mg/L were always bactericidal.
The MIC90 of CS for 55 blood isolates of P. aeruginosa was 2.0mg/L.
Conclusions: Serum concentrations of CS >2×MIC is most of the time
bactericidal against P. aeruginosa. Regimen A and regimen B yielded
Cmax of CS marginally above the MIC90 for P. aeruginosa whereas
regimen C resulted in Cmax of CS >2×MIC. These ﬁndings together
with the concentration-dependent activity of CS give a rationale for
administering the total dose of the drug once daily.
O26 Determination of pharmacokinetic/pharmacodynamic index
for patients treated with high-dose vancomycin by continuous
infusion
E. Ampe °, P. Tulkens, B. Delaere, J.D. Hecq, Y. Glupczynski (Brussels,
BE)
Background and Aims: Over the past 10 years, the susceptibility
of Staphylococci to vancomycin (VAN) has decreased. In parallel, it
has been suggested that an AUC24 h/MIC ratio of at least 400 h-1 is
necessary for optimal therapy (Moise-Broder et al. Clin Pharmacokinet.
2004;43:925−42). Since continuous infusion (CI) is easier both for
nursing and for monitoring than conventional Q12 h dosing, we have
examined whether it can be applied to patients with infections caused
by organisms with increased MICs.
Methods: 54 patients (40 documented infections) were enrolled to
receive VAN by CI with a target concentration of 25−30mg/L, a value
above which signiﬁcant increase in the risk of nephrotoxicity has been
reported (Ingram et al., J Antimicrob Chemother. 2008;62:168−71). We
used a loading dose of 20mg/kg and an infusion rate of 2.5 g/day
(adapted to renal function and corrected by therapeutic drug monitoring
of actual serum levels [immuno-assay Architect, Abbot Diagnostics,
Solna, Sweden]). MICs were measured by E-test (AB BIODISK, Solna,
Sweden)
Results: Treatment duration ranged from 1 to 37 days (mean: 12±10).
The left ﬁgure shows that the target concentration range was reached and
remained constant as an average after the ﬁrst 48 h (with correction of the
infusion rate). However, intra-individual variability was quite important
between successive determinations in individual patients (middle). MIC’s
of isolates (MRSA, 14; MSSA, 6; coagulase negative Staphylococci, 16;
others, 4) ranged between 0.25 and 3mg/L. A mean AUC24 h/MIC of
400 h-1 (calculated over the whole duration of treatment) was reached
in about half of the cases, with lower values seen mainly for patients
infected by organisms with an MIC of 1.5mg/L of greater (right).
Conclusion: High dose vancomycin by CI with adjustment based on
therapeutic drug monitoring does not allow reaching a pharmaco-
dynamic/pharmacokinetic index sufﬁcient for optimal therapy in all
patients. Patients infected with organisms having MIC’s >1.5mg/L
should be considered at risk for treatment failure. The PK/PD data
observed in this study further suggest that lowering the current EUCAST
susceptibility breakpoint of VAN (S 4/R> 8mg/L) is warranted.
O27 Anti-mutant antibiotic concentrations predicted using in
vitro dynamic models: the impact of duration of simulated
treatment
A. Firsov °, M. Smirnova, S. Zinner, Y. Portnoy (Moscow, RU;
Cambridge, US)
Objective: Time-dependent enrichment of resistant sub-populations
and/or concomitant loss in susceptibility of antibiotic-exposed bacteria
have been reported in studies with ﬂuoroquinolones and lipo- and
glycopeptides using in vitro dynamic models. Typically, at a given ratio
of the 24-hour area under the concentration-time curve (AUC) to the
MIC, greater maximal numbers of resistant mutants are seen with longer
treatments. To explore whether the duration of simulated treatment also
inﬂuences the anti-mutant AUC/MIC ratio, AUC/MIC relationships with
resistance were reconstructed from reported data.
Methods: Time courses of resistant mutants reported from studies that
expose Staphylococcus aureus to 5-day treatments with daptomycin
(Firsov, JAC 2006) and 10-day treatments with garenoxacin (Tam,
JID 2007) at sub-optimal AUC/MICs were quantiﬁed using a recently
introduced integral parameter (area under the bacterial mutant kinetic
curve − AUBCM). The AUBCMs determined within 3, 4 and 5 days
(daptomycin) and within 4, 6, 8 and 10 days (garenoxacin) were related
to simulated AUC/MIC ratios using a Gaussian-type function.
Results: Regardless of the duration of the simulated treatment, the
general pattern of AUC/MIC relationships with AUBCM was similar.
The Gaussian-type function ﬁts the AUBCM versus AUC/MIC data
well (r2 0.64−0.92 for the 3−5-day treatments with daptomycin and
0.97−0.99 for the 4−10-day treatments with garenoxacin). With an
increase in the treatment/observation period, the maximal AUBCM
increased systematically. For example, the maximal AUBCM derived
from the 5-day daptomycin treatment was 2.3 times greater than the
AUBCM based on truncated 3-day observations (Figure). However,
despite these differences, the anti-mutant AUC/MIC ratio was practically
independent of the duration of treatment (around 200 h with daptomycin
and 100–200 h with garenoxacin − both are lower than the clinically
attainable AUC/MIC ratios for S. aureus).
Conclusions: This analysis suggests that the duration of treatment might
be critical for in vitro estimates of the maximal enrichment of resistant
mutants but not the anti-mutant AUC/MIC ratio, i.e., the ratio that
prevents such enrichment and/or suppresses ampliﬁcation of resistant
mutants.
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O28 In vivo pharmacodynamics of TR-701, a new
oxazolidinone antibiotic, against methicillin-susceptible and
methicillin-resistant Staphylococcus aureus strains
A. Louie, C. Fregeau, W. Liu, H. Conde, R. Kulawy, G. Drusano °
(Albany, US)
Objectives: TR-701, the phosphate monoester prodrug of the ox-
azolidinone TR-700, demonstrates potent in vitro activity against
Gram-positive bacteria, including methicillin-susceptible Staphylococcus
aureus (MSSA) and methicillin-resistant S. aureus (MRSA). The
pharmacodynamics index linked to bacterial cell kill of TR-701 against
Staphylococcus aureus is incompletely deﬁned. It was our objective to
deﬁne this index.
Methods: Single-dose pharmacokinetic studies were conducted in mice
for TR-701 and linezolid. Forty-eight hour dose-range and 24-hour dose-
fractionation studies were conducted in a neutropenic mouse thigh model
of S. aureus infection to identify the dose and schedule of administration
of TR-701 that is linked with optimised antimicrobial effect. The dose-
range studies also compared the efﬁcacies of TR-701 and linezolid for
one MSSA and one MRSA strain. MIC values were determined by CLSI
methodology. TR701, TR700 and linezolid concentrations in mouse
serum were determined by LC/MS/MS. PK analysis was by BigNPAG.
For the Trius compound, the model included both TR701 and TR700.
Results: Population pharmacokinetic analysis showed that terminal
half-lives of TR-700 and linezolid were 5.7 and 3.4 hours, re-
spectively. The TR-700 observed–predicted plot was: observed =
1.076·predicted−0.0884; r2 = 0.969. In dose-range studies, TR-701 was
bactericidal against both MSSA and MRSA, with 37.3 and 59mg/kg/day
of TR-701 resulting in stasis and 1 log (CFU/g) decreases in bacterial
densities at 24 hours and 36.2, 47.8 and 71.1mg/kg/day of TR-701
resulting in stasis, 1 and 2 log (CFU/g) reductions at 48 hours. Linezolid
doses as high as 150mg/kg/day did not achieve stasis at either time
point. Dose-fractionation studies demonstrated that AUC/MIC was the
pharmacodynamic index that was linked with efﬁcacy for both TR-
701/700 and linezolid. The dose fractionation experiment for TR701/700
is shown in the Figure.
Conclusion: TR-701 was highly active against both MSSA and MRSA
in vivo, and was substantially more efﬁcacious than linezolid. Dose-
fractionation studies showed that AUC/MIC was the pharmacodynamic
index linked with efﬁcacy, suggesting that once-daily dosing in man is
feasible.
O29 The novel oxazolidinone radezolid (RX-1741) accumulates in
THP-1 macrophages: comparative studies with linezolid and
azithromycin
S. Lemaire, P.M. Tulkens, F. Van Bambeke ° (Brussels, BE)
Background: Radezolid is a new oxazolidinone, which shows a similar
lipophilicity as linezolid (logP: 0.73 vs. 0.47) but bears a protonable
aminogroup. Using human THP-1 macrophages, we have compared the
pharmacokinetic proﬁle of radezolid with that of linezolid (LNZ) and
of azithromycin (AZM), a more lipophilic [logP 2.98], di-protonable
macrolide known to accumulate to high levels in the acidic compartments
of eucaryotic cells and to be a substrate for P-glycoprotein [Int J Tissue
React. 1994, 16:211−20; AAC 2003, 47:1047−51].
Methods: Cellular concentration was determined using 14C RX-1741
or microbiological assay (LZD, AZM), in the following conditions:
control; + 100mM verapamil or 250mM gemﬁbrozil (as inhibitors of
P-glycoprotein and MRP, respectively [AAC, 2007; 51:2748−57]); +
60mM deoxyglucose and 5mM sodium azide (ATP-depletion [AAC
2004, 48:2673−82]), + 50mM monensin (to collapse pH gradient
between extracell. medium and intracell. compartments [AAC 2004,
48:2673−82]), or in media at different pH. Results were expressed as
cellular to extracell. concentration ratio (Cc/Ce).
Results: In contrast with LZD (Cc/Ce≈ 1−2), radezolid was quickly,
highly, and reversibly accumulated in THP-1 macrophages (apparent
plateau of 8−10-fold; t1/2 for uptake ~7min; t1/2 for release ~20min),
with no sign of saturation over a wide range of extracell. conc.
(2 to 50mg/L), and no inﬂuence of ATP-depletion. Accumulation
levels of LZD and radezolid were not affected by addition of efﬂux
pump inhibitors (2-fold increase for AZM with verapamil). Radezolid
accumulation was reduced (3-fold) at pH 5.5 (10-fold for AZM) or 5-fold
with 50mM monensin (10-fold for AZM).
Conclusions: Radezolid shows a larger cellular accumulation than LZD
in THP-1 macrophages, and is not substrate for efﬂux pumps. The lack
of saturation upon concentration increase, of ATP-dependence, and the
defeating effect of monensin strongly suggest that radezolid enters the
cells by diffusion and accumulates by proton trapping in cell acidic
compartments. Radezolid’s higher cellular accumulation rationalises
its improved potency against intracellular bacteria (see companion
abstract: O30) and may help the drug to concentrate in infected tissues,
as suggested for macrolides (Int. J. Antimicrob. Agents. 2001, 18 Suppl
1:S11−5).
O30 Radezolid (RX-1741), a novel oxazolidinone, is active against
intracellular S. aureus, L. monocytogenes and L. pneumophila
phagocytosed by human THP-1 macrophages
S. Lemaire °, P.M. Tulkens, F. Van Bambeke (Brussels, BE)
Background: Intracellular bacteria cause chronic, difﬁcult to treat, and
relapsing infections that require antibiotics capable of accumulating
and expressing activity in the infected compartment. Using 3 bacteria
sojourning in different subcellular compartments (S. aureus (S.a.).,
phagolysosomes [pH 5.4]; L. pneumophila (L.p.), acidic vacuoles
[pH 5.6]; L. monocytogenes (L.m.)., cytosol [pH 7]) and a model of
human THP-1 macrophages, we have examined the intracellular activity
of radezolid, a new oxazolidinone for which we have demonstrated a high
and acid-pH driven cellular accumulation (see companion abstract: O29)
in comparison with linezolid.
Methods: MICs were determined in MHB (S.a. ATCC 25923) or TSB
(L.m. EGD) after 24 h, or in BYEa (L.p. ATCC 33153) after 48 h.
Intracellular activity against bacteria phagocytosed by human THP-1
macrophages was assessed as previously described (AAC 2002;46:2095–
2103; AAC 2006;50:841–851) or with minor adaptations for L.p. Results
were expressed as the change from initial inoculum after 24 h (48 h for
L.p.) of exposure to the antibiotic.
Results: The Table shows the MICs and the concentration of each drug
causing intracellular static effects. Maximal efﬁcacy (Emax) for both
radezolid and linezolid were similar for all organisms tested (−0.3 to
−0.6 log CFU for S.a. and L.m. −1.2 log CFU for L.p.)
Organisms Linezolid Radezolid
MIC (mg/L) Static conca MIC (mg/L) Static conca
pH 7.4 pH infected
comp.
pH 7.4 pH infected
comp.
S. aureus ATCC 25923 2 2 4.3 (2.1) 0.25 4 0.9 (0.23)
L. pneumophila ATCC
33153
4−8 N.V.b 5.1 0.5−1 N.V.b 0.4
L. monocytogenes EGD 1−2 1−2 5.5 (5.5) 0.03−0.06 0.03−0.06 0.4 (6.9)
aExtracellular concentration (mg/L) yielding a static effect, calculated from non-linear regression [sigmoidal] of
dose-effect response studies (values in parentheses = multiples of MIC at the pH of the infected compartment).
bNo Value (because of insufﬁcient growth of L.p. in broth at pH< 6.9).
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Conclusions: Radezolid is signiﬁcantly more potent than linezolid
against pathogenic bacteria that survive inside eukaryotic cells. Overall,
the activity of radezolid is consistent with its ability to accumulate within
cells and halt the proliferation of bacteria that reside in poorly accessible
cellular compartments.
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O31 The majority of European invasive E. coli isolates is resistant
to one or more antibiotics commonly used for treatment
B. Roede °, J. Monen, N. van de Sande-Bruinsma, M. de Kraker,
H. Grundmann on behalf of EARSS
Objectives: In Europe, until 2006, the majority of invasive E. coli
isolates was still susceptible to ﬂuoroquinolones (FQ), aminoglycosides
(AMINO) or third generation cephalosporins (G3CEP). Unfortunately,
the EARSS results from 2007, described here, show a different picture.
Methods: Since 2001, EARSS (European Antimicrobial Resistance
Surveillance System) has been collecting routine antimicrobial sus-
ceptibility testing (AST) data from invasive E. coli isolates. In 2007,
over 900 laboratories in 31 European countries contributed data from
aminopenicillins (AMIPN), FQ, AMINO, and G3CEP susceptibility of
at least 43,072 isolates. Resistance proportions were calculated for each
participating country and trends in resistance were calculated using the
Cochran Armitage test (two-sided p-value <0.05).
Results: FQ resistance has increased over the past seven years all over
Europe. In 2007, all countries reported resistance proportions over 5%.
Nine countries reported FQ resistant E. coli in excess of 30%, with
three countries reporting resistance proportions above 35%: Malta (35%,
n = 117), Cyprus (40%, n = 108) and Turkey (53%, n = 1,062). From 2001
to 2007, FQ resistance increased signiﬁcantly in all countries except
Estonia.
For G3CEP most countries reported more than 5% resistance (18 of 31).
From 2001 to 2007, G3CEP resistance increased signiﬁcantly in most
countries (23 of 29). Three countries
already reported levels above 20%, Bulgaria (23%, n = 127), Romania
(28%, n = 57) and Turkey (40%, n = 1,068).
More than half of all E. coli isolates was resistant to one or more of the
four classes tested (53%). Single AMIPN resistance was most common
(31%), followed by AMIPN+FQ resistance (9%), AMIPN+FQ+AMINO
resistance (3%) and AMIPN+FQ+AMINO+G3CEP resistance (3%). In
about half of the countries FQ+AMINO+G3CEP resistance was still
below 3% (17 of 31), but in Romania and Turkey combined resistance
was already above 20%. Again, the majority of countries (24 out of 29)
showed a signiﬁcant increase from 2001 to 2007.
Conclusion: EARSS recorded an Europe-wide increase of resistance of
E. coli to all of the antimicrobial classes under surveillance. For the ﬁrst
time, most of the European E. coli isolates showed resistance to one or
more of the antibiotics commonly used for treatment. As a result, the
choice of empirical treatment for invasive E. coli infections becomes
more and more difﬁcult. Measures to reduce the increasing resistance
amongst E. coli bacteria are most urgently needed.
O32 The use of EUCAST wild-type distributions for calibration and
a quality control parameter for multi-centre surveillance data
B. Grabein, M. Hoeck, H.M. Just, I. Schwede, B. Wiedemann ° (Munich,
Berlin, Nuremberg, Frankfurt-Oder, Schaalby, DE)
Objectives: Throughout the world clinical microbiology laboratories test
bacteria for their susceptibility to antimicrobial agents. As methods and
interpretation criteria can differ markedly these data cannot be used
for surveillance purposes. [Kahlmeter and Bruinsma]. We started the
EPICENTER network, in which we want to use routine data in order to
obtain high numbers of isolates for reliable epidemiological data and to
overcome the problems of inadequate methodology and use of different
breakpoints. We used EUCAST wild type distributions to validate their
usefulness for calibration of methods for susceptibility testing, and to
verify the quality of our routine data.
Methods: At this time 4 Laboratories participate in the network
using the automated BD PHOENIX-systems measuring MICs. The BD
EPICENTER Data-Management-System is used for the evaluation of the
data in the laboratory and for the transfer of the data to the concentrator.
Here the data are interpreted using, appropriate breakpoints. Copy strains
are excluded. Quality control is mandatory.
Results: To date about 100 thousand isolates in the sample period
from July 2005 until January 2009 are availlable. Most common
species are E. coli, S. aureus, P. aeruginosa S. epidermidis, E. faecalis,
K. pneumoniae, Enterobacter cloacae, P. mirabilis, and E. faecium.
We analysed the MIC distributions of these species comprising a total
of 62,103 strains and compared them with the EUCAST wild type
populations. Not for all antibiotic-species combination the range of
concentrations was broad enough for a comparison as many strains
cumulated at an MIC category, away from the wild type population. As
an example we demonstrate here a comparison of the MIC distributions
for the above mentioned species with gentamicin (table). These, like
37 other antibiotic-species combinations, revealed good matching of the
data, demonstrating the quality of the data from routine bacteriology.
MIC distributions with gentamicin
0.016 0.032 0.064 0.125 0.25 0.5 1 2 4 8 16 32 n
Enterobacter cloacae
EUCAST 15.6 57.7 23.4 2.4
EPICENTER 77.5 19.6 0.6 0.7 1.6 2918
Enterococcus faecalis
EUCAST 1.1 2.2 5 21.1 49 20.8
EPICENTER 0.03 0.3 3 17.4 45.8 33.4 6171
Enterococcus faecium
EUCAST 3 21.3 47.4 23.3 3.6
EPICENTER 0.4 3.7 30 18.9 47.1 1679
Escherichia coli
EUCAST 1.3 18.2 48.4 26.8 5.2
EPICENTER 63 29 0.8 3.1 4.1 18733
Klebsiella pneumoniae
EUCAST 1.4 18 57.4 20.3 2.7
EPICENTER 76.7 17.5 0.5 2.5 2.9 4625
Proteus mirabilis
EUCAST 10.7 34.3 37.9 16.7
EPICENTER 12.9 68.6 12.3 3.2 3.1 3451
Pseudomonas aeruginosa
EUCAST 2.23 6.4 20.3 41.8 21.6 7.4
EPICENTER 39.8 35.8 12.5 7.4 4.6 5752
Staphylococcus aureus
EUCAST 5 27.6 43 21.1 3.9
EPICENTER 23.7 51.6 18.8 0.7 2.1 3.1 12535
Staphylococcus epidermidis
EUCAST 3.3 8.5 64.5 13.3 3.8 6.6
EPICENTER 24.1 24.2 9.9 1.1 15.2 25.5 6239
Conclusion: We demonstrated the serviceability of the EUCAST wild
type distributions for the calibration of sensitivity test methods. This tool
provides security for the routine data entering the EPICENTER Network
which will provide reliable epidemiological data for the resistance of
pathogens in the clinical laboratory without additional workload.
O33 Resistant Escherichia coli on the rise? Data from the
project Surveillance of Antimicrobial Use and Antimicrobial
Resistance in Intensive Care Units (SARI); 2001–2007
E. Meyer °, P. Gastmeier, B. Schroeren-Boersch, F. Schwab (Berlin, DE)
Objectives: To analyse E. coli resistance in intensive care units (ICUs)
participating in the project Surveillance of Antimicrobial Use and
Antimicrobial Resistance in Intensive Care Units (SARI) from 2001–
2007 and to look for temporal changes.
Methods: Prospective unit and laboratory based surveillance in 49
German ICUs from 2001–2007. The data were speciﬁed as resistant
by the clinical laboratory using interpretive criteria recommended by
CLSI or DIN. The proportion of non-duplicate resistant isolates (RP)
and resistance densities (RD; i.e. the number of resistant isolates of a
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species per 1000 patient days) were calculated. Linear regression analysis
was performed for monthly resistance data.
Results: From 1/2001−12/2007, 49 ICUs reported data on 16,576 E. coli
isolates. The median percentage of ampicillin/sulbactam resistant E. coli
was 32% (interquartile range (IQR) 20−48), of ciproﬂoxacin resistant
15% (IQR 11−21), of piperacillin/tazobactam 7% (IQR 4−11) and of
3rd generation cephalosporin resistant (3GC) E. coli 4% (IQR 2−6). RP
and RD of the above-named resistant E. coli continuously increased over
the last seven years (linear regression coefﬁcients p< 0.001). From 2001
to 2007, in the SARI-ICUs E. coli resistance to 3GC increased from 1
to 11%, to piperacillin/tazobactam from 6 to 15%, to ciproﬂoxacin from
8 to 21% and to ampicillin/sulbactam from 22 to 40%. E. coli strains
remained susceptible for imipenem and amicacin.
Conclusion: The resistance situation of E. coli in individual German
ICUs is extremely heterogeneous; however, there was a signiﬁcant
and continuous increase in E. coli resistant to ampicillin/sulbactam,
piperacillin/tazobactam, ciproﬂoxacin and 3GC from 2001–2007. The
increase was most dramatic for resistance to 3GC by 950%. Calculated
antibiotic therapy has to consider this changed resistance situation and
might reconsider aminoglycosides for combination therapy.
O34 Increase of antimicrobial resistance among major
Enterobacteriaceae species in Germany
M. Kresken °, H. Seifert, E. Leitner, B. Ko¨rber-Irrgang, F.-J. Schmitz
(Rheinbach, Cologne, Munster, Minden, DE)
Objectives: Tigecycline encompassing a broad spectrum of bacterial
pathogens has been introduced in Germany in May 2006. The German
Tigecycline Evaluation Surveillance Trial (G-TEST) is an ongoing
surveillance programme comprising 15 laboratories monitoring the
susceptibility of bacterial pathogens to tigecycline. The objective of
this study was to compare the in vitro activities of tigecycline and
comparators against clinical isolates of E. coli and four other major
Enterobacteriaceae species obtained in 2005 with those recovered in
2007.
Methods: A total of 1,869 strains (592 E. coli, 455 E. cloacae,
371 K. pneumoniae, 209 K. oxytoca, 242 S. marcescens) collected
in 2005 (n = 936) and 2007 (n = 933) was included. Agents tested
were tigecycline, doxycycline, ciproﬂoxacin, cefotaxime, imipenem,
piperacillin-tazobactam and other drugs. MICs were determined by the
broth microdilution according to the standard of the guideline EN ISO
20776−1 in a central laboratory and interpreted by EUCAST criteria, if
available. Changes in resistance over time were assessed.
Results: Comparing data of 2005 and 2007, rates of resistance (%) were
as follows: E. coli – tigecycline 0/0, doxycycline 44/40, ciproﬂoxacin
22/28, cefotaxime 5/12, imipenem 0/0, piperacillin-tazobactam 4/6;
E. cloacae – tigecycline 7/6, doxycycline 11/11, ciproﬂoxacin 6/7,
cefotaxime 41/42, imipenem 0/0, piperacillin-tazobactam 19/22; K. pneu-
moniae – tigecycline 12/7, doxycycline 27/26, ciproﬂoxacin 8/17,
cefotaxime 5/14, imipenem 0/0, piperacillin-tazobactam 8/10; K. oxy-
toca – tigecycline 2/2, doxycycline 4/17, ciproﬂoxacin 6/14, cefotaxime
3/16, imipenem 0/0, piperacillin-tazobactam 14/24; S. marcescens –
tigecycline 3/2, doxycycline 42/43, ciproﬂoxacin 6/13, cefotaxime 7/18,
imipenem 0/0, piperacillin-tazobactam 3/10. The rate of strains with
an ESBL phenotype among E. coli, K. pneumoniae and K. oxytoca
isolates rose from 5%, 4%, and 9% in 2005 to 12%, 15% and 17%
in 2007, respectively. In contrast, MIC90 values (mg/l) of tigecycline
in 2005/2007 remained almost unchanged with 0.25/0.25, 2/1, 4/2,
0.5/1, and 2/2 for E. coli, E. cloacae, K. pneumoniae, K. oxytoca, and
S. marcescens, respectively.
Conclusion: The in vitro activity of tigecycline and imipenem against
the Enterobacteriaceae species tested did not change compared to pre-
marketing baseline values. In contrast, susceptibility to ciproﬂoxacin,
cefotaxime and piperacillin-tazobactam decreased considerably in nearly
all species tested.
O35 Escherichia coli resistance to ﬂuoroquinolones at a
comprehensive cancer centre
C. Mihu °, P.R. Rhomberg, R.N. Jones, E. Coyle, R.A. Prince,
K. Rolston (Houston, North Liberty, US)
Objective: To determine the impact of quinolones as infection
prophylaxis for high risk patients with haematological malignancies
undergoing intensive chemotherapy to minimise episodes of neutropenic
fever and signiﬁcantly reduced all cause mortality. Routine use of
quinolones for infection prophylaxis started in our institution in early
1990’s. Because increased use of antibiotics leads to emergence and
spread of resistance in Enterobacteriaceae we monitored quinolone
resistance in Enterobacteriaceae that generally occurs as a result of
chromosomal mutations leading to modiﬁcation of target, but the qnr
gene via plasmids has been recently described.
Methods: Our institution has participated in the MYSTIC/USA
Surveillance Programme, along with 14 other institutions. A central,
reference laboratory (JMI Laboratories, Iowa, USA) processed all the
isolates. The broth microdilution methods and breakpoints were used
according to CLSI standards. All the isolates were tested for suscep-
tibility to 10 antimicrobials, including carbapenems, cephalosporins,
anti-pseudomonal penicillins, aminoglicosides and ﬂuoroquinolones
(screening for qnr).
Results: A total of 271 E. coli isolates from our institution were tested
over a 10 year period. Figure 1 illustrates the annual percentage of
isolates susceptible to the most commonly prescribed antimicrobials.
A decline in susceptibility of E. coli isolates to ﬂuoroquinolones and
aminoglycosides was noted over the 10-year span (p< 0.0001). When
compared to the average susceptibility of all sites, the isolates from
our institution showed signiﬁcantly reduced susceptibility to these 2
antimicrobial agents.
Two of 17 strains investigated were positive for qnr enzymes (qnrA and
qnrB2). Four clones encompassing 27 strains were identiﬁed among the
E. coli isolates submitted.
Conclusions: The introduction of quinolones prophylaxis has led
to signiﬁcant decline in susceptibility of E. coli to all quinolones.
Similarly, use of aminoglycosides as part of antimicrobial combination
regimens resulted in increasing resistance. Carbapenems, cefepime and
piperacillin/tazobactam remain most useful for severe E. coli infections.
Structured surveillance allows for detection of resistance patterns (and
mechanisms) and adjustment of empiric antibiotic choice in patients at
high risk for infection.
Figure: Annual percentage of E. coli isolates susceptible to meropenem,
cefepime, piperacillin/tazobactam, tobramycin and ciproﬂoxacin.
Gram positives
O36 Decreasing trends in MRSA in Europe
B.M. Roede °, J. Monen, N. van de Sande-Bruinsma, M. de Kraker,
H. Grundmann on behalf of EARSS
Objectives:MRSA is currently the most commonly identiﬁed antibiotic-
resistant pathogen in hospitals. Resistance proportions have risen to
alarming rates; about half of the European countries have MRSA
proportions of 25% or higher. Therefore, all available means should be
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applied to turn the tide and maintain the effectiveness of antimicrobials.
We investigated differences in MRSA proportions over time across
Europe.
Methods: Since 1999, EARSS (European Antimicrobial Resistance
Surveillance System) has been collecting routine antimicrobial suscepti-
bility testing (AST) data from invasive S. aureus isolates. In 2007, over
900 laboratories in 31 countries in the European region collected data
from 31,591 isolates. Here, we report trends in resistance from 1999
to 2007, using the Cochran Armitage test (two-sided p-value <0.05) to
identify signiﬁcant changes.
Results: MRSA proportions vary from 0% in the north to over 50%
in southern European countries. Thirteen countries reported MRSA
proportions equal or higher than 25%; in which all Mediterranean
countries, Romania, the United Kingdom and Ireland were included.
Four countries had MRSA proportions over 40%. In the northern part of
Europe, MRSA rates are below 3%, except for the Baltic States (8−9%).
From countries reporting MRSA proportions equal or higher than 25%,
France, Turkey, Italy, and the UK showed a signiﬁcant decrease; whereas
Portugal and Malta still show a continuing increase.
In Latvia (25% in 2004) and Slovenia (21% in 2000) MRSA rates
continue to decrease strongly to 8% in 2007. For the ﬁrst time in 2007,
proportions in Austria (9%) and Bulgaria (13%) also showed a signiﬁcant
decrease. In Belgium, the decrease of 2006 was maintained, although
not (yet) reﬂected as a statistically signiﬁcant trend. However, in the
Netherlands, Finland, Denmark, Czech Republic, Hungary and Germany
a signiﬁcant increase was reported.
Conclusion: The EARSS data for 2007 show that in Europe, resistance
rates of S. aureus reach levels of alarming rates of up to 50% in southern
European countries. On the other hand, more and more countries show
decreasing MRSA proportions. Therefore, it can be concluded that
antimicrobial resistance proportions can decrease, thus giving hope for
future containment of antimicrobial resistance.
O37 Antibiotic resistance of Staphylococcus aureus isolates from
intensive care units in the Netherlands over a ten-year period
M. Rijnders °, R. Deurenberg, M.L. Boumans, M. Hoogkamp-Korstanje,
P. Beisser, E. Stobberingh on behalf of the Dutch Antibiotic Resistance
Surveillance group (SWAB)
Objectives: Staphylococcus aureus is a potential pathogenic micro-
organism and a causative agent of ~25% of infections in intensive care
patients. An optimal empiric choice for the treatment of these infections
will result in a reduction in morbidity and mortality. Therefore, it is
essential to provide the clinician with resistance data of the bacterial
population to be treated. To optimise the empiric choice and to monitor
the emergence of microbial resistance, a national surveillance program
of the SWAB was started in the Netherlands in 1996.This study describes
the results of the resistance development of S. aureus from ICU’s of 14
hospitals all over the Netherlands over a ten year period.
Methods: In the ﬁrst 6 months of each year, the participating hospitals
collected clinical isolates from among others blood and respiratory
samples. In total 943 isolates were collected: 250 from 3 hospitals in
the north, 187 from 2 in the east, 229 from ﬁve in the west and 280
from four in the south. The antimicrobial susceptibility was determined
as a micro broth dilution method according to the CLSI guidelines.
Results: An increase in resistance to ciproﬂoxacin was observed from
4% until 2002 to 14% from in 2005, which dropped again to 7% in
2006. The resistance to moxiﬂoxacin was rather constant over time, i.e.
~2%, only in 2003 8% resistance was found. Resistance to clarithromycin
increased to 10% in 2003, but decreased in 2006 to 6% the level before
2003. Resistance to penicillin, clindamycin and tetracycline ﬂuctuated
over time at ~75%, 4−8% and 2−10% respectively. During the study
period seven methicillin resistant S. aureus were isolated, no resistance
to vancomycin, teicoplanin and linezolid was observed. Resistance to
gentamicin and rifampicin was sporadicly found.
Regional differences were observed for ciproﬂoxacin, being the highest
in the western and southern part and tetracycline being the lowest in the
northern part.
Conclusion: During the 10 year study period only an increase in
resistance to ciproﬂoxacin was observed. The data presented justify
the empiric choice of ﬂucloxacillin, (with rifampicin or gentamicin
depending on the indication) in case of an infection in ICU patients
probably caused by S. aureus.
O38 Clonal dissemination of vancomycin-intermediate and
methicillin-resistant Staphylococcus aureus in Taiwan
J.J. Lu °, P.R. Hsueh, S.Y. Lee (Taichung, Taipei, TW)
Objectives: To investigate the prevalence of VISA in hospitalised
patients with MRSA infections or colonisations at a teaching hospital
in Taiwan and to evaluate the possible clonal spread of VISA in the
hospital.
Methods: From September 2001 to August 2002, 1500 consecutive
MRSA isolates were collected from various clinical specimens of
637 patients hospitalised at a teaching hospital in Taiwan. Minimum
inhibitory concentrations (MICs) of vancomycin for all MRSA isolates
were determined by the broth microdilution method in accordance
with CLSI guidelines. Molecular characteristics and antimicrobial
susceptibilities of VISA isolates were investigated and Pulsed-ﬁeld gel
electrophoresis was used to evaluate the clonality of the isolates.
Results: Among the 1500 MRSA isolates, 43 (2.9%) were VISA. Of the
43 VISA isolates, 35 had vancomycin MICs of 4 microgram/mL and 8
had vancomycin MICs of 8 microgram/mL. All isolates were inhibited
by tigecycline at 0.5 microgram/mL, linezolid at 1 microgram/mL, and
ceftobiprole at 2 microgram/mL. Five (11.6%) isolates had reduced
susceptibility to daptomycin (MICs of 1−2 microgram/mL). Six of the 43
VISA isolates had decreased susceptibility to autolysis in 0.05% Triton
X-100. The 43 VISA isolates were recovered from 21 patients; 13 of
these patients had received glycopeptide treatment prior to the isolation
of VISA. Five (23.8%) patients died despite vancomycin therapy. All 43
VISA isolates carried SCCmec type III and agr group I but were negative
for PVL gene (lukS–lukF). None of the enterococcal van genes were
detected in the 43 VISA isolates. Results of PFGE analysis revealed that
one major clone of VISA isolates (90.5%, clone A exhibiting SCCmec
type III, agr group I, and absence of PVL gene) had disseminated in the
hospital.
Conclusion: This retrospective study demonstrated that clonal dissemi-
nation of VISA had occurred in the hospital. Rapid and correct detection
of VISA and proper use of antibiotics are the most effective approaches
for preventing its emergence and spread.
O39 No change in MRSA vancomycin MICs among isolates from
paediatric infections (2000–2007)
X. Zheng °, C. Qi, A. O’Leary, M. Arrieta, S. Shulman (Chicago, US)
Objectives: Vancomycin remains one of the major options for treating
methicillin-resistant S. aureus (MRSA) related infections. Some but not
all studies have shown an increase in prevalence of MRSA isolates with
elevated vancomycin MIC values among recent clinical isolates, so called
“MIC creep”. Although still within the susceptible range, higher MICs
may be associated with increased chance of treatment failure. Because
of the conﬂicting reports and lack of published data from paediatric
patients, we sought to assess possible MIC change over time and to
compare results generated by using different methodologies including
Etest, agar dilution, and broth microdilution (MicroScan) methods.
Methods: We studied 318 MRSA isolates predominantly community
acquired including all blood and normally sterile site isolates collected in
our large Children’s hospital in 2000/2001, 2003, 2005, and 2007/2008.
In addition, MRSA from non-sterile sites included all collected in
2000/2001, and the ﬁrst 70 from each of 2003, 2005, and 2007.
Antimicrobial susceptibility testing was conducted with MicroScan
Positive Combo Panel 29 plates. Vancomycin MIC was also measured
by both Etest and standard agar dilution methods. Inducible clindamycin
resistance was assessed by D-test. MRSA typing was performed by pulse
ﬁeld gel electrophoresis (PFGE).
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Results: We found no vancomycin MIC increase among paediatric
MRSA isolates collected from 2000 to 2007. The highest vancomycin
MIC value observed was 2 ug/ml. We found signiﬁcant inter-assay
variations, with proportions of isolates with vancomycin MIC=2 ug/ml
from 85−92% for Etest 43−48% for MicroScan and 2−4% for agar
dilution. We found a progressive decrease in prevalence of inducible
clindamycin resistance by D-test, from 65% in 2000 to only 5% in
2007. PFGE analysis showed that US300 accounted for 26% isolates
in 2000/2001, and increased to 95% in 2007.
Conclusions: MRSA vancomycin MICs did not increase in our
paediatric isolates from 2000 to 2007 despite the fact that US300 strains
increased dramatically. In addition, inducible clindamycin resistance
declined markedly from 2000 to 2007. Considerably different proportions
of isolates with vancomycin MIC=2 ug/ml are found when different
laboratory methodologies used, suggesting caution in their interpretation.
O40 Mupirocin resistance in staphylococci from blood in the UK
and Ireland, 2006–2007
R. Reynolds °, R. Hope on behalf of the BSAC Working Party on
Resistance Surveillance
Objective: The English Department of Health has mandated MRSA
screening for all elective hospital admissions, with few exceptions, by
March 2009, and for all emergency admissions as soon as practicable
within the next three years. The expected resulting increase in use
of mupirocin for decolonisation will increase selective pressure for
mupirocin resistance. The BSAC Bacteraemia Resistance Surveillance
Programme therefore began testing for mupA genes (encoding high-
level mupirocin resistance) in staphylococci from blood in 2006, and
measuring mupirocin MICs in 2007.
Methods: Each year, 25 laboratories in the UK and Ireland sent up to 10
isolates each of S. aureus and coagulase-negative staphylococci (CoNS)
for central MIC testing by BSAC methods. mupA and mecA genes were
sought by multiplex PCR in 2006 and 2007. (mecA encodes penicillin
binding protein 2a, conferring methicillin resistance.) Mupirocin MICs
were measured in 2007 only.
Results: In 2006–2007, mupA was found in 10/487 S. aureus (2%)
and 74/384 CoNS (19%). mupA was found much more commonly
in mecA-positive than in mecA-negative isolates (5% vs. 0.3% for
S. aureus, and 23 vs. 6% for CoNS). Based on 2007 data only, mupA
was associated with high-level mupirocin resistance (MIC> 256mg/L),
as expected. Modal mupirocin MICs were 0.25mg/L for mupA-negative
and >1024mg/L for mupA-positive isolates of both S. aureus and CoNS.
Curiously, 5 of 181 CoNS collected in 2007 lacked mupA, as tested with
standard primers, but still had high-level mupirocin resistance, all with
MICs 1024mg/L.
Conclusion: mupA was more widespread in CoNS (19%) than in
S. aureus (2%), and was strongly associated with mecA. Most high-
level mupirocin resistance was associated with mupA, but 5 isolates of
highly mupirocin-resistant CoNS appeared mupA-negative by standard
PCR and will be investigated further. Since mupA is often coded by
transferable plasmids, there is a risk of its spreading from CoNS to
S. aureus, and of accumulation in the latter species if selection pressure
is increased.
Mupirocin susceptibility S. aureus CoNS
(2007 isolates only) mupA-negative mupA-positive mupA-negative mupA-positive
Susceptible (MIC 4mg/L) 241 127 1
Low-level resistant (4<MIC 256mg/L) 1 9 4
High-level resistant (MIC>256mg/L) 3 5 35
Total 242 3 141 40
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O41 Genome sequence of a virulent, methicillin-sensitive
Staphylococcus aureus clinical isolate that encodes the
Panton-Valentine leukocidin toxin
L. Faraj, L.A.S. Snyder, N.J. Loman, D.P. Turner, M.J. Pallen,
D. Ala’Aldeen, R. James ° (Nottingham, Birmingham, UK)
Objective: To determine the genome sequence of a virulent meticillin-
sensitive Staphylococcus aureus (MSSA) clinical isolate SANOT01.
Methods: Roche 454 sequencing determined the genome sequence of
the clinical isolate at 12 times coverage. Newbler sequence assembly
(Roche) generated 10 scaffolds that were annotated using GenDB and
compared with other S. aureus genome sequences.
Results: An 11-year-old Asian girl presented with fever and a 1-week
history of knee pain following a trivial fall. An MR scan revealed a large
subperiosteal abscess around the upper tibia secondary to metaphyseal
osteomyelitis. A PVL-positive, MSSA was isolated from blood cultures
and pus. The child deteriorated, required repeated debridement and
developed septic shock. Further investigation revealed aortic valve
endocarditis with an aortic root abscess.
Whole genome sequencing revealed that SANOT01 is the ﬁrst sequence
of an ST30 S. aureus isolate to be determined. SANOT01 is agr type III
and carries three coding regions that are not found in any other S. aureus
genome sequences. Amongst the unique genes present in these regions
is a dihydrofolate reductase gene (dfrG) which is present in addition to
the usual dfrB gene. Downstream of the orfX gene, a 6.5 kb remnant of
SCCmec type IVc was found. This sequence has only previously been
found in the MRSA252 genome sequence where it is located between
the orfX and SCCmec type II sequences. MRSA252 is unique in sharing
14 genome regions with S. aureus strain RF122, a causative agent of
contagious bovine mastitis. All but one of these 14 genome regions are
also present in SANOT01.
Conclusions: Comparison of the genome sequence of SANOT01 and
the closely related MRSA252 HA-MRSA (EMRSA-16) isolate reveals
new insights in the evolution of both CA-MRSA and HA-MRSA isolates
and the link to S. aureus RF122. PVL-encoding MSSA strains can be
signiﬁcant pathogens but are not currently under mandatory surveillance
in UK. As the cost of whole genome sequencing falls further it will
become feasible to use this technology to monitor the evolution of both
MSSA and MRSA in healthcare settings and reveal clinically relevant
information that will help to improve patient outcomes.
O42 Panton-Valentine leukocidin gene sequence and the
PVL-encoding bacteriophage vary with lineage in community-
associated methicillin-resistant Staphylococcus aureus
J.A. Otter °, M.J. Ellington, A.M. Kearns, G.L. French (London, UK)
Objectives: CA-MRSA often produce Panton-Valentine leukocidin
(PVL), a leukocidin encoded by two co-transcribed genes located on
lysogenised phages. Five PVL-encoding phages have been described
in S. aureus: phiPVL, phi108PVL, phiSLT, phiSa2mw and phiSa2958.
Single nucleotide polymorphisms (SNPs) in the PVL genes tend to vary
with lineage and may have structural and functional implications. We
examined a selection of PVL-positive CA-MRSA reported in our hospital
to determine whether sequence variation and the PVL-encoding phage
vary with lineage.
Methods: Twenty-two PVL-positive isolates were chosen to reﬂect
MLST clonal complexes identiﬁed in our hospital: CC1, 5, 8, 59,
80, 88 and 154. Isolates were characterised by antimicrobial resistance
proﬁle, SCCmec and spa type, pulsed-ﬁeld gel electrophoresis (PFGE)
proﬁle and multilocus sequence typing (MLST); an oligonuleotide
array (Clondiag ArrayTube) was used to detect a range of toxin
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and antimicrobial resistance genes. Primers were designed to amplify
and sequence the lukSF-PV genes. The PVL-encoding phage was
characterised using a recently described PCR-based assay (Ma et al.
J Clin Microbiol 2008;40:3246−58).
Results: SNPs were identiﬁed at seven positions in the lukSF-PV genes
and the SNP proﬁle varied with lineage. Three of the SNPs were coding
mutations, which may have structural and functional implications. CC1
and CC80 isolates were both found to carry phiSa2mw. The PVL-
encoding phage was not deﬁnitively identiﬁed in the other lineages,
although the CC59 isolates carried a phiSa2958-like phage and the CC8,
CC80 and CC154 isolates carried elongated head-type phages. One of
the CC1 isolates had an unexpected SNP pattern compared with other
CC1 isolates; this isolate also carried a novel or variant phage.
Conclusion: PVL gene sequence and the PVL-encoding phage vary with
lineage in PVL-positive CA-MRSA isolates. This suggests that certain
lineages are susceptible to infection or lysogeny with certain phage types.
Although CA-MRSA commonly carry PVL genes, some strains do not;
it is possible that some PVL-negative types are resistant to infection
with PVL-encoding phage, perhaps via restriction modiﬁcation systems.
Crucially, our ﬁndings suggest the PVL genes have co-evolved with their
phage and are not freely transmitted between different phages. Further
work is required to characterise the PVL-encoding phage in other isolates
and to investigate whether the PVL sequence variants result in biological
differences.
O43 Characterisation of PVL phages carried by MRSA in
England and Wales
E. Boakes °, A.M. Kearns, M.J. Ellington (London, UK)
Objectives: Community-associated MRSA (CA-MRSA) of many
different MLST clonal complexes (CCs) can harbour lysogenised
bacteriophage DNA (prophage) encoding Panton-Valentine Leukocidin
(PVL). Five PVL phages (phiPVL, phiSLT, phiSa2mw, phi108PVL, and
phiSa2958) have been reported to date. We sought to determine the
distribution of chromosomally integrated copies of these lysogenised
PVL-phages amongst dominant clones of PVL MRSA in England and
Wales.
Methods: Seventy isolates of previously characterised PVL-MRSA were
analysed by PCRs developed by Ma et. al, (JCM, 2008), to identify and
discriminate between the ﬁve known PVL phages. To maximise any
underlying diversity, representatives of each CC were selected based
upon their spa, staphylococcal cassette chromosome mec (SCCmec),
toxin gene and Pulsed-ﬁeld Gel Electrophoresis (PFGE) proﬁles. These
included isolates of internationally disseminated PVL-MRSA lineages
CCs 8, 30 and 80 which resemble the USA300, South West Paciﬁc
(SWP) and European clones, respectively. In addition we analysed PVL-
MRSA from CCs 1, 5, 22, 59, 88 and ST93.
Results: All seven CC80 isolates, which included representatives of
the European clone, possessed an elongated-head-type phage and were
positive by the PCR speciﬁc for the phiSa2MW phage. One of the CC30
isolates possessed a phi108PVL phage, four SWP representatives had
elongated head type phages, whilst the remaining four CC30 isolates
harboured an icosahedral-head-type phage. One CC30 was positive for
both head shapes. The 12 CC8 (including representatives of USA300),
eight CC1, six CC88 isolates and the ST93 isolate were all positive
for elongated-head-type phage. Nine CC5 isolates were non-typeable for
phage head shape and speciﬁc phage PCRs. Three of four CC59 isolates,
harboured a phiSa2958-like phage of an unknown head type and the
other CC59 isolate was non-typeable. All 14 CC22 isolates possessed
an icosahedral-head-type phage, 13 were positive for the phiPVL phage
type and one possessed phi108PVL type.
Conclusion: We have determined the PVL phages present in a diverse
panel of distinct PVL-MRSA clones and found considerable inter-lineage
variation in the PVL prophage present. There was also evidence of intra
lineage variation in some major CCs such as CCs 22, 30 and 59. Together
with variation in MLST CC and SCCmec, these data suggest PVL-
MRSA have evolved on multiple occasions, sometimes within the same
lineage.
O44 Transcriptional proﬁling of Klebsiella pneumoniae genes
controlled by the transcription factor, ramA
T. Schneiders °, A. Ivens (Edinburgh, UK)
Objectives: RamA is an AraC/XylS family transcriptional activator
where over expression is associated with a multidrug resistance
phenotype. In both multidrug resistant Klebsiella and Salmonella
isolates, the ramA gene has been associated with increase in expression
of the acrAB efﬂux pump. In Salmonella it has been shown that a
deletion of the ramA locus prevents the emergence of multidrug resistant
mutants. Therefore in order to understand the role of this key regulator in
the emergence and development of antibiotic resistance, transcriptomic
analyses of its regulon were undertaken in K. pneumoniae.
Methods: RNA was extracted from a combination of isogenic mutants
and clinical isolates using the Qiagen or RiboPure Kits. RNA integrity
was assessed using nanodrop and Agilent Nanochip systems. The RNA
was transcribed into double stranded cDNA prior to labelling with Cy3.
The cDNA was hybridised to the Nimblegen expression array platform
designed from the K. pneumoniae MGH 78578 genome.
Results: Approximately 50 genes were found to be affected by ramA
expression, of which twenty (involved in metabolism, physiology,
transcription, drug efﬂux, protection responses and the cell envelope)
were conﬁrmed by RT-PCR. The RamA protein appears to affect drug
efﬂux operons not previously shown to be associated with multidrug
resistance and or affected by similar proteins such as MarA. Comparative
transcriptome analyses of different K. pneumoniae clinical isolates
overexpressing ramA showed that variations exist in the levels of
expression of the drug efﬂux genes. Of note genes shown to be directly
regulated by RamA have a marbox-like sequence within the promoter
sequences.
Conclusion: In this study, the transcriptome of the regulatory protein,
RamA, was determined in the pathogen K. pneumoniae. Drug efﬂux
proteins not previously associated with ramA overexpression were found
to be directly affected. The RamA regulon overlaps with the MarA and
SoxS regulons in E. coli and Salmonella but is directly associated with
regulating the expression of a subset of genes via a marbox sequence.
Interestingly, variations in the levels of the expression of the regulon
genes were found in the different ramA overexpressing strains.
O45 Rapid detection and identiﬁcation of tick-borne pathogens
directly from clinical samples using PCR and electrospray
ionisation mass spectrometry
M. Eshoo °, C. Crowder, H. Li, H. Matthews, S. Meng, S. Sefers,
R. Sampath, C. Stratton, D. Ecker, Y.W. Tang (Carlsbad, Nashville, US)
Objectives: The potential for fatal outcome from tick-borne human
infections such as ehrlichiosis emphasizes the need for rapid diagnosis.
We developed and validated an Ibis T5000 assay (Ibis Biosciences, Inc.,
Carlsbad, CA) that can detect and identify a wide range of tick-borne
pathogens from clinical samples.
Methods: A multi-locus assay was used that employs 16 broad-
range PCR primer pairs targeting all known bacterial tick-borne
pathogen families. Electrospray ionisation mass spectrometry of the PCR
amplicons was used to determine their base composition. These base
composition signatures were subsequently used to identify the organisms
found in the samples. The assay was developed using ﬁeld collected
ticks and a wide range of clinical sample types and has been shown to
be sensitive to the stochastic limits of PCR.
Results: Whole blood (198), cerebrospinal ﬂuid (20) and plasma
(1) samples, which were originally submitted for Ehrlichia species
detection by a colorimetric microtiter plate PCR (PCR-EIA), were
collected consecutively from January 5 to August 1, 2008 at Vanderbilt
University Hospital. Among the total 219 specimens, PCR-EIA detected
40 Ehrlichia species with a positive rate of 18.3%. The Ibis system
detected Ehrlichia in 38 of the 40 PCR-EIA-positive samples and
1 in 179 of the PCR-EIA-negative specimens, giving sensitivity and
speciﬁcity of 95.0% and 99.4%, respectively. The Ibis system further
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characterised the 38 Ehrlichia-dual positive specimens to the species
level (E. cheffeensis, 35; E. ewingii, 3) with a 100% agreement to
that identiﬁed by PCR-EIA using additional species-speciﬁc probes. In
addition we demonstrated the detection of Borrelia burgdorferi from the
blood and skin of a patient with Lyme disease.
Conclusions: We demonstrate broad-range detection of tick-borne
pathogens in a single assay using skin, whole blood, plasma, skin and
CSF. In addition to Ehrlichia, the Ibis system detected 4 Rickettsia
rickettsii positive specimens, which were conﬁrmed by serology and
clinical ﬁndings. The Ibis T5000 system, which can be completed within
ﬁve hours from specimen processing to result reporting, provides rapid
and accurate detection and identiﬁcation of a broad range of pathogens
causing tick-borne human infections.
Molecular biology
O46 Rapid detection and characterisation of pathogens causing
healthcare-associated infections using PCR/ESI-MS
R. Sampath °, L. Blyn, R. Ranken, C. Massire, T. Hall, M. Eshoo,
R. Lovari, H. Matthews, D. Toleno, R. Housley, S. Hofstadler, D. Ecker
(Carlsbad, US)
Objective: To investigate the use of a novel platform-based approach
for rapid characterisation of HAI organisms. Pathogens that cause
healthcare-associated infections (HAIs) pose an ongoing and increasing
challenge to hospitals, both in the clinical treatment and in the prevention
of the cross-transmission of these problematic pathogens. Here we
describe the utility of a PCR Electrospray Ionization Mass Spectrometry
(PCR/ESI-MS) detection platform as an innovative, rapid approach for
detection and complete characterisation of important HAI pathogens.
Methods: We have developed PCR/ESI-MS based methods to rapidly
identify and characterise MRSA, VRE, C. difﬁcile (NAP-1 strain),
P. aeruginosa and A. baumannii. Each target organism can be analyzed
using an independent 8-well assay that can be run on the same
platform and can provide species and strain ID, virulence factors,
antibiotic resistance and genotyping as appropriate. Validation studies
were performed using 100–300 retrospective, well-characterised clinical
isolates for each organism. This was followed by a prospective study for
one of the 5 organisms, MRSA, that included screening of 557 clinical
specimens (nares swab) from patients who were admitted to a medical
unit with a high prevalence of MRSA clinical infections.
Results: For each of the ﬁve HAI organisms, PCR/ESI-MS species
identiﬁcations were compared to Gold Standard testing results from the
clinical microbiology laboratory and showed 100% concordance. For
S. aureus, P. aeruginosa and A. baumannii, molecular genotyping by
PCR/ESI-MS was compared to pulse ﬁeld gel electrophoresis (PFGE)
clusters and showed >95% concordance. Characterisation of virulence
and/or drug resistance was performed for MRSA, VRE and C. difﬁcile
and showed 90−95% correct detection compared to existing testing
methods. Analysis of clinical specimens for MRSA showed that of
the 557 swabs, 95 (15%) contained MRSA, either singly or as a dual
infection with CoNS, 33 (5%) were MSSA and 358 (58%) contained
mecA+ coagulase negative Staphylococcus (MR-CoNS). Comparison to
gold standard analysis showed 100% sensitivity for MRSA detection
with 96.8% speciﬁcity, 84% PPV and 100%NPV.
Conclusion: The PCR/ESI-MS technology is a high throughput assay
system useful for infection control and for epidemiological studies.
It is capable of simultaneous identiﬁcation of HAI organisms while
detecting presence of key phenotypic markers and genotypic strain
characterisation.
O48 Multiplex real-time assay for the detection of 7 viruses
causing infections of the central nervous system
M. Reijans °, J. Ossel, J. Keijdener, G. Simons (Maastricht, NL)
Objective: Molecular diagnostics play an increasingly important role
in the detection of infectious agents in cerebrospinal ﬂuids. However,
the growing list of targets and the relatively small sample volumes are
challenges that demand an improved molecular diagnostic approach.
The MeningoFinder is a MultiFinder assay allowing the simultaneous
detection of 7 viruses and 1 internal control in 1 reaction. Until now,
the analysis of MultiFinder assays was based on size-fractionation,
identifying each MultiFinder probe due to its speciﬁc length. Here we
present an alternative approach allowing realtime detection of eight
MeningoFinder probes in a single tube. The realtime detection enables
a faster analysis, less handling and lowers the risk of contamination.
Method: The MeningoFinder assay is a MultiFinder assay which detects
herpes simplex virus 1 and 2 (HSV1−2), human parechovirus (HPeV),
cytomegalovirus (CMV), Epstein–Barr Virus (EBV), enterovirus (EV)
and varicella-zoster Virus (VZV) plus an internal control in a single
reaction. Each MeningoFinder probe can be distinguished based upon
the speciﬁc length of each probe by size-fractionation using gel or
capillary electrophoresis. We developed an alternative detection method
using ﬂuorescently labelled probes which allow speciﬁc identiﬁcation of
8 MultiFinder probes in a realtime PCR machine.
Results: A large number of QCMD samples (N = 44), several enterovirus
types (N= 27) and characterised clinical samples (N = 66) were analyzed
using the MeningoFinder. All MeningoFinder reactions were analyzed
by capillary electrophoresis and by ﬂuorescently labelled probes in a
realtime PCR machine. The results of the MeningoFinder showed a
very good correlation with the expected results (>95%). Furthermore,
the results of both MeningoFinder analyses showed a high degree
of correlation. The realtime detection of the MeningoFinder probes
decreases the analysis time and post PCR handling dramatically.
Conclusions: We developed a new assay for the realtime detection of
8 MeningoFinder probes. The realtime analysis showed a very good
correlation with the conventional capillary electrophoresis analysis. In
addition, the realtime detection reduced contamination risk and patient
results became available more quickly. The combination of MultiFinder
technology combined with realtime detection shows great potential in
fast and easy multiparameter screening of clinical samples for infectious
pathogens.
O49 Performance of monoplex and multiplex nucleic acid ampliﬁca-
tion tests for the detection of a range of respiratory pathogens
K. Loens °, E.C.J. Claas, F. Coenjaerts, H. Goossens, W.G. MacKay,
P. Wallace, C. Scott, A.M. Van Loon, M. Ieven on behalf of the GRACE
Study Team
Objectives: In the framework of the GRACE NoE, a panel containing
most of the respiratory viruses and atypical bacteria was developed to
evaluate the performance of different mono- and multiplex (MX) real-
time nucleic acid ampliﬁcation tests (NAATs).
Methods: The EQA panel consisted of 42 samples spiked with various
concentrations of reference strains of M. pneumoniae, C. pneumoniae,
L. pneumophila, adenovirus (ADV), inﬂuenza A and B (InfA/B), hCoV,
parainﬂuenzavirus types 1 and 3 (PIV1/3), respiratory syncytial virus
A and B (RSV A/B), human metapneumovirus (hMPV), and rhinovirus
(hRV) as the sole agent. Furthermore, a total of 6 negative samples were
also included. The panel was analyzed in 3 different centres for the
presence of M. pneumoniae, C. pneumoniae, L. pneumophila and ADV
DNA and InfA/B, CoV, PIV1/3, RSV A/B, hMPV, and hRV RNA by in-
house mono and MX NAATs. In-house NAATs were applied to nucleic
acid extracts obtained by own in-house methodology in each centre.
Results: Sensitivities for the detection of the respiratory viruses were
40% for commercial MX NAAT, 86% for in-house MW NAAT, and
90% for mono in-house NAAT. The viral load was low each time
false-negative results were obtained. False positive results were obtained
by all methods used, resulting in speciﬁcities ranging from 88%-97%.
For the atypical bacteria, the 2 multiplex NAATs failed to detect low
L. pneumophila positive samples and lowM. pneumoniae positive sample
resulting in sensitivities of 25% and 75% compared to 100% in the in-
house mono NAATs. The commercial MX NAAT also failed to detect
strong positive samples. No false positive results were obtained for the
atypical bacteria.
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Conclusion: Substantial differences between the performances of the
assays were found. The two in-house viral NAAT methods evaluated
showed no signiﬁcant differences in sensitivity and speciﬁcity. None of
the viral NAATs used were free of false positive and false negative
results. The commercial assay evaluated was signiﬁcantly less sensitive;
based on the results on this panel the assay is being adapted. Both mono
NAATs evaluated for the detection of atypical bacteria were equally
sensitive, the multiplex NAATs failed to detect the low positive samples.
O50 A novel DNA micro-array system for rapid detection of
TEM, SHV and CTX-M extended-spectrum b-lactamases in
Enterobacteriaceae
J. Cohen Stuart, D. Mevius, N. Al Naiemi, A. Karczmarek, A. van Hoek,
P. Vos, A. Fluit, C. Dierikx, J. Scharringa, B. Duim, M.A. Leverstein-van
Hall ° (Utrecht, Lelystad, Amsterdam, Wageningen, NL)
Objective: The phenotypic detection of ESBLs is time consuming,
laborious, and frequently inconclusive. Since rapid and adequate ESBL
detection is crucial for infection control measures and the outcome of
antimicrobial therapy, a faster and more accurate detection method is
desirable.
The aim of this study was to develop and evaluate a novel ESBL assay
based on the ArrayTube system of Clondiag Chip Technologies using
ligation-mediated ampliﬁcation combined with microarray analysis to
detect the most prevalent ESBLs in Enterobacteriaceae: TEM, SHV and
CTX-M.
Methods: The mutations conferring an ESBL phenotype were identiﬁed
from the Lahey database for the TEM and SHV genes. A selection
of mutations was made covering >95% of the ESBLs described in
the Western World. Oligonucleotide probes were designed to detect
amino acid changes conferring TEM and SHV ESBL phenotypes,
and sequences to distinguish CTX-M families 1, 2, 9 and 8/25.
Each microarray contained 90 DNA tags allowing parallel analysis
of 3 isolates. The reaction products were detected by hybridisation
to generic DNA tags. Software was developed to interpret the array
data. For evaluation 218 phenotypically and genotypically characterised
Enterobacteriaceae isolates were selected, covering all mutations tested
in the array except one. Initial evaluation was performed with 82 isolates
(43 ESBL positive). After this evaluation the PCR ampliﬁcation step
was modiﬁed by introduction of dUTP and incubation of the PCR
reaction with uracil-DNA-glycosylase prior to thermal cycling to prevent
cross-contamination from previous ampliﬁcations. Currently the ﬁnal
evaluation with 218 isolates takes place using this modiﬁed protocol.
Results: In the initial evaluation performance time was 8 h per 36 isolates
(3 h DNA isolation; 5 h ligation, ampliﬁcation and detection). For 42
of 43 ESBL positive isolates (13/14 TEM, all 8 SHV and 21CTX-M)
the test results were correct (sensitivity 98%; 95% conﬁdence interval
(CI) 87–100%). For 3 of 39 ESBL-negative isolates the result were
false positive (speciﬁcity 92%; 95%CI 90−97%) and for 2 of these 39
inconclusive.
Conclusion: This proof-of-principle study shows that this DNA micro-
array system may offer an attractive option for rapid and accurate
detection of CTX-M, TEM and SHV ESBL genes in Enterobacteriaceae
in the clinical laboratory. The results of the ﬁnal evaluation will be
presented.
Revisiting phage therapy against problematic
pathogens
S61 How the past feeds the future: from d’Herelle to modern
phagotherapy
T. Ha¨usler ° (Basel, CH)
The increasing antibiotic resistance problem boosts the interest in
alternative treatments for infections. A prominent example for this
is the so-called phagotherapy. It makes use of bacterial viruses −
bacteriophages − as drugs against bacterial agents.
These bacteriophages are isolated from nature, characterised and then
tested against the bacterial strains that are targeted. In theory, this
approach has several advantages. For instance, bacteriophages infect,
as a rule, their bacterial prey very speciﬁcally. Therefore, they do not
harm the commensal bacteria of the patient. Additionally, if a bacterial
strain becomes resistant against a certain bacteriophage strain, evolution
will provide for new and active bacteriophage strains.
In practice, phagotherapy has been used for a long time. Already one
of the two discoverers of bacteriophages, Fe´lix d’Herelle, was an ardent
advocate of this method. In fact, he was the ﬁrst to use bacteriophages
against infections − 1919 against bacterial diarrhoea (Shigella spp.).
After that, phagotherapy has been used to quite some extent in Europe,
the US and other parts of the world until penicillin entered the market
in the 1940 s. In some parts of the former Soviet Union and the
Eastern Bloc, the method has been utilised until today. Now, several
companies and university researchers are developing bacteriophages for
therapeutical purposes again.
Historical documents related to phagotherapy and oral history reveal
a fascinating past. Bacteriophages have been employed against a wide
variety of bacterial diseases in a time in which there were virtually no
other anti-infectives. For example, in India, millions of cholera patients
were treated with bacteriophages in the 1930 s. Anti-cholera phages were
also poured into drinking wells as prophylactics. Bacterial viruses have
also been utilised by the German and Soviet armies in the Second World
War.
The history of phagotherapy makes for more than an exciting story,
however. Analysis of the old literature helps identify important factors
for success and failure. This is especially relevant for a ﬁeld which holds
promise but which has had limited funds at its disposal in the past few
years − and which, therefore, has been making rather slow progress.
Additionally, examination of the strategy used for phagotherapy in the
Soviet Union and Poland also contributes to a better application of this
method today.
S64 Experience and perspectives of phage therapy in Eastern
Europe
M. Kutateladze ° (Tbilisi, GE)
The discovery of bacteriophages, particularly their ability to replicate
and lyse pathogenic bacteria may have been among the most important
milestones in the history of biomedical sciences. In the pre-antibiotic
era of the early 20th century, phage therapy was becoming a powerful
weapon against infectious diseases of bacterial aetiology. Unfortunately,
phage treatment and research was largely forgotten in the Western world
as antibiotics became widely available. Nowadays, the rapid propagation
of multi-drug resistant bacterial strains is leading to renewed interest in
phage therapy.
In contrast to its decline in the West, phage therapy remained a standard
part of the healthcare systems in Eastern Europe and the USSR during
the second half of the 20th century. Phage preparations were used for
diagnostic, therapeutic and prophylactic purposes to combat various
bacterial infections.
The Eliava Institute of Bacteriophages, Microbiology and Virology
(Tbilisi, Georgia) is perhaps the most famous institution in the world
focused on the study of bacteriophages, particularly the isolation and
selection of phages active against various bacterial pathogens. Phages
have been isolated against bacterial strains received from all over the
former USSR and socialist East European countries; consequently, a
huge collection of phages and pathogenic bacterial strains has been
constructed at the Institute. Thousands of people were treated with
individual phages and phage mixtures during the Soviet era. The
preparations developed in Tbilisi have been studied through extensive
preclinical and clinical trials. However, little of this information has
ever been published and even when details are available, the trial reports
do not meet internationally approved regulations and standards.
Bacteriophages have a number of advantages in comparison to
antibiotics. Phage therapy as an alternative approach for treatment of
infections has become an evident and promising remedy. Today, many
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people from various parts of the world express their willingness to take
phage treatment against different infections, including those that are
caused by antibiotic-resistant bacterial pathogens. The Eliava Institute
has elaborated new, phage-based products and technological schemes
for their production. Strong collaboration with the medical community
in the design of clinical trials according to international standards is
absolutely critical to supporting the broader implementation of phage
therapy.
New aspects of viral disease and
transplantation
S65 The new LCM-like arenavirus and transplantation
P. Charles ° (Melbourne, AU)
An Australian male aged 57 years died from an intracerebral
haemorrhage ten days after he returned from a trip to rural Yugoslavia.
His kidneys and liver were donated to three female recipients aged
44 years (kidney), 63 years (kidney), and 64 years (liver). Four to
ﬁve weeks after the organ donation, all three recipients died. All
had febrile illnesses with altered mental status. Subsequent testing of
post-mortem tissues from the recipients identiﬁed a novel arenavirus,
which was related to lymphocyctic choriomeningitis virus (LCMV). This
viral detection process involved the use of high-throughput sequencing
techniques to identify novel microbial RNA sequences. Conﬁrmatory
testing was performed using the techniques of reverse transcriptase-
polymerase chain reaction, immunohistochemical analysis for arenavirus
antigens, and immunoﬂuorescent testing for IgG and IgM antibodies. The
clinical features in these four patients as well as other similar problems
with transplant-related illness from classic LCMV will be discussed, as
well as details of the laboratory identiﬁcation of this new virus, and
implications for organ transplantation protocols in future.
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S69 Yeast susceptibility testing: CLSI and EUCAST
J.L. Rodriguez-Tudela ° (Madrid, ES)
Yeast antifungal susceptibility testing has become a routine diagnostic
test in many laboratories. EUCAST and CLSI have published the
reference standards for Europe and USA respectively. Once this task
has been achieved, the main commitment is the development of
breakpoints. CLSI has published breakpoints (BPs) for ﬂuconazole,
itraconazole, voriconazole and the candins and EUCAST for ﬂuconazole
and voriconazole. Posaconazole is in the agenda of EUCAST for
2009 whereas the breakpoints for candins will have to wait until the
development of a new standard that identiﬁes properly the resistant
strains. Recent studies have proved that resistant strains to candins are
not properly detected by EUCAST or CLSI standards. BPs are crucial
to advice on therapy in the patient as well as for measuring resistance
development in hospitals and the community and for measuring the
effect of interventions and for developing strategies to counteract further
resistance development. Unfortunately, EUCAST and CLSI BPs are
different as it can be seen in the table.
The reasons for these discrepancies are not straightforward. The
process for establishing BPs designed by EUCAST takes into account
pharmacokinetic (PK)-pharmacodynamic (PD) data and other factors,
such as dosing regimens, toxicology, resistance mechanisms, wild
type MIC distributions, and clinical outcome data. EUCAST develops
species speciﬁc breakpoints with the basic principle that they cannot
divide wild type MIC distributions for target species. This ensures
that all microorganisms lacking of resistance mechanisms are uniformly
categorised as susceptible, intermediate or resistant. This also warrants
a good reproducibility of MIC results. CLSI follows a similar process
but they do not produce species speciﬁc BPs. Clinical outcome data has
been always analyzed following the 90−60 rule. This rule states that
infections due to susceptible isolates respond to therapy approximately
90% of the time, whereas infections due to resistant isolates respond
approximately 60% of the time. Recently, EUCAST has used data mining
tools to analyze and interpret clinical outcome data. Data mining models
develops a complex statistical analysis including performance measures
like sensitivity, speciﬁcity, false positive rate and area under the ROC
curve which enable to assess whether the results have statistical relevance
or they are chosen at random. This presentation will deal with data
mining analysis of clinical outcome data produced by EUCAST and
CLSI in order to ascertain the statistical support of the data as well as
whether this kind of analysis explain or not the differences in the BPs
developed by both organisations.
EUCAST BPs (mg/L) CLSI BPs (mg/L)
Susceptible Intermediate Resistant Susceptible S-DDa Resistant
Fluconazole 2 4 >4 8 16−32 64
Itraconazole NA NA NA 0.125 0.25−0.5 1
Voriconazole 0.12 – 0.12 1 2 4
Caspofungin NA NA NA 2 – >2
Micafungin NA NA NA 2 – >2
Anidulafungin NA NA NA 2 – >2
aS-DD: susceptible dependent upon dose.
S70 Recent advances for the routine mycology laboratory
M. Arendrup ° (Copenhagen, DK)
Successful management of invasive fungal infections depends on timely
and correct treatment. Over the last decades a number of new tests have
become available which have improved the diagnostic options.
In contrast to the scenario for bacterial infections, acquired resistance
in fungi is rare and thus species identiﬁcation is a valuable tool guiding
choice of treatment. Therefore, microscopy & culture is still a corner
stone in diagnosis, but culture and identiﬁcation are time consuming
(app. 1−5 and 1−3 days, respectively).
The sensitivity and speed of microscopy have been improved by the use
of ﬂuorescent brighteners such as calcoﬂuor white or blankophor. But
only with the recent development of PNA probes speciﬁc for a number
of the Candida spp. has species identiﬁcation become possible directly
from a positive blood culture before subculture on agar media.
Chromogenic agars allow a presumptive identiﬁcation of several Candida
spp. and facilitate the recognition of yeast isolates in samples containing
several yeasts or yeast and bacteria in combination. The use of such
plates has been shown to lead to a better identiﬁcation of mixed cultures
in a recent Nordic EQA scheme including more than 50 laboratories.
Rapid species identiﬁcation of the most important Candida spp. is
possible in the routine laboratory using easy commercially available
kits. Thus, a species identiﬁcation of C. albicans, C. dubliniensis and
C. krusei can be obtained within minutes using latex agglutination
kits (BICHRO-DUBLI, KRUSEI-COLOR; Fumouze Diagnostics) and
C. glabrata can be rapidly identiﬁed due to its high amounts of preformed
intracellular trehalase enzyme (Glabrata RTT; Fumouze Diagnostics).
Finally, PNA probes and ﬂuorescence microscopy can also be used for
a same day identiﬁcation of a range of the clinically relevant Candida
spp. (AdvanDx).
Susceptibility testing is possible using Etest and the results are
comparable with those obtained by reference methodologies in head
to head comparisons. However, recent data from EQA distributions
suggest that detection of isolates with acquired resistance causes many
laboratories difﬁculties. This illustrates that a critical number of isolates
should be tested per technician per week and quality control strains
should be included on a regular basis.
In conclusion, a number of new diagnostic tests have become available
over the last decade and the diagnostic laboratories are encouraged to
take advantage of these new options.
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S72 Molecular mycology tissue diagnosis
V. Rickerts ° (Seattle, US)
Since the introduction of newer antifungals with different in vitro spectra,
the aetiology of invasive fungal infections (IFI) has become a major
diagnostic issue as a prerequisite for a guided antifungal therapy.
While molecular methods, such as PCR and Sequencing for the
diagnosis of IFI have been evaluated from specimens such as blood
and bronchoalveolar lavage ﬂuid for some years, they have been
less studied for biopsies. Characteristics inherent to these molecular
methods, e.g. sensitivity, speciﬁcity and short turnaround time makes
them promising as adjuncts to conventional diagnostic tests, e.g. culture
and histopathology from organ biopsies.
Studies using tissue from animal models of mould infections suggest that
PCR might be more sensitive than culture and allows for a better species
identiﬁcation than histopathology. However, most of these studies used
assays detecting only a small range of agents or even single organisms.
While this may increase the sensitivity of the assays and reduces the
likelihood of contaminations it limits the usefulness in the clinical
setting, given the broad range of potential fungal pathogens.
Studies using fresh clinical samples suggest that the detection and
identiﬁcation of a wide range of fungi is possible using broad range
assays in combination with sequencing or by combining more speciﬁc
PCR assays. Further studies are needed to optimise DNA extraction,
deﬁne the best molecular targets and the best method for amplicon
detection. The prevention of contaminations due to ubiquitous fungi
and unspeciﬁc ampliﬁcations are a major problem, especially when
using broad range assays. In contrast, FISH probes may potentially be
more speciﬁc than PCR due to the visualisation of fungal elements in
tissue. In contrast to PCR, they appear to work well with formalin ﬁxed
specimens. Species identiﬁcation might be more challenging than by
PCR and sequencing. Direct comparisons between FISH and PCR are
needed to characterise the pros and cons of each method in determining
the aetiology of IFI.
Molecular tissue diagnosis has the potential to evolve into a useful
method to describe the aetiology of IFI even in culture negative samples.
Results might be obtained fast enough to guide the antifungal therapy
in patients with IFI progressive to empiric antifungal therapy. In these
patients, the risk associated with invasive tissue sampling might be
outweighed by potential beneﬁts of a guided antifungal therapy.
Plasmid-mediated emerging resistance to
antibiotics
S73 Carbapenem resistance
T. Walsh ° (Cardiff, UK)
The two groups of carbapenemases (serine carbapenemases and metallo-
beta-lactamases (MBLs)) can be encoded by genes that can be carried
on plasmids. The serine carbapenemases are distinctly either class A or
OXA (class D); the latter being mainly associated with Acinetobacter
spp.
The dominant MBL subgroups, VIM and IMP have genes that are
reportedly carried on plasmids and chromosomes. Recent evidence has
shown that the majority of blaVIM-2, even those initially reported,
are indeed plasmid mediated and probably accounts for their rapid
dissemination. blaVIM-1 genes have been recently shown to be carried
on IncN and IncW plasmids. The “Brazilian” MBL gene, blaSPM-1,
is exclusively chromosomally encoded. The MBLs SIM-1 and AIM-1
are both chromosomally encoded whereas GIM-1 is encoded from a
plasmid of approx. 48 kb. The recently described blaKMH-1 gene is
also carried on a plasmid (200 kb). Hitherto, only two MBL-positive
plasmid sequences are available thus far – those carrying blaIMP-8 and
blaVIM-7. The former carries other resistance genes and are approx.
302 kb (IncHI2), whereas the latter is a small plasmid (24 kb) and shows
similarities with IncP plasmids.
OXA carbapenemase genes have been shown to be both plasmid and
chromosomally mediated. Thus far, the blaOXA-23 and blaOXA-24/40
clusters can be both plasmid and chromosomal and have mainly been
found in Acinetobacter spp. The blaOXA-48 and blaOXA-58 clusters
have been found in K. pneumoniae and Acinetobacter spp., respectively,
and both are plasmid mediated. blaOXA-48 and blaOXA-58 have been
shown to be carried on 70 kb and 28–100 kb plasmids, respectively. A
blaOXA-58 plasmid has been recently sequenced and shown to carry
two different replicases.
The class A carbapenemase genes, blaKPC, blaIMI-2 and blaGES are
all carried on plasmids. blaKPC is found mainly in K. pneumoniae and
carried on plasmids that vary in size 12−95 kb and mostly possessing the
origin of replication IncN. However, KPC-2 has recently described in a
Pseudomonas as being chromosomally mediated. blaIMI-2 is exclusive
to the USA and carried on a 66 kb plasmid although blaIMI-1 is
chromosomal. The blaGES genes have been found in P. aeruginosa and
Enterobacteriaceae of which GES-2, 4, 5 and 6 have been shown to be
plasmid mediated although little else in known.
This lecture will provide a synopsis, discuss the evolution of resistance
due to plasmids and brieﬂy predict what we may face in the 21C with
respect to carbapenemase resistance.
S74 Aminoglycoside resistance and plasmid-mediated 16S rRNA
methylases
Y. Arakawa ° (Tokyo, JP)
Nosocomial infections caused by multidrug-resistant pathogens, espe-
cially Gram-negative bacilli, have become a serious clinical concern
in every healthcare setting worldwide. As well as carpapenem-
hydrolysing metallo-b-lactamases, CTX-M-type b-lactamases, and
qunolone-resistance genetic determinants such as qnr, aac(6′′)-Ib-cr, and
qepA, plasmid-mediated novel molecular mechanisms such as RmtA,
RmtB, RmtC, RmtD, ArmA, and NpmA responsible for pan-resistance
to aminoglycosides have recently been identiﬁed in Pseudomonas
aeruginosa, Acinetobacter spp., Serratia marcescens, Esherichia coli,
Klebsiella pneumoniae, Proteus mirabilis etc. since 2003, and these
enzymes have indeed methylation activity of 1405G or 1408A at the
A-site of the bacterial 16S rRNA as found in aminoglycoside-producing
actinomycetes.
These plasmid-mediated 16S rRNA methylases are speculated to
be originated from some nonpathogenic environmental microbes that
produce aminoglycosides or some similar compounds, so it is quite
natural that several new enzymes would be further identiﬁed hereafter
in both clinical and livestock farming environments. RmtB and ArmA
have widely spread in Asia, Europe, America and Australia via various
pathogenic Gram-negative bacilli, we should pay special attention to the
further spread of such hazardous microbes.
In my talk, I would like to give an outline of newly identiﬁed molecular
mechanisms that confer pan-resistance to aminoglycosides in pathogenic
microbes isolated from both human and veterinary environments.
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S75 Quinolone resistance
V. Cattoir ° (Caen, FR)
Acquired resistance to quinolones mainly results from chromosomal mu-
tations responsible for modiﬁcation(s) of DNA gyrase and topoisomerase
IV, and for a decrease of drug accumulation into bacteria due to decreased
permeability and/or overexpression of efﬂux systems. Plasmid-mediated
quinolone resistance (PMQR) was ﬁrst reported in 1998 from the USA,
and two other mechanisms have been identiﬁed to date.
The ﬁrst PMQR determinants, Qnr proteins, belong to the family of
pentapeptide repeat proteins. Five determinants have been identiﬁed:
QnrA, QnrB, QnrC, QnrD, and QnrS with 6, 20, 1, 1, and 3
different variants, respectively. They may act by binding directly to
both DNA gyrase and topoisomerase IV leading to protect them from
quinolone inhibition. They confer resistance to nalidixic acid and reduced
susceptibility to ﬂuoroquinolones (FQs), but may facilitate recovery
of mutants with higher level of resistance. The overall prevalence of
QnrA, QnrB, and QnrS determinants generally ranges from 1 to 5%,
and they have been identiﬁed worldwide mostly in ESBL-producing
enterobacterial isolates. The origin of the qnrA and qnrS genes were
identiﬁed as Shewanella algae and Vibrio splendidus, respectively.
The second type of PMQR determinant, AAC(6′)-Ib-cr, is a variant of the
aminoglycoside acetyltransferase AAC(6′)-Ib which confers resistance
to kanamycin, tobramycin and amikacin. This variant possesses
two substitutions (Trp102Arg and Asp179Tyr) that are sufﬁcient to
acetylation of ciproﬂoxacin and norﬂoxacin with a 2-to-4-fold MIC
increase. The overall prevalence of aac(6′)-Ib-cr may range from 0.4
to up to 34%, and it has been reported mainly in Escherichia coli and
Klebsiella pneumoniae.
The third type of PMQR determinant, QepA, has been identiﬁed in two
E. coli clinical isolates from Japan and Belgium. The qepA gene encodes
a 14-transmembrane-segment putative efﬂux pump belonging to the ma-
jor facilitator superfamily. This protein confers decreased susceptibility
to hydrophilic FQs (e.g. norﬂoxacin, ciproﬂoxacin and enroﬂoxacin)
with an 8-to-32-fold MIC increase. The two epidemiological surveys
for QepA may indicate its low prevalence (<1%). The natural reservoir
of qepA remains unknown but might be an actinomycetal species.
Discovering of three main mechanisms of PMQR within the last ten
years is peculiar. It may reﬂect the emergence of novel mechanisms of
resistance but also a deeper investigation of resistance mechanisms in
clinical isolates.
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O77 Seroprevalence of tularaemia under foxes and raccoon dogs
in Germany
A. Ku¨hn °, C. Schulze, H. Ranisch, P. Kutzer, H. Nattermann,
R. Grunow (Berlin, Frankfurt-Oder, DE)
Objective: Little is known about the prevalence of Francisella tularensis
in humans and animals in Germany. Interestingly, the pathogen
emerged recently when several marmosets (Callithrix jacchus) died from
tularaemia and a group of hunters became infected in the areas of western
Germany. To ﬁnd out more about the distribution of the pathogen also in
eastern Germany we investigated the seroprevalence of tularaemia under
foxes (Vulpes vulpes) and raccoon dogs (Nyctereutes procyonoides) in
the area of Brandenburg (around Berlin).
Methods: Sera of animals (n = 351 and n = 32, respectively) from the
years 2007 and 2008 were tested for F. tularensis − LPS antibodies in
an indirect ELISA and suspicious samples were conﬁrmed by Western
blot for LPS ladder recognition using Protein G − POD conjugate.
Furthermore we investigated the serum samples by a competitive ELISA
using a peroxidase-conjugated anti − LPS monoclonal antibody.
Results: From the serum collection, we tested 31 (8.8%) foxes and 3
raccoon dogs (9.4%) positive for speciﬁc F. tularensis antibodies. The
geographical distribution showed hot spots in the area of the investigated
region.
Conclusions: Our results indicate for a higher seroprevalence in wildlife
for tularaemia in eastern regions of Germany than assumed. Since the
reported human cases for the last decade seem to be underestimated,
the real prevalence of the pathogen is unknown. The high number of
tularaemia antibody positive foxes and raccoon dogs indicates that this
zoonose is present in wildlife in eastern Germany. However, the impact
of transmission of zoonotic pathogens from wildlife to domestic animals
and humans is not yet well studied.
O78 Aetiological and epidemiological studies on Q fever and
Mediterranean spotted fever in animals
S. Martinov ° (Soﬁa, BG)
Q fever and Mediterranean spotted fever (MSF) are leading in presence
and importance rickettsial diseases in Bulgaria. The aim of the work
is to present the contemporary state of these diseases on the basias of
vast aetiological, clinical and eppidemiological investigations. Employed
were complement ﬁxation test, microimmunoﬂuorescent test, isolation of
the agent, immunoﬂuorescent haemocytic test (IFHT). A retrospective
analysis of the state of the agricultural foci of Q fever was carried
out by examination of more than 320 000 blood sera. During 2003–
2008 the mean seropositivity for C. burnettii in domestic ruminants
was 10, 11%. Seropositive swine, geese, ducks, cats and dogs were
also established. In general 88 Coxiella burnettii isolates from animal
clinical and pathological materials were obtained. By means of IFHT was
found that 16.8% ixodic ticks out of 1769 examined were infected with
C. burnettii. Eleven Coxiella strains were isolated from ticks. Signiﬁcant
seropositive rate (20, 42%) for Rickettsia conorii was established in 2473
sheep, goats and cattle from MSF endemic and non-endemic regions.
The IFHT examination of 865 ticks revealed 19.76% R. conorii positive.
From ticks were isolated three strains of R. conorii and two of R. sibirica.
In conclusion, the obtained data will contribute for creating of up-to-date
strategy for more efﬁcient control of the two rickettsial zoonoses.
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O79 High rate of Pneumocystis jirovecii colonisation among
inpatients and hospital healthcare workers
F. Medrano, V. Friaza °, R. Morilla, C. de la Horra, I. Martı´n-Garrido,
A. Gasch, R. Valencia, M. Montes-Cano, J. Varela, E. Caldero´n
(Seville, ES)
Objectives: In two recent pilot studies Pneumocystis has been detected in
immunocompetent health care workers (HCW) suggesting the possibility
of nosocomial transmission of the infection. The aim of this study was
to evaluate the prevalence of P. jirovecii carriage among hospitalised
patients (HP) and staff members in a general hospital.
Methods: Cross-sectional study carried out from 2004 to 2006 including
130 HP hospitalised at the Virgen del Rocio University Hospital in
different areas at risk for Pneumocystis: (i) High risk units (Paediatric
Onco-haematology, Paediatric HIV, Adults HIV and Neumology, n = 57);
(ii) Indeterminate risk units (Internal Medicine and Gynaecology, n = 73).
At the same time in each unit were evaluated a total of 145 HCW.
Each participant underwent a clinical-epidemiologic examination, and
oropharyngeal wash (OW) samples were collected for analysis.
P. jirovecii colonisation was identiﬁed by nested PCR at mtLSUrRNA
gene using the external primers pAZ102-E/-H and the internal primers
pAZ102-X/-Y in OW samples. The genotyping was based in analysis
of two independent genetic loci of P. jirovecii: mtLSUrRNA fragment
by direct sequencing, and dihydropteroate synthase (DHPS) locus by a
restriction fragment length polymorphism assay.
Results: P. jirovecii DNA was identiﬁed in 39/130 (30%) of HP and in
40/145 (27.6%) of HCW. None of colonised patients had PcP. Among
HP the prevalence rates of colonisation ranged from 27.2% to 40% in
high risk units and from 17.6% to 33.3% in indeterminate risk units.
Among HCW the prevalence rates ranged from 18.2% to 53.8%. All
colonised HCW were asymptomatic at the time of their enrolment in the
study and none have any evident cause of immunosuppression or risk
factors for HIV infection. The distribution of genotypes among HP and
HCW were similar: (i) mtLSUrRNA type 1 in 11/30 of HP and in 15/31
of HCW; (ii) Mutant DHPS genotypes associated with sulfa-resistence
in 3/30 of HP and in 2/30 of HCW. DNA was ampliﬁed by PCR in 2/8
air samples from the rooms of hospitalised patients.
Conclusion: The study shows for the ﬁrst time a high rate of P. jirovecii
colonisation among hospitalised patients and staff members in all
the evaluated areas of a general hospital. This ﬁnding, besides the
concordance of genotypes in both groups and the detection of DNA of
the pathogen in the hospital environment air support the role of potential
nosocomial transmission of Pneumocystis infection.
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O80 Isolation of Helicobacter bizzozeronii from a Finnish patient
with severe dyspeptic symptoms and chronic active gastritis
R. Kivisto¨ °, J. Linros, M. Rossi, H. Rautelin, M.L. Ha¨nninen (Helsinki,
Kerava, FI)
Objective: Helicobacter pylori is established as the primary cause
of gastritis and peptic ulceration in humans. In a minority of
patients with upper gastrointestinal symptoms long tightly coiled spiral
bacteria, clearly distinct from H. pylori, and provisionally named as
“H. heilmannii”, can be observed in gastric biopsies. Our objective was
to isolate and identify the spiral organism, resembling “H. heilmannii”
from the gastric mucosa of a Finnish patient presenting with severe
dyspeptic symptoms.
Methods: We used two different selective media for the isolation of
the bacteria from gastric biopsy samples before and after treatment
of the patient with a 7-day course with lansoprazole, tetracycline and
metronidazole. The isolates were characterised by testing for urease
and catalase activity, light and electron microscopy, and sequencing the
partial 16S rRNA and ureAB genes. Single enzyme AFLP was used to
analyse the genetic diversity among the isolates.
Results: Growth of long spiral organisms was obtained from 7 out of 8
antrum and all 8 corpus biopsies before and all three antrum biopsies
after treatment of the patient. The partial 16S rRNA gene sequence
showed high sequence similarities with other gastric Helicobacter
species. The partial ureAB gene showed high sequence similarity with
H. bizzozeronii and was clearly distinct from other gastric Helicobacter
species. AFLP indicated that the isolates belonged to the same clone
however some minor genetic diversity was observed among the isolates.
Conclusions: H. bizzozeronii remains as the only “H. heilmannii”
species isolated from the human gastric mucosa. The treatment
with lansoprazole, tetracycline and metronidazole did not clear the
H. bizzozeronii infection neither were the symptoms totally resolved.
AFLP analysis suggested that all the isolates belong to the same clone
with some evidence of genetic diversity among the H. bizzozeronii
isolates in the human gastric mucosa. Further studies are needed to
clarify this in more detail.
O81 The habitat of the melioidosis bacterium Burkholderia
pseudomallei in endemic tropical Australia
M. Kaestli °, G. Yang, G. Williamson, M. Mayo, L. Ward,
G. Harrington, F. Watt, A.C. Cheng, B.J. Currie (Darwin, AU)
Objectives: The soil bacterium Burkholderia pseudomallei causes the
severe disease melioidosis in humans and animals and is endemic
in tropical Australia and Southeast Asia. Despite the recognition that
melioidosis is an emerging infectious disease, its natural habitat and
distribution are unknown in tropical northern Australia, as well as
worldwide, which is a major limitation for public health education
programs. We aim to characterise the habitat of B. pseudomallei and
based on our ﬁndings, generate prediction maps for endemic northern
Australia to reveal areas with increased risk for exposure to these
potentially deadly bacteria.
Methods: 809 soil samples from rural Darwin in northern Australia
collected in the dry and wet season 2006/2007 were screened for
B. pseudomallei using a previously validated real-time PCR-based
direct soil B. pseudomallei detection method. Multivariate cluster
logistic regression analysis was performed to assess the association
of B. pseudomallei with environmental factors. These factors were
incorporated into a Bayesian model which was used to generate
maps predicting the presence of B. pseudomallei in endemic northern
Australia.
Results: B. pseudomallei was primarily found in close proximity
to streams and in grass-rich areas but was also correlated with
environmentally disturbed soil such as caused by the presence of animals,
farming or irrigation. Prediction maps are currently being veriﬁed by
sampling predicted B. pseudomallei “hot-” and “cold-spots”. See in
ﬁgure a prediction map for rural Darwin with red areas indicating high
probability for presence of B. pseudomallei.
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Conclusions: This study contributes to the elucidation of the environ-
mental distribution of B. pseudomallei in endemic tropical Australia and
to the clariﬁcation of environmental factors inﬂuencing its occurrence. It
also raises concerns that B. pseudomallei are spreading due to changes
in land management.
O82 Concurrent multi-serotypic dengue infections in various body
ﬂuids
W. Kulwichit °, S. Krajiw, D. Chansinghakul, G. Suwanpimolkul,
O. Prommalikit, P. Suandork, J. Pupaibool, K. Arunyingmongkol,
C. Pancharoen, U. Thisyakorn (Bangkok, TH)
Objectives: Dengue virus infection is one of the rapidly-spreading
emerging diseases worldwide. The virus is divided into 4 distinct
serotypes with limited cross-protective immunity; therefore, one can
be reinfected with different serotypes. While each episode is usually
caused by a single serotype, an individual can occasionally be infected
by concurrent multiple ones. Our group has previously detected dengue
virus from urine and oral specimens of some patients. In this study, we
sought to determine the characteristics of multi-serotype infections when
analysing beyond the patients’ blood compartments.
Methods: During 2003–2007, paediatric and adult patients suspected of
dengue infections were enrolled. Plasma, peripheral blood mononuclear
cells (PBMC), urine pellets, buccal brushes, and saliva were collected
during and after the febrile episode. Only specimens from patients
with both positive dengue serology and pan-dengue-speciﬁc RT-PCR
were included. Serotype-speciﬁc RT-PCR was then performed on the
aforementioned various specimens of each patient.
Results: 95 patients met the above criteria. Serotyping was successful
in 85 patients. DEN-4 was the most common serotype, accounting
for half of the cases. 20 of these 85 (23.5%) demonstrated multi-
serotypic infections when combining data from all specimen types in
each individual. Serotyping using single, conventional serum/plasma
specimens, however, would detect only half of the cases. The
phenomenon of concurrent multi-serotypic infections was present in
all examined specimen types, including urine pellets, buccal brushes,
and saliva. The most frequent combinations were DEN-1 + DEN-4
and DEN-2 + DEN-4 (5 cases each). Two patients were simultaneously
infected by serotypes 1, 2, and 4 and one by serotypes 1, 3, and 4. There
was no demonstrable signiﬁcant difference in clinical severity between
single- and multi-serotypic infections.
Conclusion: In a dengue-hyperendemic country with simultaneous
circulation of all four serotypes, the phenomenon of concurrent multi-
serotypic infections are more common than previously demonstrated
by traditional serotyping on single serum/plasma specimens. This may
be explained by the sensitivity limitation of the detection method or
by biological behaviour of the virus. Our ﬁndings have an implication
for potentially more accurate epidemiologic studies in the future, and
for further exploratory investigations regarding dengue virus in various
secretions and excretions.
O83 Emerging concepts about the evolutionary history of
hantaviruses
H.J. Kang, S.N. Bennett, L. Sumibcay, S. Arai, A.G. Hope, J.A. Cook,
J.W. Song, R. Yanagihara ° (Honolulu, Albuquerque, US; Tokyo, JP;
Seoul, KR)
Objective: Recent discovery of genetically distinct hantaviruses in
shrews (family Soricidae), captured in widely separated geographic
regions, challenges the conventional view that rodents are the principal
and progenitor reservoir hosts of hantaviruses, and raises the possibility
that other soricomorphs, notably moles (family Talpidae), harbour
hantaviruses.
Methods: Using oligonucleotide primers based on conserved genomic
regions of rodent- and soricid-borne hantaviruses, RNA extracts from
tissues of the Japanese shrew mole (Urotrichus talpoides), American
shrew mole (Neurotrichus gibbsii) and European common mole (Talpa
europaea) were analyzed for hantavirus sequences by RT-PCR. Newfound
S-, M- and L-segment sequences were aligned using Clustal W and
were analyzed phylogenetically by the maximum-likelihood and Markov
Chain Monte Carlo tree-sampling methods, with the GTR+I+G model
of evolution.
Results: Novel hantavirus genomes, designated Asama virus (ASAV),
Oxbow virus (OXBV) and Nova virus (NVAV), were detected in
tissues of Urotrichus talpoides, Neurotrichus gibbsii and Talpa europaea,
respectively. Sequence and phylogenetic analyses indicated that ASAV
and OXBV were related to hantaviruses harboured by soricine shrews
in Eurasia and North America, respectively. By contrast, phylogenetic
analyses of full-length S- and L-segment sequences showed that NVAV
formed a unique clade, clearly distinct and evolutionarily distant from
all other hantaviruses. Despite the high degree of sequence divergence
at the nucleotide and amino acid levels, the secondary structures of the
nucleocapsid proteins, as well as the L-segment motifs, of the mole-
associated hantaviruses were well conserved.
Conclusions:While cross-species transmission has inﬂuenced the course
of hantavirus evolution, such host-switching events alone do not
satisfactorily explain the co-existence and distribution of genetically
distinct hantaviruses among species in two taxonomic orders of small
mammals spanning four continents. When viewed within the context of
molecular phylogeny and zoogeography, the close association between
distinct hantavirus clades and speciﬁc subfamilies of rodents, shrews
and moles is likely the result of alternating and variable periodic co-
divergence at certain taxonomic levels through evolutionary time. Thus,
the primeval hantavirus might have arisen from an insect-borne virus,
with ancestral soricomorphs, rather than rodents, serving as the original
mammalian hosts.
O84 High transmission of hepatitis E virus among piglets in farms
from south-eastern France
M. Kaba, B. Davoust, J.L. Marie´, M. Barthet, M. Henry, C. Tamalet,
J.M. Rolain, D. Raoult, P. Colson ° (Marseille, Toulon, FR)
Objectives: Autochthonous hepatitis E is currently considered as an
emerging disease in industrialised countries and several studies suggest
that hepatitis E is a zoonosis, especially in pigs, boars and deer. We
aimed to study whether hepatitis E virus (HEV) is commonly present
in domestic pigs in southern France, and to determine the relationship
between HEV sequences detected from pigs and those described in
human hepatitis E cases.
Methods: Serum and stools samples were collected from 207 three or
six-month-old pigs from different regions of southern France. 107 six-
month-old pigs were from a slaughterhouse, and 100 three-month-old
pigs were from a pig farm. Swine IgG anti-HEV antibodies testing was
performed using a commercial ELISA kit for clinical diagnosis with
minor modiﬁcations. Swine HEV RNA detection was conducted by real-
time PCR and ampliﬁcation/sequencing assays using in house protocols
targeting the 5′ORF2 region of the HEV genome.
Results: 40% of pigs were seropositive, and 65% of three-month-
old pigs were HEV RNA-positive, whereas none of the six-month-
old pigs were HEV RNA-positive. HEV RNA was signiﬁcantly more
frequently detected from stools than from serum (65% versus 22%;
p< 0.001). Phylogenetic analysis showed that swine HEV sequences
belong to genotype 3f or 3e and formed two clusters within which
sequences showed high nucleotide homology (>97%). These clusters
were correlated with the geographical origin of pigs as well as with
their repartition into pens and buildings in the pig farm where samples
were collected. Swine HEV sequences from the present study were
genetically close to HEV sequences found from humans or swine in
Europe, although no strong phylogenetic link could be observed neither
with these latter sequences nor with those from human hepatitis E cases
diagnosed in the laboratory.
Conclusion: Our data indicate that three-month-old farm pigs from
southern France might represent a potential source of contamination
to humans, and they underscore the great potential of HEV to cause
epizootic infections in populations of farm pigs.
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O85 Clostridium difﬁcile: changing epidemiology trends, 2000–2007
S.N. Reddy °, S. Taori, P. Kalima, I.R. Poxton (Edinburgh, UK)
Objectives: Clostridium difﬁcile Infection (CDI) has become a growing
concern world-wide with an increased reported incidence and an increase
in the associated ﬁnancial burden. Our aim therefore was to review trends
in CDI occurring from 2000–2007 inclusive.
Methods: All patients admitted to Lothian University Hospitals Division
(LUHD) tested for C. difﬁcile toxins A+B by EIA were included.
Retrospective analysis of prospectively collected data was performed.
The number of occupied bed days was provided by NHS-Lothian
Statistics Department. The most recent published costs associated with
CDI were used to estimate potential costs to Lothian NHS Trust.
Results: 50,590 faecal samples were tested for C. difﬁcile toxins from
2000–2007 inclusive; of these 7301 samples were positive. Overall CDI
was identiﬁed in 15.2 cases/10000 patient days and 5.8 cases/1000 in-
patient hospital admissions.
The incidence of identiﬁed CDI rose from 3.6cases/10000 patient days in
2000 to 14.8cases/10000 patient days in 2007. Incidence also increased
with age from 3.3cases/10000 patient days in the 0−20 years age group
to 18.1cases/10000 patient days in the 61−80 years age group.
Renal Medicine and Intensive Care had the highest incidences of
identiﬁed CDI with greater than 57cases/10000 patient days each
followed by Infectious Diseases and Gastrointestinal Medicine whose
rates were 47.5 and 42.6 cases/10000 patient days respectively. Medicine
of the Elderly in comparison had an incidence of 19.5cases/10000 patient
days.
Of note 10% of all patients were transferred through a minimum of
two specialties during the period in which they remained positive for
C. difﬁcile toxins.
Estimated costs over the study period for toxin testing alone were in the
region of £126,500 and the minimal potential hospitalisation costs of
patients with CDI was in the region of £20,000,000.
Conclusion: The incidence of patients identiﬁed with CDI has risen
markedly and not surprisingly the incidence has also been noted to
increase with age. Medicine of the Elderly however had a much lower
incidence than several other specialties and therefore risk assessment of
CDI development and containment should now also be targeted within
other specialties.
With 10% of identiﬁed CDI patients transferred through different
specialties and the signiﬁcant ﬁnancial burden CDI imposes on
healthcare institutions judicious application of infection control measures
remains an important factor to prevent CDI spread.
O86 First results of the European Clostridium difﬁcile infection
survey (ECDIS)
M.P. Bauer °, D.W. Notermans, B.H.B. van Benthem, M.H. Wilcox,
D.L. Monnet, J.T. van Dissel, E.J. Kuijper on behalf of the ECDIS
Study Group and local coordinators
Objectives: To perform a survey on the incidence and the demographic,
clinical and microbiological characteristics of Clostridium difﬁcile
infection (CDI) in hospitals in Europe.
Methods: We organised a network of 106 laboratories capable of
isolating C. difﬁcile strains in 34 European countries. In November
2008, 1−7 hospitals per country, depending on population size, tested
all stool samples of patients >2 years of age who developed diarrhoea
after3 days of admission or were suspected of CDI. CDI was deﬁned as
having a positive enzyme immunoassay for C. difﬁcile toxin A and/or B,
a positive cytotoxicity test or a positive toxinogenic culture. Hospitals
collected clinical data of the ﬁrst 10 CDI patients and cultured their
stools for C. difﬁcile. Isolates were characterised by PCR-ribotyping and
toxin A, toxin B and binary toxin genes.
Results: Detailed information was obtained for 506 patients in 69
hospitals in 28 countries. Eighty percent of cases were healthcare-
associated (HA), 15% community-associated (CA) and 6% of indeter-
minate association (i.e., 4 to 12 weeks after discharge from a healthcare
facility) (ECDC deﬁnitions; data available for 480 cases). Median age
was 71 (IQR 56−81) yrs. Fever, ileus, leukocyte count 15 10E9/l and
creatinin increase >50%, used as markers of severe CDI, were present
in 37%, 4%, 29% and 8%, respectively. Colonoscopy was performed
in 28 cases, revealing ulceration in 46% and pseudomembranes in 21%
of cases. Bowel distension was observed in 26 (23%) of 115 imaging
studies and colonic wall thickening in 26 (42%) of 62 CT scans. Serious
comorbidity, as deﬁned by an APACHE II chronic health score >0 was
present in 42%. Of 460 patients, 79% had used antibiotics in the month
and 92% in the 3 months preceding CDI. The most frequently used
antibiotics were ﬂuoroquinolones, cephalosporins and aminopenicillins
with beta-lactamase inhibitors. The extrapolated median incidence of
HA CDI was 3.8 cases per 10,000 patient-days (IQR: 0.8 to 8.1), based
on 48 hospitals that had submitted data on all CDI cases by February
23rd, 2009. Results of the typing studies and follow-up of CDI patients
3 months after the inclusion will be available in May 2009.
Conclusion: In this pan-European hospital-based study, the median
incidence of HA CDI was 3.8 per 10,000 patient-days. Most patients
fulﬁlled the classical risk proﬁle of the elderly patient with signiﬁcant
co-morbidities and recent antibiotic use.
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O87 Clinical and bacteriologic characteristics of a 5-year cohort
of MRSA patients at a large U.S. metropolitan hospital
M. Pastagia °, L. Kleinman, S. Huprikar, S. Jenkins (New York, US)
Objective: Vancomycin therapy for methicillin resistant Staphylococcus
aureus (MRSA) may fail even when minimum inhibitory concentrations
(MIC) indicate susceptibility. Patients also fail therapy when heteroresis-
tant vancomycin intermediate Staphylococcus aureus (hVISA) develops.
This study integrates laboratory and clinical data to identify factors
correlated with mortality in patients with MRSA sepsis.
Methods: In a large urban hospital, 699 blood culture isolates of MRSA
from 2002–2007 with vancomycin MIC initially reported as <2mg/mL
using an automated system were retrieved from a −70ºC freezer and
subcultured. Etest (AB Biodisk) MIC determinations for vancomycin,
daptomycin, and linezolid were performed on the isolates. Strains for
which the MIC exceeded 1mg/mL were tested with teicoplanin by
Etest to detect possible hVISA. VISA was deﬁned using Clinical and
Laboratory Standards Institute criteria of 4−8mg/mL, and hVISA using
published criteria. We abstracted clinical and demographic data from all
699 medical charts. Outcomes data included in-hospital mortality and
facility of discharge. We performed univariate and bivariate analyses,
and multiple logistic regression.
Strain N Admitted from Discharged Dead
Home Outside
hospital
Nursing
home
Home to Rehab to Nursing
home
to Hospice
hVISA 45 60% 22% 18% 27% 18% 13% 2% 40%
VISA 118 59% 15% 26% 32% 14% 16% 4% 34%
Neither hVISA
nor VISA
536 61% 21% 18% 35% 17% 19% 3% 26%
“Healthy”
admission
“Sick or Frail”
admission
“Good or Healthy”
discharge
“Frail or Bad” discharge
hVISA 45 60% 40% 45% 55%
VISA 118 59% 41% 46% 54%
Neither hVISA
nor VISA
536 61% 39% 52% 48%
Results: Mortality was 28.3%; 16.9% of isolates were VISA and
6.4%, hVISA. Bivariate analysis revealed higher mortality associated
with several clinical factors: admission from a long term facility,
hospitalisation in the past month, surgery in the past 90 days,
endocarditis, soft tissue infections, infections of nonvascular prosthetics
or the presence of cirrhosis, diabetes mellitus, or renal failure (all
p< 0.05). Infectious diseases (ID) consult was protective (p< 0.001).
Although VISA and hVISA did not predict MRSA-attributed mortality
(p=.43), having either increased the odds of all cause mortality even
after controlling for age, race, and ID consult, with an adjusted odds ratio
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(AOR)=1.6 (p = 0.03) in multivariable models. Asian race had AOR=1.8
(p = 0.02). The AOR for ID consult was 0.8, but not signiﬁcant (p = 0.29).
Table 1 shows: many patients deteriorate from their pre-morbid health
status (p = 0.06)
Conclusions: Many patients with MRSA sepsis will die; others leave
the hospital needing more care than when admitted. Integrating clinical
and laboratory data may permit risk stratiﬁcation, identify patients most
likely to beneﬁt from an ID consult, and provide prognostic information.
Comorbidities and recent medical history should be included in future
studies of MRSA care and outcomes.
O88 Modelling the effect of time-dependent exposure on hospital
mortality using data from the BURDEN study group
M. Wolkewitz °, M. Schumacher, P. Davey for the BURDEN Study Group
Objectives: To explore the time dynamics of exposure to hospital
acquired Staph aureus bacteraemia (SAB) and its impact on hospital
mortality by using modern survival models.
Methods: The study population was adults resident in Tayside, Scotland,
who had a new admission to Ninewells Hospital between 1st July 2005
and 30th June 2006. The cohort enrolled patients from this population
who stayed in hospital for at least two days and were admitted to
wards with at least one case of SAB in the study period. Our primary
analysis used a survival model, which has two key differences compared
to a logistic regression model. First the exposure to SAB is regarded
as a time-dependent variable. Second the primary outcome (hospital
mortality) is recognised as a competing event for the secondary outcome
of being discharged alive from hospital. This is furthermore important
because increased length of stay is likely to be associated with increased
risk of death in hospital.
Results: The cohort enrolled 3132 patients of whom 203 died in hospital.
There were 58 cases of SAB, 31 patients had MRSAB (SAB with
meticillin resistant Staph aureus) of whom 12 died and 27 had MSSAB
(SAB with meticillin sensitive Staph aureus) of whom 5 died. MRSAB
occurred later than MSSAB (median 14.5 days after admission, inter
quartile range 9 to 34 days versus 8 days, inter quartile range 5 to
12 days for MSSAB). After adjusting for age, sex, comorbidity and
previous hospitalisation the hazard ratio for hospital mortality from
the subdistribution hazard model was 15.1 (95%-CI: 8.3 to 27.4) for
MRSAB and 5.9 (95%-CI: 2.4 to 14.7) for MSSAB. Cause-speciﬁc
hazard analysis showed that both MRSAB and MSSAB signiﬁcantly
reduced the hazard of being discharged alive and suggested that increased
length of stay contributed to the increased hazard of death in hospital.
Conclusion: The timing of events is crucial in hospital epidemiology
when time-dependent exposures and competing events are present.
Standard logistic regression ignores the time-dependent nature of the
data and is only a crude approach. Cumulative hazards and probability
plots provided additional insights into the mechanism, suggesting SAB
has both a direct impact on hospital mortality and an indirect effect
through increased length of stay.
O89 Update on mandatory bacteraemia surveillance in English
national health service acute trusts: trends and sources of
methicillin-resistant Staphylococcus aureus
A. Pearson °, R. Guy, R. Blackburn, R. Mandalia, J. Davies, M. Murray,
M. Painter, S. Batley, B. Duerden, J. Giltrow, M. Fleming (London, UK)
Objectives: This paper describes the trends in mandatory reporting
of Meticillin-resistant Staphylococcus aureus (MRSA) bacteraemia
identiﬁed in community and hospital healthcare facilities and reviews
the available information on the presumed source of these infections.
Methods: Data were collected via a web-enabled data capture system.
All National Health Service (NHS) Trusts (hospital groups) are required
to report all MRSA bacteraemia cases, with the exception of those
reoccurring within 14 days of the ﬁrst report. Cases of MRSA
bacteraemia diagnosed on presentation or within 2 days following
admission to an acute NHS hospital are deﬁned as “community
associated” whilst cases diagnosed 2 or more days after admission are
deﬁned as “healthcare acquired” as the bacteraemia is believed to be
acquired during the current hospital stay. Cases were excluded from
analysis if either there was missing data or the blood culture was taken
outside of an acute Trust setting.
Enhanced data has been collected since May 2006, since then Trusts
provided data on more than 12,400 MRSA bacteraemia cases. 45%
of cases (64% of which were reported with an acceptable degree of
certainty) had data on source of bacteraemia.
Results: More than 16,500 reports of MRSA bacteraemia were received
from 170 English NHS acute Trusts between October 2005 and
December 2008.
Two thirds of MRSA bacteraemia cases were diagnosed two or more days
after admission indicating hospital acquisition during the current stay.
The remaining third of cases either acquired their MRSA bacteraemia in
the community, or from nursing care homes (18%) or from the healthcare
facility from which they were admitted (6%).
The suspected source of bacteraemia varied according to timing of
detection. In community associated cases the most frequently identiﬁed
source was skin or soft tissue infection (26%) while in healthcare
acquired cases intravenous catheters were the most frequently identiﬁed
source of bacteraemia (37%).
Conclusion: Reports of healthcare associated MRSA bacteraemia cases
between Quarter 4 in 2005 and Quarter 4 in 2008 have reduced by more
than 70% as compared to a 51% decrease in community associated
cases. These data also provide an important means of identifying
sources of bacteraemia, enabling target of infection control measures
(care bundles) to speciﬁc routes of transmission and source. Mandatory
enhanced surveillance has provided an evidence base on which to target
interventions.
O90 Molecular characterisation of S. aureus involved in varicella
superinfections in France
O. Raulin, G. Durand, M. Croze, M. Bes, H. Meugnier, F. Vandenesch,
Y. Gillet, G. Lina, F. Laurent °, J. Etienne (Lyon, FR)
Varicella has traditionally been regarded as a benign disease that
most commonly occurs in childhood, but serious complications are
reported. One can estimate that patients with complications represent
4 to 9% of all varicella cases. The most common complications are
bacterial superinfections (31 to 70%) and particularly superﬁcial skin
infections (20 to 50% of all complications). Streptococcus pyogenes and
Staphylococcus aureus are the bacteria more frequently related to these
superinfections.
Method: Between 2002 and 2007 the French Reference Center for
Staphylococci received 58 S. aureus isolates involved in varicella
superinfections. The aim of this study was to characterise their toxin
proﬁles and to seek correlation between toxin expression and clinical
manifestations. The toxinic proﬁle (eta, etb, tst, pvl, sea-c, seh, sek-m,
seo, hlb, lukM) and the presence of gene mecA were determined by PCR
completed by the determination of the agr group; spa typing was used
to complete characterisation of some strains.
Results: Results show a high incidence of MRSA (n = 19, 32%) among
which a majority (n = 12, 63%) belonged to the emergent Geraldine
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clone (agr2, ST5, tst+); the PVL positive MRSA ST80 clone was
detected for 2 isolates and the exfoliatin positive MRSA ST88 was
detected for one. Overall, the presence of a major toxin such as
TSST-1, ETA and/or ETB, and PVL was detected for 54% (35/58)
of the isolates (TSST-1 28%, ETA/ETB 17%, PVL 9%). Clinical
manifestations were correlated with manifestations usually described
for these toxins: exfoliatins were associated with bullous impetigo or
staphylococcal scalded-skin syndrome whereas PVL was associated with
abscesses. Nevertheless, for TSST-1, clinical manifestations were more
heterogeneous, including staphylococcal scarlet fever, toxic shock, septic
shock, and suppurative diseases. When TSST-1, ETA/ETB and PVL were
absent, clinical manifestations were polymorphous.
Conclusion: These data lead i) to discuss the empiric antibiotherapy
of these community-acquired superinfections, and ii) to highlight the
severity of staphylococcal varicella complications.
O91 Differentiation of CC59 community-acquired MRSA strains
S. Monecke °, F. O’Brien, G. Coombs, H.L. Tan, J. Pearson, R. Ehricht
(Dresden, Jena, DE; Perth, AU)
Objectives: A collection of clonal complex 59 community acquired
MRSA strains collected in Western Australia (WA) from 2003 to 2008
was to be characterised with special emphasis on PVL and SCCmec
elements.
Methods: Previously described (Monecke & Ehricht 2006–2008)
diagnostic microarrays as well as PFGE, MLST and several PCRs for
characterisation of SCCmec elements were used.
Results: Carriage of toxin genes and SCCmec elements allowed to
distinguish six strains. One strain, ST87-MRSA-IV (WA MRSA-24)
carried a SCCmec IV element, enterotoxins seb, sek and seq, but no PVL.
There was one deviant isolate related to that strain which warrants further
characterisation, especially with regard to its SCCmec element. A second
strain included ST59-MRSA-IV and ST922-MRSA-IV (WA MRSA-49
and -55), which differed in pta and yqil alleles. It carried a SCCmec
IV element, seb, sek and seq, and it was PVL-positive. A third strain,
ST59-MRSA-IV (WA MRSA-56) carried a SCCmec IV. It was positive
for PVL and enterotoxin genes sea, seb, sek and seq. A fourth strain
was ST59-MRSA-IV+V (WA MRSA-15) carrying SCCmec elements
of type IV and V, or a composite element combining features of both.
Isolates of this strain were PVL negative, but positive for enterotoxin A
(sea) and, in most cases, also for seb, sek and seq. A ﬁfth strain was
the “Taiwan Clone”, ST59/952-MRSA-V (WA MRSA-9 and -52) which
also comprised two closely related sequence types. This strain carried a
SCCmec element of type V(T) or VII as well as PVL and, usually, seb,
sek and seq. It was the most common CC59 strain in WA. The sixth
strain differed from the “Taiwan Clone” in the presence of a SCCmec
type V element and in the absence of PVL.
Conclusion: The differentiation of this clonal complex into various
different strains indicates a rapid evolution and spread of SCCmec
elements, and the diagnostic microarray technology allows one to
distinguish beyond MLST level and hence to accurately trace outbreaks
and spread of these strains.
O92 Identiﬁcation of a clinical methicillin-resistant Staphylococcus
aureus strain containing both SCCmec type IV and
SCC476-like sequences
P. Beisser °, C. von Wintersdorff, M.L. Boumans, H. de Neeling,
E. Stobberingh (Maastricht, Bilthoven, NL)
Objectives: SCCmec typing has become a valuable tool for the
molecular epidemiology of methicillin-resistant Staphylococcus aureus
(MRSA) infections. To date, 8 SCCmec types have been described
worldwide. The aim of the study was to characterise a new, yet untypable
SCCmec from a clinical MRSA isolate.
Methods: Samples from an outbreak in a paediatric ward in a Dutch
university hospital were subjected to both previously described PCR-
based SCCmec typing assays, and a novel typing assay involving
multiplex realtime-PCR. From one isolate, SCCmec DNA was obtained
using long-range PCR. The DNA sequence was subsequently obtained
by shotgun-sequencing.
Results: Two isolates (Spa type 447, PFGE cluster 55) from a hospital
outbreak were investigated and identiﬁed as type II SCCmec MRSA by
conventional SCCmec typing. Interestingly, by using a novel typing assay
(see Abtract 1354) both ccr1- and ccr2-like sequences were detected
in each of these samples--a combination that has not been reported
before. Preliminary sequence data reveal that the untypable SCCmec
(approximately 50 kb) contains both SCC476-like and SCCmec type IV-
like sequences in tandem.
Conclusions: The previously published SCC467 sequence was identiﬁed
in an MLST ST1 strain, whereas the strain containing the untypable
SCC467/SCCmec type IV-like cassette has MLST CC5-like traits. It is
likely that this new SCCmec variant is prevalent MRSA outbreaks in
several Dutch hospitals. To investgate this further, a larger collection of
PFGE cluster 55 isolates is currently being screened.
O93 Acquisition and persistence of methicillin-resistant
Staphylococcus aureus Clonal Complex 398 during
occupational exposure
B. van Cleef °, A. Haenen, M. van den Broek, X.W. Huijsdens,
M. Mulders, J. Kluytmans (Bilthoven, Zutphen, Amsterdam, NL)
Objective: To determine the risk of acquiring Methicillin-resistant
Staphylococcus aureus Clonal Complex 398 (MRSA-CC398) after short-
duration occupational exposure to pigs, and to determine the persistence
of MRSA-CC398 colonisation after acquisition.
Methods: In a pilot study on the prevalence of MRSA-CC398 in pig
farms [1] veterinary sample takers were tested before, directly after
and 24 hours after visiting the farm. These sample takers all had short
contact with pigs and dust on the farms, and were therefore at risk of
acquiring MRSA if it was present on the particular farm. Data on farm
characteristics (i.e. kind of farm, number of pigs, other animals present,
and hygiene measures), veterinary samples and nasal samples of sample
takers were collected. MRSA isolates were typed by staphylococcal
protein A (spa) typing.
Table. Positive MRSA-tests of sample takers. Tests were taken before, directly after
and 24 hours after visiting a farm. MRSA-status is indicated as + (positive) and
− (negative), spa-types are shown between brackets.
Sample farm MRSA-status MRSA-test (spa-type)
taker (spa-type) before
visit
directly after
visit
24 hours after
visit
1 + (t011) − + (t011) −
2 + (t011) − + (t011) −
3 + (t011) − + (t011) −
+ (t108) − + (t108) −
4 + (t108) − + (t108) −
+ (t011) − + (t011) −
+ (t108) − + (t108) −
5 + (t011) − + (t108)b −
6 + (t011, t108, t1456) − − + (t108)c
7 + (t011, t108, t2330) − + (t108) −
+ (t567) − + (t567) −
8 + (t108) − + (t108) −
9 + (t011) − + (t011) + (t011)d
10 + (t011) − + (t011) −
11 + (t108) − + (t108) −
12a + (t899) + (t011) + (t011) + (t011)
+ (t011) + (t011) + (t011) + (t011)
− + (t108) + (t108) + (t108)
aSample taker 12 has daily contact with poultry and is excluded from analysis.
bSample taker 5 reported no contact with livestock elsewhere than in this study at
that moment (spa-types of sample taker 5 and farm are not corresponding).
cSample taker 6 tested MRSA-negative in following tests.
dSample taker 9 was not tested again.
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Results: Complete data sets (samples taken before, directly after and
24 hours after a visit) were collected on 141 visits by 29 sample takers
visiting 50 farms. On 28 farms MRSA was collected from pigs or stable-
dust (56%). These farms were visited 78 times by 23 different sample
takers. One sample taker (#12) was positive for MRSA before visiting a
farm, he was removed from the following analysis.
Fifteen of the 78 (19%) visits to MRSA-positive farms resulted in
acquisition of MRSA and 11/23 (48%) sample takers acquired MRSA
at least once after visiting a positive farm. Of these 11 positive sample
takers 2 acquired MRSA twice and 1 sample taker acquired MRSA
three times after separate visits. Of the 15 acquisitions of MRSA, 13
were negative after 24 hours. The spa-types of MRSA isolates found
on the farms and sample takers were grossly comparable. On the 32
negative farms, none of the 60 visits resulted in MRSA acquisition.
For further information see the table.
Discussion: MRSA-CC398 was acquired by 48% of the sample takers
after occupational exposure in this study. However, in 11 of the 13 cases
the strain was not recovered the next day, therefore acquisition was of
short duration, posing a limited treat to human health. Some persons
seemed to be more vulnerable to acquire MRSA during their work. The
sample size of this study was too small to draw ﬁnal conclusions concern-
ing this inter-personal variation. This requires a more extensive study.
Reference(s)
[1] Van den Broek et al. Methicillin-resistant Staphylococcus aureus in
people living and working in pig farms. Epidemiol. Infect., published
online 24 October 2008 (doi:10.1017/S0950268808001507).
O94 Methicillin-resistant Staphylococcus aureus in retail pork
J.S. Weese, R. Reid-Smith °, J. Rousseau, B. Avery (Guelph, CA)
Objectives: Community-associated MRSA is an increasing problem and
an association with food animal contact has been made in some regions.
This has led to concerns about the potential role of food in MRSA
transmission. The objective of this study was to evaluate the prevalence
of MRSA colonisation of retail pork in Canada.
Methods: Pork chops, ground pork and pork shoulders were purchased
at retail outlets in four Canadian provinces in conjunction with the
Canadian Integrated Program for Antimicrobial Resistance Surveillance.
Both direct inoculation of meat into enrichment broth and rinsing of
meat in broth were performed for pork chops and shoulders, followed
by inoculation onto Chromogenic agar. Ground pork was tested only
using the direct method. MRSA isolates were typed by PFGE and spa
typing. Real time PCR was used to detect Panton-Valentine leukocidin
genes.
Results: MRSA was isolated from 31/402 (7.7%, 95% CI 5.5−10.7%)
of samples. There was a signiﬁcant difference between provinces
(P< 0.001) but no difference between different products, with MRSA
isolated from 23/296 (7.7%) pork chops, 7/94 (7.4%) ground pork and
1/12 (8.3%) pork shoulders (P = 0.99). 21/403 (5.2%) samples were
positive using direct culture while MRSA was isolated from 15/355
(4.2%) of samples testing using the rinse method. Nine samples were
positive on direct culture but negative using the rinse method, while
10 others were positive only with the rinse method and only 5 were
positive with both methods. Seven samples (ground pork) that were
positive on direct culture were not tested using the rinse method. 3
main clones were present. The most common (40% of isolates) was a
group of 3 related spa types (t064, t008 and new related type) were
classiﬁed as Canadian epidemic MRSA-5 by PFGE, an ST8 human
epidemic clone that has been associated with horses. PFGE-non-typable
spa t034 were not surprisingly common, accounting for 30% of isolates.
The 3rd main group was 3 related spa types (t002, t045 and new type)
that were CMRSA-2 (USA100), an ST5 clone that is common in humans
in Canada, that also accounted for 30% of isolates.
Discussion: The clinical relevance of MRSA contamination of pork is
currently unclear. It is possible that contact with contaminated food
could be a mode of MRSA transmission in the community, although
further study of the prevalence of contamination, amount of MRSA in
contaminated samples, sources of contamination and implications on
human health are required.
O95 Prevalence of the novel trimethoprim resistance gene dfrK
among German staphylococcal isolates of the Bft-GermVet
monitoring study
K. Kadlec °, S. Schwarz (Neustadt-Mariensee, DE)
Objectives: Very recently a novel trimethoprim resistance gene, dfrK,
was identiﬁed on a tet(L)-harbouring plasmid in a porcine MRSA
isolate from the BfT-GermVet monitoring study. This study included
in total 248 independent coagulase-positive and coagulase-variable
staphylococci collected between 2004 and 2006 all over Germany: 46
isolates from infections of the urinary-genital tract of pigs, 44 isolates
from skin infections of pigs, 57 isolates from respiratory tract infections
of dogs/cats, and 101 isolates from infections of skin/ear/mouth of
dogs/cats. In this study, we investigated the prevalence and the plasmid
location of the dfrK gene among these isolates.
Methods: PCR primers were designed and a PCR with subsequent
restriction analysis of the PCR product was established to detect dfrK.
Isolates with positive results were tested for a plasmid location of dfrK by
transfer experiments and dfrK-carrying plasmids were further analysed.
Results: The trimethoprim resistance gene dfrK was detected in another
10 isolates. All isolates were from pigs: 9 from skin infections and the
remaining 1 from a urinary-genital tract infection. Six Staphylococcus
hyicus subsp. hyicus isolates, 3 S. aureus isolates (2 MRSA and
1 MSSA) and 1 S. pseudintermedius. All these isolates harboured
plasmids. In 7 isolates (4 S. hyicus, 2 MRSA and the single
S. pseudintermedius), the plasmid location of dfrK was conﬁrmed by
protoplast transformation with subsequent susceptibility testing and PCR
analysis of the transformants. In all 7 cases, the plasmids harbouring
dfrK also carried a tet(L) tetracycline resistance gene. The results of a
combined PCR assay with primers from tet(L) and dfrK conﬁrmed that
the dfrK gene was always located immediately downstream of the tet(L)
gene. Further analysis of these dfrK- and tet(L)-harbouring plasmids
showed that they varied in size between 6 and 40 kb and that similar
sized plasmids differed in their EcoRV and HindIII restriction patterns.
Conclusion: The novel trimethoprim resistance gene dfrK occurred in 11
(12.2%) of the 90 porcine staphylococcal isolates from the BfT-GermVet
study. In 8 (72.7%) of the 11 isolates, it was located on structurally
diverse plasmids, however, always in close proximity to a tet(L) gene.
The linkage of the dfrK and tet(L) genes allows the maintenance and co-
selection of such plasmids under selective pressure by either tetracyclines
or trimethoprim, both of which are widely used in veterinary medicine.
O96 Acquisition of cfr gene by an epidemic cluster of
S. epidermidis causing bloodstream infections in hospitalised
patients from Rome, Italy
R. Mendes °, L. Deshpande, T. Spanu, R. Jones, G. Fadda (North
Liberty, US; Rome, IT)
Objectives: S. aureus and S. epidermidis (SE) are the most frequent
species recovered from nosocomial bloodstream infections. Increasing
prevalence of methicillin-resistant staphylococci has been reported.
Vancomycin and linezolid are the antimicrobial options for treating
infections caused by these organisms. Linezolid resistance remains rare
in staphylococci; however, sporadic occurrence has been documented.
Here we report the acquisition of the cfr gene by an epidemic cluster of
SE in Rome, Italy.
Methods: Strains recovered as part of the SENTRY Antimicrobial
Surveillance Program were tested for susceptibility by the CLSI broth
microdilution method. Identiﬁcation was performed by Vitek 2. Isolates
displaying linezolid MIC values at 4mg/L were further screened for
mutations at the central loop of domain V of 23S rRNA, L4 and L22
genes followed by sequencing. The isolates were also screened for cfr
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gene and clonality assessed by PFGE. Gene location was performed by
Southern blot and hybridisation.
Results: Ten SE recovered from blood cultures during February 06
through May 2008 met the screening criteria. Strains displayed linezolid
MIC values of 4 or 8mg/L, except for one isolate showing an MIC
value of 64mg/L (Table). The isolates were resistant to ciproﬂoxacin,
clindamycin, erythromycin, gentamicin but susceptible to vancomycin.
Only one SE was methicillin-susceptible and two isolates were quin-
upristin/dalfopristin non-susceptible. All strains were clonally related and
clustered into three subtypes (A, A1 and A2). cfr gene was detected in
a linezolid non-susceptible strain (MIC, 64mg/L), which was recovered
from a 57 y/o male who underwent liver transplantation. Plasmid analysis
identiﬁed six plasmid bands ranging from c.a. 1.5- to 154-kb in the cfr-
carrying strain. Hybridisation signals were observed from the 154-kb
plasmid band as well as from a chromosomal band after I-CeuI digestion.
Mutations at the 23S rRNA, L4 or L22 were not detected.
Conclusion: The cfr increased the linezolid MIC value between 8- and
16-fold. This report highlights the ability of SE to acquire linezolid
resistances. The potential mobility of cfr combined with the clonal
tendency for dissemination among Staphylococcus spp., represent a
serious threat to several potent Gram-positive-active agents, including
oxazolidinones. Active surveillance combined with effective infection
control and molecular studies seem prudent to minimise the spread of
these resistance mechanisms.
Isolate
no.
PFGE cfr LZ CP CM EM GM Q/D Age Sex Year ICU
5174 A Neg 8 >4 >2 >2 >8 2 46 F 2006 Y
15443 A Neg 8 >4 >2 >2 >8 1 60 M 2006 Y
12327 A1 Neg 4 >4 >2 >2 >8 1 60 F 2007 N
12332 A1 Neg 4 >4 >2 >2 >8 1 37 F 2007 N
12337 A1 Neg 4 >4 >2 >2 >8 1 29 M 2007 Y
12375 A2 Neg 8 >4 >2 >2 >8 0.25 78 M 2007 Y
12382 A Neg 8 >4 >2 >2 >8 1 78 F 2007 N
12417 A Neg 8 >4 >2 >2 >8 0.25 58 M 2007 Y
12421 A1 Neg 4 >4 >2 >2 >8 0.5 45 M 2007 Y
4303 A Pos 64 >4 >2 >2 >8 >2 57 M 2008 Y
LZ, linezolid; CP, ciproﬂoxacin; CM, clindamycin; EM, erythromycin; GM,
gentamicin; Q/D, quinupristin/dalfopristin; ICU, intensive care unit.
Reﬂections of infectious diseases in music
K105 Reﬂections of infectious diseases in music
H. Peltola ° (Helsinki, FI)
The objective is to get a glimpse of the potential impact of infectious
diseases on music, as regards to the composer’s or performing musician’s
own disease, living conditions or other relevant elements which might
have affected the end result, the music we enjoy today.
As music is an art of senses, full of drama, despair, realities of
life − or just the opposite, blissful ignorance of those realities, full of
romance, beauty, and delicacy − various forms of music was researched
paying special attention to infections which potentially have played a
signiﬁcant role in the birth of that particular piece or performance. The
entire research process was subjective, biased, and emotional, but done
wholeheartedly. It aimed at to taking into account, not only the personal
life of a composer or performing musician, but also the historical context
in which the music was born.
Musical examples, served to the audience along with the essential
background data, will show the extent to which infections have impacted
music. Regarding the aetiology of those infections, bacterial, viral and
parasitic agents are well represented. In addition, many epochs in history
have played their role. Sometimes, the connections are surprising, even
dramatic.
If listened to with a tender ear, music quite often turns out to be
affected also by infectious diseases. As physicians we should realise the
strength with which some people are driven by this demonic, divine −
but altogether beautiful force: music.
Common problems in antibiotic abuse and
solutions from around the globe
S114 Asia
A. Kamarulzaman ° (Kuala Lumpur, MY)
The prevalence of antibiotic resistance has been increasing in Asian
countries in recent years. This problem has most likely arisen due to
a combination of inadequate infection control practices particularly in
hospital settings and the widespread misuse of antibiotics in hospital and
community settings.
Factors that lead to antibiotic misuse include inappropriate antibiotic
prescription due to a lack of clinical, microbiological and/or imaging
data in many clinical settings in the Asian region. A lack of separation
of prescribing and dispensing by medical practitioners as practised in
many countries in Asia as well as the easy availability of over the counter
medications also contribute to antibiotic misuse.
Optimal control of antibiotic use can only be achieved through a multi-
pronged approach that includes better education of the public and
medical practitioners on rational use of antibiotic, a review of the health
system structure, as well as better control of over the counter sales
of antibiotics. Upgrading of microbiology and other laboratories and
radiological facilities that will enhance the accuracy of clinical diagnosis
is also urgently needed in most developing countries to keep pace with
the complexities of managing patients in this new era to minimise the
widespread practise of inappropriate antibiotic use.
Bacterial meningitis (Symposium arranged
with EMESG)
S117 Old and new diagnostic tests
C. Østergaard ° (Herlev, DK)
Examination of the CSF for microorganisms, WBC and differential
counts, and concentrations of glucose and protein is the primary
investigation to diagnose meningitis. However, this CSF examination
may not always be conclusive, and it can be difﬁcult to distinguish
bacterial from viral meningitis. Therefore, improvement in diagnostic
sensitivity and speciﬁcity of bacterial meningitis and development of
rapid test for a bacterial aetiology are still needed. This presentation
gives a review of the strength and weakness of several analyses and
methods to reveal the microbiological agent (i.e. CSF microscopy and
culture, antigen or antibody detection, molecular methods to detect DNA
or RNA) and the use of several mediators of the host immune response
for diagnostic and prognostic purposes.
S118 Management of acute bacterial meningitis
D. van de Beek ° (Amsterdam, NL)
Bacterial meningitis is a medical emergency that requires a multidisci-
plinary approach. A diagnosis of bacterial meningitis is often considered,
but the disease can be difﬁcult to recognize. Recommendations for
antimicrobial therapy are changing as a result of the emergence of
antimicrobial resistance. In this lecture, current concepts of the initial
approach to the treatment of adults with bacterial meningitis will be
summarised. The management of the critically ill patient with bacterial
meningitis poses important dilemmas. Controversial areas (i.e., pre-
hospital admission antibiotics) will be reviewed and relevant literature
will be discussed in the framework of current treatment guidelines,
highlighting new developments in adjunctive dexamethasone therapy.
A clinician’s approach to managing difﬁcult infections S25
S119 Pathogenesis and pathophysiology: potential adjunctive
therapies
U. Koedel ° (Munich, DE)
Acute bacterial meningitis (ABM), especiﬁcally when caused by
infection with Streptococcus pneumoniae, still has an unacceptably poor
prognosis with a mortality of 10−30%.
Bacterial infection of the meninges causes one of the most powerful
inﬂammatory reactions known in medicine. Yet 50 years ago, this
inﬂammatory reaction was suggested to contribute substantially to brain
damage. This concept underlies the use of anti-inﬂammatory agents as
adjunctive therapy in ABM. Of all adjunctive treatments in ABM, only
corticosteroids have been properly evaluated in clinical trials. These trials
recommend corticosteroids in patients with Haemophilus inﬂuenzae
type B and pneumococcal meningitis (PM). However, adjunctive
corticosteroid therapy has several weaknesses such as a narrow treatment
window and borderline effects on neurologic sequelae. Thus, there is still
the need for additional or alternate adjuvants in the therapy of ABM.
Experimental studies using animal models (predominantly of PM)
have provided insight into the pathogenic mechanisms underlying brain
injury in ABM. It is now clear that the autodestructive inﬂammatory
reaction is initiated by the interaction of bacterial components with
host pattern recognition receptors (PRR) like Toll-like receptors (TLR).
PRR signaling results in the activation of transcription factors like NF-
kB which up-regulate the production of proinﬂammatory cytokines.
Cytokines like IL-1b are also potent triggers of NF-kB activation and
therefore can exaggerate the inﬂammatory reaction (via positive feedback
loops). As a consequence, great numbers of neutrophils are recruited to
the meninges. Activated neutrophils release many potentially cytotoxic
agents including oxidants and matrix metalloproteinases that can cause
collateral damage to brain tissue. Additionally to the inﬂammatory
response, direct bacterial cytotoxicty has been identiﬁed as a contributor
to tissue damage in ABM.
Thus, experimental studies point at four different targets of adjunctive
therapy, namely interference with (I) the induction of inﬂammation
(e.g., TLR blockade), (II) the exaggeration of inﬂammation (e.g., IL-1
antagonism), and (III+IV) the generation of cytotoxic factors (either of
host or bacterial origin, e.g., scavenging of oxidants). This presentation
will give an overview of the pathophysiology of ABM (with special
emphasis on PM) and highlight promising targets for adjunctive therapy
in ABM, as deduced from experimental studies.
A clinician’s approach to managing difﬁcult
infections
S120 Acute post-surgical prosthetic joint infection
J. Cobo ° (Madrid, ES)
Optimal management of prosthetic joint infections (PJI) remains
undeﬁned. Important issues such us when the implant can be retained
(conservative strategy), optimal duration of antimicrobial therapy (AT)
or the role of rifampin are yet matter of controversy. In spite of a
number of reports, literature appears confusing. Among the limitations
of the literature we must emphasize: 1) Different criteria to classify
PJI; 2) Different criteria to select for conservative strategy (CS);
3) No description of the initial population from which patients were
selected for CS; 4) Very different AT (from 4 weeks to chronic
suppressive therapy); 5) Low numbers of patients or short follow-up;
6) Absence of clinical trials. It is not so surprising that the rates
of CS success have varied from 0 to almost 100%. The most useful
classiﬁcation to approach PJI was proposed by Tsukayama (1996). In
his series 25 out of 35 patients with early PJI managed by a CS
(debridement, exchange of polyethylen and implant retention) were cured
after 4 weeks of AT. The Spanish group for the study of PJI was
constituted in 2003 within the Spanish network for the study of infectious
pathology (REIPI), a public funded initiative. Data from 139 consecutive
cases of early PJI attended in 10 hospitals were recorded in an online
database. 117 cases managed with CS could be analysed (mean follow-
up of 2 years). Sixty-seven patients (57.3%) were cured after a mean
of 81 days of AT. In 35 (29.9%) the infection was not controlled (or
relapsed) after a mean of 84 days of AT, and the implant had to be
removed. In other 15 patients (12.8%) the implant was not removed,
but suppressive AT was given because of suspected ongoing infection.
Results were signiﬁcantly worse in one hospital. No other factors resulted
statistically signiﬁcant, but there was a trend of worse results for MRSA
produced infections (p = 0.06). Time from the symptoms appearance to
debridement was shorter in successfully treated cases (median, 7 days)
than in failures (median, 10 days); p = 0.08. Good functional results were
obtained in patients with successfully CS. In summary, a substantial
proportion of early PJI can be managed with CS strategy and a deﬁnite
(non suppressive) AT. It is difﬁcult to identify patients at higher risk
for failure, although MRSA aetiology and longer time until debridement
seem to predict failures. Different outcomes in some centres suggest that
surgical technique could be an important factor for failure.
S121 Pacemaker infections with multiresistant pathogens
J.L. Mainardi ° (Paris, FR)
More than 3 million cardiac pacing systems are implanted worldwide
and the estimated rate of infections after implantation of permanent
endocardial leads is 1% to 2%, but varies between 0.1 to 20%.
Pacemaker infections correspond to different clinical situations including
localised infection in the device pocket, pacemaker leads to systemic
infection associated with bacteraemia and lead-associated endocarditis.
This latter represents 10 to 25% of all cases of pacemaker infections.
The severity of pacemaker related infective endocarditis is sustained
by a mortality range between 10 to 20%. Risk factors related to
infections of implanted pacemakers are correlated with fever before
24 h before implantation, temporary pacing before implantation and
early re-interventions (haematoma, lead dislodgment). In contrast, an
inverse correlation is observed between development of infection and
antibiotic prophylaxis and implantation of a new system. Data to
guide therapy in patients with pacemaker infection are limited and the
most appropriate management remains to be determined. According
to different series, staphylococci accounted for 60 to >90% of the
responsible organisms. Coagulase-negative staphylococci (CNS) are
reported as predominant pathogens following by Staphylocococcus
aureus. The bioﬁlm production, responsible for bacterial survival, and
the emergence of methicillin-resistant in S. aureus and CNS have
complicated the management of pacemaker infections. This implies that
empiric treatment of suspected pacemaker infection should coverage
for staphylococci including methicillin-resistant strains. Streptococci,
Corynebacterium spp, Propionibacterium acnes, Gram-negative bacilli
and Candida spp can cause occasional infections. The optimal therapy
combines complete device extraction (percutaneous ablation or surgical
removal during extracorporeal circulation) and prolonged course of
antibiotics, in particular in case of multiresistant bacteria. Leaving the
device intact is associated with increased mortality and risk of relapsing
or persistent infections. In absence of prospective studies, the duration
of antibiotic treatment remains to be determined but 1 month has been
shown not to be associated with an increased incidence of relapse.
Shortest course of treatment (2 weeks) has been proposed in case of
vegetations strictly localised to leads without affecting cardiac valves.
Antibiotic therapy working alone should be reserved for highly selected
patients.
S122 Difﬁcult ventricular shunt infections
S. Sacar ° (Denizli, TR)
Infection remains the most critical complication of ventriculoperitoneal
shunt placement with an incidence of 2.2−39%. Factors as the age
of patient, aetiology of hydrocephalus, the type of shunt implanted,
and the surgeon’s experience are determined to be associated with
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increased risk of infection. Children are more likely than adults to
acquire shunt infection. The possible reasons are longer hospital stay,
higher skin bacterial concentrations, immature immune systems, or more
adherent strains of bacteria. Staphylococci, as skin commensals, are the
main causative organisms. Nevertheless, in recent years a change in
the epidemiology of microorganisms was observed with an increase
of Gram-negative bacteria. Appropriate systemic antibiotics according
to the antimicrobial susceptibility testing and surgical removal of the
shunt with temporary external cerebrospinal ﬂuid drainage and shunt
replacement following the eradication of the infection are the cornerstone
of the treatment of cerebrospinal ﬂuid shunt infections. Good compliance
with infection control practices, inserion of the catheter under aseptic
techniques and short-term perioperative antimicrobial prophylaxis in
order to prevent the emergence of drug-resistant subpopulations are
important steps in the prevention of shunt infections.
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O124 Epidemiology of inﬂuenza illness requiring intensive care
unit admission in Toronto, Canada
A. McGeer °, K. Green, S. Drews, I. Davis, J. Downey, K. Katz,
D. Rose, A. Sarabia, A. Simor, J. Pataki, R. Fowler, S. Lapinsky,
D. McRitchie, C. Simone for the ICU Inﬂuenza Working Group, Toronto
Invasive Bacterial Diseases Network
Background: The epidemiology of illness requiring ICU admission in
association with inﬂuenza infection in adults has not been well studied.
Methods: Population-based surveillance for laboratory conﬁrmed
inﬂuenza in adults (>15 yrs) requiring ICU admission in Toronto/Peel
(pop 4M) was performed from 12/04 to 5/08. Consenting patients with
a positive direct test (antigen or PCR) or culture for inﬂuenza were
enrolled. During the 2006/7 and 2007/8 seasons, active surveillance for
inﬂuenza was conducted in 6 of 19 ICUs in the surveillance area.
Results: From 1/12/04 to 31/5/08, 161 adults with LCI requiring ICU
admission were identiﬁed (1.3/100000/yr). The median age was 73 years
(range 17−97 years); 85 (50%) were male. 156 (92%) had at least one
chronic underlying condition qualifying them for inﬂuenza vaccine, but
only 61% had been vaccinated; the median Charlson score was 1 (range
0−8); 28 (17%) were residents of long term care facilities. 123 (73%)
of infections were due to inﬂuenza A, and 46 (27%) due to inﬂuenza
B. Most (103 61%) had an admitting diagnosis of pneumonia; 33 (20%)
had another cardio-respiratory diagnosis. Fifteen (9%) had a concomitant
bacteraemia (8 S. aureus, 4 S. pneumoniae, 2 E. coli, 1 GAS). 151
(90%) of patients received antibacterials at admission; 68 (40%) were
treated with antivirals (all with oseltamivir). Forty-two patients (25%)
died within 15 days of the onset of symptoms; these included 8/68
(12%) patients treated with oseltamivir and 34/100 (34%) other patients
(P = 0.002). In multivariable analysis, only APACHEII score and failure
to treat with oseltamivir therapy predicted mortality (odds ratio for death
with oseltamivir treatment=0.27, 95%CL 0.12−0.64, P = 0.001).
Conclusions: Inﬂuenza is an important cause of respiratory illness
requiring ICU admission during the winter season, particularly in
unvaccinated, at-risk adults. S. aureus is the most common complicating
bacterial infection. Treatment with oseltamivir was associated with a
signiﬁcant reduction in mortality.
O125 Inﬂuenza in adults admitted to Canadian hospitals: data
from two seasons
A. McGeer, D. Gravel, G. Taylor °, C. Weir, C. Frenette, J. Vayalumkal,
A. Wong, D. Moore, S. Michaud, B. Amihod (Toronto, Ottawa,
Edmonton, Montreal, Saskatoon, Sherbrooke, CA)
Objective: Seasonal inﬂuenza (ﬂu) remains a cause of substantial
morbidity and mortality. Antiviral treatment should be considered
for all hospitalised patients with inﬂuenza. To better understand the
epidemiology and burden of illness within the hospital sector in Canada
and the current use of antiviral therapy, we carried out a multihospital
survey of virologically conﬁrmed ﬂu in hospitalised adults.
Methods: CNISP is a network of largely teaching hospitals across
Canada that collaborates to collect data on infections in hospitalised
patients. During two consecutive years (2006/2007 and 2007/2008)
hospitals within CNISP identiﬁed inpatients >16 years who had
virologically conﬁrmed ﬂu. Case patient charts were reviewed to capture
demographic and clinical data and to determine whether ﬂu was
community (CA) or hospital acquired (HA). Cases were reviewed at
30 days to determine outcomes. Deaths at 30 days were reviewed to
determine whether ﬂu was a main or contributing cause.
Results: Fifteen (06/07) and 11 (07/08) hospitals were recruited from
the CNISP network. 532 virologically conﬁrmed cases of ﬂu were found,
182 in 06/07 (95% ﬂu A) and 358 in 07/08 (56% ﬂu A). Mean patient
age was 67 years, 52% were male. There was documentation of patient
vaccination that season in 29%. Incidence of CA ﬂu was 11/10,000
admissions in 06/07 (range by hospital 2 − 23) and 27 in 07/08 (1 − 47).
Admitting diagnoses in CA cases were: pneumonia or inﬂuenza 48%,
exacerbation of COPD 20%, sepsis or fever not otherwise speciﬁed 9%,
cardiac diagnoses 7%, other diagnoses 16%. 24% of cases were HA,
range by hospital 3.9 − 5.4/100,000 patient days. 68% of patients were
managed with droplet and contact isolation practices, an N-95 mask was
used in 19%. 29% of CA cases but 75% of HA cases received antiviral
therapy p< 0.01, almost entirely oseltamivir. 9% of cases were admitted
to an ICU; 30-day mortality was 8% with 2.6% attributed to inﬂuenza.
Conclusion: There is considerable season-season and hospital-hospital
variation in ﬂu in patients in Canadian hospitals. Hospitalised patients
CA ﬂu present with a wide spectrum of clinical diagnoses; nearly a
quarter of all cases were HA. Few CA cases but most HA cases were
treated with antiviral drugs. Attributable 30 day mortality was 2.6%.
O126 Inﬂuenza vaccination coverage among Greek adults
V. Papastamopoulos, E. Kakalou °, T. Panagiotopoulos, J. Baraboutis,
M. Samarkos, A. Skoutelis (Athens, GR)
Objectives: Our study sought to describe inﬂuenza vaccination coverage
among adults in Greece for the season 2007/08.
Methods: We conducted a random-sampling, telephone based house-
hold survey among adult individuals in Greece. For this purpose
a sample of 1104 adults representative of the basic demographic,
social and geographical characteristics of the overall Greek population
according to the latest national survey, was used. Two target groups
were determined for analysis: persons >65 years of age and persons
with chronic conditions such as respiratory and heart conditions (other
than hypertension), diabetes mellitus and other conditions.
Results: The inﬂuenza vaccination rate for the season 2007/08 among
the adult population in Greece was: 16% for the overall adult population
(19.5% for men, 12.7% for women), 48.1% for people >65 years of age,
31% for persons with chronic illness (32.5% for persons with respiratory
illness, 50.2 for persons with heart conditions, 35% for persons with
diabetes mellitus). A high rate of 81% of the overall population reaching
88% among persons with chronic conditions report having had any type
of contact with the National Health System or a private physician within
the last three years. Among them only 20.1% had been recommended to
get vaccinated. Among the ones recommended any vaccination, 80.5% of
persons with respiratory illness, 100% of persons with diabetes mellitus
and 89.1% of persons with heart conditions had been recommended to
get the inﬂuenza vaccine.
Conclusions: Available data show unacceptably low levels of inﬂuenza
vaccination coverage among vulnerable groups such as the population
over 65 years of age and people living with chronic illness. Inﬂuenza
vaccination is the only preventive measure reducing inﬂuenza morbidity
and mortality and its use has proven cost-effective among high risk
groups. It is also the main vaccine recommended by physicians. However
the overall rate of physicians recommendation of vaccination is very low.
Dynamic efforts are thus needed to design and implement strategies and
policies that have demonstrated their rigorous effectiveness in enhancing
inﬂuenza vaccination coverage rates.
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O127 The role of respiratory viruses and M. pneumoniae in lower
respiratory tract infections in primary care
M. Ieven °, K. Loens, F. Coenjaerts, C. Lammens, A. Vanderstraeten,
T. Verheij, P. Little, H. Goossens, E.C.J. Claas, A.M. Van Loon on
behalf of the GRACE Study Team
Objectives: The role of viruses and especially of the newly recognised
viruses is not well known in adult respiratory infections in the
community. We therefore investigated the viral aetiology and the role
of M. pneumoniae in lower respiratory tract infections (LRTI) at the
GPs ofﬁce in the European GRACE primary care network (PCN) using
sensitive real-time nucleic acid ampliﬁcation tests (NAATs).
Materials and Methods: From October 2007 through May 2008, a
total of 711 adult patients with LRTI in the community were enrolled
during the ﬁrst winter period in a prospective study in 11 PCNs in
8 European countries. Among other samples, nasopharyngeal ﬂocked
swabs (COPAN) were collected and sent to the local laboratory to
be frozen. Specimens were transported regularly to the central lab
in Antwerp for subsequent nucleic acid extraction by the NucliSens
EasyMAG (bioMe´rieux) and in-house real-time PCR for M. pneumoniae
detection. Aliquots of nucleic acid extracts were sent to the collaborating
LUMC and UMC-UTRECHT for detection of inﬂuenzavirus (INF)
A/B, parainﬂuenzavirus (PIV)1−4, human rhinoviruses (HRV), human
metapneumovirus (hMPV), respiratory syncytial virus (RSV), adenovirus
(ADE), Bocavirus (BOCA), coronaviruses (COR) OC43, NL-63, 229E,
polyomaviruses KI and WU by in-house mono and multiplex real-time
PCR.
Results: In 618/711 (86.9%) of the patients, a nasopharyngeal specimen
could be collected. In 302 (48.9%) patients a respiratory virus was
detected. A total of 322 respiratory viruses were detected in 618
specimens: 114 HRV (18.5%), 78 INF (12.6%), 41 CoV (6.6%),
28 hMPV (4.5%), 23 RSV (3.7%), 19 polyomaviruses (3.1%), 12 PIV
(1.9%), 4 ADE (0.7), 3 BOCA (0.5%). The new polyomaviruses WU and
KI were detected in 13 and 6 specimens, respectively. M. pneumoniae
was not detected. 19 viral double infections (3.1%) were detected: in
10/19 double infections a human polyomavirus was involved, and in
8/19 cases a co-infection of HRV with another virus was found.
Conclusions: Nasopharyngeal sampling with ﬂocked swabs is well
tolerated and suitable to be used in an outpatient setting. Implementation
of real-time mono and multiplex NAATs results in a signiﬁcant
improvement of the rate in diagnosing LRTI. HRV account for the
majority of viral LRTI in primary care followed by inﬂuenza and
coronaviruses but also RSV and hMPV are prevalent in an adult
population. In this study, 19 polyomaviruses were detected of which
10 were involved in a double infection.
O128 PVL-SA as a cause of CAP in England: A review of cases
during 2008
A.M. Kearns °, M. Ganner, C. Perry, B.D. Cookson, M.J. Ellington
(London, UK)
Objectives: The association of Panton-Valentine Leukocidin-positive
Staphylococcus aureus (PVL-SA) with severe necrotising Community-
Acquired Pneumonia (CAP) is well recognised, with mortality rates of up
to 75% reported. Through the implementation of an initiative to enhance
the ascertainment for disease associated with PVL-SA nationally, we
sought to identify and characterise cases of CAP occurring in England
during 2008.
Methods: Isolates of S. aureus referred to the National Staphylococcus
Reference Unit from patients with suspected CAP were tested for
the PVL genes by PCR. All PVL-positive isolates were characterised
genotypically, including screening for additional toxin genes and mecA.
All MRSAs were also subjected to Pulsed-Field Gel Electrophoresis to
assist with assigning lineage. Patient demographic and clinical data were
sought in all microbiologically conﬁrmed cases.
Results: During 2008, 33 cases of CAP due to PVL-SA were identiﬁed
in England. Cases were sporadic in occurrence, and were geographically
and temporally dispersed. Patients were previously healthy; ages ranged
from 0 to 82 years (median 24 y); 17 (51.5%) were female. All
infections were community-acquired and most patients (24; 72.7%)
required admission to ICU. Twelve (36.4%) cases were fatal, half of
these died within 48 hours of admission to hospital. Airway bleeding
and raised CRP levels were common features; WCCs were variable
(range 0.5 to 28); Inﬂuenza A or B was conﬁrmed in 7 individuals.
The majority of PVL-SA (27; 81.8%) were susceptible to oxacillin, and
multiple lineages were identiﬁed (including clonal complexes 1, 8, 22,
25, 30, 80 and 121).
Conclusion: The propensity of PVL-SA to cause life-threatening disease
in young, previously healthy individuals is a public health concern. Based
on our experience, the mortality rate of PVL-related CAP (36.4%) was
lower than previously published data. The majority of infections were
caused by PVL-MSSA, no single lineage of S. aureus predominated.
To inform algorithms for prompt recognition and diagnosis of suspected
cases, and therapeutic strategies to improve patient outcomes, continued
vigilance is required at an international level.
O129 Biomarkers improve the ability of clinical scores to
predict intensive care unit admission in patients with
community-acquired pneumonia
W.C. Albrich °, P. Schuetz, M. Batschwaroff, M. Christ-Crain,
W. Zimmerli, H.C. Bucher, B. Mu¨ller (Aarau, Basel, Liestal, CH)
Objectives: A clinical prediction tool (SMART-COP), based on eight
clinical, laboratory and radiologic parameters, compared favourably
with the PSI and CURB65 scores to predict intensive respiratory and
vasopressor support in patients with community-acquired pneumonia
(CAP) (Charles et al. Clin Inf Dis 2008;47:375−84). We compared the
diagnostic accuracy to predict Intensive Care Unit (ICU) requirements
in CAP between clinical scores and biomarkers.
Methods: In patients with CAP enrolled in the Swiss multicentre Pro-
HOSP study, receiver operating characteristic curves (ROC) to predict
ICU admission were compared between the clinical scores SMART-COP,
PSI and CURB65 and the biomarkers Pro-Adrenomedullin (Pro-ADM)
and Endothelin-1 precursor peptides (Pro-ET1).
Results: In preliminary analysis, a SMART-COP score of3 was present
in 30 of 83 (36.2%) patients requiring ICU admission compared with
only 64 of 842 (7.6%) without ICU admission (p 0.0001). The ROC
values of ICU admission were highest for SMART-COP score (0.75, 95%
CI: 0.69−0.81), Pro-ET1 (0.73, 95% CI: 0.68−0.79) and Pro-ADM (0.72,
95% CI: 0.66−0.77), and lower for PSI score (0.68, 95% CI: 0.63−0.73)
and CURB65 score (0.64, 95% CI: 0.58−0.70). Combining Pro-ET1 and
the SMART-COP score (AUC=0.80, 95% CI: 0.75−0.85) in a combined
logistic model signiﬁcantly improved the diagnostic accuracy for ICU
admission over each individual predictor (p< 0.01, for each comparison).
To predict the outcome of death (n T50) and ICU admission or both (n
T118), the combination of Pro-ADM and the SMART-COP score was
signiﬁcantly better (AUC=0.80; p< 0.05 for each comparison) than any
predictor individually (AUC: Pro-ADM 0.72, SMART-COP 0.73, PSI
0.73, CURB65 0.68, Pro-ET1 0.73).
Conclusion: As biomarkers Pro-ADM and Pro-ET1 are prognostic
markers for a severe course of CAP, combining biomarkers and clinical
severity assessment tools might become useful measures for more
appropriately triaging CAP patients in an era of limited healthcare
resources. This hypothesis has to be tested in intervention studies.
O130 Pneumococcal pneumonia presenting with septic shock:
characteristics, outcomes, serotypes and genotypes
C. Garcia-Vidal °, C. Ardanuy, F. Tubau, D. Viasus, J. Lin˜ares,
F. Gudiol, J. Carratala` and CIBER de Enfermedades Infecciosas
Objectives: We aimed to ascertain the characteristics, outcomes,
serotypes and genotypes of pneumococcal pneumonia (PP) presenting
with septic shock.
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Methods: Observational analysis of a prospective cohort of 1041
nonseverely immunosuppressed adults with PP requiring hospitalisation
(1995–2008). Of them, 556 were diagnosed by urinary antigen and/or
650 were diagnosed by culture. Overall, 86% of pneumococcal strains
were available for serotyping (Quellung) and 58% for PFGE (Smal)
and or MLST. The diagnosis of septic shock was based on a systolic
blood pressure <90mmHg and peripheral hypoperfusion with clinical or
bacteriologic evidence of uncontrolled infection.
Results: A total of 114 (11%) patients with PP had septic shock at
presentation. Patients with shock were younger (61 vs 66 yrs; p = 0.003),
were more frequently current smokers (45% vs 28%; p = 0.002), had
received more commonly corticosteroid therapy (13% vs 6%; p = 0.015),
and were more frequently classiﬁed into high-risk PSI classes (81% vs
60%; p< 0.001) than those who did not have this complication. They
were also less likely to have received prior inﬂuenza vaccine (31% vs
48%; p = 0.007) and had more frequently bacteraemia (41% vs 30%;
p = 0.014). No signiﬁcant differences were found in rates of penicillin-
(2% vs 2%) and erythromycin-resistance (16% vs 12%). Serotype 3
was more commonly associated with shock (40% vs 24%; p = 0.007),
whereas serotype 1 was rarely associated with this complication (2%
vs 9%; p = 0.041). No signiﬁcant differences were found regarding
genotypes: ST2603 (26% vs 16%), Netherlands-ser8-ST53 (10% vs
3%), Netherlands-ser3-ST180 (10% vs 8%), Spain-ser9V-ST156 (10%
vs 12%). Patients with shock required more frequently mechanical
ventilation (38% vs 4%; p< 0.001), and had longer LOS (19 vs 10 days;
p< 0.001). Early (10% vs 1%; p< 0.001) and overall case-fatality rates
(25% vs 5%; p< 0.001) were higher in patients with shock.
Conclusions: PP presenting with septic shock is still associated with a
poor outcome. It occurs mainly in current smokers, patients receiving
corticosteroids, and in those infections caused by serotype 3. Prior
inﬂuenza vaccination and PP caused by serotype 1 are associated with
a lower risk of shock.
O131 High long-term mortality rate after initial recovery from
severe community-acquired pneumonia
A. Bruns, J.J. Oosterheert °, M. Cucciolillo, A. Hoepelman on behalf
of the SAT-P Study Group
Background: Despite the presence of antibiotics and vaccination
strategies against pneumocci, community-acquired pneumonia (CAP) is
still a major cause for mortality in developed countries. However, it
is unclear how an episode of CAP inﬂuences long-term survival after
initial recovery. Therefore, we determined mortality up to 5 years after
discharge in patients hospitalised because of an episode of severe CAP
in a non-intensive care setting.
Methods: In 5 hospitals in the Netherlands, patients (pts) with severe
CAP (PSI class IV and V without need for treatment in ICU) were
prospectively followed for 28 days and mortality up to 5 years after
discharge was determined using the Dutch Municipal Public Records
Database. We used Cox regression analysis to examine predictors for
mortality.
Results: 276 patients were included. 246/276 (89%) pts survived to
hospital discharge. Of those, 7 (3%) pts died in the ﬁrst month after
hospitalisation. Cumulative 1, 2, 3, 4 and 5-year mortality rates were
(n = 56) 23%, (n = 83) 34%, (n = 104) 43%, (n = 117) 48% and (n = 138)
56% respectively.
In a Cox model, pleural ﬂuid on chest X-ray on admission was
a strong predictor for mortality in the ﬁrst month after discharge
(Hazard ratio (HR) 12.6, 95%CI 2.45−65.00). Increasing age, (HR
1.04, 95%CI 1.02−1.05), arterial pH <7.35 on admission (HR 1.64,
95%CI 1.02−2.64), co-morbid malignancy (HR 1.78, 95%CI 1.24−2.56)
and liver disease (HR 4.46, 95%CI 1.38−14.40) were associated with
increased 5-year mortality.
Conclusions: After initial recovery from an episode of severe CAP,
5-year mortality rate is almost 60%. Factors associated with 5 year
mortality are mostly co-morbidity related and not pneumonia related.
Therefore, vaccination strategies are unlikely to increase long-time
survival in patients after an episode of severe CAP.
O132 Direct costs in adults with community-acquired pneumonia
in emergency clinical hospital
S. Ratchina °, E. Shal, I. Ustuzhanin, O. Asafjeva, Y. Vandenzhan
(Smolensk, RU)
Objectives: Community-acquired pneumonia (CAP) is a widespread
disease associated with a large economic burden, mostly due to inpatient
treatment. Identiﬁcation of determinants of health care costs could help
deﬁne strategies for efﬁcient use of existing resources. This study was
conducted to identify the direct hospitalisation costs of treating adult
patients with CAP in an emergency clinical hospital of RF.
Methods: A prospective observational study was performed in patients
admitted to a hospital ward between July 2006 and December 2007 with
conﬁrmed diagnosis of CAP. Direct medical costs (year 2007 values,
calculated in Russian rubles and converted to Euros) of infection-related
hospital resources, including hotel cost, laboratory tests, diagnostic
procedures, treatment (antibacterial therapy, adjunctive medical treatment
and nondrug therapy) were analyzed.
Results: A total of 127 patients aged from 16 to 87 years (mean age
51.3±17.7 years), 91/127 (71.7%) males, were enrolled. Complications
were diagnosed in 88/127 (69%) and concomitant diseases in 105/127
(83%) of patients; 46/127 (36.2%) received antibacterial treatment before
admission. Severe CAP was diagnosed in 26/127 (20.5%) of cases;
in total 3/127 patients died. Mean ±SD length of hospital stay was
13.4 ± 4.1 days. The median (interquartile range) total hospital cost
was €273 (€224–317); the distribution of each component was as
follows: hotel cost €107 (€92–122); laboratory tests €40 (€34−52),
diagnostic procedures €36 (€23−50), antibacterial therapy €56 (€32−90),
non-antibacterial medical treatment €11 (€6−20), non-drug therapy €2
(€0−6).
Conclusion: Major determinants of direct costs in hospitalised adults
with CAP were hotel cost due to prolonged hospital stay and antibacterial
therapy. They should be considered as key components for further
analysis and intervention programs.
O133 Anti-pneumococcal polysaccharide antibody proﬁles during
community-acquired pneumonia
G.T. Rijkers °, E. van Hannen, S. Meijvis, D. van Kessel, H. Endeman,
D.H. Biesma, J.C. Grutters, B.J. Vlaminckx, H. van Velzen-Blad
(Nieuwegein, Utrecht, NL)
Objectives: Streptococcus pneumoniae and Haemophilus inﬂuenzae are
the main causative micro-organisms of community acquired pneumonia
(CAP). We were interested to ﬁnd out whether natural exposure to
S. pneumoniae would lead to a systemic, serotype-speciﬁc antibody
response. As a secondary aim we studied whether changes in
pneumococcal antibody levels could be used as an additional diagnostic
tool for CAP patients in which the causative micro-organism could not
be identiﬁed.
Methods: In the St. Antonius Hospital, Nieuwegein, the Netherlands, we
have conducted a prospective study in which 200 consecutive patients
above 18 years of age with CAP hospitalised in the period October 2004–
August 2006 were included. Plasma samples were obtained at day 1
(= day of admission), day 2, 3, 5, 10 and 30 and stored at −80ºC. In
60 patients, S. pneumoniae was identiﬁed as causative micro-organism,
H. inﬂuenzae in 7%. In 28% of patients other micro-organisms were
identiﬁed and in 36% the cause of CAP remained unknown. As control
populations for the S. pneumoniae CAP patients, age and Fine-score
matched patients with CAP from the same cohort but with another
micro-organism as causative agent or with an unknown cause were
used. A number of patients with an S. pneumoniae CAP was, after
recovering from the disease, vaccinated with the 23-valent pneumococcal
polysaccharide vaccine. Antibodies were also be determined in the post-
vaccination samples. Pneumococcal antibodies against serotypes 1, 3, 4,
6B, 7F, 8, 9N, 9V, 12F, 14, 18C, 19A, 19F, and 23F were determined
with the XMAP Pneumococcal Immunity Panel (Luminex Inc. Austin
TX USA).
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Results: Preliminary data indicate that in most but not all patients with
pneumococcal CAP, serum IgG antibodies to the causative pneumococcal
serotype increase between 10 to 30 days after onset of disease. Antibody
levels to other serotypes do not change during the course of CAP.
Conclusions: Multiplex serotype-speciﬁc antibody determination can
monitor (the kinetics of) the antibody response to causative pneumococci
in CAP.
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O134 Cost-effectiveness analysis of universal rapid screening
for methicillin-resistant Staphylococcus aureus at hospital
admission
A. Murthy °, G. De Angelis, D. Pittet, J. Schrenzel, S. Harbarth
(Geneva, CH)
Objective: Policy-makers have called for universal screening on
admission to reduce nosocomial MRSA infection. Risk-proﬁling tools
and rapid PCR tests are now available and have been evaluated in
controlled trials. However, data on the cost-effectiveness of rapid MRSA
screening is limited. This study aimed to assess the cost-effectiveness of
such screening.
Methods: A decision analytic Markov model from the hospital
perspective compared costs and effects of 3 control strategies: (1)
rapid PCR screening; (2) screening for risk-factors (hospitalisation
or antibiotics within past year) plus pre-emptive isolation & contact
precautions pending chromogenic agar screening results; (3) no
screening. Data, taken from clinical trials at a Swiss teaching hospital
and published literature, included test turn-around-time & performance,
MRSA cross-transmission, isolation & contact precaution efﬁcacy, and
prevalence of colonisation on admission. Costs, derived from hospital
accounting systems, included tests, laboratory & staff time, surgical bed-
days, contact precautions, decolonisation and MRSA infection.
Results: Compared to strategy 2, strategy 1 resulted in slightly higher
costs (CHF 8,748 vs. 8,981) but fewer infections (.008 vs. 0.006)
during patients’ mean length-of-stay, producing an incremental cost-
effectiveness ratio (ICER) of CHF 83,303 per MRSA infection avoided.
Strategy 3 was dominated by strategies 1 and 2 (both more costly and less
effective). Sensitivity analyses suggest that prevalence of colonisation on
admission is a stronger predictor of cost-effectiveness than the costs of
infection or rapid screening, the probability of cross-transmission, or
the incremental costs of isolation and contact precautions. Increasing
the relatively low on-admission prevalence at our centre by 20% lowers
the ICER to CHF 60,973 per infection avoided. In contrast, increasing
the cost of each infection, the cost of rapid screening, or the risk of
cross-transmission by 20% only marginally affects the ICER.
Conclusion: This analysis suggests that compared to risk factor
identiﬁcation and pre-emptive isolation, universal rapid screening upon
surgical admission is not strongly cost-effective at our centre. However,
local epidemiology plays an important role. In particular, settings with
higher prevalence of colonisation on admission may ﬁnd universal rapid
screening more cost-effective. Of note, no screening is undesirable, as
costs and infections would be higher.
O135 Model-based assessment of the effectiveness and cost-
effectiveness of methicillin-resistant Staphylococcus aureus
infection control programmes in the intensive care unit
J. Robotham °, A. Barnett, N. Graves, B. Cookson, J. Wilson, B. Cooper
(London, UK; Brisbane, AU)
Objectives: To provide model-based assessments of the effectiveness
and cost-effectiveness of methicillin-resistant Staphylococcus aureus
(MRSA) infection control programmes in intensive care units (ICUs),
with a particular emphasis on comparing currently available screening
technologies.
Methods: Screening technologies evaluated included conventional
culture, chromogenic agar and polymerase chain reaction (PCR) based
systems. Estimates of sensitivity, speciﬁcity and turnaround time were
obtained from the literature. A dynamic stochastic individual-based
model of MRSA transmission in the ICU was developed to enable
the comparison of different policies. Model calibration was performed
by synthesizing evidence from multiple sources including longitudinal
MRSA surveillance data, published literature and formally elicited expert
opinion. The model was then used to assess changes in health beneﬁts
and resource use associated with different policies.
Results: Admission and weekly screening coupled with patient isolation
was found to dramatically reduce the number of MRSA acquisitions.
The largest reductions were obtained with PCR technology, followed
by chromogenic agar. The differences, however, were surprisingly
small, and all screening technologies achieved reductions in MRSA
acquisition of close to 80% compared with the no-intervention scenario.
Nonetheless, chromogenic and PCR-based systems were able to decrease
the number of unisolated MRSA-bed-days by approximately 15 and 35%
respectively.
Conclusions: The small differences in the ability of the screening
technologies to reduce MRSA acquisition reﬂect both a relatively low
estimated isolation efﬁcacy and the observed highly skewed distribution
of ICU-stays, and may provide some important insights into the reasons
for recent disappointing trial results. In particular, the skewed length
of stay distribution means that most MRSA-bed days are accounted for
by relatively long-stay patients for whom rapid detection will make the
least difference. Key sources of uncertainty were found to be isolation
effectiveness and attributable mortality due to MRSA infections, both of
which are difﬁcult to accurately estimate with currently available data.
The model results allow us to quantify the expected value of reducing
these key uncertainties, and help to provide a rational basis for setting
future research priorities.
O136 Infection control practices associated with methicillin-
resistant Staphylococcus aureus rates of 116 German hospitals
I.F. Chaberny °, F. Schwab, A. Cohrs, M. Behnke, P. Gastmeier
(Hanover, Berlin, DE)
Background: The German guideline for MRSA infection control was
published in 1999. Despite these recommendations a continuous increase
of MRSA could be observed in hospitals.
Objectives: To test the hypothesis whether the recommendations were
not adequately implemented or whether they were insufﬁcient to prevent
MRSA spread.
Methods: This study analyzed MRSA prevention measures in MRSA
KISS hospitals by the use of a questionnaire. Then, a validation study
was performed by local side visits. The prevention measures and
structure parameters were associated with the MRSA incidence densities
in a multiple logistic regression analysis.
Results: In 2007, a questionnaire was sent via internet to 145 MRSA
KISS hospitals. 134 completed forms were retrieved and analyzed.
A random sample of 35 hospitals was created for validation. After
visiting and validating these hospitals, the data of 116 hospitals were
used for further analysis. Hospitals with the main focus on transplant
medicine (OR 8.1; CI95 1.8−36.1; p = 0.006) and hospitals, which have
implemented an admission MRSA screening in at least one ICU in
addition to standard screening (known MRSA patients and roommates),
(OR 2.9; CI95 1.17−7.4; p = 0.031) were associated with the highest
incidence of MRSA case-patients per 1,000 patient days. The hospitals
with transplant medicine (OR 8.0; CI95 1.7−38.4; p = 0.01) and the
hospitals with an admission screening on at least one ICU (OR 4.8;
CI95 1.7−12.9; p = 0.002) showed a high incidence of nosocomial MRSA
case-patients per 1,000 patient days (>75th percentile); a decolonisation
procedure with mupirocin nasal ointment and antiseptic body wash was
protective (OR 0.3; CI95 0.1−0.9; p = 0.023).
Conclusion: This study highlighted signiﬁcant associations between
MRSA incidence densities and various prevention measures. However,
due to the uncertain cause-effect relation between screening frequencies
and infection rates it remains difﬁcult to evaluate the real inﬂuence
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of intensiﬁed screening activities. The results of this study conﬁrm
decolonisation procedures as a protective factor.
O137 Methicillin-resistant Staphylococcus aureus in nursing
homes: can an improvement in infection control practices
decrease MRSA prevalence?
N. Baldwin, D. Gilpin °, C. Hughes, P. Kearney, C. Cardwell,
M. Tunney (Belfast, Antrim, UK)
Objectives: We have shown that there is substantial colonisation of
MRSA among nursing home residents and staff with our recently
conducted point prevalence study in 45 nursing homes which revealed an
overall prevalence rate of 24% in residents and 7.6% in staff.1 The aim
of this study was, therefore, to test the effectiveness of an intervention
in nursing homes which sought to improve standards of infection control
as a means of reducing MRSA prevalence.
Methods: A cluster randomised controlled trial (cRCT) involving 32
nursing homes, with each home representing the unit of analysis, was
performed. The study ran for 12 months with data collected at baseline,
3, 6 and 12 months. Nasal swabs were taken at baseline from consenting
residents and staff in all homes prior to randomisation with an audit
of infection control procedures also undertaken. Following collection of
these baseline data, nursing homes were allocated to the intervention
or control arm (1:1). Intervention home staff were trained in infection
control, speciﬁcally hand hygiene, catheter care, barrier approaches
such as use of gloves, aprons and masks, and decontamination of
equipment and the environment with usual practice continuing in control
homes. After each data collection timepoint, feedback was given to
the intervention homes in terms of their performance and further
education and training provided as required. The primary outcome was
the prevalence of MRSA in intervention homes compared to control
sites.
Results: Preliminary analysis of the data has revealed no signiﬁcant
change in the prevalence of MRSA in the intervention and control homes,
taking account of the clustering, over the one-year intervention period
[risk ratio 0.83; 95% conﬁdence intervals (CI) 0.53−1.29]. However,
there was an improvement in infection control audit scores in the
intervention homes, with a mean score in control homes at 12 months
of 64.4% compared with 81.7% in the intervention sites; these scores
were signiﬁcantly different (paired t-test, p< 0.0001).
Conclusions: The results suggest that infection control education and
training as implemented in this study was not sufﬁcient to affect MRSA
prevalence. Therefore, a more detailed education and training package
either alone or in combination with MRSA decolonisation of staff and
residents, may be required to reduce MRSA prevalence within this
unique environment.
Reference(s)
[1] Baldwin NS et al. Clinical Microbiology and Infection. 2008; 14:
S416.
O138 Psychological impact of short-term isolation for infection
control
M. Wassenberg °, D. Severs, M. Bonten (Utrecht, NL)
Objectives: In a response to the rapid global increase in the
nosocomial prevalence of multi-resistant micro-organisms, infection
control measures, such as patient isolation, are increasingly used. It
is unknown how these measures inﬂuence the quality of life (QOL)
of patients during short-term isolation, and this was determined in a
prospective matched cohort study.
Methods: All adult patients needing isolation in a single-patient room
between 11/06 and 03/07 in the UMC Utrecht were eligible and included
24−48 hours after start of isolation (after giving informed consent
and being able to fulﬁl study requirements). For each index patient
we identiﬁed two control patients, admitted to the same wards at the
same time, yet not subjected to any isolation measure. Anxiety and
depression and QOL were assessed using the Hospital Anxiety and
Depression Scale (HADS) and Visual Analogue Scale (EQ-5D-VAS) in
all patients. Opinions on and experiences with isolation were measured
in isolated patients by means of a self-developed ‘isolation evaluation
questionnaire’.
Results: 42 isolated patients and 84 controls were included, with
comparable baseline characteristics (age, sex, nationality, level of
education, length of hospital stay and severity of underlying disease
and co-morbidity (using the Cumulative Illness Rating Scale)). Reasons
for isolation were clostridium difﬁcile-associated disease (n = 17, 40%),
high risk for MRSA carriage (n = 12, 29%), or resistant Gram-negative
bacteria (n = 7, 17%). Mean scores of questionnaires are presented in
table 1. isIn univariate analysis only duration of isolation of 48 hours
(compared to 24 hours) was associated with a reduced quality of life
(VAS 57.7 compared to 68.7, p 0.02). On a visual analogue score of
opposite terms isolation measures were rated with means of 87.5, 83.3
and 70.8 for safety, usefulness and quietness, respectively.
Conclusion: Short-term isolation (up to 48 hours) is not associated
with anxiousness or depression, but with positive feelings about safety,
usefulness and quietness.
HADS-A HADS-D HADS-total VAS
Index patients (n = 42), mean (SD) 4.7 (3.5) 5.3 (3.5) 9.9 (6.0) 62.3 (15.5)
Control patients (n = 84), mean (SD) 5.4 (3.7) 5.2 (3.6) 10.6 (6.5) 63.0 (15.3)
p-value 0.61 0 90 0.31 0.64
O139 The burden of healthcare-associated infection: the patient
experience
E. Burnett °, K. Lee, R. Rushmer, M. Ellis, M. Noble, P. Davey
(Dundee, UK)
Objectives: There is a lack of data about the impact of Healthcare
Associated Infection (HAI) on the experience of individual patients. This
information is essential to empower health organisations to understand,
prioritise, develop and implement solutions that will minimise risks to
patients. This study explored comparable narratives from patients who
had experienced a Staphylococcus aureus blood stream infection with
patients who had not.
Methods: We conducted qualitative semi-structured interviews with
eighteen adults who had previously been an in-patient in an acute
teaching hospital in Scotland. Nine patients had had a laboratory
diagnosed Staphylococcus aureus blood stream infection and nine had no
blood stream infection. All patients were interviewed for 20−40 minutes.
The interviewer asked patients about their thoughts around HAI, what
concerns they had or still do, what measures they took to safeguard
themselves from HAI and how their experience impacted on their
conﬁdence of the NHS. Probing questions were then asked depending on
the responses given to the initial questions. All interviews were recorded,
transcribed and analysed thematically.
Results: Analysis of transcribed interviews is ongoing. Preliminary
analysis showed that all patients had positive and negative comments
about infection prevention and control practice in the hospital. Speciﬁc
concerns included poor communication, poor cleanliness, awareness of
patient boarding, lack of facilities, staff shortages and multi-tasking.
Some patients who had experienced bacteraemia said they had not been
informed about the infection. Those who had been informed were not
given clear information about treatment or subsequent results. Most
patients were not speciﬁcally told what they or their family should do
to safeguard them from infection and little or no written information
about HAI was provided. Most patients are worried about HAI on future
admissions.
Conclusions: The concerns of patients were not fundamentally different
if they did or did not experience blood stream infection. The patient’s
reported experiences show that they have a broad awareness of systems
issues that may increase risk of infection. Consequently we need to
involve patients in the design and evaluation of systems change and
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information that will improve patient experience. Improving the safety
and reliability of the system will have direct beneﬁts for all patients in
the hospital, not just the ones at risk of HAI.
O140 The success and effectiveness of the world’s ﬁrst national
cleanyourhands campaign in England and Wales 2004–2008:
a prospective observational interrupted time-series
S. Stone °, C. Fuller, R. Slade, J. Savage, A. Charlett, B. Cookson,
B. Cooper, G. Duckworth, M. Murray, A. Hayward, A. Jeanes,
J. Roberts, L. Teare, J. McAteer, S. Michie (London, UK)
Objectives: The world’s ﬁrst national hand hygiene (HH) campaign
(cleanyourhands CYHC) targeting healthcare workers (HCW) was rolled
out in Jan-Jun 2005 to all acute hospitals in England & Wales. It
comprised: bedside availability of alcohol handrub (AHR); ward posters
endorsing HH; materials helping patients to ask HCWs to perform
HH; audit & feedback of HH compliance. An independent 4 year
study assessed its implementation, sustainability, & effects on HH and
Healthcare associated infection (HCAI).
Methods: CYHC implementation was assessed by 6-monthly question-
naires to 187 acute hospitals. Monthly procurement data for soap and
AHR acted as a proxy for HH compliance. National mandatory quarterly
HCAI data [meticillin resistant & sensitive S. aureus bacteraemia
(MRSAB & MSSAB) & C. difﬁcile infection] & bed occupancy
were collected for each hospital & data on potentially confounding
national interventions (Saving Lives, Department of Health Improvement
Team Visits & MRSA screening). Analyses: Generalised estimating
equation (population-averaged) models with an exchangeable within-
group correlation structure.
Results: 82% of all hospitals responded to the last questionnaire (June
2008). Even after 3 years, CYHC was still a top priority in 92%
of hospitals, with bedside AHR in most wards in 94%. Posters were
displayed in most wards by 96% of hospitals, with Audit & Feedback in
most wards in 86%. Patient Empowerment materials were less successful.
Procurement of AHR, but not soap, rose signiﬁcantly during CYHC roll
out, plateaued for a year, before rising continuously & signiﬁcantly, as
did soap, from mid 2006 (Figure). Combined soap & AHR procurement
tripled over the study period.
MRSAB rates halved (Figure) but no other HCAI fell. From July
2006-Dec 2007, each extra ml of AHR per patient-bed-day was
signiﬁcantly associated (p< 0.0001) with a 1% fall in MRSAB but this
association did not continue in Jan-Jun 2008. Specialist & Teaching
Hospitals (p< 0.001) & Improvement team visits (p = 0.004) were
strongly associated with MRSAB rates.
Conclusions: The CYHC is associated with a sustained change in
HH behaviour in acute hospitals nationally, with a three-fold rise
in procurement/use of AHR & soap. There appears to be a strong
association between reduction in MRSAB & use of AHR. This
may reﬂect interactions between improvement team visits or other
confounders & CYHC. The campaign should be continued & is a model
that other countries could adopt/adapt.
O141 Effect of peri-operative mupirocin and chlorhexidine on
mortality in nasal carriers of Staphylococcus aureus
M.M.L. van Rijen °, L.G.M. Bode, M.C. Vos, J.A.J.W. Kluytmans for
the STEP Study Group
Objectives: A multicentre double-blind randomised-controlled trial (M-
RCT), carried out in the Netherlands between October 2005 and June
2007, showed that hospitalised patients with S. aureus nasal carriage
who were treated with mupirocin nasal ointment and chlorhexidine
gluconate medicated soap (MUP-CHX), had a signiﬁcantly lower risk of
nosocomial S. aureus infections than patients receiving placebo (3.4%
vs. 7.7%, 95% CI 0.23−0.75). In this study the effect of MUP-CHX
on mortality in surgical patients with S. aureus nasal carriage was
determined.
Methods: Patients were followed for survival up to one year after
inclusion in the M-RCT. Mortality within one week after surgery was
excluded from the analysis, based on the assumption that nosocomial
S. aureus infection is unlikely to be the cause of death in these
cases. Sub-group analysis was performed for cardiothoracic surgery,
orthopaedic surgery, and for all other surgical specialties.
Results: In total, 799 surgical patients were included in the M-RCT. Two
patients were lost to follow up and ﬁve patients died within one week
after surgery. So, for mortality analysis 792 patients were included, i.e.
431 in the MUP-CHX group and 361 in the placebo group. Mortality
after one year in all surgical specialties combined was 4.6% (20/431) in
the MUP-CHX group vs. 7.5% (27/361) in the placebo group (p = 0.092).
Analysis of surgical specialties separately revealed a signiﬁcant reduction
of mortality in cardiothoracic surgery who had been treated with MUP-
CHX (2.3% (5/218) vs. 6.5% (11/170), p = 0.040, ﬁgure). In other
surgical specialties no signiﬁcant difference was found.
Conclusion: Peri-operative application of MUP-CHX in nasal carriers
of S. aureus undergoing cardiothoracic surgery results in a threefold
reduction of mortality after one year.
O142 A lot done, more to do − a survey of teaching about
healthcare-associated infections in UK and Irish medical
schools
H. Humphreys °, D. O’Brien, J. Richards, K. Walton, G. Phillips
(Dublin, IE; Norwich, Newcastle-upon-Tyne, Dundee, UK)
Objectives: Patient safety and the prevention of healthcare-associated
infections (HCAI) are increasingly important health issues. Medical
doctors have traditionally been poor in complying with preventative
measures to minimise HCAI such as hand hygiene compliance. We
surveyed medical schools in the UK and Ireland to assess what is being
taught and assessed in this area.
Methods: A questionnaire was drafted, piloted and then subsequently
forwarded to the heads of medical schools as well as to known contact
professionals with an interest in HCAI in 38 medical schools. The
questionnaire surveyed topics covered in the curricula, the modalities
used to assess knowledge and practice, the usefulness of various teaching
methods and materials, e.g. lectures, and what education resources were
available.
Results: Replies were received from 31 (82%) medical schools; two
supplied data on their undergraduate and postgraduate courses. Only
18 (60%) covered HCAI as a quality and safety issue but over
90% covered prevalence, recognised risk factors, transmission, and
preventative measures. 24 (80%) medical schools assessed competence
in undertaking aseptic techniques and the disposal of sharps and MCQs
S32 19th ECCMID, Oral presentations
were the most common (87%) means of assessment. Case scenarios,
resource materials and clinical skills stations were used in educating
students in 26 (87%), 22 (73%) and 22 (73%) medicals schools
respectively. 25 (83%) medical schools would be willing to share
educational resources on HCAI with other medical schools.
Conclusions: Medical schools in the UK and Ireland include HCAI in
their curricula but its importance as a safety and quality issue needs to be
further emphasized. There is potential for agreeing a core curriculum on
HCAI and for sharing teaching resources such as videos and e-learning
material.
O143 Modelling transmission and control of norovirus in
healthcare settings
Z. Sadique °, B. Cooper, J. Edmunds, B. Lopman (London, UK)
Objectives: Noroviruses are most common cause of outbreaks of
gastroenteritis in UK National Health Service hospitals, leading to ward
closure costing as much as £115 million per annum. Using a detailed data
set on norovirus outbreaks from three hospital systems in the South West
of England, we estimated (1) the relative importance of introduction of
norovirus from the community and within the hospital and (2) the cost
effectiveness of ward closure at different time points during an outbreak.
Methods: Using regression models we examined the association between
number of new outbreaks in a hospital and community levels of activity
and number of outbreaks currently occurring in other wards within the
hospital. We examined the effect of different ward types (admission,
general and long stay units) and whether the ward was open or closed to
new admissions on a given day. We then undertook as analysis of cost
(-effectiveness) of unit closure by developing a dynamic transmission
model taking into account that ward closure may reduce norovirus
transmission within and between wards. The stochastic simulation model
was based on the actual characteristics of an acute hospital and the
norovirus transmission parameters quantiﬁed in the statistical analysis.
We measured the costs and beneﬁts of closing affected wards at 1, 3 and
5 days after the onset of symptoms in the ﬁrst case.
Results: Community level of norovirus infection had a signiﬁcant effect
on the occurrence of new outbreaks as did outbreaks in admission and
general medical units. The cost of closing wards to new admissions
varied between £0.5 million to £0.9 million depending on the assumed
effectiveness of closure in curtailing transmission. Cost of bed day loss −
compared with staff illness – accounted for around 90% of the total cost
of closure. Although the total number of cases tends to fall with rapid
ward closure (by around 50% compared with no closure), the actual cost
of control is similar regardless of when the closure is performed.
Conclusion: We have developed a modelling framework to assess the
effectiveness and cost-effectiveness of strategies to control norovirus
outbreaks in hospital settings. Ward closure is effective at preventing
cases but since closure itself is an expensive intervention, it may not
always be cost-effective.
Clostridium difﬁcile
O144 Clindamycin resistance among Clostridium difﬁcile PCR
ribotype 027 in Scotland
D.J. Brown, C. Wiuff °, H. Mather, J. Coia (Glasgow, UK)
Objectives: To determine the susceptibility of Clostridium difﬁcile
PCR ribotype 027 isolates towards clindamycin and 8 other antibiotics
obtained from patients with CDAD in Scottish healthcare facilities, and
to compare resistance patterns to those of other prevalent ribotypes.
Methods: In Scotland testing for C. difﬁcile toxin is mandatory for
all patients aged 65 and over with diarrhoea. Since November 2007
culture of C. difﬁcile has been mandatory for all severe cases of CDAD
and/or cases from outbreaks. Isolates are typed centrally by the Scottish
C. difﬁcile Reference Laboratory using PCR ribotyping according to
the method of O’Neill et al. (1996). Isolates of PCR ribotype 027 were
susceptibility tested against 9 antibiotics using Etest (AB Biodisk, Solna,
Sweden). Breakpoints were derived from the Clinical and Laboratory
Standards Institute (CLSI) criteria and aligned with those used in
England and Wales.
Results: A total of 635 isolates of C. difﬁcile were obtained from
patients in healthcare facilities in Scotland in the period November
2007-October 2008. Of the 635 isolates 75 were PCR ribotype 027
(12%). Other prevalent ribotypes were 001 (25%) and 106 (36%).
76% of the 027 isolates originated from 5 hospitals located in 2
healthboard areas. The remaining 18 isolates of ribotype 027 originated
from 11 hospitals across Scotland. In vitro 96% of 027 isolates were
resistant to clindamycin with a MIC range of 8−24mg/L, MIC50
of 12mg/L and MIC90 of 16mg/L. Furthermore 100% of the 027-
isolates were highly resistant to erythromycin (MIC50 256mg/L,
MIC90 256mg/L), and to levoﬂoxacin and moxiﬂoxacin (MIC50
32mg/L, MIC90 32mg/L for both), while 65% of these isolates were
resistant to cefotaxime (MIC50=64mg/L, MIC90=96mg/L). All 027-
isolates were susceptible to metronidazole, vancomycin, meropenem and
piperacillin-tazobactam. High frequencies of clindamycin, erythromycin,
levoﬂoxacin, moxiﬂoxacin and cefotaxime resistance were also found
among isolates of ribotype 001 (90−99%) and 106 (94–100%).
Conclusion: Until 2008 C. difﬁcile ribotype 027 was only reported
infrequently in Scotland. In 2008, reports of ribotype 027 became more
frequent and clusters were detected in 5 hospitals. The majority (96%)
of ribotype 027 isolates were resistant to clindamycin. Three other
European countries have previously reported clindamycin resistance in
PCR ribotype 027, albeit with a higher MIC90 of >256mg/L.
O145 Trends in mortality due to Clostridium difﬁcile enterocolitis
in Brussels and Flanders, 1998–2006
I. Gutie´rrez °, M.L. Lambert, A. Kongs, D. Mazina, H. van Oyen
(Brussels, BE)
Objectives: To analyze trends in mortality due to Clostridium difﬁcile
enterocolitis and to describe the most affected groups in order to better
understand current Clostridium difﬁcile changing epidemiology.
Methods: We reviewed mortality data from the Flanders and Brussels
regions in Belgium (about 7 million inhabitants). We selected those
records in which ICD-10 code A04.7 (enterocolitis due to Clostridium
difﬁcile) appeared as underlying cause of death within the death
certiﬁcate. Age- and sex-speciﬁc mortality rates were calculated for
the period 1998–2006. Direct standardisation was performed using
the European standard population and 95% conﬁdence intervals were
calculated. Stata 10® and Excel® were used as statistical software.
Table 1. Standardised and crude ratesa of enterocolitis due to Clostridium difﬁcile as underlying cause of death in
Brussels and Flanders, 1998–2006
1998 1999 2000 2001 2002 2003 2004 2005 2006
Crude mortality rate 0.1 0.1 0.1 0.2 0.3 0.7 1.7 1.7 1.6
Standardised mortality rate 0.1 0.1 0.1 0.1 0.2 0.4 1.0 0.9 0.9
males standardised 0.1 0.1 0.2 0.1 0.1 0.4 0.9 0.9 0.9
females standardised 0.1 0.1 0.1 0.1 0.3 0.5 1.0 0.9 0.8
Age- and sex-speciﬁc mortality
Males <65 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.1
65−79 0.3 0.5 0.7 0.5 0.2 0.7 4.6 2.2 2.9
80 0.0 0.0 4.0 2.5 2.3 14.3 20.9 29.7 26.3
Females <65 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1
65−79 0.4 0.2 0.0 0.6 1.4 2.0 3.5 1.8 1.6
80 1.2 1.8 1.2 2.9 6.6 12.2 32.4 31.3 29.3
aRates are expressed as deaths per 100,000 population.
Results: Standardised mortality rate increased from 0.06 deaths per
100,000 persons in 1998 to 0.85 deaths per 100,000 persons in 2006.
A marked increase in mortality started in year 2002 (0.21 deaths per
100,000) and continued in 2003 and 2004 (0.43 and 0.95 deaths per
100,000).
In the age group of over eighty, crude mortality rate increased from 0.00
to 26.32 deaths per 100,000 persons for males, and from 1.16 to 29.31
deaths per 100,000 persons for females for the period 1998 to 2006.
Standardised mortality rates for men of 0.05 (CI 95%:0.03−0.08) to 0.90
(CI 95%:0.82−0.99) deaths per 100,000 persons, were similar to those
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for women, 0.06 (CI 95%:0.04−0.08) to 0.79 (CI 95%: 0.73−0.85) deaths
per 100,000 persons from 1998 to 2006.
Conclusion: Mortality due to Clostridium difﬁcile enterocolitis has
dramatically increased in Brussels and Flanders, mainly in the oldest
age group during the period 1998–2006. We did not ﬁnd signiﬁcant
differences between sexes. Further studies should address the causes of
the described increase in mortality by Clostridium difﬁcile.
O146 Contamination of a public tap water distribution system and
possible water-borne transmission of Clostridium difﬁcile
S. Kotila °, T. Pitka¨nen, A. Virolainen, E. Ko¨no¨nen, M. Kuusi,
I.T. Miettinen, E. Eerola, R. Vuento, J. Brazier (Helsinki, Kuopio,
Turku, Tampere, FI; Cardiff, UK)
Objectives: Toxigenic Clostridium difﬁcile is an enteric pathogen typical
in the hospital environment but also community-acquired cases have
been reported. However, relatively few attempts have been made to
clarify the role of soil or water as a source of C. difﬁcile infection.
In November-December 2007, the drinking water distribution system in
the town of Nokia, Finland was massively contaminated with treated
sewage efﬂuent resulting in a large gastroenteritis outbreak. The aim of
the present study was to evaluate if contaminated water in this outbreak
was also a potential source of C. difﬁcile infection.
Methods: A sample from the contaminated tap water and a treated
sewage efﬂuent sample were collected as soon as possible after the
massive faecal contamination of the drinking water distribution system
had occurred. C. difﬁcile was isolated from heat-treated water samples
by ﬁltrating of 100ml, 10ml and 1ml volumes of water and placing the
membranes on selective CCEY agar plates, which were anaerobically
incubated for 3 d. Stool samples from the patients fallen ill during the
epidemic were examined for enteric pathogens, including C. difﬁcile.
All potential C. difﬁcile colonies were subcultured on CCFA agar plates
and toxin-positive isolates were identiﬁed by PCR. PCR ribotyping was
performed according to the protocol of the Anaerobe Reference Unit
in Cardiff, UK, using the Cardiff-ECDC culture collection as a set
of reference strains. After gel electrophoresis, the band patterns were
analyzed using the BioNumerics software.
Results: Altogether 22 C. difﬁcile isolates were found in water samples.
Twelve isolates were toxin-positive; 5 isolates were from contaminated
tap water and 7 isolates from treated sewage efﬂuent, the latter being the
contamination source. Among the tap water and sewage efﬂuent isolates,
4 and 5 distinct PCR ribotype proﬁles were identiﬁed, respectively. The
9 human faecal C. difﬁcile isolates detected were divided into 4 distinct
PCR ribotype proﬁles. None of the proﬁles were identical with that of the
hypervirulent PCR ribotype 027. Two isolates, one from tap water and
another from a patient, had an indistinguishable PCR ribotype proﬁle.
Conclusion: Our observation implies that C. difﬁcile contamination of a
tap water distribution system had occurred. Waterborne transmission of
toxigenic C. difﬁcile and subsequent C. difﬁcile infection seems possible.
O147 Typing of Clostridium difﬁcile strains with an automated
repetitive PCR system in comparison to PCR ribotyping
T. Pasanen °, S. Kotila, S. Mero, J. Antikainen, E. Tarkka, E. Eerola,
J. Jalava, A. Virolainen-Julkunen, E. Ko¨no¨nen, M. Vaara, P. Tissari
(Helsinki, Turku, FI)
Objectives: An accurate and rapid method is needed for typing of
toxigenic Clostridium difﬁcile. A commercial automated repetitive PCR
system (rep-PCR; DiversiLab®, Biome´rieux Inc., St Louis, USA) utilises
ampliﬁcation and subsequent automated electrophoretic separation of the
repetitive extragenic palindromic sequences of C. difﬁcile. Our aim was
to evaluate the performance of this rep-PCR method for genotyping of
C. difﬁcile isolates and to compare it to PCR ribotyping. In addition,
the correlation between the rep-PCR and the virulence gene proﬁles of
C. difﬁcile strains was studied.
Methods: A total of 195 toxin-positive C. difﬁcile isolates were studied.
We included consecutive isolates from two laboratories in Finland,
containing also strains of the hypervirulent C. difﬁcile ribotype 027.
In addition, selected C. difﬁcile strains with >18 bp deletions in their
tcdC genes were analyzed.
The DNA was extracted and the rep-PCR performed according to the
manufacturer’s instructions. The ampliﬁcation products of rep-PCR were
detected and analyzed using the DiversiLab system. Further analysis was
performed with the web-based software accompanying the system. The
usefulness of the library construction option of the DiversLab system for
isolate comparison was tested. The virulence genes (tcdA, tcdB, cdtA,
cdtB and tcdC) were analyzed by conventional PCR and the whole gene
sequencing of tcdC was performed from isolates with deletions >18 bp.
PCR ribotyping was performed using the protocol of the Anaerobe
Reference Unit in Cardiff, UK.
Results: The correlation between the rep-PCR proﬁle and the ribotype
was excellent. All major ribotype groups were clustered in their own
rep-PCR groups. Interestingly, subgroups could be found with rep-PCR
within two most prevalent ribotypes 001 and 027.
The automated rep-PCR proved to be reproducible; the results from
separate DNA isolations and PCR-runs/microﬂuid electrophoresis as well
as the results performed by different individuals of laboratory personnel
were comparable. The rep-PCR proﬁles and PCR ribotypes correlated
also with the virulence gene proﬁles.
Conclusion: This automated rep-PCR represents an effective and
reproducible method for the genetic characterisation of C. difﬁcile strains
in clinical laboratories with molecular biology facilities. The constructed
C. difﬁcile library allows comparing the relatedness of C. difﬁcile strains
and their ﬁngerprints over time.
O148 A randomised, double-blind clinical trial of OPT-80 versus
vancomycin in Clostridium difﬁcile infection
T.J. Louie °, K.M. Mullane, K. Weiss, A. Lentnek, Y. Golan, S. Gorbach,
P. Sears, Y.K. Shue, M.A. Miller (Alberta, CA; Chicago, US; Montreal,
CA; Marietta, Boston, San Diego, US)
Objectives: Clostridium difﬁcile infection (CDI) is a serious diarrhoeal
illness associated with high morbidity and mortality. Currently available
treatments (oral vancomycin or metronidazole) usually produce good
resolution of diarrhoea but are associated with a 20% to 30% incidence
of recurrence. OPT-80, the ﬁrst in a new class of macrocyclic antibiotics,
is bactericidal via unique inhibition of RNA polymerase. This phase 3,
non-inferiority clinical trial was conducted in more than 100 sites in
North America and compared the efﬁcacy and safety of OPT-80 and
vancomycin in treating CDI.
Methods: Eligible patients were adults with acute CDI symptoms and
a positive stool toxin test. Patients received oral OPT-80 (200mg twice
daily) or oral vancomycin (125mg 4 times daily) for 10 days. Primary
end point was clinical cure (resolution of symptoms and no further need
for CDI therapy 2 days after stopping study drug). Secondary end point
was CDI recurrence (diarrhoea and positive stool toxin test within 4
weeks after treatment). Global cure was deﬁned as a clinical cure with
no recurrence.
Results: 629 patients were enrolled and 87% were evaluable. In the
per protocol (PP) population (n = 548), mean age was 61.3±17.1 years
and 44.0% of patients were male. Equivalent rates of clinical cure were
observed with OPT-80 (92%) and vancomycin (90%) in the PP analysis;
similar outcomes were observed in a modiﬁed intent-to-treat (mITT)
analysis. Signiﬁcantly fewer patients treated with OPT-80 (13%) than
vancomycin (24%) experienced recurrence in the PP analysis (P = 0.004)
and in the mITT analysis (15% vs 25%; P = 0.005). Signiﬁcantly more
OPT-80-treated patients achieved global cure (78%) than vancomycin-
treated patients in the PP analysis (67%; P = 0.006) and in the mITT
analysis (75% vs 64%; P = 0.006). OPT-80 was well tolerated with an
adverse event proﬁle similar to that of vancomycin.
Conclusions: In this study – the largest comparative trial of a new
antimicrobial agent versus vancomycin for the treatment of CDI – clinical
cure rates after treatment with OPT-80 or vancomycin were equivalent.
However, OPT-80 was associated with a signiﬁcantly lower recurrence
rate and a higher global cure rate than vancomycin. OPT-80 is an oral,
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non-absorbed agent that has a convenient (twice daily) dosing schedule
and low risk of adverse events. OPT-80 represents a potential new
treatment option for CDI that is associated with a lower recurrence rate
than currently available treatments.
OPT-80
(200mg bid)
Vancomycin
(125mg qid)
P-value 95%CI
Per Protocol Analysis
Clinical cure, % (n/N) 92.1% (244/265) 89.8% (254/283) NA −2.6, a
Recurrence, % (n/N) 13.3% (28/211) 24.0% (53/221) 0.004 −17.9, −3.3
Global cure, % (n/N) 77.7% (206/265) 67.1% (190/283) 0.006 3.1, 17.9
Modiﬁed Intent-to-Treat (mITT) Analysis
Clinical cure, % (n/N) 88.2% (253/287) 85.8% (265/309) NA −3.1, a
Recurrence, % (n/N) 15.4% (39/253) 25.3% (67/265) 0.005 −16.6, −2.9
Global cure, % (n/N) 74.6% (214/287) 64.1% (198/309) 0.006 3.1, 17.7
aOne-sided 97.5%CI.
CI, conﬁdence interval; NA, not applicable (non-inferiority end point was met).
O149 Tackling Clostridium difﬁcile at Kingston hospital − a case
study
J. Yang °, S. Furrows, H. Lo, A. Jones, F. Brooke-Pearce, K. Lyons
(London, UK)
Objectives: Kingston Hospital is a general hospital in London and, in
common with acute Trusts, sees a number of cases of C. difﬁcile toxin
(CDT) associated disease.
The objective of the audits of CDT conducted in 2007 and 2008
was to develop a better understanding of CDT infections at Kingston
Hospital: to investigate antibiotic prescribing, to understand the risk
factors associated with CDT, to determine if CDT patients are treated in
accordance with Trust guidelines and to study CDT-related mortality.
Methods: Both samples included all patients with a CDT positive stool
sample in May-July 2007 and March-May 2008. Patient demographics,
medical history and information on the CDT episode were collected
retrospectively from medical notes, drug charts and multidisciplinary
forms. Double entry ensured data quality. When relevant, consultant
opinion on cause of death and information on the death certiﬁcate were
compared.
Results: In 2008, 26% of CDT patients had diarrhoea on admission
compared to 36% in 2007.
The mean time between diarrhoea onset and CDT diagnosis was 2.5 days.
85% diagnosed patients were seen every day or every other day by
a doctor. 89% cases were discussed with Microbiology. Proton pump
inhibitor prescribing decreased from 63% in 2007 to 48% in 2008.
96% patients took antibiotics during the 3-month period before
developing CDT. Cephalosporins were prescribed for 19% patients,
compared to 37% in 2007. Ciproﬂoxacin was not prescribed at all,
compared to 45% patients prescribed ciproﬂoxacin in 2007 (p = 0.001,
df=1). All patients were treated for CDT according to Trust guidelines.
In 2007, the percentage of patients with CDT who died was 40%
and this dropped to 30% in 2008. However, according to Consultant
opinion, CDT was only a deﬁnite/probable case of death in 3.7% patients.
Consultant opinion on the death and information available on the death
certiﬁcate differed in 4 out of the 8 patients who died.
Conclusion: The 2007 audit led to the implementation of an action plan
and CDT rates gradually decreased in 2007−08. There was a marked
improvement in antibiotic prescribing and in CDT treatment. These
results are due to enhanced cleaning, a restricted antibiotic policy, a
new isolation policy, an integrated care pathway for CDT, a new policy
for management of CDT, new equipment, improved staff education and
regular auditing.
In 2008, Kingston Hospital was one of only ﬁve Trusts out of 51 in
England to be fully compliant with the Health Act.
O150 Optimisation and application of a multi-locus variable
tandem repeat analysis for Clostridium difﬁcile ribotype 078,
toxinotype
D. Bakker °, J. Corver, C. Harmanus, W. Fawley, M. Wilcox,
E.J. Kuijper (Leiden, NL; Leeds, UK)
Background: Recently, we reported an increase in C. difﬁcile infection
(CDI) caused by PCR-ribotype 078 (Type 078) in the Netherlands.
C. difﬁcile Type 078 is also the predominant ribotype in cattle. To
investigate the relatedness between human and animal strains we
optimised a Multi Locus Variable tandem repeat Analysis (MLVA)
developed for Type 027, for type 078. MLVA was applied on 54 Type 078
strains of human (n = 43) and porcine (n = 11) origin, and on a further
67 human Type 078 isolates obtained in 2007−8 from England (E) and
N. Ireland (NI).
Methods: Sequencing of the MLVA loci originally described for type
027 by van den Berg et al, J Clin Microbiol. 2007) was done in 15
type 078 strains, both human and porcine origin using primers in the
adjacent ORFs. The Variable Number Tandem Repeats (VNTR) was
determinate by manual examination of the sequence data. PCR products
sizes were analyzed with ABI 3100 sequence analyzer and the VNTR
were calculated from the PCR product sizes. To validate the calculated
VNTR we compared it with the manual analyzed VNTR sequence data.
Finally, we applied the optimised MLVA on all available type 078 strains
which were previously tested with a ﬁrst generation MLVA.
Results: Sequence analysis (SA) revealed that locus A is absent in Type
078 and that some mismatches are present in the primer annealing
sites for loci B, C and G. Lowering the annealing temperature and
increasing the magnesium chloride concentration for loci B, C and G
resolved the low yield of PCR products. Applying the MLVA on 54
type 078 strains revealed that 42 (80%) strains, encompassing isolates
from human (n = 42) and porcine (n = 11) origin, are genetically related
with a summed tandem repeat differences (STRD) 10). Three clonal
complexes (CC, deﬁned by STRD 2) were recognized; one CC
contained both human (n = 4) and porcine (n = 3) strains. The optimised
MLVA identiﬁed 3 genetically related clusters and 6 CC among the 67
isolates from E and NI. CCs contain isolates from more than one hospital
and indeed for several clusters isolates from both E and NI. 2 isolates
obtained from NI 8 years earlier were part of one large CC.
Conclusions: The optimised MLVA can distinguish and/or group Type
078 strains from distinct settings. Type 078 strains from human and
animal origin are genetically related. The clustering of some isolates
from distinct settings is consistent with community sources for Type
078. The last 2 observations suggest zoonotic transmission.
O151 Community-associated Clostridium difﬁcile infection: an
analysis of cases reported to the English NHS mandatory
surveillance system from April 2007 to September 2008
A. Pearson °, R. Guy, R. Blackburn, R. Mandalia, J. Davies, M. Murray,
S. Batley, B. Duerden, J. Giltrow, M. Painter, M. Fleming (London, UK)
Objectives: This paper updates our assessment of the contribution that
community-associated Clostridium difﬁcile infection (CDI), as reported
to the English mandatory surveillance scheme since 2007, makes to both
the acute and community sectors of the National Health Service (NHS)
in England.
Methods: NHS acute Trusts (hospital groups) in England are required
to report all C. difﬁcile toxin positive diarrhoeal specimens processed by
their laboratories whether the patients were in hospital or the community
at the time of onset of the illness or when the specimen was taken via a
web enabled reporting system. Positive specimens from the same patient
within 28 days are not reported. Reported cases in patients under 2 years
of age were omitted from this analysis.
Enhanced surveillance data (including information on date of admission,
patient location prior to testing, sex, age and patient category) on CDI
have been collected through a web-enabled reporting system since April
2007. Risk factor information is completed on a voluntary basis.
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Results: More than 75,000 cases of CDI in patients aged >2 years were
reported, 23% of these cases were taken in non-acute settings of which
74% were taken by a General Practitioner. A further 17% of specimens
were taken on presentation or <2 days of admission into an acute Trust.
Approximately 32% of all cases had at least one risk factor ﬁeld
completed, >19,000 cases reported risk factor information on episode
category; 23% of these cases were community associated and 77% were
hospital acquired. The information reported suggests that only 3% of the
community associated cases were from patients with continued infection
or relapsed episodes of CDI, this is compared to 8% of the hospital
acquired cases who had continued infection or relapsed episodes of CDI.
Conclusions: 23% of the C. difﬁcile specimens reported by acute Trusts
were diagnosed in a community setting. Published studies suggest that
12−15% of these might be expected to have been acquired during a
hospital stay within the previous month (i.e. were community onset
hospital acquired cases). Future work is required to investigate whether
there are differences in the epidemiology, risk factors e.g. antibiotic
exposure and outcome of patients with community onset disease.
O152 Clostridium difﬁcile-associated disease: a newly notiﬁable
disease in Ireland
M. Skally, F. Roche, D. O’Flanagan, P. McKeown, F. Fitzpatrick °
(Dublin, IE)
New cases of Clostridium difﬁcile-associated disease (CDAD) became
notiﬁable in Ireland on 4th May 2008. The main objective of this
new notiﬁcation process was to provide a national overview of the
epidemiology and burden of CDAD. This paper review the ﬁrst six
months of preliminary data notiﬁed.
Methods: The interim case deﬁnitions for new and recurrent CDAD
cases proposed by the European Society for Clinical Microbiology
and Infectious Diseases (ESCMID) Study Group for C. difﬁcile were
employed. This report reviews the weekly events of CDAD extracted
from the Computerised Infectious Disease Reporting (CIDR) system
in January 2009. Census of Population 2006 ﬁgures were used as
denominator data in the calculation of incidence rates. Results presented
represent 34 weeks of data submitted.
Table 1: Number of cases and CIR of human CDAD in Ireland, May–
December 2008 (CIDR)
Region Number of
cases
CIR incl. 95%CI Estimated annual CIR
incl. 95%CI
ERHA 747 49.8 [46.2−53.38] 76.2 [71.8−80.6]
MHB 37 14.7 [9.97−19.4] 22.5 [16.6−28.3]
MWHB 79 21.9 [17.1−26.7] 33.5 [27.5−39.4]
NEHB 36 9.1 [6.2−12.1] 14.0 [10.3−17.7]
NWHB 93 39.2 [31.3−47.2] 60.0 [50.1−69.8]
SEHB 118 25.6 [21.0−30.2] 39.2 [33.5−44.9]
SHB 254 40.9 [35.9−45.9] 62.5 [56.3−68.8]
WHB 217 52.4 [45.4−59.35] 80.1 [71.5−88.7]
Ireland 1581 37.3 [35.5−39.1] 57.03 [54.8−59.3]
Results: There were 1581 new CDAD cases notiﬁed on CIDR between
the 4th May 2008 and 27th December 2008, representing a crude
incidence rate (CIR) of 37.3 cases/100000 population (estimated annual
CIR is 57.0 cases/100,000). All cases were laboratory conﬁrmed. There
was a higher occurrence of cases in females. The male:female ratio for
the period was 1:1.6. In 0.4% of cases the sex was unknown. 71.4% of
cases were in the greater than 65 years age category. The preliminary data
submitted on CIDR indicate that 63.0% of cases were hospital inpatients
and 8.9% of cases were either GP patients or outpatients. The origin of
28.1% of samples is unknown. There was large variation between the 8
public health regions (Table 1).
Conclusions: The incidence of CDAD in Ireland is prominent in older
age groups and in healthcare settings. What is more remarkable is the
regional variation of cases reported. This varies from 9.1 per 100,000
in the North East to 52.4 per 100,000 in the West. The seasonal trend
is indistinguishable at present due to late and batch notiﬁcations from
institutions.
O153 Clostridium difﬁcile-associated diarrhoea in
immunosuppressed patients with cancer
C. Gudiol °, C. Garcia-Vidal, J. Niubo´, R. Duarte, L. Jime´nez,
J. Carratala` (Barcelona, ES)
Objective: To assess the epidemiology, clinical features and outcome
of Clostridium difﬁcile (CD) associated diarrhoea in immunosuppressed
patients with cancer.
Methods: Review of all episodes of CD associated diarrhoea
documented in adults with cancer and haematopoietic stem cell recipients
(2000–2008). Microbiologic diagnosis included CD isolation from
stool samples, direct detection of CD toxin, and testing for cytotoxin
production by the isolated strain.
Results: We documented a signiﬁcant increase of CD associated
diarrhoea, from 0.34/1000 admissions in 2000 to 4.05/1000 admissions
in 2008 (p< 0.01). There were 56 episodes in 54 patients. Thirty-one
patients were male (55%) with a mean age of 52 years (± 16). Forty
three (77%) patients had an haematological underlying disease and 13
had solid tumour; 41 (73%) had received previous chemotherapy, 14
(25%) were stem cell transplant recipients (3 presenting with GVHD)
and 17 (30%) were neutropenic (<500). In the previous month 52 patients
(93%) had received one or more antibiotics (cephalosporins 63.5%,
glycopeptides 40%, carbapenems 38.5%, betalactam + betalactam
inhibitors 29%, quinolones 19%). Fever >38ºC (71%) and abdominal
pain (44%) were the most frequent manifestations, and the diarrhoea
was hemorrhagic in 8% of the cases. Most patients (77%) were treated
with metronidazole (median 11 days), and the antibiotic therapy was
discontinued in 56%. In 5 patients who had recovered from neutropenia,
the diarrhoea resolved just by discontinuing the antibiotic therapy. No
patient developed toxic megacolon or needed surgery. Three patients
(5.5%) had relapses. Overall mortality (<30 days) was 22% (12 patients).
Conclusion: The incidence of CD associated diarrhoea in cancer patients
has increased signiﬁcantly in recent years. It is related with important
morbidity and mortality. Better strategies to improve its prevention and
treatment are needed.
From lab to ward: optimising treatment
strategies for invasive Candida infections
(Symposium organised by Astellas)
S154 Linking research to the clinic: how laboratory ﬁndings relate
to management of invasive Candida infections
F. Odds ° (Aberdeen, UK)
The role of the research laboratory in the management of invasive
Candida infections goes beyond routinely available tests for identiﬁcation
of Candida species and susceptibility testing of antifungal agents.
Cutting-edge molecular epidemiology technologies have been used to
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type isolates of Candida species based on their DNA sequences. Multi-
locus sequence typing schemes have been designed for C. albicans,
C. dubliniensis, C. glabrata, C. krusei and C. tropicalis.
Multi-locus sequence typing can be used to investigate possible hospital
outbreaks of infection (ﬁnding widely different strain types within a unit
indicates no outbreak, although the converse is not true). For C. albicans,
typing multiple isolates from the same patient has shown that people tend
to harbour as commensals a mixture of closely related but different strain
types, which may provide for selection of the most appropriate type for
invasion of a particular tissue or in response to antifungal treatment.
Strains in C. albicans clade 1, the largest group of related strain types,
have a higher proportion of isolates resistant to ﬂucytosine than other
clades, and they all share a common resistance mechanism. Research
on mechanisms of resistance of Candida species to many types of
antifungal has progressed to the point that some investigators are looking
to design DNA chips that could be used both for identiﬁcation and for
susceptibility testing of a Candida isolate.
Much research effort goes into detailed study of host–fungus crosstalk
in experimental Candida infections. Animal models of infection have
been greatly reﬁned and the latest research shows how early release of
chemokines that attract neutrophils into infected tissues contributes to
the immunopathology of Candida infection. This rapid, innate immune
response also emphasizes the need for antifungal intervention at the
earliest possible stage to provide the best chance for successful treatment
of a disseminated Candida infection − a ﬁnding now supported by
clinical data as well as experimental models.
Translation of the latest research advances into practical diagnostic
tests and new therapeutic approaches for Candida infections always
takes a long time − typically years − and not all research results
ﬁnd clinical applications. However, the level of effort invested in basic
Candida research ensures support for steady progress in diagnosis and
management.
S155 Pharmacokinetics and pharmacodynamics of the
echinocandins: from models to medicine
W. Hope ° (Manchester, UK)
The echinocandins are semi-synthetic lipopeptides that are increasingly
used for the prevention and treatment of invasive fungal infections.
Understanding the pharmacokinetic and pharmacodynamic (PK/PD)
characteristics of these compounds is critical for their optimal clinical
use.
The echinocandins have potent in vitro activity against Candida spp.,
although C. parapsilosis is less susceptible than other Candida species.
The molecular mechanisms of resistance in Candida species, which
relate to amino acid substitutions in ‘hot spots’ within the FKS1
gene, are becoming well characterised. Susceptibility breakpoints for
all three clinically available compounds have been determined recently
by the Clinical Laboratory Standards Institute, with a ‘susceptible-only’
breakpoint of >2mg/l suggested.
The PK/PD of the echinocandins have been determined in experimental
models of disseminated candidiasis, and of both disseminated and
pulmonary invasive aspergillosis. These studies suggest that the
echinocandins: (1) display concentration-dependent antifungal killing
(or effect); (2) are extensively distributed into peripheral tissues, where
they exhibit prolonged mean residence times at the site of infection;
(3) are fungicidal against Candida spp. and induce dose-dependent
morphological changes in Aspergillus spp.; and (4) result in a diminished
propensity for angioinvasion by Aspergillus spp. Recent evidence also
suggests that the echinocandins have important immunomodulatory
properties, which may contribute signiﬁcantly to their observed
antifungal effect. PK/PD modelling and laboratory animal-to-human
bridging techniques have been used to identify safe and effective dosages
for the echinocandins for relatively uncommon clinical syndromes
such as neonatal haematogenous Candida meningoencephalitis. These
techniques are an efﬁcient method of identifying effective regimens for
humans that can be expedited for study in clinical trials.
PK/PD modelling techniques can and should be used to address
outstanding clinical queries in relation to these compounds, including
optimal dosages, decision-support analysis for the setting of in vitro
antifungal susceptibility breakpoints and the clinical relevance of
inherent or acquired reduced antifungal susceptibility.
S156 Invasive candidiasis: which antifungal treatment for which
patient?
B. Dupont ° (Paris, FR)
Management of patients with invasive candidiasis represents a complex
issue owing to the heterogeneity of patients in whom these infections
occur. Established risk factors for invasive candidiasis, which include
total parenteral nutrition, multiple organ failure and Candida coloni-
sation, are common to many types of patients that are treated within
the critical care setting. Furthermore, the severity of the underlying
condition in these patients necessitates swift antifungal treatment to
ensure optimal outcomes. An additional factor for consideration when
treating Candida infections is the changing epidemiology of Candida
species; potentially ﬂuconazole-resistant species such as C. glabrata and
C. krusei are becoming more common, particularly in patients with prior
ﬂuconazole exposure.
A range of antifungal agents is available with in vitro activity against
Candida species. However, not all of these agents are suitable options for
the clinical management of invasive candidiasis because of the overall
complexity of both infection and underlying condition. For example, the
position of the polyenes, particularly amphotericin B deoxycholate, is
becoming less tenable as the risk of renal complications is increasingly
regarded as unacceptable in patients that are likely to have or be at risk of
multiple organ failure. Furthermore, because of the increasing prevalence
of ﬂuconazole-resistant species, recent guidelines no longer recommend
the use of azoles as ﬁrst-line treatment for invasive candidiasis except
in special cases, focusing instead on the echinocandin agents.
There is now a wealth of clinical data available for the echinocandins.
Micafungin, for example, has been assessed in invasive candidiasis in
clinical trials that included a wide variety of underlying conditions
and patterns of infection, including neutropenic patients and those with
deep infections such as peritonitis. Furthermore, micafungin is the most
extensively evaluated of the echinocandins in paediatric patients, having
been tested both in children up to the age of 16 years and in premature
infants and neonates.
Optimal management of patients with invasive candidiasis depends on
a strategy that takes into account the complex nature of the disease.
Judicious selection of antifungal treatment should be accompanied
by consideration of non-drug-related factors that improve survival,
such as careful assessment of intravenous catheters and their potential
involvement in Candida infections.
S157 Effective treatment of invasive candidiasis: case studies
J. Perfect ° (Durham, US)
Patients with invasive candidiasis often have underlying conditions that
are severe illnesses in themselves. These range from neutropenia during
cancer chemotherapy to the multi-organ failure of intensive care unit
patients. Against this background of severe underlying illness, it can be
difﬁcult to appreciate the success or otherwise of treatment strategies for
Candida infections.
In the last decade, major advances have been made in antifungal therapy
with the introduction of
1. echinocandins;
2. extended-spectrum azoles; and
3. lipid formulations of amphotericin B.
Robust clinical studies for their successful use in candidaemia have been
published. However, it is important to translate these studies into practical
strategies for the care of individual patients.
In this presentation, individual cases will be used to provide insights into
the successes and failures of these antifungal classes for the management
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of invasive candidiasis. Speciﬁc interest will be focused on the use of
ﬂuconazole versus the echinocandins. These micafungin-based cases will
be supported by insights from the evidence-based literature combined
with practical experiences at the bedside. The factors to be considered
are:
1. spectrum of activity;
2. drug toxicity;
3. drug interactions;
4. drug resistance;
5. pharmacology;
6. diagnosis;
7. site of infection;
8. use of biomarkers/cultures in treatment strategies; and
9. costs.
It is important to realise that large clinical trials exclude many patients
with invasive candidiasis. Therefore, with the use of individual cases,
it is possible to provide further insights into the clinical use of these
outstanding antifungal agents.
Patient management: the era of rapid
diagnostic results (Symposium organised by
Cepheid)
S161 Will community MRSA and Clostridium difﬁcile change
infection control in hospitals?
F.C. Turnover ° (Sunnyvale, US)
Infections caused by methicillin-resistant Staphylococcus aureus
(MRSA), vancomycin-resistant enterococci, and Clostridium difﬁcile
are inter-related in healthcare institutions. The emergence of epidemic
MRSA and C. difﬁcile strains has placed a greater burden on infection
control systems in healthcare facilities, which often must increase
surveillance and change disinfection strategies to halt the transmission
of these pathogens in hospitals. Ironically, the USA300 MRSA strain
arose in the community but now is being transmitted frequently in
healthcare settings, while the epidemic NAP1/BI/027 C. difﬁcile strain
was originally a healthcare-associated pathogen, which now is causing
considerable morbidity in community settings. To successfully slow the
spread of these pathogens, infection control must work closely with both
the laboratory and pharmacy services to ensure that these organisms are
detected rapidly and that the selective pressure to maintain the organisms
in the institution are reduced. Clearly, bundles of interventions, rather
than single approaches, are necessary to contain the spread of these
organisms in hospitals. The continued inﬂux of patients with community-
acquired MRSA and C. difﬁcile infections into healthcare institutions is
a challenge for infection control practitioners that will clearly increase
in the future.
The bacterial pathogen Listeria
monocytogenes: a multi-faceted model
K170 Listeria monocytogenes: a bacterial pathogen responsible for
severe infections and a multi-faceted model in biology
P. Cossart ° (Paris, FR)
The food borne pathogen L. monocytogenes discovered by Murray
in 1926 is responsible for a severe infection with various clinical
features (gastroenteritis, meningitis, meningoencephalitis and materno
foetal infections) and a high mortality rate (30%). The disease is due to
the ability of Listeria to cross three host barriers during infection: the
intestinal barrier, the placental barrier and the blood brain barrier. It is
also due to Listeria capacity to survive in macrophages and to enter into
non phagocytic cells, such epithelial cells. Recovery from infection and
protection against reinfection are due to a T-cell response, explaining
why Listeria has since many years has become a model in immunology.
Nearly three decades of molecular biology and cell biology approaches
coupled to genetic and post-genomic studies have promoted Listeria
among the best models in infection biology. In depth studies of the
mechanism of entry into cells has help unraveling how Listeria crosses
the intestinal and placental barrier. Unsuspected concepts in cell biology
were discovered. Post-genomic studies have recently allowed to unveil
the Listeria transcriptional landscape during switch from saprophytism
to virulence.
The talk will give an overview highlighting recent results in the frame
work of well established data.
FUN-gi: thoughts on yeasts, moulds and
medicine
K172 FUN-gi: thoughts on yeasts, moulds and medicine
F. Odds ° (Aberdeen, UK)
The last several decades of research in medical mycology have offered
great insights into fungal cell biology, epidemiology, phylogenetics
and the cells and molecules involved in the pathogenesis of fungal
disease. A legitimate question is to ask to what extent our extensive
advances in comprehension of the biology of fungal pathogens have
contributed to improvements in diagnosis and treatment. To what extent
do patients beneﬁt from translation of basic research into tools for
clinical management? And the equally valid question: to what extent
does biological science beneﬁt from study of fungi that are opportunistic
pathogens?
The speaker will examine some of these questions from the perspective
of long experience in the ﬁeld and the curmudgeonly attitude that
develops with age.
News from the world of vaccines in a nutshell
O173 Meningococcal vaccines and vaccination strategy in the
Czech Republic
J. Kalmusova, M. Musilek, P. Kriz ° (Prague, CZ)
Objectives: The incidence of invasive meningococcal disease (IMD)
has been reported in the Czech Republic since 1943. In response to
the emergence of a new hypervirulent clonal complex, cc11, nation-
wide enhanced surveillance of invasive meningococcal disease was
implemented by the National Reference Laboratory for Meningococcal
Infections (NRL) in 1993.
Methods: The case deﬁnition is consistent with the ECDC guidelines.
Culture and PCR are used for conﬁrmation of cases. Notiﬁcation
is compulsory and is performed by local epidemiologists. Strains of
Neisseria meningitidis isolated from IMD cases are referred by the
ﬁeld laboratories to the NRL to be characterised by serogrouping, PorA
and FetA sequencing (http://neisseria.org/nm/typing/) and multilocus
sequence typing (MLST) (http://pubmlst.org/neisseria/). In the NRL, the
epidemiological database is matched against that of strains to avoid
duplicate reporting in the ﬁnal enhanced surveillance database.
Results: Despite the stable trend in IMD incidence (0.8/100 000) since
2005, the case fatality rate was high (11.8%) in 2007. The disease was
caused mainly by serogroup B meningococci (67.4%) in 2007, followed
by serogroups C (20.9%) and Y (9.3%). The most frequent clonal
complexes were cc18, cc41/44 and cc32 (typical for serogroup B) and
cc11 (typical for serogroup C). The highest age-speciﬁc morbidity rates
were observed in the lowest age groups, i.e. 0−11 months and 1−4 years
(11.4/100 000 and 4.5/100 000, respectively), and were associated with
high prevalence of serogroup B. The case fatality rate was the highest
in infants under 1 year of age (38.5%). The incidence of IMD caused
by serogroup C is currently low and there is no indication for mass
vaccination with MenC conjugate vaccine. MenB vaccine is needed
for infants, but the sero/subtype coverage by the currently developed
porin-based vaccines is low for Czech meningococcal isolates (maximum
56.8% for nine-valent meningococcal PorA vaccine).
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Conclusion: There is no indication for mass vaccination with MenC
conjugate vaccine in the Czech Republic, but MenB vaccine and
conjugated tetravalent ACYW135 vaccines are required. Other than
porin-based vaccine effective against N. meningitidis B needs to be
developed.
O174 The impact of structured vaccine programme of care on
vaccine uptake in the HIV population attending an urban
clinic − a 5-year review
C. Rock °, A. Dillon, E. de Barra, C. Dowling, S. Kelly, C. McNally,
C. Bergin (Dublin, IE)
Objectives: HIV infected persons may experience considerable mor-
bidity and mortality due to vaccine preventable diseases. Vaccination
guidelines for HIV patients are constantly under review. Current British
HIV Association Guidelines recommend regardless of CD 4 count
that all should get annual inﬂuenza, 1−2 doses pneumococcal and if
not immune hepatitis vaccination. MMR and varicella vaccination are
considered for those non-immune with CD4> 200. This is particularly
signiﬁcant for HIV positive patients migrating from COHP.
In 2002 a structured multi-disciplinary vaccination programme was
established. In our clinic we routinely offer annual inﬂuenza vaccination,
pneumococcal vaccination, hepatitis B, A and varicella vaccinations to
all non immune and travel vaccinations as appropriate.
Methods:The vaccination programme incorporates dedicated vaccine
clinic with a multi-disciplinary team including a nurse, data manager, a
pharmacist speciﬁcally appointed to the unit. Additional interventions to
improve vaccine uptake and outcome have included use of SMS texting
to announce availability of inﬂuenza annually and improve adherence to
completion of hepatitis B vaccination, educational programmes changes
in guidelines e.g. varicella vaccination and creation of a vaccine passport.
We reviewed vaccination clinic activity in the cohort of 1,700 HIV
positive patients since introduction of a dedicated vaccine service.
Results:There has been a large increase in the uptake of vaccinations
since introduction of this service. The varicella vaccination uptake
increased from 8 (2007) to 43 (2008) due to targeted vaccine
programme.(see graphic, legend reads left to right)
Conclusion: Strategies implemented increased the uptake of recom-
mended vaccinations in our HIV population. These included appointment
of a dedicated health professional team, use of IT supports, education of
staff and patients and development of a vaccine passport. We developed
the vaccine passport to help with patient education and awareness and it
will serve as a record of vaccine administration for physicians off site.
In the latter year, post guideline change, we have targeted our varicella
non immune population. The next intervention planned is to assess all
late entrants to our healthcare system to determine need for catch up
vaccines, including MMR.
O175 An umbilical cord blood model of dendritic cell vaccination
demonstrates the ex vivo generation of de novo strain-speciﬁc
T-lymphocyte responses
W. Decker, E. Shpall, A. Safdar ° (Houston, US)
Background: In patients with haematologic malignancy response to
standard inﬂuenza vaccine is not encouraging (Safdar et al. JID 2006).
Toward the goal of addressing this issue, we have developed an in vitro
model of dendritic cell (DC) immunotherapy utilising DCs generated
from umbilical cord blood (UCB). Here we demonstrate that this model
can truly generate immune responses de novo, excluding the possibility
that in utero priming contributes to observed antigen-speciﬁc responses.
Methods: UCB units were obtained from the MD Anderson Cord
Blood Bank under research protocol Lab03–0796 with IRB approval.
UCB monocytes were harvested by adherence, and UCB DCs were
generated by incubation in GM-CSF and IL-4. Immature DCs were
loaded with puriﬁed rHA protein [A/New Caledonia/20/99 (H1N1),
A/Vietnam/1203/2004 (H5/N1), and A/Netherlands/219/03 (H7/N7)]
(Protein Sciences, Meridian, CT) or with puriﬁed rLuciferase (Promega,
Madison, WI). DC were loaded both individually and with a mix of all
three rHA isoforms. Subsequently, loaded DC were matured and used to
stimulate autologous non-adherent lymphocytes. T-lymphocyte priming
and development were supported by supplementation with IL-12, IL-2,
IL-7, and IL-15 (R&D Systems, Mineapolis, MN). Following two
restimulations and expansion, antigen speciﬁc responses were veriﬁed
by IFN-gamma ELISpot. Following priming and restimulation with New
Caledonia-loaded, Vietnam-loaded, Netherlands-loaded, mixture-loaded,
luciferase-loaded, or unloaded DC, T-lymphocytes were stimulated a
third time, and IFN-gamma secretion was quantitated by ELISpot
analysis.
Results: T-cells primed by New Caledonia-loaded DC responded only to
restimulation with New Caledonia-loaded DC (p< 0.004). T-cells primed
by Vietnam-loaded DC responded only to restimulation with Vietnam-
loaded DC (p< 0.02) with only slight cross-reactivity to New Caledonia-
loaded DC. T-cells primed by Netherlands-loaded DC responded only
to restimulation with Netherlands-loaded DC (p< 0.005). T-cells primed
by luciferase-loaded DC responded only to restimulation with luciferase-
loaded DC (p< 0.006). T-cells primed by DC loaded with all a mix of
all three HA isoforms were also able to respond to restimulation by
singly-loaded DC.
Conclusions: The model demonstrates that de novo HA-speciﬁc immune
responses may be generated from UCB lymphocytes, excluding the
possibility that observed responses were generated by in utero priming.
O176 SspB1 − streptococcal surface protein as possible component
of recombinant streptococcal vaccine
K. Grabovskaya, T. Gupalova, G. Leontieva, A. Korjueva, L. Meringova,
E. Kuleshevitch, A. Totolian, A. Suvorov ° (St. Petersburg, RU)
Objectives: Group A (GAS) and group B (GBS) streptococci are the
most common human pathogens of bacterial origin causing various
diseases including severe invasive cases. Recently several laboratories
of the world attempted to generate a vaccine but there is none on
the market so far. Previously we demonstrated that effective protection
against streptococci can be achieved by the immunisation with complex
of recombinant surface expressed proteins where different proteins
provide different degree of protection against different individual strains
belonging to various serotypes. Here we describe the features of the
novel vaccine candidate − surface protein SspB1 encoded by the gene
localised on the pathogenicity island.
Methods: Recombinant protein SspB1 was obtained after cloning of
3000 bp fragment of the sspB1 gene in the expression vector pQE30
and puriﬁcation of the protein on His-tag columns. Protein was used for
immunisation of mice and rabbits. Raised antibodies were tested for in
vitro protection against GBS serotypes I, II and III and GAS (M type 49)
in opsonophagocytosis and in the experiments in vivo employing passive
and active protection on mice model. Adherence of GBS expressing
SspB1 was tested on tissue cultures Hep-2 and A-431.
Results: Column puriﬁed recombinant protein SspB1 was found to be
a good antigen for both groups of animals used for immunisation.
Antibodies against the recombinant SspB1 tested by opsonophagocytosis
were found to enhance phagocytosis of 4 GBS strains belonging to
different serotypes at the average 5.5 times relatively to control. Affect
against GAS strains was less pronounced (2.5 times) but still statistically
signiﬁcant. Antibodies were also capable to interfere with adherence of
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GBS strains carrying SspB1 relatively to the strain without the protein.
Adherence of the strain with SspB1 towards different cell lines was
dramatically higher which proves the function of the protein as adhesin.
In passive protection test carried out with mice challenged with virulent
GBS or GAS strains introduced intranasaly were eliminated from the
lungs of the animals 20 times faster in case of the usage of anti SspB1
serum relatively the control. In the experiments with active protection
SspB1 immunised animals were found be signiﬁcantly better protected
against GBS and GAS infection.
Conclusion: SspB1 − novel GBS adhesion might be considered as
candidate for generation of recombinant streptococcal vaccine.
O177 Effect of vaccines made in developing countries on measles
mortality: a case study
H. Peltola °, S.V. Kapre, S.S. Jadhav, P.S. Kulkarni (Helsinki, FI; Pune,
IN)
Objectives: UNICEF started procuring vaccines for low- and middle-
income countries in 1978. In 1993, for the ﬁrst time, a measles vaccine
from a developing country, India, was prequaliﬁed by WHO. Since then
it has been the most commonly used vaccine across the developing
world. Here we correlate its use to the reduction of measles mortality
worldwide.
Methods: Measles data were collected from literature and the WHO
press releases for 1990 and 2007. Since we have an access to the database
of the largest Indian company, we calculated the number of vaccine
doses it supplied to UNICEF and PAHO from 1996 till 2008. We also
found out the price UNICEF paid for the measles, measles-rubella, and
measles-mumps-rubella vaccines.
Results: In 1990, there were 872,000 measles deaths worldwide of which
no less than 869,000 (>99%) occurred in the less privileged countries.
The vaccine prices were not attractive enough to the manufacturers in
industrialised countries to prequalify and supply UNICEF and PAHO.
Since only 1993 large enough quantities of measles vaccine have been
available from a developing country company, which in the 12-year
period (1996–2008), supplied these agents with >1.6 billion doses of
the measles component containing vaccines. Now, the largest supplier to
UNICEF and PAHO is India, not an industrialised country. Since these
agents purchase low-price vaccines, the costs almost certainly have been
much less than for the Big Pharma vaccines. In 2007, UNICEF paid just
USD0.222, 0.525, and 0.860 per dose of the measles, measles-rubella,
and measles-mumps-rubella vaccine, respectively. Global measles deaths
in 2000–2007 declined by 74%, from estimated 750,000 to 197,000,
respectively (BMJ 2008;337:a2949).
Conclusions:While costly new vaccines are pushed forwards with lavish
campaigns, “old”, and often considerably more relevant vaccines are left
behind. Measles is a good example of severe disease, still rampant in the
non-industrialised world, to which little attention is paid by Big Pharma.
Some less privileged countries such as India have taken the initiative in
their own hands and started own vaccine manufacturing. Availability of
good-quality vaccines at affordable price in huge quantities is the main
reason of the spectacular reduction of the measles mortality; now also
countries with the highest burden can afford this pivotal vaccination.
Contribution of the high-standard developing country manufacturers
credits recognition.
Bacteraemia
O178 Mortality impact of positive blood cultures in patients
with suspected community-acquired bacteraemia. A Danish
population-based cohort study
M. Søgaard °, M. Nørgaard, H.T. Sørensen, H.C. Schønheyder
(Aalborg, Aarhus, DK)
Objective:We examined the prognostic impact of positive blood cultures
compared to negative cultures on mortality in patients, who had blood
cultures obtained during the ﬁrst 72 hours of admission to a medical
ward.
Methods: We conducted this population-based cohort study of adults
(n = 20,210) with a ﬁrst-time registered blood culture during 1995
through 2006 in Northern Denmark. We obtained information on blood
cultures, coexisting chronic diseases (for this study identiﬁed as the
19 chronic diseases included in the Charlson Comorbidity Index),
laboratory ﬁndings, and immunosuppressive therapy from medical
databases. Positive cultures were deﬁned as those with growth of one
or more pathogen given an aetiological role based on joint clinical and
microbiological assessment.
Mortality within 180 days following the date of ﬁrst blood culture was
determined through the Danish Civil Registration System. We computed
Kaplan-Meier curves and product limit estimates for the main study
variables. Next, time-dependent Cox regression analyses was used to
compare the risk of death in patients with positive blood cultures
and patients with negative cultures at days 0−7, 8−30, and 31–180,
controlling for age, gender, coexisting chronic diseases, marital status,
use of immunosuppressives, and calendar period. Further, we conducted
analyses restricted to patients a discharge diagnose of infectious diseases
(ICD-10 codes A00-B99).
Results: In total, 1,665 (8.2%) patients had positive blood culture.
Mortality among patients with positive cultures was higher than among
patients with negative during the ﬁrst 30 days of follow-up: 8.4% vs.
4.6% after 7 days, and 5.5% vs. 4.9% during days 8−30, corresponding
to adjusted mortality rate ratios (MRRs) of 1.5 (95% CI: 1.2−1.8) and
0.9 (95% CI: 0.7−1.2), respectively. Beyond day 30, mortality was 8.2%
among patients with negative culture and 10.4% among patients with
positive culture (adjusted MRR 1.0, 95% CI: 0.9−1.2). 2,934 patients had
a discharge diagnosis of infectious disease, of which the blood culture
was positive in 646 (22.0%). Among these patients the prognostic impact
of bacteraemia persisted throughout the follow-up period (0−7 days:
MRR= 1.7 (95% CI 1.2−2.6); 8−30 days: MRR= 1.2 (95% CI 0.7−1.9);
31–180 days: MRR= 1.6 (95% CI 1.0−2.1)).
Conclusion: Positive blood culture is a predictor of mortality in patients
with suspected bacteraemia.
O179 Mortality of Staphylococcus aureus bacteraemia and
infectious diseases specialist consultation − a study of 521
patients at a tertiary care centre in Germany
S. Rieg °, G. Peyerl-Hoffmann, K. de With, C. Theilacker, D. Wagner,
J. Hu¨bner, M. Dettenkofer, A. Kaasch, H. Seifert, C. Schneider,
W. Kern (Freiburg, Cologne, DE)
Objectives: To evaluate the relationship between mortality of S. aureus
bacteraemia (SAB) and infectious diseases (ID) specialist consultation
and other factors potentially associated with outcomes.
Methods: A new ID service was established in 2002 at a 1,600-
bed university hospital in southwestern Germany. Consecutive adult
patients with SAB admitted between January 1, 2002 and December
31, 2007, were assessed using a standardised data collection and
review form. Patients admitted during the ﬁrst three years of the study
were evaluated retrospectively, patients of the second three years were
evaluated prospectively. ID consultation included physical examination,
chart and laboratory result review and written recommendations for
therapy and follow-up examinations based on established guidelines,
literature review and individual case discussions.
Results: A total of 521 patients with SAB were enrolled and evaluated
for in-hospital mortality; 430 patients completed a 90-day follow-up.
ID consultation rates increased from 33% cases in 2002 to >80% in
2007. Overall, ID consultation was performed in 67% of SAB cases.
All-cause in-hospital mortality was 21.7%, and 90-day mortality was
32.1%. Factors signiﬁcantly associated with in-hospital mortality in a
multivariate logistic regression analysis were comorbidity, expressed as
McCabe ultimately fatal (OR 4.0, CI 2.3−6.9) or as McCabe rapidly
fatal (OR 7.9, CI 2.9−21.7), initial ICU admission (OR 5.9, CI 3.6−9.7),
MRSA (OR 2.7, CI 1.4−5.0), age 60 years (OR 2.4, CI 1.4−4.2),
a diagnosis of endocarditis (OR 2.9, CI 1.4−5.8), and ID specialist
consultation (OR 0.6, CI 0.4−1.0). There was no statistically signiﬁcant
relationship between mortality and mode of acquisition, source of
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bacteraemia, or presence of metastatic disease (Table 1). Similar results
were obtained in the analysis of factors associated with 90-day mortality.
Conclusion: These data suggest that outcomes of both community-onset
and nosocomial bloodstream infections due to S. aureusmay be improved
by an expert consultation service. The factors most critical for better
outcomes and modiﬁable in time by ID specialist consultation remain to
be determined and may be explored as process of care quality indicators.
Table 1. Univariate end multivariate analysis of inhouse mortality of 521 SAB patients
Parameter/Risk factor Inhouse deaths (113 of 521 patients, 21.7%)
Univariate analysis Multivariate analysis
Number (%) p value OR (95%CI) p value
MSSA vs. MRSA
MSSA 85/454 (18.7%)
MRSA 28/67 (41.8%) <0.01 2.7 (1.4−5.0) <0.01
Mode of acquisition
community-acquired 25/109 (22.9%)
healthcare-associated 31/147 (21.1%)
nosocomial 57/265 (21.5%) 0.93 NI
Age
<60 years 28/204 (13.7%)
60 years 85/317 (26.8%) <0.01 2.4 (1.4−4.2) <0.01
Source
unknown or catheter-related 74/364 (20.3%)
others 39/157 (24.8%) 0.25 NI
Metastatic infection
no 69/332 (20.8%)
yes 44/189 (23.3%) 0.51 NI
ID consultation
no 47/171 (27.5%)
yes 66/350 (18.9%) 0.03 0.6 (0.4−1.0) 0.05
Endocarditis
no 91/465 (19.6%)
yes 22/56 (39.3%) <0.01 2.9 (1.4−5.8) <0.01
Comorbidity
McCabe non-fatal 25/239 (10.5%)
McCabe ultimately fatal 77/258 (29.8%)a <0.01 4.0 (2.3−6.9)a
McCabe rapidly fatal 11/24 (45.8%)a 7.9 (2.9−21.7)a <0.01
Initial ICU admission
no 40/335 (11.9%)
yes 73/186 (39.2%) <0.01 5.9 (3.6−9.7) <0.01
OR, odds ratio; CI, conﬁdence interval. NI, not included in ﬁnal regression model.
aCompared to McCabe non-fatal.
O180 Nosocomial, community and healthcare-associated
bloodstream infections in Spain
P. Retamar °, J. Rodrı´guez-Ban˜o, M.D. Lo´pez-Prieto, M.M. Portillo,
F. Rodrı´guez, M.V. Garcı´a, M. Herrero, F. Ferna´ndez, A. Mun˜oz,
A. Sa´nchez, B. Becerril, A. Martı´n, J.C. Alados, R. Moya, C. Florez,
L. Leo´n, T. Escobar, A. Arroyo and SAEI/SAMPAC
Objectives: Health care-associated (HCA) bloodstream infections (BSI)
has been proposed as a new subclass of community-acquired (CA) BSI
in USA. There are scarce data from other health care systems. We
analysed the epidemiology and clinical features of bacteraemia according
to acquisition in Andalucı´a, Spain.
Methods: A prospective multicentre cohort study including of all
BSI episodes in 15 public hospitals (11 tertiary, 4 community) from
Andalucı´a, Spain, from November 2005 throughout March 2006, was
performed. BSI were classiﬁed as nosocomial (NOS), HCA or CA
according to Friedman’s criteria (Ann Intern Med 2002). Etiology,
epidemiologic and clinical data were collected.
Results: 822 episodes of BSI were included: 476 (58%) were NOS,
227 (28%) HCA, and 119 (14%) CA. Chronic renal failure and
liver disease were more frequent in HCA than in NOS (23% vs
9%, p< 0.001; and 13% vs 7%, p = 0.004); renal failure, cancer, and
immunodeﬁciency were also more frequent in HCA than in CA. Venous
catheter was more frequent in NOS than in HCA (87% vs 41%,
p< 0.001). Urinary catheter use was similar in HCA and in CA (13%
vs 13%, p = 0.9). The most frequent sources in NOS, HCA and CA
were: unknown (27%, 23%, 14%), venous catheter (25%, 2%, 0),
urinary tract (15%, 21%, 31%), gastrointestinal tract (14%, 21.6%,
22.2%), and respiratory tract (12%, 11%, 19%). The most frequent
organisms in NOS, HCA and CA BSI were: Escherichia coli (20%, 37%,
36%), Streptococcus pneumoniae (1%, 6%, 18%), coagulase-negative
staphylococci (CNS) (14%, 10%, 5%), Staphylococcus aureus (14%,
11%, 7%), and Pseudomonas aeruginosa (6%, 7%, 1%). Methicillin-
resistant S. aureus (MRSA) was found in 3%, 5% and 0% of the
episodes. Empirical treatment was appropriate in 69%, 81% and 84%,
and mortality at day 14 was 20%, 19% and 15%, respectively.
Conclusion: There were signiﬁcant differences between HCA and COM
episodes. MRSA, CNS or P. aeruginosa caused BSI with similar
frequency in NOS and HCA episodes, but were rare in COM BSI. HCA
BSI should be considered as a distinct class within CA also in Spain.
O181 The value of FDG-PET for detection of metastatic infectious
foci complicating Gram-positive bacteraemia
F. Vos °, C. Bleeker-Rovers, P. Sturm, B.J. Kullberg, W. Oyen (Nijmegen,
NL)
Objectives: Timely detection of metastatic infectious foci in Gram
positive bacteraemia is crucial, because they often require prolonged
antibiotic treatment or drainage. Diagnosis of complicating infectious
foci is difﬁcult, since up to 32% of these foci do not have localising
symptoms and signs.
Methods: A prospective, descriptive analysis with a matched historical
control group was performed. All non-neutropenic, adult patients having
positive blood cultures growing S. aureus, Streptococcus species or
Enterococcus species were eligible when at least one risk factor for
the presence of complicating infectious foci was present. FDG-PET was
performed within 2 weeks after the ﬁrst positive blood culture.
Results: The results of 115 study patients and 230 control patients were
analysed. Signiﬁcantly more metastatic foci were found in study patients.
FDG-PET was the ﬁrst to delineate infectious foci in 35 patients.
Sensitivity and speciﬁcity of FDG-PET were 100% and 87% respectively.
The NPV was 100% with a PPV of 89%. Relapse rates decreased from
7.4% to 2.6%, p = 0.09, and from 8.9% to 1.4% in the S. aureus subgroup
(P = 0.038). Infection related mortality decreased from 24% to 15% after
6 months, (p = 0.049).
Conclusion: Addition of FDG-PET to the diagnostic work-up of patients
with Gram positive bacteraemia with at least one additional risk factor
for developing metastatic infection results in both a decrease relapse
rates, which is signiﬁcant among patients with a Staphylococcus aureus
bacteraemia and lower mortality rates. FDG-PET is a valuable technique
in the diagnostic work-up of all high risk patients with Gram positive
bacteraemia.
O182 Incidence of zoonotic Salmonella species bacteraemia: a
multi-national population-based study
K. Laupland °, H. Schonheyder, O. Lyytika¨inen, L. Valiquette,
K. Kennedy, P. Collignon on behalf of the International Bacteraemia
Surveillance Collaborative
Objectives: Although zoonotic (non-typhoidal) Salmonella species are
important causes of invasive infections worldwide, few studies have
investigated their epidemiology at the population level. The objective
of this study was to deﬁne the incidence of zoonotic Salmonella species
bacteraemia in a large multi-national population and to evaluate temporal
and regional differences.
Methods: Population-based laboratory surveillance for all zoonotic
Salmonella species bacteraemias was conducted in ﬁve regions (Finland,
Canberra, Australia, North Jutland Region, Denmark, and Calgary
and Sherbrooke, Canada; combined population 7.5 million residents
annually) during 2000–2007.
Results: A total of 480 zoonotic Salmonella species bacteraemias were
identiﬁed for an overall annual incidence of 8.1 per million population.
The incidence was lowest in the spring and highest in the summer,
and progressively increased during the eight years of the study with
a doubling of the rate from 6.1 per million in 2000 to 12.2 per million
in 2007. Overall the acquisition risk increased with advancing age and
males were at signiﬁcantly higher risk as compared to females (10.2
vs. 6.2/million; relative risk 1.7; 95% conﬁdence interval 1.4−2.0). The
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occurrence varied signiﬁcantly among the ﬁve study regions with annual
incidence rates per million population of 22.2 in Sherbrooke, 18.7 in
North Jutland Region, 7.5 in Finland, 6.1 in Calgary, and 4.2 in Canberra.
Conclusions: Zoonotic Salmonella species bacteraemias are increasing.
The determinants of increased risk among males, older individuals, and
between regions merit further investigation.
Tuberculosis
O184 Dominance of Beijing family strains in XDR tuberculosis in
Samara Oblast, Russian Federation
V. Nikolayevskyy °, Y. Balabanova, N. Malomanova, I. Fedorin, T. Simak,
I. Kontsevaya, O. Ignatyeva, S. Mironova, Y. Mashkova, A. Naumov,
A. Kovalev, A. Shakhmistova, F. Drobniewski (London, UK; Samara, RU)
Objectives: Russian Federation is of one of the WHO-deﬁned high
tuberculosis (TB) incidence countries with high prevalence of multidrug
resistant TB (MDRTB). Signiﬁcant associations between MDRTB and
Beijing family strains have been reported for many regions in the
Russian Federation. In Samara oblast (Central Russia) converging HIV
and TB epidemics, including MDRTB and extensively drug resistant
TB (XDRTB) pose a signiﬁcant public health problem. The aim of the
study was to characterise transmission of XDRTB in Samara oblast using
molecular tools.
Methods: A total of 189 individual XDR M. tuberculosis strains
isolated from patients between January-September 2008 in Samara
were genotyped using spoligotyping and multilocus VNTR typing using
an extended 24-loci panel (Supply et al., 2006) supplemented by an
additional panel of hypervariable loci (VNTR 3232, 1982, 2163A, 3336)
speciﬁcally for differentiation within highly conserved groups. First
and second line drug susceptibility tests (DST) were performed using
standardised protocols (Kruuner et al., 2007); mutations associated with
resistance to rifampicin (RIF) and isoniazid (INH) were detected using
a non-commercial reverse hybridisation assay (Brown et al., 2006).
Results: Mutations responsible for resistance to RIF and INH were
detected in 187 (98.9%) and 185 (97.9%) strains demonstrating excellent
agreement between phenotypical and molecular DST results. Beijing
strains dominated comprising 92.6% with minority of strains (7.4%,
N=13) belonging to other modern TB lineages including LAM9,
Haarlem 3, T1, T4, and Family 33. Multilocus VNTR typing allowed
the differentiation of Beijing strains into 43 types although clustering
rates remained substantial (82.3%) indicating high rates of active drug
resistant TB transmission. Five major clusters within the Beijing family
included 130 isolates (74.3% of a total; clone size varied from 4
to 78 strains) with four clusters being indistinguishable with those
identiﬁed in Samara oblast in 2002–2004 suggesting that a limited
number of emerging Beijing clones is responsible for an MDR and
XDRTB transmission in Samara oblast.
Conclusions: VNTR genotyping using highly discriminative loci includ-
ing MIRU26, VNTR3232, 1982, and 4052 allowed the differentiation of
strains within the Beijing family. XDRTB in Samara is associated with
a limited number of expanding Beijing family M. tuberculosis clones.
O185 Rapid detection of Mycobacterium tuberculosis and
rifampin-resistance from sputum samples with an
easy-to-use PCR test system with near-patient capability
M. Jones °, D. Helb, E. Story, C. Boehme, E. Wallace, K. Ho,
J. Kop, M. Owens, R. Rodgers, P. Banada, H. Saﬁ, R. Blakemore,
N. Lan, E. Jones-Lo´pez, M. Levi, M. Burday, I. Ayakaka, R. Mugerwa,
B. McMillan, E. Winn-Deen, L. Christel, P. Dailey, M. Perkins,
D. Persing, D. Alland (Sunnyvale, Newark, Bronx, US; Geneva, CH;
Ho Chi Minh City, VN; Kampala, UG)
Background: Current nucleic acid ampliﬁcation methods used to
detect Mycobacterium tuberculosis are complex, labour-intensive and
technically challenging. The Xpert™ MTB real-time PCR assay
was developed to overcome these limitations and to rapidly and
simultaneously detect M. tuberculosis and rifampin resistance-associated
mutations in sputum samples with minimal hands-on effort. Sample
processing and real-time nested PCR reactions are integrated in a single,
disposable plastic cartridge which contains all of the reagents necessary
for sample processing and PCR reactions so that the technician need only
add the sample to the cartridge. All steps following sample addition are
done automatically on the GeneXpert platform in less than 2 hours.
Objective: The objective was to evaluate the Xpert™ MTB assay
sensitivity and speciﬁcity for bothM. tuberculosis detection and rifampin
resistance.
Methods: Analytical studies were performed using sputum spiked with
known numbers of M. tuberculosis colony forming units (cfu). Clinical
studies were performed with sputum samples from tuberculosis patients
in Uganda and Vietnam.
Results: The limit of detection for M. tuberculosis in sputum samples
was 131 cfu/mL. As few as ten cfu of M. tuberculosis could be detected
in 35% of the samples. All common rifampin-resistance-associated
mutations could also be detected. Analysis of samples collected from
suspected tuberculosis cases in Vietnam and Uganda showed a sensitivity
of 98–100% for smear-positive sputum samples. Sensitivity in smear-
negative samples was 84.6% (33/39) whenM. tuberculosis was identiﬁed
by solid media culture, and 71.7% (38/53) when both solid and
liquid media were used for identiﬁcation. Speciﬁcity was 100% in all
cases. Tests of 64 smear-positive samples collected from retreatment
tuberculosis cases in Uganda showed a sensitivity of 100% for detecting
rifampin-resistance. Speciﬁcity for rifampin-resistance was 98% (63/64),
but this rose to 100% after correcting for an error in conventional
susceptibility test results.
Conclusions: The Xpert™ MTB Assay is highly effective at detecting
smear-positive and smear-negative tuberculosis and rifampin-resistance.
This simple-to-use system can perform point-of-care detection of
M. tuberculosis directly from sputum in less than two hours.
O186 Drug-resistant tuberculosis: quantitative drug susceptibility
testing and correlation with genotyping
B. Springer, K. Lucke, R. Calligaris-Maibach, C. Ritter, E. Boettger °
(Graz, AT; Zurich, CH)
Objective:Worldwide, the present tuberculosis epidemic is characterised
by an alarming emergence in drug resistance. Given the limited
therapeutic options in MDR (and especially XDR) tuberculosis, there is
a need to deﬁne the resistance levels and mechanisms present in clinical
isolates categorised as drug resistant on the basis of critical concentration
testing, so as to facilitate rapid therapeutic decisions.
Methods: We determined quantitative resistance levels of drug resistant
isolates of Mycobacterium tuberculosis sampled in Switzerland over the
past 3 years. Resistance-conferring genetic alterations were identiﬁed by
probe assays and PCR-mediated gene sequencing.
Results: Rifampicin resistant isolates unanimously showed a high-level
resistant phenotype (>50mg/L) associated with mutations in rpoB. In
contrast, a signiﬁcant fraction of clinical TB isolates categorised as
isoniazid resistant on the basis of critical concentration testing showed a
low-level resistant phenotype (mostly mutations in inhA); heterogeneous
phenotypic resistance levels were associated with mutations in katG. One
third of streptomycin resistant clinical isolates had a low-level resistance
phenotype (<10mg/L). Ethambutol resistance occurred mostly in MDR
strains and was linked to alterations in embB, but resistance never
exceeded 25mg/L.
Conclusions: Our data indicate that some ﬁrst line agents may be
considered as therapeutic treatment option despite in vitro resistance
at the critical concentration. Diagnostic mycobacteriology would beneﬁt
from standardised measures of quantitative drug susceptibility testing
in particular for those drugs were signiﬁcant variations in phenotypic
resistance levels are found in clinical isolates, e.g. isoniazid, ethambutol
and streptomycin.
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O187 Impact of XDR-TB on treatment outcome of patients with
MDR-TB
P. Tabarsi °, P. Baghaei, M. Marjani, M. Amiri, M. Masjedi,
J. Caminero (Tehran, IR; Las Palmas, ES)
Design: The very limited experience treating patients with extensively
drug-resistant tuberculosis (XDR-TB) shows a therapeutic success rate
under 50 to 60% and there are not publications regarding the outcome
of these patients treated with standardised regimes.
Material and Methods: All MDR-TB patients hospitalised at
Masih Daneshvari Hospital in Tehran, Iran during 2004–2007. A drug
susceptibility to 13 drugs (included 8 second line drugs − SLD) were
performed and a standardised regimen with oﬂoxacin, cycloserine,
prothionamide, and amikacin was administered. Outcome of the patients
was studied, comparing between the MDR-TB non XDR-TB and the
XDR-TB.
Results: 51 patients were included, 12 with XDR-TB criteria. XDR-
TB infection was signiﬁcantly only associated with age (p = 0.039). The
success rate for the 51 total MDR-TB, the 39 MDR-TB non XDR-
TB and the 12 XDR-TB patients was 76.5% (39 patients), 87.2% (34
patients) and 41.6% (5 patients), respectively. Resistance to Oﬂoxacin,
Ciproﬂoxacin, and Amikacin, were found to have statistically signiﬁcant
association with unsuccessful outcome.
Conclusions: In this setting, a standardised SLD regimen produces high
treatment success rates in MDR-TB patients unless XDR-TB is present.
Introduction
Contemporary issues in varicella zoster virus
infections
S188 Varicella zoster virus encephalitis and cerebral vasculitis
T. Bergstro¨m ° (Gothenburg, SE)
Recent advances in the diagnostics of varicella zoster virus (VZV)
infections have changed the perception of this virus as a CNS pathogen.
A real-time PCR method amplifying a 70 nt segment of the VZV gB
region gave 0.5 log improved sensitivity over conventional PCR and was
employed for routine diagnosis of VZV DNA in samples of cerebrospinal
ﬂuid (CSF). In addition, a new ELISA method for detection of antibodies
in the CSF to glycoprotein E was developed, using a mammalian
cell expression system for optimal glycosylation of the antigen. These
methods were utilised for studies of VZV-induced CNS infections.
In a retrospective study, almost all patients had a reactivated VZV
infection, but only 60% showed skin lesions. The following diagnoses
were made: acute aseptic meningitis (AAM), n = 34; encephalitis,
n= 22; meningoencephalitis, n = 6; cranial nerve affections, n = 20;
encephalopathy, n = 5; and cerebrovascular disease, n = 6. In 66 patients
in whom VZV DNA levels were determined, signiﬁcantly higher viral
loads were found in those with AAM and encephalitis compared to
patients with cranial nerve affection (including Ramsay Hunt syndrome).
Of the 50% (n = 50) who had a follow-up, 50% (n = 25) had neurological
complications after 3 months. Sixty-two percent had a CT/MRI scan of
the brain performed and 46% of these had pathological ﬁndings.
VZV encephalitis showed a more broad disease spectrum as compared
with herpes simplex encephalitis (HSE), as will be presented. Detection
of intrathecal synthesis of VZV gE antibodies was positive in the VZV
encephalitis patients, as well as in some of the HSE patients, arguing
for a previous suggested role for VZV as a co-pathogen at least in some
cases of the latter disease.
VZV vasculitis was a more common ﬁnding (6% of all cases) than
expected from the literature of case reports. MR ﬁndings showed that
middle and posterior cerebral arteries were targeted. Surprisingly, despite
substantial VZV DNA loads in the CSF of these patients, investigated
serum samples were PCR negative. Thus, VZV might be suggested to be
neuronally transported to the arterial walls rather than haematogenously
spread.
Conclusions: VZV is a serious and underestimated cause of CNS
infection. A substantial number of the patients presented with serious
neurological symptoms and sequela, and pathological ﬁndings on
CT/MRI of the brain were abundant, especially in patients with
encephalitis and vasculitis.
PK/PD controversies for the clinician
S190 PK/PD and azoles
W. Hope ° (Manchester, UK)
The triazoles have revolutionised the treatment of invasive and allergic
fungal diseases. Fluconazole, itraconazole, voriconazole and posacona-
zole are available for clinical use. Isavuconazole and ravuconazole are
in development. The triazoles have broad spectrum antifungal activity.
The pharmacokinetics and pharmacodynamics (PK-PD) of the triazoles
have been extensively investigated in murine models of disseminated
candidiasis. The PD parameter that optimally links drug exposure
with the observed antifungal effect is the ratio of the area under the
concentration-time curve (AUC) to MIC (AUC:MIC). There is increasing
information on the magnitude of the AUC:MIC that is required for
optimal antifungal effect. PK-PD principles have been used to deﬁne
in vitro susceptibility breakpoints. The triazoles are fungistatic against
Candida spp. Their mode of action against Aspergillus spp. is less
well deﬁned, although they clearly exhibit dose-dependant decrement
in fungal burden in laboratory animal models of invasive pulmonary
aspergillosis. The triazoles accumulate in tissues and this is important
for an understanding of their antifungal effect.
In humans, the triazoles are characterised by complicated pharmacoki-
netic properties. Both itraconazole and voriconazole exhibit nonlinear
pharmacokinetics. The triazoles all exhibit clinically relevant exposure-
response relationships. Recent work from our laboratory suggests
that itraconazole exhibits clinically relevant concentration-toxicity
relationships. Higher concentrations of voriconazole are associated with
a progressively higher probability of hepatotoxicity, photopsia and central
nervous system toxicity.
Because of the signiﬁcant pharmacokinetic variability and clinically rel-
evant drug exposure-response relationships, therapeutic drug monitoring
(TDM) is frequently used. A strong argument can be made for the
routine monitoring of itraconazole and voriconazole. There may also
be grounds to consider monitoring posaconazole levels. TDM should
be considered for all patients receiving triazoles who have refractory
disease. Furthermore, TDM should be considered when compliance, drug
interactions and variable pharmacokinetics result in uncertainty about
resultant drug exposures.
An understanding of the PK-PD relationships of the triazoles has been
instrumental in optimising their clinical efﬁcacy.
Innate immunity
S192 The inﬂammasomes: danger sensing complexes triggering
innate immunity
J. Tschopp ° (Lausanne, CH)
The NOD-like receptors (NLR) are a family of intracellular sensors of
microbial motifs and ‘danger signals’ that have emerged as being crucial
components of the innate immune responses and inﬂammation. Several
NLRs (NALPs and IPAF) form a caspase-1-activating multiprotein com-
plex, termed inﬂammasome, that processes proinﬂammatory cytokines
including IL-1beta. Amongst the various inﬂammasomes, the NALP3
inﬂammasome is particularly qualiﬁed to sense a plethora of diverse
molecules, ranging from bacterial muramyldipeptide to monosodium
urate crystals. The important role of the NALP3 inﬂammasome is
emphasized by the identiﬁcation of mutations in the NALP3 gene that
are associated with a susceptibility to inﬂammatory disorders. These and
other issues related to the inﬂammasome will be presented.
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S193 Critical players in signalling control
N. Gay ° (Cambridge, UK)
It is now 20 years since Charles Janeway hypothesized the existence
of clonally derived pattern recognition receptors and pointed to the
importance of these in initial responses to bacterial and viral infections.
Janeway’s hypothesis has been validated by the discovery of three
groups of PRRs. First, are the Toll-like receptors which detect microbial
lipids and non-self nucleic acids at the cell surface an in intracellular
compartments. In addition cytoplasmic sensors of bacteria (NODs) and
of viral nucleic acids (RIGs) have also been characterised. As well as
being critical for responses to infections, these PRRs also underlie a
large burden of autoimmune and inﬂammatory disease in the human
population and are thus important targets for therapy.
In my talk I will describe the molecular mechanisms by which these
conserved pathogen associated moecules are recognized by the TLRs
with particular reference to lipo polysaccharide and single stranded viral
RNAs. I will also present new results which show how receptor activation
is coupled to downstream signal transduction and in particular the role
played by oligomeric signaling platforms assembled form adaptors and
other signaling molecules involved in the pathway. I will discuss the
potential for structural analysis to be used in the rational design of new
drugs.
The year in infection control
S195 The year in infection control
M. Struelens ° (Brussels, BE), D. Pittet ° (Geneva, CH)
This session proposes a critical review of the most salient recently
published papers in the ﬁeld with a special focus on control of multi
drug-resistant organisms, prevention of infections in the intensive care
unit, surgery etc. and highlights the need for validity/scope assessment.
It emphasizes also the importance to prioritise information published
in the abundant literature available so as to be able to summarise
and understand the potential changes in clinical practice, and identify
unresolved issues and areas of possible future clinical research.
Infectious diseases on the move
S199 Travellers and tourists from Latin America
R. Isturiz ° (Caracas, VE)
Tourism is Europe’s face to the world. It is also a major source of
revenue, employment and productivity. Each year over 450 million
arrivals are recorded into the continent, and of those, approximately
4 million are from Latin America. Returning travelers are even more
numerous and more often associated with disease transmission into
Europe.
Within countries of the European continent, imported cases of
environmental and zoonotic illnesses such as cholera, dengue, malaria,
viral haemorrhagic fevers and West Nile virus infections are a rare
but established fact. Diseases imported from Latin America with the
potential for autochthonous transmission (chikungunya, malaria, yellow
fever) and or high infectivity (viral haemorrhagic fevers) will be
described in detail and the possibility of European outbreaks from
Latin American countries will be discussed. The importance of early
clinical recognition of individual cases and prevention of spread to large
populations make this discussion relevant in 2009.
External migration to European has been responsible for impoverished
outskirt areas, where cases of tuberculosis and food and waterborne
diseases have increased, but the role of immigrants from Latin America
seems less that that of African countries.
The returning European traveler poses infrequent but important
challenges to clinicians and epidemiologists; the risk of travelers
from Europe to Latin America of acquiring, incubating, suffering
and transmitting Yellow Fever, Dengue, Malaria, Leptospirosis, Chagas
Disease, Meningococcal disease, TB, Measles, Varicella, Rabies,
Traveler’s Diarrhoea, HIV, Cysticercosis, Leishmaniasis, or a multi-
resistant bacteria, as well as the vaccination and behavioural strategies
to prevent them will be discussed.
The overall patterns of communicable diseases in Europe have not been
noticeably affected by travelers and tourists from the Latin American
region, and the opposite is also probably true, but the wide range
of diseases with different modes of transmission and with different
relevance for European Public Health and individual practitioners would
require closer monitoring of imported cases to uncover minimal trends.
News from the tropical front
O200 Clinical and epidemiological study of imported Chagas
disease in Madrid, Spain
A. Pe´rez de Ayala, F. Norman, J.A. Pe´rez-Molina, J.M. Herrero,
B. Monge, M. Navarro, R. Lo´pez-Ve´lez* on behalf of RICET
Objectives: Description of epidemiological and clinical characteristics
of a cohort of Latin American immigrants in Madrid diagnosed with
Trypanosoma cruzi infection.
Methods: All Latin American immigrants attended at the Tropical
Medicine Unit of the Ramon y Cajal Hospital between January 2003
and December 2008 were tested for T. cruzi infection. Diagnosis was
considered when two different serological tests (IFAT and ELISA) were
positive, PCR was also performed. A clinical/epidemiological protocol
was performed for all positive patients. An ECG, echocardiogram and
oesophageal manometry was performed in all asymptomatic patients and
cardiac MRI, barium swallow or barium enema if speciﬁc symptoms
were present. Treatment with benznidazole (5mg/kg/d/60 days) was
given to all infected patients. An estimation of the potential number of
chagasic cardiomyopathies in Spain was calculated taking into account
the number of Latin Americans registered and the infection prevalence
rates in their countries of origin.
Results: A total of 710 patients were analyzed for T. cruzi infection:
196 (27.6%) were positive. Most of them (95.9%) were Bolivians,
69.4% women, with a mean age of 36 years. Regarding possible
transmission routes, 83.7% had seen the vector in their houses, 12.2%
had received a blood transfusion in their country of origin, and in 12.8%
of cases vertical transmission was suspected (mother with positive test,
although 42.3% maternal test results were not available). 60 patients
(30.6%) were still under clinical study and 136 had a completed
clinical evaluation: 93 patients (68.3%) were in the indeterminate
form of the disease and 43 (31.6%) had chronic Chagas disease: 37
(27.2%) with cardiac involvement, 4 (2.9%) with digestive involvement
and 2 (1.4%) with both. 90 patients had received antitrypanosomal
treatment: 35 (38.8%) had adverse side effects, and 18 of them (20%)
stopped treatment because of cutaneous intolerance: The main side
effects were cutaneous hypersensitivity, observed in 28 patients (31.1%),
gastrointestinal symptoms in 9 (10%), perifheral polyneuropathy in 2
(2.2%) and transitory leucopenia in one patient (1.1%).
An estimated 29,500 cardiomyopathies may occur in adult Latin
American immigrants in Spain in the near future.
Conclusions: Chagas disease has now become a public health problem
in European countries receiving a large proportion of Latin American
immigrants.
O201 Double-blind, randomised controlled trial, to evaluate the
effectiveness of a controlled nitric oxide releasing patch
versus meglumine antimoniate in the treatment of cutaneous
leishmaniasis
R.G. Garcı´a °, M. Rinco´n Acelas, S.Y. Silva, M. Lopez, I.D. Velez,
D. Smith, H. Mosquera, C. Garcı´a, J.P. Lopez Jaramillo (Floridablanca,
Medellı´n, Bucaramanga, CO; Ohio, US)
Cutaneous Leishmaniasis (CL) is a worldwide disease, endemic in 88
countries, that has shown an increasing incidence over the last two
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decades. So far, pentavalent antimony compounds have been considered
the treatment of choice, with rates of curing close to 85%. However,
the high efﬁcacy of these drugs is counteracted by their adverse events.
Recently, in vitro and in vivo studies have shown that NO plays a key
role in the eradication of the leishmania parasite
Objective: To determine whether a NO donor patch (developed by
electrospinning technique) is as effective as meglumine antimoniate in
the treatment of CL while causing less adverse events
Methods: A double-blind, randomised, placebo-controlled clinical trial
was conducted with 178 patients diagnosed with CL in Santander,
Colombia, South-America. The patients were randomly assigned to two
groups. During 20 days Group 1 received simultaneously meglumine
antimoniate and placebo of nitric oxide patches while Group 2
received active nitric oxide patches and placebo of meglumine
antimoniate. Biochemical determinations (aspartate aminotransferase,
alanine aminotransferase, creatinine and pancreatic amilase) were
measured at he beginning and at the end of the treatment. A follow
up was realised 21, 45 and 90 days after the beginning of the treatment
Results: The study included 69 (38.77%) women and 109 (61.23%)
men. The average age in group 1 was 30.80±14.23 years; while in
group 2 it was 27.88±13.79 years. Clinical and demographic data were
similar in the two groups. After the follow up period, the complete
clinical healing of Group 1 was 94.81% versus 37.14% for Group 2 (p=
0.0001). Treatment with NO patches generated both, a lower frequency
of non-serious adverse events (fever, anorexia, myalgia, arthralgia,
headache), and a reduced variation in biochemistry determinations
(ASAT 26.93±8.61 vs 41.02 ±27.87UI p = 0.99; ALAT 25.05±8.79 vs
39.06 ± 35.89UI p= 0.001 and Amylase 77.13±21.1 vs 90.87±34.62UI
p= 0.0008)
Conclusions: The treatment with NO patches resulted in a lower
percentage of complete clinical response compared with meglumine
antimoniate. Despite its inferior effectiveness, the safety, the lower
frequency of adverse events, the facility of administration (topical) and
the low cost of the patches justiﬁes its evaluation in further poblational
studies, especially in populations as the Colombian ones, where the
serious adverse events due to glucantime have increased dramatically.
O202 First documented outbreak of human trichinellosis in
Taiwan: association with soft-shelled turtles
Y.C. Lo °, D.S. Jiang, C.H. Chiu (Taipei, TW)
Objectives: Trichinellosis is a zoonotic disease which has never been
reported in Taiwan and is rarely linked to consumption of reptiles. We
investigated the ﬁrst documented outbreak of trichinellosis in Taiwan
consisting of 8 patients who became acutely ill after eating at the same
restaurant in May 2008.
Methods:We conducted a retrospective cohort study by interviewing the
patients and persons who ate together with them. A case was deﬁned as
illness in an attendee who had fever (>38.0ºC) or myalgia 4 weeks after
the festivals and was seropositive to Trichinella antigen using an enzyme-
linked immunoassay and immunohistochemical staining. Environmental
study of the soft-shelled turtle farm was performed.
Results: Of the 23 attendees, 8 persons met the case deﬁnition (attack
rate = 35%). The most common presenting symptoms were myalgia
(88%), fever (88%), and periorbital swelling (38%). All 8 patients sought
medical care; ﬁve were hospitalised. Of the 7 patients who underwent
blood test, all had moderate eosinophilia. All 8 patients’ serum samples
were strongly reactive to Trichinella excretory-secretory antigen. The
only food item signiﬁcantly associated with illness was the raw soft-
shelled turtle meat (relative risk undeﬁned; p = 0.005). Traced back to
the farm, histological examination of soft-shelled turtles was negative
for Trichinella species.
Conclusion: The most likely cause of this outbreak was consumption of
raw soft-shelled turtle served in the festivals. This investigation indicates
Taiwan is not free of trichinellosis. Prevention and control programs of
trichinellosis should be established. The public should be aware of the
risk of acquiring trichinellosis from consumption of raw soft-shelled
turtle.
O203 Rapid ﬁve-minute Giemsa staining for detection of malaria
parasites in blood smears
M. Jager °, R. Pique, C. Vandenbroucke-Grauls, T. Hekker (Amsterdam,
NL)
Objective: To develop and evaluate a modiﬁed, rapid Giemsa
staining procedure for detection of malaria parasites in blood smears.
Disadvantage of the rapid commercially available staining methods is
that they require highly experienced technicians for interpretation of
results because the interpretation can be difﬁcult. For this reason, many
laboratories use the Giemsa stain. Shorter Giemsa staining times have
been reported previously, however, to our knowledge, the effect of 5 and
10 minute staining in different Giemsa dilutions have not been evaluated.
Methods: The stock solution of Giemsa stain (Merck, Darmstadt,
Germany) was used in different dilutions (1:10 and 1:5) and incubated
for different lengths of time (10min and 5min). The staining effect was
compared to our standard Giemsa stain (1:40, 45min). Sensitivity was
determined by examining smears of P. falciparum from fresh and EDTA
blood. The level of parasitaemia was followed in two patients admitted
to our hospital with P. falciparum parasitaemia’s of 21.5% and 28.8%
(see table; patient A and B) by examination of blood smears taken at
different time points after initiation of therapy. These samples were used
to evaluate the different Giemsa dilutions and staining times. Smears
were read by three independent observers (a clinical microbiologist,
a laboratory technician specialised in parasitology, and a resident in
clinical microbiology).
Results: In the table results of the three staining methods on blood
from two patients from Ghana with high parasitaemia’s on admission
and during follow-up are shown. All smears were equally easy to read
and yielded parasite counts within internationally accepted ranges of
variation (see United Kingdom National External Quality Assessment
Service).
Conclusion: Staining blood smears for detection of Plasmodium
falciparum parasites with a 1:5 dilution of Giemsa stain for ﬁve minutes
provides easy to read slides and results comparable to those obtained
with the standard Giemsa staining. Advantage of the rapid method is the
shorter turnaround time, disadvantage is the larger amount of stain used.
O204 Innovation in diagnosis of gastrointestinal protozoan
parasites
S. Gross, V. Hurgin °, J. Kopelowitz, O. Babai, A. Hananel, V. Sasson,
Z. Greenberg (Ashdod, IL)
Objectives: Diarrhoeal diseases are common in developed and
developing countries and are major causes of morbidity and mortality
worldwide. The need to differentially diagnose protozoan parasites
versus other gastrointestinal (GI) aetiologies is well recognized. The
most common GI protozoan parasites infecting humans worldwide are
considered to be Entamoeba histolytica, Giardia lamblia, Blastocystis
hominis, Dientamoeba fragilis and Cryptosporidium spp. Laboratory
detection of these parasites is relying on microscopic analysis of stool
samples and water concentrates, as well as enzyme immunoassay (EIA)
tests. Utilising the microscopic examination usually results in under-
detection of GI parasites, while usage of EIA is often not cost-effective.
Methods: Savyon Diagnostics is currently engaged with developing an
approach aiming to address the unmet needs and the current limitations in
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this ﬁeld. This approach includes 3 major aspects: (1) the ability to detect
a panel of all the above 5 organisms in one test kit, (2) the possibility
to perform the diagnosis in two steps − ﬁrst, simultaneous detection of
these organisms without distinguishing between the different species for
screening of large number of specimens, and second, distinctive detection
of the speciﬁc aetiology in the positively-found specimens, and (3) the
ability to apply EIA diagnosis in formalin-preserved specimens for all
the mentioned parasites.
Results: Polyclonal antibodies were produced in-house based on native
antigen extracts, recombinant antigens and synthetic peptides. The
resulted inventory of antibodies enabled ﬁnding the optimal combination
that provided the desired performance parameters for separate detection
of each of the parasites in fresh, frozen or formalin preserved faeces
specimens. The analytical limit of detection and the performance in
characterised clinical specimens were comparable to microscopy or to
reference EIA, when available. The results show unique detection of
E. histolytica in formalin-preserved specimens, which is comparable to
detection in fresh specimens.
Furthermore, we demonstrate simultaneous detection of the parasites
without compromising performance characteristics in fresh or preserved
specimens.
Conclusions: The presented work is a paradigm of an innovative
approach, expected to advance the diagnosis of protozoan parasites in
GI patients, thus, enabling appropriate and cost-effective diagnosis and
treatment.
Bacterial bioﬁlm: from formation to
treatment
O205 Bioﬁlm formation during tumour colonisation by Salmonella
typhimurium
K. Kochru¨be °, K. Westphal, H. Lo¨ssner, M. Rhode, K. Wolf, S. Weiss
(Braunschweig, DE)
Objectives: Systemic administration of certain facultative anaerob
bacteria to mice bearing solid tumours leads to accumulation in tumours
compared to normal target organs, like spleen and liver, and to
retardation of tumour growth. Salmonella enterica serovar Typhimurium
(S. typhimurium) as well as Escherichia coli 1917 Nissle (EcN) are such
bacteria. Preliminary experiments showed that such bacteria that exhibit
the ability to form bioﬁlms in vitro might also do so in tumours. In the
present study this was systematically investigated.
Methods: Bioﬁlm formation of bacteria were detected on low-salt
bioﬁlm plates. Additionally, Salmonella- or E. coli-infected CT26-
tumours of BALB/c mice that were left untreated or were treated with
anti-Gr1 to deplete neutrophilic granulocytes were removed two days
post infection, ﬁxed and prepared for electron microscope analysis. The
expression of different genes which are probably involved in the bioﬁlm
formation were tested via Real-time PCR.
Results: When examined after colonising tumours S. typhimurium
SL7207 and SL1344 as well as EcN are almost exclusively found
extracellular although they are able to invade the CT26 cells in vitro.
Interestingly, like in vitro all three bacteria form bioﬁlms to various
extend when residing in the tumours. This was followed in more detail
for S. typhimurium SL7207. Bioﬁlms were not formed by SL7207 when
neutrophils had been removed by antibodies. In addition, when ardA a
central switch for bioﬁlm formation in the Salmonellla had been deleted
no bioﬁlms could be found. Importantly, now bacteria could be found
intracellularly most likely in neutrophilic granulocytes.
Conclusion: The formation of bioﬁlms by facultative anaerobic bacteria
when residing in solid tumours is a novel and surprising ﬁnding. When
neutrophils were removed, no bioﬁlms are formed, while uptake into
neutrophils is allowed when the ability of the bacteria to form bioﬁlms
was blocked. Hence, it appears that the bacteria use bioﬁlm formation
as a defence system against the immune system of the host.
O206 RamR: a dual regulator of antibiotic susceptibility and
bioﬁlm formation in Klebsiella pneumoniae Kp342
J. Findlay, T. Schneiders ° (Edinburgh, UK)
Objectives: RamA is an AraC/XylS family transcriptional activator
found in Klebsiella pneumoniae, Salmonella spp. and Enterobacter spp.,
the overexpression of which is associated with an MDR phenotype.
Recently a tetR-like gene that lies upstream of ramA, known as ramR,
has been identiﬁed as a repressor of ramA. K. pneumoniae Kp342 is
a diazotrophic endophyte strain which has been reported to exhibit
notable resistance to antibiotics. Despite its MDR phenotype Kp342
has been shown to exhibit attenuated pathogenicity in mouse models
in comparison to clinical K. pneumoniae strains. The aims of this
study were to: determine the levels of ramA expression and establish
its role in Kp342’s MDR phenotype; determine the effect of ramR
complementation on ramA expression and antibiotic susceptibility.
Methods: Genome and sequence analysis performed in K. pneumoniae
strain Kp342 demonstrated a 96 bp deletion within the ramR gene.
Cloning and complementation with full size wild type ramR was
performed in Kp342 (hereby known as Kp342/ramR). RT-PCR was used
to assess levels of gene expression which were subsequently quantiﬁed
using Bio-Rad Quantity One software. MIC testing was performed
against chloramphenicol (Cm), norﬂoxacin (Nor) and tetracycline (Tet)
according to BSAC guidelines. Bioﬁlm formation was measured using
a modiﬁed protocol of O’Toole and Kolter.
Results: Kp342 containing the mutated ramR gene (96 bp deletion) was
shown to overexpress ramA and the putative outer membrane protein
romA. Complementation of the ramR gene resulted in the repression of
both ramA and romA transcription by 3−4 fold. Interestingly, the ramR
complemented strain demonstrated increased bioﬁlm formation (up to
9-fold increase) over a 72 hour period in both LB and M9 medium after
static growth at 37ºC. MICs of the tested antibiotics were reduced up to
16-fold in Kp342/ramR compared to the ramR mutated Kp342.
Conclusions: This result demonstrates that ramR acts as a repressor of
both ramA and putative outer membrane protein romA thereby increasing
its susceptibility to antibiotics. However the restoration of a functional
ramR in Kp342 also increases bioﬁlm formation signiﬁcantly, suggesting
that ramR plays a role in the regulation of bioﬁlm formation genes and
possibly bacterial virulence.
O207 In vitro effect of different classes of antibiotics on viable
mass and matrix of Staphylococcus aureus and Pseudomonas
aeruginosa bioﬁlms
K. Tote´ °, M. Deschacht, T. Horemans, D. Vanden Berghe, L. Maes,
P. Cos (Antwerp, BE)
Objectives: Bacteria and matrix are essential for the development
and maintenance of bioﬁlms; hence, antibacterials should be tested
against both components. The aim of this study was to determine class-
speciﬁc inhibitory effects of different antibiotics against bioﬁlm-forming
Staphylococcus aureus (Sa) and Pseudomonas aeruginosa (Pa) strains,
using in vitro discriminatory assays.
Methods: Twelve antibiotics were selected that represent different
classes and mechanisms of action. For every antibiotic, MIC and MBC
against planktonic microbes were determined. The antibiotics were
evaluated on bioﬁlms at concentrations ranging from 16× MBC to
MIC/4. To determine the anti-bioﬁlm spectrum of antibiotics in greater
detail, tests were performed with one bioﬁlm-producing Sa strain and
two adherent Pa strains. Sa bioﬁlms were quantiﬁed using the DMMB-
resazurin test system.[1] The dye dimethylmethylene blue (DMMB)
allows the speciﬁc colorimetric detection of the Sa bioﬁlm matrix, while
the ﬂuorescent redox indicator resazurin detects the viable bacterial
burden. Mature Pa bioﬁlms were quantiﬁed using crystal violet and
resazurin.
Results: Only four out of twelve antibiotics showed adequate efﬁcacy
against Sa bioﬁlms. Rifampicin had 50% inhibitory activity on both
matrix and bacteria at 16×MBC. Polymyxin B killed nearly all bacteria
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at 8×MBC, but leaving the matrix undisturbed. Both Pa bioﬁlms
responded differently on antibiotic treatment. Rifampicin showed highest
activity against Pa viable mass with a minimum of 93% killing of
microorganisms at MBC. Surprisingly, this was combined with a 90%
matrix inhibition at 4×MBC for only one Pa strain. The results also
showed a signiﬁcant stimulatory effect of doxycycline and polymyxin B
at sub MIC concentrations through an increase in bacterial population.
Conclusion: This study conﬁrms the unusual high resistance of both
Sa and Pa bioﬁlms to several antibiotic classes as no complete bioﬁlm
destruction is achieved at concentrations higher than their MBC.
Rifampicin showed the highest activity on bioﬁlm matrix and bacteria in
Sa and Pa bioﬁlms. Results also indicated that bioﬁlm viable mass was
more susceptible to treatment than the bioﬁlm matrix, which is mainly
responsible for bioﬁlm persistence. Further research should speciﬁcally
focus on compounds destroying matrix and which can be used as an
adjunct to antibiotic therapy.
Reference(s)
[1] Tote´ K. et al., Letters in Applied Microbiology (2008), 46, 249–254.
O208 Immunisation against SesC reduces S. epidermidis bioﬁlm
formation
M. Shahrooei °, V. Hira, B. Stijlemans, S. Kucharikova, H. Heremans,
R. Merckx, P. Van Dijck, P.W.M. Hermans, J. Van Eldere (Leuven,
BE; Rotterdam, NL; Brussels, BE; Nijmegen, NL)
Objectives: Staphylococcus epidermidis is a common cause of foreign-
body infections (FBI) because of its ability to form bioﬁlms. Bioﬁlms
are very resistant to antibiotics. Active and passive immunisation
against bioﬁlm-associated bacterial antigens may be an alternative. We
studied the effect of immunisation against the LPXTG protein SesC in
S. epidermidis bioﬁlms in vitro and in vivo. We previously reported
that SesC is present in all S. epidermidis strains tested. SesC is mainly
expressed during the early and late FBI and at a higher level in sessile
cells than in planktonic cells.
Methods: We used rabbit polyclonal anti-SesC-IgGs (4mg/ml) to study
bioﬁlm inhibition in vitro and in vivo in our rat model (50mg IgG per
rat) on 1-day old bioﬁlms. We also vaccinated rats twice with SesC
according to standard protocols. Serum samples taken at day 0 and 2
weeks after the 1st and 2nd immunisation were tested by ELISA and
showed an increase in anti-SesC antibody levels. S. epidermidis strains
10b and 1457 are bioﬁlm forming strains and have been described before.
For in vitro experiments, S. epidermidis 10b or 1457 were mixed with
anti-SesC-IgGs and incubated for 2 hours at 4ºC. Subsequently 106
cells were added to each well. After 24 h at 37ºC bioﬁlms were washed
and stained with crystal violet and OD595 was measured. For in vivo
experiments, catheter fragments were pre-incubated with S. epidermidis
10b and implanted subcutaneously in each rat. After explantation, the
average number of CFU was determined after 24 hrs.
Fig 1. Effect of active immunisation against SesC on S. epidermidis
bioﬁlms 1 and 3 days after catheter implantation.
Results: Our data show that rabbit anti-SesC-IgGs inhibit in vitro bioﬁlm
formation by S. epidermidis strains 10b and 1457 by 74% and 65%,
respectively (n = 9). In the in vivo rat model, rabbit anti-SesC-IgGs
reduced the bacteria in a 1-day old bioﬁlm 60-fold (n = 18). Active
immunisation with recombinant SesC led to a 10-fold reduction of CFU
compared to control rats in 1 day-old bioﬁlms (n = 10). After 3 days,
the reduction in bioﬁlm-associated bacteria in the immunised rats was
15-fold (n = 10) (Fig 1.).
Conclusion: SesC represents a promising target for prevention of
S. epidermidis bioﬁlm formation. The higher effect of passive
immunisation compared with active immunisation is probably due to
the subcutaneous injection of anti-SesC-IgGs at the place of catheter
insertion.
O209 Relative reverse-transcription real-time PCR and microscopy
for studying slime production by Staphylococcus epidermidis
under various physicochemical and ﬂow conditions
A. Foka °, M. Katsikogianni, V. Chini, Y.F. Missirlis, E.D. Anastassiou,
I. Spiliopoulou (Patras, GR)
Objectives: Staphylococcus epidermidis has emerged as a pathogen
associated with infections of implanted medical devices impeding their
long-term use. Characteristics of S. epidermidis that allow persistence of
infection are the ability of bacteria to adhere to surfaces in multilayered
cell clusters, followed by the production of a mucoid substance more
commonly known as slime, encoded by the ica operon. The adherent
bacteria and slime are collectively known as bioﬁlm. The coupled effects
of speciﬁc chemical terminal surface groups and ﬂow conditions on slime
production and bioﬁlm formation by S. epidermidis were investigated in
correlation to the expression of two genes of the ica operon.
Methods: Reference control strains (ATCC35984, slime-positive and
ATCC12228, slime-negative), and two clinical strains isolated from
different hospitalised patients, (one ica-positive/slime-positive and one
ica-positive/slime-negative) were tested. Bacteria grown in BHI medium
were suspended in physiological saline at a concentration of ~3×109
cells/ml. Hydroxyl (OH)-terminated (hydrophilic) and methyl (CH3)-
terminated (hydrophobic) glass surfaces were used as substrates in a
parallel plate ﬂow chamber. Bacterial adhesion was examined under two
ﬂow rates: 2ml/min and 20ml/min for two and four hours. Total RNA
from both planktonic (p) and adherent (a) bacteria, after detachment
with trypsin, was isolated by the Trizol method. Reverse transcription
followed by relative Real-Time PCR (rRT-PCR) towards a 207 bp part
of 23S rRNA gene, allowed the detection of expression levels of icaA
and icaD. Adherent bacteria were investigated with Scanning Electron
and Confocal Laser microscopes.
Results: Higher expression levels of both icaA and icaD genes onto
glass and especially methyl-terminated glass surfaces were calculated by
rRT-PCR, under higher ﬂow rate in two hours by the reference and the
clinical slime-positive strains. These results correlate well with adherent
bacterial cell counts and images taken by both microscopes. The ica-
positive slime-negative clinical strain showed lower expression levels of
ica genes, less adherent ability and PIA production on glass surfaces, as
observed by microscopes.
Conclusions: Higher ﬂow rate enhances the expression level of both ica
genes, with a peak in two hours. Hydrophobic biomaterial surfaces seem
to play a crucial role to initial adherence, increasing ica gene expression
and PIA synthesis.
Clinical trials of antibiotics: what can be
proven?
O210 Appropriate vs. inappropriate empirical antibiotic treatment:
systematic review and meta-analysis of effects and modiﬁers
V. Shani °, G. Kariv, E. Muchtar, L. Leibovici, M. Paul (Petach-Tikva, IL)
Objectives: To quantify the effect of appropriate empirical antibiotic
treatment on mortality and to assess methodological and biological
modiﬁers of this effect.
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Methods: Systematic review of prospective studies assessing the
effect of appropriate (matching in-vitro susceptibility) vs. inappropriate
empirical initial antibiotic treatment (prior to availability of susceptibility
results, IET) among adults with sepsis and microbiologically documented
infections. Duplicate reports were excluded. Unadjusted and adjusted
effect estimates were extracted and pooled using the random effects
model. Modiﬁers were assessed through subgroup analyses and meta-
regression, including baseline patient characteristics, covariates used
in adjusted analyses and study methods. Odds ratios (OR) with 95%
conﬁdence intervals for all-cause mortality are reported. OR= 1 was
imputed when results for IET were not signiﬁcant, with standard errors
matched for study’s weight.
Results: The pooled effect of IET was 2.19 (1.81−2.64, N=63 studies)
when unadjusted and 2.17 (1.73−2.72, N=47) when adjusted for other
risk factors for mortality. Unadjusted ORs underestimated the effect
of IET by 24% in studies reporting both analyses. All analyses were
signiﬁcantly heterogenous. Studies varied signiﬁcantly in the covariates
evaluated for inclusion in adjusted analyses. Assessment of in-hospital
rather then 30-day mortality (p = 0.004) and lack of adjustment for
severity score (p = 0.046) and background conditions (p = 0.013) were
associated with signiﬁcantly lower adjusted ORs for mortality. Lack
of adjustment for septic shock and neutropenia were non-signiﬁcantly
associated with higher ORs. Adjusted ORs increased with increasing
rates of IET in the studies (p = 0.002). Age was negatively associated
with ORs (p = 0.038). The effect was higher in intensive care units (OR
2.65, 1.62−4.34) than elsewhere in the hospital (OR 1.77, 1.47−2.13),
but the difference was not statistically signiﬁcant. Prospective planning
to assess the effects of IET was associated with non-signiﬁcantly higher
ORs than post-hoc analyses. The types of pathogens assessed did not
signiﬁcantly affect the observed ORs. There was no association between
study years and the effects of IET.
Conclusions: The pooled odds for mortality with IET is 2.17 with
narrow conﬁdence intervals. Methodological variables, more than
biological effects, affect the ORs reported in different studies.
O211 Efﬁcacy and safety of linezolid as treatment of proven diabetic
foot infections caused by methicillin-resistant S. aureus.
Preliminary report of a non-comparative Spanish trial
R. Zaragoza °, J. Blanes, J. Flores, A. Chaco´n, E. Escudero on behalf
of the MRSA Foot Infections Spanish Group
Background: The aim of this study was to assess the clinical efﬁcacy
and safety of linezolid (L) treating documented diabetic foot infections
(DFI) caused by MRSA.
Methods: This non-comparative multicentre open-label trial was
conducted at 10 sites in Spain from September 2006 through Jan 2008.
Consenting men and women with DFI (predeﬁned by clinical signs and
symptoms) caused by MRSA were potentially eligible including those
associated with bacteraemia. Patients with initial osteomyelitis were
excluded. Patients could receive L 600mg bid either iv or po. Primary
end point were cure or improvement rates (C+I) and microbiologic
eradication (ME) at 60 days after the beginning of L. Secondary end
points were C+I on days 5 and 30 after the beginning of treatment
and hospital discharge day, need of amputation, duration of therapy and
mortality rates. All the adverse events were collected.
Results: 70 patients were enrolled. Relation men:women was 2.1.The
age of patients was 63.2±13 years and the average period from the
diagnosis of diabetes was 16.5±9.7 years. Associated bacteraemia was
present in 27.1% of patients included. Primary end points: C+I 60 days
after the beginning of L was achieved in 91.4% of patients and ME
was obtained in 84.3% of patients. Secondary end points: C+I on day
5, hospital discharge day and day 30 after the beginning of treatment
and were; 70%; 84.3% and 88.6% respectively. Only 8 patients needed
a minor amputation. The primary and secondary end points in the
subgroup of bacteraemic episodes were not statistically different of those
previously described. The mean duration of therapy was 29.5±18.4 days.
Global mortality was 4.3%. Only one episode of polineuropathy was
reported. Neither thrombocytopenia nor lactic acidosis was found.
Conclusions: L achieved excellent C+I even at ﬁrst evaluation visit
in documented DFI caused by MRSA. L also showed high ME rates.
Although patients received prolonged periods of treatment, L was a safe
drug.
O212 Single-dose azithromycin microspheres versus 5-day
moxiﬂoxacin in acute exacerbation of chronic bronchitis
Y. Zhang °, D. Zhu, T.C. Atienza, M.L. Ong on behalf of the ASSET
Study Group
Objectives: Azithromycin microspheres formulation (AZM) was devel-
oped to enable a higher dosage of 2 g to be administered as a single oral
dose without decreasing the safety proﬁle. This study compared AZM
with moxiﬂoxacin (MOX) aimed at conﬁrming the efﬁcacy and safety
of AZM in acute exacerbations of chronic bronchitis (AECB).
Methods: This prospective, multicentre, randomised, double-blind,
double dummy study compared AZM 2g single dose with MOX 400mg
once daily for 5 days, enrolled AECB patients 50 years old and above,
with Anthonisen Type 1 exacerbations, and with at least 2 exacerbations
of AECB in the past 12 months. Subjects were to have a history of
smoking of at least 20 pack-years and documented forced expiratory
volume in 1 second (FEV1) less than 80% of predicted. They were
followed up for up to 9 months.
Results: A total of 396 patients were treated (198 in each of the treatment
groups) The distribution of the age, and mean FEV1 were similar for the
2 treatment groups. Pathogens were isolated from 62.9% of the patients
(61.1% of patients on AZM and 62.9% of patients on MOX).
The clinical success (signs and symptoms related to the acute infection
had returned to the subject’s normal baseline level, or clinical
improvement was such that no additional antibiotics were deemed
necessary) rate for the Per Protocol Population at Test of Cure (TOC)
at Day 12−19 was 93.0% for AZM and 94.2% for MOX group (95%
CI −5.8, 3.9). Bacterial eradication rate (Bacteriologic Pre Protocol
population) at TOC was 96.0% for AZM group and 96.7% for MOX
group (95% CI −4.5, 3.3). Although the study population had history
of at least 2 exacerbation in the past 12 months, less than half of
the subjects experienced a recurrence during the follow-up, and there
was no statistically signiﬁcant treatment difference in time taken to ﬁrst
occurrence of AECB.
Both treatments were well tolerated. The incidence of treatment related
adverse events was low, being reported by 17% of subjects receiving
AZM and 12% of subjects receiving MOX. Most AEs were mild or
moderate in severity. The most common AEs were gastrointestinal
disorders, being reported by 14% of subjects receiving AZM and 8%
of subjects receiving MOX.
Conclusions: A single oral dose of AZM was as effective as a 5-day
course of MOX in the treatment of AECB and was well tolerated.
O213 Optimal duration of gentamicin containing regimen for the
treatment of uncomplicated brucellosis
M.R. Hasanjani Roushan °, M.J. Soleimani Amiri, N. Janmohammadi,
M. Javanian, M. Baiani (Babol, IR)
Objectives: Optimal duration of gentamicin containing regimen for
therapy of human brucellosis is not clearly determined.
Methods: This randomised clinical study was conducted to compare
the efﬁcacy of gentamicin 5mg/day for 5 days plus doxycycline 100mg
twice daily for eight weeks (GD group) versus streptomycin 1gr IM for
2 weeks plus the same dose of doxycycline for 45 days (SD group). All
cases were followed for one year after cessation of therapy. Efﬁcacy of
both regimens (failure of therapy or relapse) were compared.
Results: Seventy-nine patients with the mean age of 35±14.5 years
and 75 cases with the mean age of 36.7±13.9 years were treated with
regimen of GD or SD, respectively. The clinical manifestations in these
two treated groups were similar. Failure of therapy was seen in one
patient in GD group and in 2 cases in SD group (95%CI, 0.042 to
5.271, OR= 0.468, p = 0.613). Relapse was seen in 2 (2.5%) cases in
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GD group and in 5 (6.7%) cases in SD group (95%CI, 0.067 to 1.905,
OR= 0.358, p = 0.264)
Efﬁcacy of therapy was seen in 76 (96.2%) cases treated in GD group and
in 68 (90.7%) cases in SD group (95%CI, 0.095 to 1.542, OR= 0.383,
p = 0.201). Risk for developing of relapse and failure of treatment in
patients treated with SD group was 2.61 times higher than those treated
with SD group (95% CI, 0.649−10.486, p = 0.201).
Conclusion: Efﬁcacy of gentamicin for 5 days plus doxycycline for 8
weeks is similar with that of streptomycin for 2 weeks plus doxycycline
for 45 days.
O214 Telavancin for the treatment of major skin and soft tissue
abscesses: the ATLAS studies
G.R. Corey, E. Rubinstein, S.L. Barriere, A. Hopkins, M.E. Stryjewski °
on behalf of the ATLAS Study Group
Objectives: To study the efﬁcacy of telavancin (TLV), an investigational
bactericidal lipoglycopeptide, for the treatment of complicated skin and
soft tissue infections (cSSTI) caused by presumed or conﬁrmed Gram-
positive organisms.
Methods: ATLAS 1 and ATLAS 2 were methodologically identical,
double-blind, randomised, multinational, Phase 3 studies. Adult men and
women presenting with cSSTI including major abscess were randomised
1:1 to TLV 10mg/kg intravenous (IV) q24 h or vancomycin (VAN) 1 g
IV q12 h for 7 to 14 days. Test-of-cure (TOC) visit was conducted
7 to 14 days after end of study treatment. The all-treated population
(AT) included patients with conﬁrmed diagnosis of cSSTI who received
1 dose of study medication. This analysis examined the baseline
characteristics and cure rates at TOC for patients with major abscess
in the combined ATLAS AT population.
Results: In the pooled AT population of ATLAS, 772 patients
presented with major abscess. More than 60% of these patients required
hospitalisation. The baseline lesion surface area exceeded 5 cm2 in 98%
of the cases, while 65% of the patients presented with lesions exceeding
50 cm2 (Table 1). Elevated white blood cell counts were found in more
than 40% of the cases (Table 1). Nearly all patients required surgical
drainage, with approximately 2/3 performed prior to the ﬁrst dose of
study medication. Very few patients required a surgical procedure more
than 4 days after the start of study medication. Clinical cure rates at TOC
are presented in Table 1. Overall, adverse events in the AT population
were similar between the treatment groups with regard to type and
severity.
Conclusion: Telavancin administered once daily was non-inferior to
vancomycin for the treatment of major abscess.
Table 1. Signs, symptoms and cure rates in patients with major abscess −
combined all-treated population
TLV
(N= 375)
VAN
(N= 397)
Fever >38ºC 44 (12%) 52 (13%)
WBC >10×109/L 152 (41%) 169 (43%)
Bacteraemia 10 (3%) 7 (2%)
Lesion size 5 cm2 368 (98%) 385 (97%)
Lesion size 50 cm2 248 (66%) 252 (64%)
Cure rates at TOC 289 (77%) 296 (75%)
Does antibiotic resistance matter when
treating anaerobic infections? (Symposium
arranged with the ESGARAB)
S217 Changes in the antibiotic resistance of Bacteroides fragilis
group strains in Europe: 20 years of experience
E. Nagy ° (Szeged, HU)
Objectives: B. fragilis and related species, members of the normal bowel
ﬂora, are the most widely isolated anaerobic bacteria from different
infections. To follow the development and spread of the resistance among
these strains is difﬁcult, as antibiotic susceptibility testing of clinically
relevant anaerobes in different routine laboratories in Europe is less and
less frequently carried out due to the fact, that clinicians treat many
presumed anaerobic infections empirically. To follow the changes in the
antibiotic resistance of Bacteroides strains three Europe-wide studies
were organised during the past twenty years. The evaluation of the results
of these studies may show changes in the resistance to different anti-
anaerobic drugs.
Methods: Only clinical isolates and no normal ﬂora members of
Bacteroides strains belonging to different species were collected from
different countries throughout Europe during these studies. Agar dilution
method was used for the antibiotic susceptibility determination. Actual
breakpoints accepted by NCCLS (CLSI) and EUCAST were used.
Molecular genetic investigations were carried out to detect resistance
mechanisms.
Results and Conclusions: Since the ﬁrst study the chromosomally
mediated beta-lactamase production and tetracyclin resistance is the most
prevalent among Bacteroides strains in Europe. Clindamycin resistance
in Bacteroides is mediated by a macrolide-lincomycin-streptogramin
(MLS) mechanism and its frequency differs in different countries in
Europe. Resistance to beta-lactam-beta-lactamase inhibitor combinations
was studied using amoxicillin-clavulanic acid and/or piperacillin-
tazobactam. Increase in resistance was observed to both combinations
throughout the years. The same is true for cefoxitine and in the third
study several hetero-resistant isolates were found. The occurrence and
spread of resistance to imipenem and metronidazole among Bacteroides
strains merit special clinical importance. The presence of the cﬁA
gene is much more prevalent than the expression of the imipenem
resistance; however the spread of the cﬁA gene among species other
than B. fragilis is still very rare. The molecular genetic methods looking
for the resistance genes among strains with elevated MICs against these
antibiotics prove that resistance breakpoints should be reconsidered. The
resistance to moxiﬂoxacin shows great differences in different countries.
The lowest resistance rate was observed in the case of tigecyclin.
S218 The relevance of susceptibility testing in anaerobes
L. Dubreuil ° (Lille, FR)
Many factors may affect the response to treatment such as site of
infection, surgical procedures, severity of the illness, patient status,
presence of other pathogens (mixed infection), Pk/Pd parameters of
the antibacterial drugs. Thus, correlation between treatment failure
and antibiotic resistance among anaerobes remains difﬁcult to assess.
The main discrepancies came from intra-abdominal infections and a
worrisome disjunction between surgeon and microbiologist opinions
emerged in the 1990’s. But, patients in whom primary therapy failed
had more resistant strains compared with patients in whom therapy
succeeded. In contrast many failures may be due to the lack of isolation
of anaerobes from clinical samples! During anaerobic bacteraemia,
Salonen et al. demonstrated that mortality increased dramatically from
17% for initially effective treatment to 55% when an ineffective treatment
was started. Facing new mechanisms of resistance and global increase
resistance to many antibiotics among anaerobes may lead nowadays to
a different answer. Clindamycin vs. penicillin studies for the treatment
of lung infections pointed out the failure due to b-lactamase production
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among Gram-negative anaerobes. We found many reports of failure after
clindamycin treatment in osteomyelitis, septic arthritis, brain abscess in
presence of clindamycin-resistant anaerobes (Bacteroides fragilis group
and Prevotella), probably because when resistance occurs, clindamycin
MIC’s are high. Similarly, the lack of coverage of an undetected resistant
anaerobe allows the selection of an anaerobic strain resistant to the
treatment chosen against the associated aerobes such as imipenem-
resistant Eghertella lenta or metronidazole-resistant strains of Prevotella
or Bacteroides fragilis. The later failures may give opportunity to set
up a new metronidazole breakpoint for resistance (MIC> 4mg/L). The
main problem is related to the difﬁculty to detect some heterogeneous
resistant strains, that needs prolonged incubation period on agar medium.
This kind of situation is probably the most suitable to correlate the
bacterial antibiotic resistance with the failure of the antibiotic treatment.
The difﬁculty to detect heterogeneous resistant strains may explain
some failures observed during metronidazole treatment of C. difﬁcile.
Clinicians should be encouraged to publish the clinical failures of their
ﬁrst line treatments when associated with a bacterial resistance among
anaerobic bacteria.
Community-acquired MRSA (Symposium
arranged with the ICAAC Program
Committee)
S221 What we know about the pathogenesis of CA-MRSA
infections?
J. Etienne °, G. Lina, F. Vandenesch (Lyon, FR)
The pathogenesis of CA-MRSA has to be considered according to the
spectrum of human infections. The USA300 and the European ST80-
IV clones which contain the Panton Valentine leukocidin (PVL) genes,
are responsible for skin and soft tissue infections. PVL is expressed
in skin abscesses with concentrations up to 2mg/L and PVL-positive
S. aureus strains elicit signiﬁcant anti-PVL antibody production in
humans. Intra-dermal injection of PVL (rLukS-PV and rLukF-PV) in
rabbits caused a severe dermonecrosis. Mice infected intradermally with
USA300 S. aureus or the isogenic D-pvl derivative did not differ in the
superﬁcial sizes of the lesions but in the depth of the infection. Active
immunisation with rLukS-PV or LukF-PV protects rabbits against PVL
induced dermonecrosis. Mice subcutaneously vaccinated with LukF-PV
and LukS-PV are protected against an intradermal infection.
PVL-positive CA-MRSA are responsible for necrotising pneumonia.
PVL is detected in broncho-alveolar lavages from patients with
necrotising pneumonia with concentrations up to 20mg/L. In a murine
model of pneumonia, PVL-positive clinical strains of S. aureus,
laboratory strains lysogenised with the PVL-encoding phage, and
puriﬁed PVL all cause histological lung changes similar to those seen in
patients with necrotising pneumonia. The LukS-PV subunit administered
intranasally protects mice against USA300-induced pneumonia.
PVL-positive CA-MRSA bone and joint infections need repeated
surgical drainage and require prolonged treatment. Experimental
osteomyelitis with PVL positive strain in rabbits are characterised
as an aggressive infection with rapid local extension, in contrast to
osteomyelitis due to PVL negative strain.
Other clones of CA-MRSA contain other virulence factors such as the
toxic-shock toxin (tst) gene. A tst-positive MRSA clone is associated
with community infections such as cellulitis and systemic infections
(scarlet fever and toxic shock syndrome). This clone has not been tested
in any experimental models, but the role of superantigens such as TSST-1
in the pathogenesis of certain infections is well known.
In total, a diversity of virulence factors is associated with the diversity
of CA-MRSA clones and CA-MRSA infections. Depending of the type
of infections, certain virulence factors have a predominant role. For
instance, PVL appears to play a crucial pathogenic role in CA-MRSA
necrotising pneumonia.
S223 Paediatric approach to the management of CA-MRSA
infections
S. Kaplan ° (Houston, US)
Methicillin-resistant S. aureus isolates causing community-acquired
infections (CA-MRSA) in children is a major problem in several
areas around the world. CA-MRSA are associated with both skin and
soft tissue infections and invasive infections. Recurrent soft tissue
infections and infections within the family caused by CA-MRSA
isolates are common. CA-MRSA S. aureus isolates containing gene
coding for PVL have been associated with serious staphylococcal
pneumonia as well as osteomyelitis complicated by subperiosteal
abscesses or venous thromboses. In addition to vancomycin, CA-
MRSA generally are susceptible to clindamycin and trimethoprim-
sulfamethoxazole. Treatment of superﬁcial skin and soft tissue infections
involves surgical drainage of abscesses followed by an oral agent
such as TMP-SMX or clindamycin. Minocycline or doxycycline is
a consideration for children >8 years old. Empiric vancomycin is
typically administered for more serious and invasive infections such
as osteomyelitis, septic arthritis, serious head and neck infections or
suspected Staphylococcal pneumonia. Clindamycin is efﬁcacious in
treating invasive CA-MRSA infections caused by susceptible organisms.
Linezolid or daptomycin is another option in selected circumstances.
MRI is the optimal imaging modality for assessing children with CA-
MRSA osteomyelitis. Aggressive surgical drainage of subperiosteal
abscesses or sites of pyomyositis is recommended. Venous thombosis is
increasingly recognized as a complication of CA-MRSA osteomyelitis.
Anti-coagulation until the thrombus has resolved is recommended. The
optimal approach to prevention of recurrent CA-MRSA infections is
unclear but a strategy that includes emphasizing personal hygiene,
plus/minus antimicrobial soaps, mupirocin to the nose or “bleach baths”
is frequently suggested.
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S226 Understanding the pathogenesis of group A streptococcal
disease: the bedside-to-bench approach
S. Sriskandan ° (London, UK)
Invasive group A streptococcal (GAS) infection presents itself in a range
of guises, most notoriously necrotising fasciitis and the streptococcal
toxic shock syndrome. As a human pathogen, GAS pathogenesis research
should ideally be shaped by clinical questions arising from either
epidemiological or case-based investigation of human disease. In the mid
1990 s, large epidemiological studies pointed to a central role for speciﬁc
T cell-stimulating superantigens in the aetiology of streptococcal toxic
shock. This sparked a series of clinical and laboratory investigations
that demonstrated production of superantigens during infection which
were indeed capable of triggering massive T cell activation in patients
but were unlikely, alone, to account for all the features observed in
toxic shock. Genomic, clinical and laboratory-based investigations have
identiﬁed novel and highly potent superantigens that appear to directly
contribute to sepsis pathogenesis and, together, may constitute targets
for adjunctive treatments in invasive disease.
Epidemiological, clinical, and laboratory studies have highlighted a role
for blunt trauma in the aetiology of at least a quarter of cases of GAS
necrotising fasciitis. One of the most striking ﬁndings on examination of
tissues from patients suffering with necrotising fasciitis is the failure of
neutrophils to migrate to the focus of infection. Investigation of patients
with invasive GAS infection led to the discovery that GAS produces
an enzyme that can cleave and inactivate human chemokines and study
of patients with bacteraemia has highlighted a likely role for the causal
enzyme SpyCEP in disease pathogenesis; this bacterial surface enzyme
has also shown promise as a potential vaccine antigen. Notwithstanding
a potential role for individual virulence factors in disease causation,
clinical studies have demonstrated that GAS bacteria may persist at the
site of infection despite high concentrations of bactericidal antibiotics,
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and this has been borne out by experimental studies; the reasons behind
such persistence are unclear but may include internalisation of GAS by
immune cells, formation of bioﬁlm, and antibiotic penetration of necrotic
tissues. The persistence of viable bacteria in such cases is not widely
recognized and deserves focused consideration in the research laboratory.
S227 New understanding of group A Streptococcus pathogenesis
provided by integrated systems biology studies
J.M. Musser ° (Houston, US)
Genome-wide analysis of microbial pathogens and molecular pathogen-
esis processes has become an area of considerable activity in the last
10 years. These studies have been made possible by several advances,
including completion of the human genome sequence, publication
of genome sequences for many human pathogens, development of
microarray technology and high-throughput proteomics, and maturation
of bioinformatics. Despite these advances, relatively little effort has
been expended in the bacterial pathogenesis arena to develop and use
integrated research platforms in a systems biology approach to enhance
our understanding of disease processes. We have exploited an integrated
genome-wide research platform to gain new knowledge about how
the human bacterial pathogen group A Streptococcus causes disease.
Results of these studies have provided many new avenues for basic
pathogenesis research and translational research focused on development
of an efﬁcacious human vaccine and novel therapeutics. New data
stemming from use of a systems biology approach to provide new data
about group A Streptococcus pathogenesis will be presented.
S228 Managing group A streptococcal infection: the role of IVIg
A. Norrby-Teglund ° (Stockholm, SE)
Streptococcal toxic shock syndrome and necrotising fasciitis caused by
group A streptococcus are rapidly progressive invasive diseases that
are associated with signiﬁcant morbidity and mortality, ranging from
30−80% despite prompt antibiotic therapy and surgical debridement.
S. pyogenes is known to primarily cause disease by activating and
modulating host immune responses. The exotoxins with superantigenic
activities have been demonstrated to be crucial triggers of excessive
inﬂammatory responses and consequently systemic toxicity, organ
dysfunction, tissue necrosis and shock. Another important virulence
determinant is the M-protein, which is classically known for its anti-
phagocytic properties, and lately, was shown to trigger pro-inﬂammatory
responses as well as induction of vascular leakage and shock. This likely
represents important mechanisms contributing to the rapid development
of shock and systemic toxicity in patients with severe invasive group A
streptococcal infections. The understanding of these infections as hyper-
inﬂammatory diseases highlighted the potential of immunotherapy to
improve outcome. One such strategy includes the administration of
intravenous polyspeciﬁc immunoglobulin (IVIG) as adjunctive therapy.
The mechanistic actions of IVIG in this setting are believed to
include opsonisation of the bacteria, neutralisation of the superantigens
and suppression of the pro-inﬂammatory responses. There is growing
evidence to support the use of IVIG in patients with streptococcal toxic
shock syndrome. These studies include one observational cohort study
based on Canadian patients identiﬁed through active surveillance of
invasive group A streptococcal infections, and one European multicentre
placebo-controlled trial.
However, the question remains whether IVIG is efﬁcacious also for
the severe streptococcal deep tissue infections. An observational study
of seven patients with severe streptococcal deep tissue infections
suggested that the use of high-dose IVIG in patients with severe GAS
soft tissue infections may allow an initial non-operative or minimally
invasive approach, which can limit the need to perform immediate wide
debridements and amputations in unstable patients. The fact that seven
patients with severe group A streptococcal infections survived with this
approach deﬁnitely warrants further studies to be conducted on the use
of IVIG in these severe infections.
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O229 Prevalence and outcome of pregnancy in chronic hepatitis C
virus infection
I. Julkunen °, A. Sariola, M. Sillanpa¨a¨, K. Melen, P. Koskela, P. Finne,
A.L. Ja¨rvenpa¨a¨, S. Riikonen, H.M. Surcel (Helsinki, Oulu, FI)
Objectives: In the Western countries the incidence of hepatitis C virus
(HCV) infection has steadily been increasing especially among young
adults. It is thus likely that an increasing prevalence of HCV infection
is also found in pregnant women.
Methods: To assess the frequency of HCV infection in the metropolitan
area of Helsinki selected anti-HCV antibody testing was carried out
for pregnant women during the years 1991–1999. In addition, HCV
prevalence was analysed in serum specimens collected from pregnant
maters during the years of 1985–2005.
Results: Altogether 145 mothers were identiﬁed among 44680 mothers.
The frequency of anti-HCV positivity rose from 0.13% in 1991 to
0.43−0.53 in 1997–1999. In early 90’s only 20% of mothers knew
about their seropositivity, whereas by the end of the follow-up period
almost 70% of mothers knew about their HCV infection already before
the pregnancy. Intravenous drug abuse was the major risk factor (71%
of cases) for contracting the disease. In 90% of the mothers chronic
HCV infection was well under control and in this population the mean
serum alanine aminotransferase (ALT) values decreased towards the
end of the pregnancy. However, 10% of anti-HCV Ab positive mothers
developed intrahepatic cholestasis (odds ratio 16.4) as characterised by
itching and elevated serum bile acid levels. The correspondig value in
the control pregnancies was only 0.7%. Anti-HCV Ab positive mothers
were younger, delivered earlier and gave birth to babies with smaller birth
weight as compared to control deliveries. To have a more comprehensive
view of the problem of HCV infection during pregnancy randomly
selected serum specimens from the Finnish maternity cohort were tested.
2000–5000 serum specimens were tested in selected cohorts (1985, 1990,
1995, 2000 and 2005). In 1985 the nationwide prevalence was 0.19% and
it steadily role to 0.50% in 2005. In the metropolitan area of Helsinki
the prevalence was higher being 0.68% and 0.70 in 1997 and 2002,
respectively.
Conclusion: Our study indicates that there is an increasing problem of
HCV infection in pregnant women in Finland. Although most women
cope well with their disease during pregnancy there is a subpopulation
of mothers who develop cholestasis and their liver status should thus
be followed-up carefully. Testing of all mothers for serum anti-HCV
antibodies is recommended.
O230 HCV core, NS3, NS4B and NS5A are the major immunogenic
proteins in humoral immunity in chronic HCV infection
M. Sillanpa¨a¨ °, K. Melen, P. Keskinen, R. Fagerlund, K. Nevalainen,
K. Lamminaho, M. Lappalainen, I. Julkunen (Helsinki, FI)
Objectives: The viral genome of hepatitis C virus constitutes a 9.6-
kb single-stranded positive-sense RNA which encodes altogether 11
viral proteins. In order to study the humoral immune responses against
different HCV proteins in patients suffering from chronic HCV infection,
we produced three structural (C, E1 and E2) and six nonstructural
proteins (NS2, NS3, NS4A, NS4B, NS5A and NS5B) in Sf9 insect cells
by using the baculovirus expression system.
Methods: The recombinant HCV proteins were puriﬁed and used in
Western blot analysis to determine antibody responses against individual
HCV protein in 68 HCV RNA and antibody positive human sera that
were obtained from patients suffering from genotype 1, 2, 3 or 4
infection.
Results: These sera were also analysed with INNO-LIA Score test for
HCV antibodies against core, NS3, NS4AB and NS5A, and the results
were similar to our Western blot method. Based on our Western blot
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analyses we found that the major viral antigens were the core, NS4B,
NS3 and NS5A proteins and they were recognized in 97%, 86%, 68%
and 53% of patient sera, respectively. There were no major genotype
speciﬁc differences in antibody responses to individual HCV proteins.
A common feature within the studied sera was that all except two sera
recognized the core protein in high titers, whereas none of the sera
recognized NS2 protein and only three sera (from genotype 3) recognised
NS5B.
Conclusion: The data shows signiﬁcant variation in the speciﬁcity in
humoral immunity in chronic HCV patients. Anti-HCV antibody pattern
also remains very stable within one individual.
O231 Occult hepatitis B virus infection in “anti-HBc alone”
haemodialysis patients
A. Ramezani, A. Aghakhani, M. Mohraz, A. Eslamifar,
A. Khadem-Sadegh, M. Banifazl °, A.A. Velayati (Tehran, IR)
Objectives: Occult hepatitis B virus (HBV) infection is characterised
by presence of HBV infection with undetectable hepatitis B surface
antigen (HBsAg). Occult HBV infection harbours potential risk of HBV
transmission through haemodialysis (HD). The aim of this study was to
assess the occult HBV infection in hepatitis B core antibody (anti-HBc)
alone haemodialysis patients.
Methods: A total of 289 HD patients from ﬁve dialysis units in Tehran,
Iran were included in this study. HBsAg, anti-HBs, anti-HBc, anti-HCV,
ALT and AST levels were tested in all subjects. The presence of HBV-
DNA was determined quantitatively in plasma samples of HD patients
with anti-HBc alone (HBsAg negative, anti-HBs negative and anti-HBc
positive) by real-time PCR using the artus HBV RG PCR kit on the
Rotor-Gene 3000 real-time thermal cycler.
Results: Of 289 patients enrolled in this study, 18 subjects (6.2%, 95%
CI, 3.5%-8.9%) had anti-HBc alone. HBV-DNA was detectable in 9 of
18 HD patients (50%, 95% CI, 27%-73%) with anti-HBc alone. Plasma
HBV-DNA load was less than 50 IU/ml in all of these patients.
Conclusion: Our study showed that detection of anti-HBc alone could
reﬂect unrecognized occult HBV infection in HD patients. The majority
of these infections are associated with low viral loads.
O232 Long-term protection against carriage of hepatitis B virus
after newborn vaccination
L. Roznovsky °, A. Kloudova, L. Kabieszova, L. Hozakova, I. Orsagova,
I. Lochman, J. Mrazek, A. Zjevikova (Ostrava, CZ)
Objectives: Carriage of hepatitis B virus is a major risk factor for
liver cirrhosis and hepatocellular carcinoma. Vaccination of newborn
of hepatitis B surface antigen (HBsAg) positive mothers practically
interrupted the vertical transmission of hepatitis B virus. However it
is unknown whether protection is maintained into early adulthood.
Methods: Combine passive-active immunisation of newborns of HBsAg
positive mothers against hepatitis B was commenced in northeastern
part of the Czech Republic in 1988 year. The number of immunised
children gradually increased till the January 2009. All 715 children
were protected with hepatitis B immunoglobulin at birth. The children
received 10 microgram doses of plasma-derived or recombinant vaccine
at interval 0, 1 and 6 months, only thirty children of HBeAg positive
mothers at interval of 0, 1 and 2 months. Since 2007 year, after ﬁrst
dose of monovalent hepatitis B vaccine at birth, next 4 doses of combine
hexavalent vaccine were used. Combine vaccine contained 10 microgram
of HBsAg; ﬁrst dose was used at 6 weeks of age. Blood samples were
obtained after immunisation, at 2 years of age, and biennially thereafter.
Samples were tested by ELISA method for HBsAg, anti-HBs and anti-
HBc. The immunisation schedules were completed in 674 children.
Results: Vertical transmission of hepatitis B virus with chronic HBsAg
carrier status was proved in 2 children, escape mutant of HBsAg infected
one of them. No other breakthrough infection was observed in toddlers
or older children.
Asymptomatic infections with new appearance or long-term presence
of anti-HBc antibodies were observed in 10 children. The anamnestic
response with double increase of anti-HBs without revaccination was
proved in 68 children. Two anamnestic responses were observed in
6 of them. Anti-HBs antibodies were tested in 657 children after
immunisation; protective anti-HBs antibodies were proved in 613 of them
(93%). Waning of protective anti-HBs antibodies was detected in 30%,
49% and 62% children in 5, 10 and 13 years of their life.
Conclusion: The vaccination of neonates of HBsAg positive mothers
practically interrupted the vertical transmission of hepatitis B virus. The
study have shown persistent protection at least for 15 years after new-
born vaccination despite waning anti-HBs antibodies, suggesting there
is no need for booster before adolescence.
Grant support: IGA Ministry of Health, Czech Republic, NR/9257–
3/2007.
O233 Effectiveness of hepatitis B virus (HBV) vaccination among
persons at high risk for HIV transmission two decades after
implementation of nationwide HBV vaccination programme
in Taiwan
W.C. Liu, C.H. Wu, H.Y. Sun, C.C. Hung °, S.C. Chang (Taipei, TW)
Background: Taiwan used to be hyperendemic for hepatitis B virus
(HBV) infection and perinatal or childhood infection is the main route
for HBV transmission. Seroprevalence of HBV surface antigen (HBsAg)
was estimated 15−20% among the adults, regardless of HIV serostatus.
After implementation of nationwide HBV vaccination program in Taiwan
in 1 July, 1984, several epidemiological studies among children have
shown that seroprevalence of HBsAg has declined signiﬁcantly among
the children who were born after 1984. Long-term effectiveness of this
program among persons at high risk for HIV transmission, however, is
unknown in Taiwan.
Methods: HBV serological markers (HBsAg, anti-HBs antibody, anti-
HBc antibody) were determined among HIV-negative homosexuals
or heterosexuals who presented for voluntary HIV counseling and
testing (VCT group) (N = 397), HIV-positive homosexuals or het-
erosexuals (HIV sexually-transmitted group) (N = 69), HIV-positive
and HIV-negative injecting drug users (IDU group) (N = 59), and
persons undergoing health check-up for military services (healthy
controls) (N = 856). All of the subjects were born after July 1, 1984.
HBV serological markers were determined using a commercial kit
(ANTICORASE B-96, General Biologics Corp., Hsin-Chu, Taiwan).
Results: Seroprevalence of HBsAg, anti-HBs antibody and anti-HBc
antibody was 2.8%, 52.4%, and 27.7%, respectively, for VCT group
(mean age, 20.7 years). The respective value of the three HBV
serological markers for HIV-positive sexually-transmitted group (mean
age, 22.3 years) was 1.7%, 73.1%, and 20.5%; for IDU group (mean age,
22.6 years), 3.7%, 80.9%, and 35.3%; and for healthy controls (mean age,
23.0 years), 8.5%, 66.7%, and 27.9%. The seroprevalences of HBsAg
and anti-HBc antibody were not statistically signiﬁcantly different when
comparisons were made among the three groups of persons at risk for
HIV infection, while VCT group had a lower prevalence of HBsAg
compared with control group (P< 0.001). In contrast, seroprevalence
of anti-HCV antibody was 5.2% for HIV-positive sexually-transmitted
group and 96.2% for IDU (P< 0.0001).
Conclusions: Our ﬁndings suggest that persons born in the era of
nationwide HBV vaccination that was initiated in Taiwan two decades
earlier remain to have a low prevalence of HBV infection despite their
risky behaviours for both HIV and HBV transmission.
AIDS and HIV
O234 Primary resistance among HIV-1 positive patients naive to
antiretroviral therapy
L. Skoura °, A. Papoutsi, E. Papadimitriou, P. Kollaras, I. Ntoutsos,
P. Nikolaidis, N. Malisiovas (Thessaloniki, GR)
Objective: The aim of the study was to estimate the prevalence
of genotypic resistance among HIV-1 positive patients naive to
antiretroviral therapy, since primary resistance has emerged as a potential
S52 19th ECCMID, Oral presentations
barrier to the successful antiretroviral therapy and a threat for further
transmission of resistant variants.
Methods: 218 newly diagnosed cases, reported to the National AIDS
Reference Laboratory of Northern Greece between 2006 and 2008,
were included in the study. All the subjects had never been exposed
to antiretroviral therapy. Genotypic resistance testing was performed at
the time of diagnosis with a sequence-based assay (TRUGENE HIV-1
genotyping test) targeted at the protease region (codons 1 to 99) and RT
region (codon 40 to 247) of the HIV-l genome.
Results: 21 of 218 patients (9.63%) harboured a virus with at least one
mutation associated with phenotypic resistance; 1/218 with mutations
associated with resistance to nucleoside reverse-transcriptase inhibitors
(NRTIs), 17/218 to non-nucleoside reverse-transcriptase inhibitors
(NNRTIs) and 3/218 to protease inhibitors (PI). Resistance to NRTIs was
associated with the key mutation M184V, while resistance to NNRTIs
was associated with Y181C and K103N mutations. Among mutations
to PI, major resistance mutations L90M and D30N were found in three
patients, whereas there was a high prevalence of accessory PI resistance
mutations at positions 10, 20, 36 and 63.
Conclusion: Our data estimate the prevalence of primary resistance and
mutations patterns among naive HIV patients, underlining the importance
of genotypic resistance testing in HIV patients before starting treatment,
especially when NNRTIs would be included in the initial antiretroviral
therapy.
O235 Comparison of protease inhibitor resistance-associated
mutations between protease inhibitor-naive and protease
inhibitor-experienced HIV-1 infected patients in Thailand
where subtype A/E is predominant
S. Wiboonchutikul, S. Sungkanuparph °, C. Sukasem, W. Chantratita
(Bangkok, TH)
Objectives: Few data are available on the genetic mechanisms of
protease inhibitor (PI) resistance in non-B HIV-1, and PI resistance-
associated mutations (RAMs) are commonly observed in PI-naive
patients with subtype A/E infection. This study aimed to compare PI-
RAMs between PI-naive and -experienced patients.
Methods: Genotypic resistance testing was conducted among a cohort
of HIV-1 infected patients who had virologic failure. Patients were
categorised into 2 groups: PI-naive and PI-experienced. We focused on
PI-RAMs previously described by IAS-USA 2008.
Results: We studied 137 patients (mean age, 41.8 years; 64% male).
Median CD4 cell count and HIV-1 RNA at virologic failure were 169
cells/cu.mm. and 14100 copies/mL, respectively. 85% of patients were
infected with subtype A/E; the others had subtype B (12%), AB (2%),
and C (1%). There were 75 patients in PI-naive group and 62 patients
in PI-experienced group. The clinical characteristics between 2 groups
were similar (p> 0.05) except for the duration of antiretroviral therapy
which was shorter in PI-naive group (31.5 vs. 46.8 months, p = 0.028).
Percentage of patients who had primary PI-RAMs was 1% in PI-
naive and 19% in PI-experienced groups (p = 0.001). The most common
primary PI-RAMs in the latter group were V82A (10%) and I54V (7%).
Percentage of patients with secondary PI-RAMs in the corresponding
groups was 99% and 98%, respectively (p = 1.000). Median number of
secondary PI-RAMs was also similar between 2 groups (p = 0.244).
The most common secondary PI-RAMs in both groups were M36I
(91%), H69K (34%), L89M (30%), I13V (26%), L63P (25%), L10I
(18%), and K20R (18%). Interpretation of genotypic test results with
TRUGENE HIV-1 Software showed that resistance to atazanavir,
darunavir, indinavir, lopinavir, nelﬁnavir, and saquinavir were observed
only in PI-experienced patients and signiﬁcantly higher (p< 0.05)
whereas resistance to amprenavir, fosamprenavir, and tipranavir were
found in both PI-naive and PI-experienced patients (p> 0.05).
Conclusion: Primary PI-RAMs are observed exclusively among PI-
experienced patients whereas secondary PI-RAMs are equally found
in both PI-naive and PI-experienced patients. Secondary PI-RAMs
previously described by IAS-USA are common among PI-naive
patients with subtype A/E infection. PI resistance (esp. amprenavir,
fosamprenavir, and tipranavir) should be interpreted with caution.
Further study for clinical validation of PI-RAMs in HIV-1 subtype A/E
is essentially needed.
O236 HIV-1 pol evolution under lamivudine pressure
V. Micheli °, M. Zazzi, P. Meraviglia, P. Corsi, A. Gonnelli, G. Penco,
A. Callegaro, F. Maggiolo, N. Gianotti, L. Calza, L. Butini, G. Casazza,
M.R. Gismondo (Milan, Siena, Florence, Genoa, Bergamo, Bologna,
Ancona, IT)
Background: In vitro assays on HIV-1 RT suggest that replicative
ﬁdelity is increased in enzymes with RT-M184V mutation. That could
be associated with a reduced ﬁtness shown by M184V+ strains. M184V
can affect replicative capacity in vivo too.
Objective: to assess the impact of M184V on the genetic stability of
HIV-1 PR and RT.
Methods: We selected 280 HIV-1 experienced patients analysed for
PR and RT sequences from the Italian ARCA database (Antiretroviral
Resistance Cohort Analysis): 151 M184V+ (group A) and 129 M184V−
(group B) [mean (sd) VL: 4.01 Log (0.72) cps/mL]. Two consecutive
HIV-1 genotypic tests were available for all patients with a median (IQR)
distance of 247 (161–411) days; in all cases M184V presence/absence in
the second test was conﬁrmed. All patients were on therapy, none made
STI, none changed the ARV regimen after the ﬁrst test and none reached
VL< 50 cps/mL in the period between the tests, in order to minimise the
changes of the selection pressure exerted on the viruses.
Comparing the sequences of PR and RT, between 2 consecutive
tests, we recorded: Jukes-Cantor distance (DJC), Kimura 2 parameters
distance (DK2p), ds/dn (ratio between synonymous mutations per
synonymous site and non synonymous mutations per non synonymous
site), # synonymous mutations and # resistance mutations (IAS 2008).
We also deﬁned a “silent score” (SS) and a “resistance score” (RS) as
the number of synonymous mutations and of resistance mutations (in the
second sequence in comparison with the ﬁrst one) divided by number of
days between the two tests, respectively.
Results:We compared all above-mentioned parameters between group A
and B by means of Mann Withney two-tailed test: we didn’t ﬁnd any
statistically signiﬁcant difference. The only relevant ﬁnding is a trend in
a lower ds/dn in the M184V+ group [median (IQR) 4.062 (2.771−6.596)
versus 4.221 (2.205−7.076; p: ns]. This could mean a wider variability of
M184V+ viruses (higher dn represents more efforts to generate mutant
escape viruses), consistent with the great genetic variation acrrued
among patients who had slow development of disease relative to patients
with a rapid progression to AIDS (published data).
Conclusion: The clinical beneﬁt (lower VL and higher CD4+) due to
the presence of M184V observed in vivo should be interpreted as the
impact of the immune pressure on viral load control instead of a crude
effect on the replication capacity.
O237 Drug resistance mutations and sub-type circulation in newly
diagnosed HIV-infected subjects
S. Parisi °, C. Boldrin, M. Cruciani, R. Scaggiante, O. Bosco,
V. Manfrin, R. Ferretto, S. Panese, M.C. Rossi, F. Dal Bello,
M.G. Cecchetto, S. Andreis, G. Palu` (Padua, Verona, Vicenza, Schio,
Venice, Treviso, Rovigo, IT)
Objectives: to evaluate circulation trends of drug resistance mutations
(DRM) and viral sub-types (ST) among subjects recently diagnosed as
HIV infected (pts), over a ﬁve years period in a region with a wide
availability of therapeutic options.
Methods: Plasma from 832 pts diagnosed from July 2004 to December
2008 in the Veneto region (Italy) were studied. The protease (PR) and the
reverse transcriptase (RT) were sequenced and analysed for the presence
of major DRMs, for drug susceptibility proﬁle (Stanford database) and
ST. Potential low level resistance were not considered. A c-square test
for linear trends was applied.
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Results: The main results were as follows: in four different periods,
2004−5, 2006, 2007 and 2008, were recruited 168, 166, 244 and 254 pts
respectively; mean cd4 percentage (±SD) were 20.9 (±11), 21 (±10.6),
22 (±10.5), 20.9 (±10.8); B-ST pts (% of total) were 138 (82.2), 123
(74.1), 173 (70.9) and 183 (72); pts with DRMs in B-ST (% of total
B-pts) were 30 (21.7), 25 (20.3), 20 (11.6) and 22 (12); pts with DRMs
in Non-B-ST (%) were 7 (23.3), 6 (14), 5 (7) and 3 (4.2). A signiﬁcant
increase of non-B-ST (p = 0.021) and a signiﬁcant decrease in DRMs
(p< 0.001) were observed. CRF02_AG was the prevalent non-B ST
(44%). 35.3% of non-B ST pts were italians. Among B-ST, DRMs
predicted a reduced susceptibility to one drug class in 23, 17, 15 and 14
cases in the different periods; to two drug classes in 4, 6, 5 and 8; to
three classes in 3, 2, 0 and 0. In non-B-ST, a reduced susceptibility to
one drug class was found in 6, 6, 4 and 0 cases; to two drug classes in
1, 0, 0 and 2; to three drug classes in 0, 0, 1 and 1, respectively. Among
pts with one or two classes of resistance, a decrease of percentage of
Protease Inhibitors related DRMs, and a persistence of Non Nucleoside
RT Inhibitors involving DRMs, mainly 103N and 190A, were observed.
Conclusions: An increase of non-B strains was observed, only partially
related to a modiﬁcation of the ethnic composition of the cohort.
The observed decrease of the DRMs prevalence and of the multidrug
resistant strains in both B and non-B groups is probably related to the
reduction of viraemic and failing pts spreading resistant viruses, and
to the increase of subjects unaware of their infection and transmitting
wild-type viruses. The substantial circulation of NNRTI-related DRMs
has important implications on the selection of the ﬁrst-line HAART.
O238 Longitudinal local immune analysis in HIV+ persons with
oropharyngeal candidiasis
E. Lilly, J. Rufener, M. Zacharek, M. Barousse, K. McNulty, J. Leigh,
T. Wiegand, J. Vazquez °, P. Fidel (New Orleans, Detroit, US)
Oropharyngeal candidiasis (OPC), caused by Candida albicans, is the
most common infection in HIV-infected persons. An evaluation of tissue-
associated T cells and adhesion molecules in OPC lesions of HIV+
persons with reduced CD4+ T cells showed an accumulation of activated
memory CD8+ T cells at the epithelial-lamina propria interface together
with reduced expression of E-cadherin. These results suggested a role for
CD8+ T cells against OPC, but a dysfunction in the mucosal migration
of the cells in those with OPC.
Objective: To evaluate changes in tissue-associated CD8+ T cells and
E-cadherin expression of HIV+ persons during and after an episode of
OPC.
Methods: From HIV+ persons with a history of, or an acute episode
of OPC, oral fungal burden was evaluated bi-weekly and buccal
mucosa tissue was collected bimonthly for a period of one year. Tissue
was evaluated for the presence of CD8+ T cells and E-cadherin by
immunohistochemistry or ﬂow cytometry.
Results: Patients evaluated under OPC− conditions and low oral fungal
burden revealed the presence of CD8+ T cells and E-cadherin, but
expression was usually unremarkable over time. In situations where
OPC− patients had increased oral Candida colonisation (indicative
of a potential pre-clinical OPC condition), higher numbers of CD8+
T cells were observed throughout the tissue with normal E-cadherin
expression. In patients with an acute episode of OPC where CD8+ T
cells were accumulated at the epithelial-lamina propria interface together
with reduced E-cadherin expression, evaluations following successful
treatment revealed normal conditions. Finally, viable CD8+ T cells could
be extracted from OPC+ lesions.
Conclusion: These results suggest that under reduced CD4+ T cells,
CD8+ T cells typically migrate to the site of a pre-clinical infection
under normal expression of E-cadherin and that reduced E-cadherin
expression in those with OPC is not permanent. This work was supported
by R01DE-12178 from NIDCR.
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O239 The increasing incidence of candidaemia and the increasing
importance of non-ICU/non-haematology patients: secular
trends, Queensland, Australia, 1999–2008
E.G. Playford °, G.R. Nimmo, M. Tilse, T.C. Sorrell (Brisbane, Sydney,
AU)
Objectives: To deﬁne the secular trends in the epidemiology of
candidaemia in Queensland, Australia (population, 4.1 million) over a
10-year period.
Methods: All episodes of candidaemia within Queensland public
hospitals from 1999–2008 were identiﬁed from laboratory information
systems. Data on species identiﬁcation, antifungal susceptibility,
demographics, and hospital ward of diagnosis, and denominator data
(hospital admissions, accrued patient-days (pt-days) and ﬂuconazole
usage) were collected.
Results: Over the 10-year period, 1137 unique episodes (100% case
ascertainment) were identiﬁed from 42 healthcare facilities (8 tertiary, 2
paediatric, 11 secondary and 21 smaller hospitals). The median patient
age was 56.4 years. The overall incidence-density was 0.45/10000 pt-
days, highest in paediatric (1.28/10000 pt-days) and tertiary hospitals
(0.62/10000 pt-days). Over the 10 years, the incidence-density increased
3.2-fold in tertiary hospitals and 6.6-fold in secondary hospitals (both
p< 0.0001 for trend), but not in paediatric or smaller hospitals. The
incidence-density in ICUs (5.2/10000 pt-days) was 10-fold higher
than in non-ICU wards, but did not signiﬁcantly increase over the
study period. The relative proportion of episodes occurring in adult
general medical/surgical (ie non-oncology/non-ICU) wards signiﬁcantly
increased (p< 0.001), accounting for 62% of episodes at the end of
the 10-year period, whereas that occurring in paediatric and adult
oncology wards decreased (p< 0.001 and p = 0.07 respectively). Overall,
C. albicans accounted for 44%, C. parapsilosis 27% and C. glabrata
13%. Although the incidence-density of all species increased over the
study period, the relative proportion caused by C. albicans decreased
(p = 0.007) and C. parapsilosis increased (p = 0.01). Despite signiﬁcantly
increased ﬂuconazole usage (from 19.7 to 30.6 DDD/1000 pt-days,
p< 0.0001), the relative proportion caused by C. glabrata/C. krusei did
not change (p = 0.5).
Conclusions: The overall incidence of candidaemia has increased almost
400% in Queensland public hospitals over the last 10 years. The
relative proportion of episodes occurring among general medical/surgical
patients and caused by C. parapsilosis has increased. Candidaemia is an
increasing problem the epidemiology of which continues to evolve. It is
increasingly affecting patients outside traditional risk groups.
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O240 Invasive candidiasis: role of pharmaco-economic modelling in
improving patient care, diagnosis and guiding cost-effective
therapy at a large district hospital in northern England
A. Guleri °, J. Patterson, S. Ellershaw, B. Lunt, E. Trautt, R. Palmer
(Blackpool, UK)
Background: Nosocomial candidaemia is a serious life threatening
infection with considerable mortality and healthcare costs. Average
daily cost of treatment varies from £10.36 (ﬂuconazole) to £568.05
(liposomal amphotericin). Overall mortality rate varies between 30
and 40% worldwide. Blackpool Victoria is a large district hospital in
northwest England offering referral haematology and cardiac centres.
Objectives: Epidemiological surveillance of candidaemia over 5-years,
comparing turnaround times [TAT]; choice/cost of antifungal and
processing costs[outsourcing versus in-house testing]and trends in
mortality over this period.
Methods: In-house identiﬁcation and ﬂuconazole susceptibility testing
[FST] by E-test strip was introduced in September 2006. Surveillance of
candidaemias from laboratory database between Jan 2004 to Oct 2008
included TAT, cost of in-house processing versus outsourcing to Bristol
Mycology laboratory [BML], cost of antifungals and mortality.
Results: During the study period, there were 61 candidaemia episodes
(non-duplicated). Rate of candidaemia rose from 15.4%[ 2004] to
24.62% [projected – 2008]. C albicans was the commonest cause
[28.7%], followed by C glabrata[16%] and C parapsilosis[11.7%]. C
albicans candidaemia varied from 16.7%[2008]to 64.3%[2006]. Resis-
tance to ﬂuconazole was noted in 3.3%(2 glabrata/61 isolates]. Overall
associated mortality was 24.2% [30% in 2004 to 16.7% estimated for
2008]. C albicans was associated with highest associated mortality
[79%]. Preceeding in-house testing and this surveillance study, all germ-
tube negative candida species required empiric antifungal treatment
with either liposomal amphotericin, caspofungin or voriconazole. The
average duration of treatment as per hospital formulary is 2 weeks.
Cost of a two week treatment Fluconazole [£72.52]; Caspofungin
[£6268.92]; voriconazole [£6814.08]; posaconazole [£1647.38] and
liposomal ampotericin [£7952.7]. TAT and cost comparison per isolate
of inhouse processing [72-h and £6.04] versus outsourcing to BML [15d
and £103.76).
Conclusions: This surveillance study and pharmaco-economic mod-
elling has proved immensely beneﬁcial in setting up inhouse processing,
improved TAT, reduced costs of outsourcing and subsequent use of
expensive antifungals. Reduction in mortality has been noted but is
not statistically signiﬁcant. C. albicans was the commonest isolate;
ﬂuconazole resistance is minimal and associated mortality is lower than
reported from Europe.
O241 Invasive aspergillosis in acute myeloid leukaemia: report of
Seifem-2008 multi-centre survey
M. Caira, A. Candoni, M. Picardi, M. Ofﬁdani, G. Specchia,
M. Stanzani, C. Cattaneo, R. Fanci, C. Caramatti, F. Rossini, L. Potenza,
F. Ferrara, M.E. Mitra, R. Invernizzi, T. Aloisi, B. Martino, A. Bonini,
G. Lanasa, A. Chierichini, L. Melillo, C. de Waure, L. Fianchi, M. Riva,
F. Aversa, G. Leone, A. Nosari, L. Pagano ° on behalf of SEIFEM group
(Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne)
Objectives: To evaluate epidemiological characteristics and outcome of
invasive aspergillosis (IA) in acute myeloid leukaemia patients (AMLs)
and to analyse efﬁcacy of different therapeutic approaches.
Methods: A survey was conducted over 2004–2007 in 21 Italian
Haematology Divisions. All proven/probable IA were reported. AMLs
submitted to transplant were excluded. The parameters we analyzed
were: age, sex, AML phase, site of IA, severity, duration and recovery
from neutropenia, antifungal prophylaxis, empirical/pre-emptive therapy,
1st/2nd line target therapy, aetiologic agent, G-CSF use, neutrophil
transfusion, outcome. We also collected date of symptoms onset,
diagnosis, antifungal therapy start and exitus. All variables were
investigated as predictors of death. Follow up was assessed at 90th day
from diagnosis.
Results: 140 cases were collected. Infection mostly occurs after the
1st course of chemotherapy (61%). The majority of AMLs experienced
a deep neutropenia before symptoms onset (90%). Probable IA were
66%. As expected, pulmonary localisation was predominant (126/140,
90%). Infection disseminated in 5 pts. Aspergillus subtype was known
in 55 pts only. Overall attributable mortality rate was 27% (38/140);
it remained stable over years. Outcome was signiﬁcantly inﬂuenced
by AML phase (p< 0.001), duration of (p = 0.05) and recovery from
neutropenia (p< 0.001). Role of neutropenia duration was conﬁrmed at
multivariate analysis (p< 0.005).
Antifungal approaches are reported in table 1.
AMLs Deaths (AMR%) p value
Systemic prophylaxis
Not administered 39 8 (20.5) 0.27
Administered 101 30 (30)
Empirical/pre-emptive
Caspofungin 28 9 (32)
L-AmB 54 12 (22)
Itraconazole 5 2 (40) 0.79
Voriconazole 25 6 (24)
Other 16 5 (31)
Not done 12 4 (33)
First-line therapya
Caspofungin 28 9 (32)
L-AmB 37 9 (24) 0.65
Voriconazole 38 7 (18)
Combined 22 5 (23)
Other 11 4 (36)
a4 early deaths
Many pts received systemic prophylaxis (72%); itraconazole and
ﬂuconazole were used in 68 and 33 pts respectively. No differences
emerged between empirical vs pre-emptive therapy and none of the
drugs resulted to signiﬁcantly inﬂuence outcome. In 66% of pts initial
empirical/pre-emptive drug remained unchanged after IA diagnosis,
while in 16% clinicians shifted to a combined treatment.
Conclusion: This study allows as to analyzed multiple factors as
potentially inﬂuencing outcome. We conﬁrmed that AML phase and
neutropenia inﬂuence IA outcome. Present data conﬁrm the perception
that during last years the application of a correct and timely diagnostic
work-up and the availability of more efﬁcacious and less toxic drugs (i.e.
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voriconazole, liposomal amphotericin B, caspofungin) have modiﬁed the
course of IA. However none of the new drugs emerged as the most
efﬁcacious in our series. Even combined treatment did not confer any
advantage in survival analysis.
O242 Prospective surveillance of invasive aspergillosis in 4 French
regions: 2005–2007
O. Lortholary, J.P. Gangneux, K. Sitbon, B. Lebeau, F. de Maubrisson,
F. Dromer, B. Coignard, S. Bretagne ° (Paris, Rennes, Grenoble, Lyon,
St-Maurice, Cre´teil, FR)
Objective: An active prospective collection of invasive aspergillosis (IA)
cases was implemented in 2005 in 12 French academic hospitals from 4
geographical regions, to describe IA epidemiology, diagnostic modalities
and therapeutic practices.
Methods: Each notiﬁcation was reported by hospital microbiologists
through a secured website and missing data were checked at the national
reference centre. Only proven and probable IA according to 2002
EORTC/MSG criteria were considered. Numbers of patient admissions
per hospital were obtained from national health statistics.
Results: From 2005 to 2007, 442 case-patients (male gender 62%,
median age 55 yrs) were included, 71 of whom (16%) had proven IA.
Overall, the median incidence of IA was 0.223 per 1000 admissions
(range 0.095 to 1.078). Among the 442 case-patients, 354 (80%)
had haematological malignancies, with acute leukaemia and lymphoid
malignancies including myeloma representing 60% and 32% of cases,
respectively. Cancer and solid organ transplantation patients represented
8 and 9%, respectively. IA involved the lungs (94%), brain (12%),
sinus (10%), or was disseminated (6%). CT scan was performed for
373 (84%) patients and showed major signs in 201 (halo sign in
56; cavitation in 145). Galactomannan serum detection was performed
for 433 (98%) patients, and 362 (82%) had samples processed for
mycological culture, mainly through BAL. When positive (n = 268),
culture yielded A. fumigatus (85%), A. ﬂavus (4.5%), or few other spp.
(<3% each). The ﬁrst line therapy was monotherapy with voriconazole
(49%), caspofungin (14%), lipid formulations of AMB (9%) or used
antifungal drugs combination (20%). The mortality rate at day 90 was
41% when ﬁrst line therapy included voriconazole compared to 60%
when it did not (p< 0.001).
Conclusion: Comprehensive collections of cases based on systematic
reporting and description of cases using a dedicated network of hospitals
in selected regions and stringent deﬁnition criteria applied by trained
clinicians and microbiologists are useful to describe IA, to assess
its burden and secular trends, and to identify potential changes in
diagnostic and therapeutic procedures. This network will expand to other
regions in the near future, and data will help assessing the impact of
new management strategies such as prophylaxis with posaconazole, the
impact of modiﬁcation of new diagnostic criteria as recently proposed
(Clin Infect Dis, 2008), and identifying new populations at risk for IA.
O243 Airborne fungus − exposure prior hospitalisation as risk
factor for mould infections in immunocompromised patients
C. Lass-Flo¨rl °, S. Eschertzhuber, J. Auberger, C. Geltner, D. Nachbaur
(Innsbruck, AT)
Nosocomial aspergillosis represents a serious threat for severely
immunocompromised patients and outbreaks have been attributed to
airborne sources. The role of hospital-independent fungal spread sources
e.g. the private homes or business suites are not known. We investigated
the relationship between fungal exposure prior hospitalisation and the
ensuing onset of invasive mould infections (IMI) in patients at risk.
Patients admitted to the Department of Haematology and Oncology
or to the Department of Transplant Surgery of the Innsbruck
Medical University received a structured questionnaire regarding their
fungal exposure prior hospitalisation. Questions inquired heavy fungal
exposures up to ﬁve days prior hospitalisation.
234 patients were enrolled in this study and 19% were smokers, 22%
suffered from an airborne allergy, 62% lived in old buildings, 73%
were ruralists, 82% and 92% were exposed to any outdoor or indoor
fungus sources. Poor housing conditions and other fungus exposures
were associated with the onset of community-acquired IMI only in
patients with acute myelogenous leukaemia (P< 0.01). AML patients
being more at risk for IMI when smoking cigarettes (P< 0.05), living
on the country site (P< 0.05), having two or more fungus exposures
(P< 0.05) and suffering from allergy to dust, pollen and/or moulds
(P< 0.05). A similar trend was for lung transplant recipients receiving
extensive immunosuppressive agents to treat allograft rejection. Overall,
88% of IMI were community-acquired cases.
Hospital-independent fungal sources highlight risk-factors for IMI
in severe immunocompromised patients and the rate of community-
acquired IMI does increase. An analysis of an individual patient’s risk
factors for fungal infection and the type of fungus to which they are
most susceptible, indicates the preventative strategies that are likely to
be successful.
O244 Outbreak of invasive aspergillosis in an intensive care unit
for major heart surgery. The case for abnormally high
levels of airborne Aspergillus conidia: presence of similar
genotypes in air and clinical samples
T. Pela´ez °, J. Guinea, C. Klaassen, P. Mun˜oz, J. Meis, D. Garcı´a
de Viedma, R. Flores, B. Gama, S. Recio, E. Bouza (Madrid, ES;
Nijmegen, NL)
Objectives: Invasive aspergillosis (IA) is presumed to be caused by
airborne Aspergillus conidia. However, few studies have shown the
presence of similar genotypes of Aspergillus fumigatus in the air
and clinical samples of patients with IA. We aimed to evaluate the
relationship between the presence of airborne Aspergillus conidia and
IA in a major heart surgery intensive care unit (ICU-MHS).
Methods: From November 2006 to May 2008, 11 patients were admitted
to the ICU-MHS with Aspergillus spp detected in signiﬁcant amounts
in clinical samples. The underlying conditions of the patients were heart
transplantation (n = 5), major heart surgery (n = 4), and other (n = 2).
Eight (72.7%) patients developed proven/probable IA (4 with lung
infection, 2 with mediastinitis, 1 with disseminated IA, and 1 with
prostate involvement). The mortality of patients with IA was 87.5%. The
ICU-MHS is divided into 3 areas, one of which is equipped with HEPA
ﬁlters. Only 1 case of IA occurred in the protected area. We measured
the fungal conidia levels in the air of each of the 3 areas (508 samples
analyzed) monthly. A total of 172 strains of A. fumigatus (110 clinical
strains from 10 patients and 62 environmental strains) were genotyped
using microsatellites (de Valk et al, JCM 2005).
Results: The mean airborne conidia levels (6 months) before and after
the outbreak were, respectively, 5.6 (0−15) CFU/m3 and 1.8 (0−10)
CFU/m3. No cases of IA occurred during these periods. However, all
cases of IA were linked to 4 peaks of abnormally high airborne conidia
levels (65, 70, 200 and 500 CFU/m3). A. fumigatus was involved in 7
cases of IA; 1 patient was infected by non-fumigatus Aspergillus (not
further genotyped). In 4 patients (1 mediastinitis, 2 pulmonary IA and
1 colonisation), we demonstrated similar genotypes in the air and in
clinical samples. Patient 1 was located in the protected area and had a
unique genotype. Patient 2 had two different clusters of genotypes: one
cluster was similar to that of patient 3 and the other was also found in
patient 4 and in the air. The genotype present in patients 2 and 4 was
also detected in the air during a 6-month period.
Conclusions: Epidemiologic and molecular typing suggests that there is
a causal relationship between Aspergillus causing IA and those present
in the air. Our ﬁnding also supports the need for HEPA ﬁltration in
ICU-MHS. J. Guinea is contracted by FIS (CM05/00171).
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O245 Galactomannan testing in the bronchoalveolar lavage for the
diagnosis of invasive aspergillosis in lung transplant recipients
M.O. Xavier, A.C. Pasqualotto °, I.C.E. Cardoso, S.M. Schio,
L. Sa´nchez, C.O. Costa, L.C. Severo (Porto Alegre, BR)
Objectives: This prospective study was performed to evaluate the
performance of galactomannan (GM) detection in the diagnosis
of invasive aspergillosis (IA) in lung transplant recipients, using
bronchoalveolar lavage (BAL) samples.
Methods: 117 BAL samples from 60 lung transplant recipients were
studied, during Mar 2007-Nov 2008. The EORTC/MSG criteria for
the diagnosis of IA were modiﬁed to allow lung transplantation as a
host factor. BAL samples were processed according with manufacturer’s
instructions for serum samples (Platelia Aspergillus EIA, Bio-Rad).
Sensitivity, speciﬁcity, positive predictive value (PPV) and negative
predictive value (NPV) were calculated in reference to proven and
probable cases of IA. Reasons for performing bronchoscopy on patients
were also recorded. The protocol received approval by the local ethic
committee.
Results: From the 117 samples studied, 5 (4.3%) were classiﬁed as
proven, 6 (5.1%) as probable, and 35 (29.9%) as possible cases of
aspergillosis. Twelve samples (10.3%) represented colonisation, and 59
BAL samples were obtained during routine surveillance. Pulmonary
aspergillosis was the main clinical presentation of IA (63.6%). Using
ROC analysis, the best cut-off for galactomannan testing in BAL was
deﬁned as 1.5 (sensitivity 90.9%, speciﬁcity 90.6%, PPV 48% and
NPV 99.1%). Median BAL GM index for the group of patients with
proven/probable aspergillosis and for ‘negative cases’ were 3.3 and 0.5,
respectively (p< 0.001). Overall mortality was 20% (n = 12). The odds
for death for patients diagnosed with IA were 11.8, in comparison to
patients who did not have this infection (95% CI 2.9−48.4).
Conclusion: GM testing in the BAL added to the diagnosis of IA in
lung transplant recipients. In order to avoid false-positive results, a
higher test cut-off should be applied to BAL samples, in comparison
to sera. Increasing the cut-off to 1.5 resulted in a very high NPV, with
an associated sensitivity of >90%.
O246 Prospective evaluation of clinical utility and pronostic
value of broncho-alveolar lavage galactomannan assay in
haematology-oncology patients
M.L. Luong °, C. Filion, A.C. Labbe, J. Cardin-Tourigny, S. Carrignan,
S. Belanger, J. Roy, M. Laverdiere (Montreal, CA)
Objectives: 1) Determine the performance characteristics of the
Galactomannan (GM) assay in broncho-alveolar lavage (BAL) in
haematology-oncology patients; 2) Evaluate the prognostic value of the
GM assay in this particular population.
Methods: The Platelia GM EIA assay (Bio-Rad) was performed on all
BAL specimens obtained from haematology-oncology patients at our
institution between March 2005 and April 2008, in addition to routine
laboratory stains and cultures. All results were reported to physicians. We
conducted chart reviews to classify cases as proven, probable, possible
or without invasive pulmonary aspergillosis (IPA) according to the
Revised Deﬁnitions of Invasive Fungal Disease from the EORTC/MSG
Consensus Group. For performance characteristics, proven and probable
cases were considered as IPA; possible cases were considered as without
IPA. The result of BAL GM was not considered as a criterium to classify
cases in order to avoid incorporation bias. In patients with >1 positive
(GM index >0.5) specimen, only the ﬁrst one was considered for the
analysis. Mortality was calculated at 60 days following the ﬁrst BAL
procurement. Data were analyzed with Stata 8.0.
Results: There were 173 BAL samples from 145 patients, including
101 haematopoietic stem cell transplant (HSCT) recipients. We found
5 proven, 7 probable and 35 possible cases of IPA (total of 12 IPA
cases; 6.9%). GM on BAL was positive in 47 (27.2%) specimens. The
sensitivity and speciﬁcity of the GM assay in BAL were 100% and
78.3% respectively. Positive predictive and negative predictive values
were 25.5% and 100%, respectively. False-positive results were found in
21 patients without IPA and in 14 with possible IPA. An index value
0.5 was signiﬁcantly associated with a 60-day mortality risk (12/39
patients with a positive GM died within 60 days after BAL compared to
13/106 with a negative GM (OR= 3.2, 95%CI 1.3−7.8; p = 0.01). This
association was even stronger when restricted to HSC recipients (OR
=4.6, 95%CI 1.5−13.6; p = 0.006).
Conclusions: The clinical utility of GM assay in BAL mainly lies in its
negative predictive value, identifying patients at low risk of IPA. This
test also carries a prognostic value in predicting patients at higher risk
of mortality.
O247 Pneumocystis jirovecii colonisation induces the systemic
inﬂammatory response in COPD patients
R. Morilla, L. Rivero, V. Friaza, E. Campano, N. Respaldiza,
S. Gutierrez-Rivero, M.A. Montes-Cano, F.J. Medrano, J.M. Varela,
E. Caldero´n, C. de la Horra ° (Seville, ES)
Background: Chronic obstructive pulmonary disease (COPD) is a
slowly progressive condition characterised by air ﬂow limitation, which
is not fully reversible. The air ﬂow limitation is associated with a chronic
inﬂammatory response in both airways and lung parenchyma. Besides the
presence of chronic local inﬂammation in the respiratory organ, there is
increasing the evidence of the important role systemic inﬂammation in
these patients. Thus high levels of airway and systemic inﬂammatory
markers are associated with a faster decline in lung function. In a
recent pilot study, Pneumcystis-colonisation in COPD patients has been
associated with increase of systemic inﬂammation, suggesting a possible
pathogenic link with COPD.
Aim: To conﬁrm the ability of P. jirovecii colonisation to increase the
inﬂammatory response in COPD
Patients and Methods: 126 COPD patients diagnosed according to
GOLD classiﬁcation. Identiﬁcation of P. jirovecii was performed by
nested PCR at mt LSU rRNA from respiratory samples. The systemic
inﬂammatory levels were analysed in serum samples from all patients.
The assay were performed using a commercial ELISA (R&D systems)
for IL-6, IL-8, TNF-alpha and MCP-1.
Results: The systemic inﬂammatory response was evaluated in 84 COPD
subjects non colonised vs 42 COPD patients colonised by P. jirovecii
paired by clinical characteristics and COPD severity. The analysis
shows a signiﬁcant increase in the systemic proinﬂammatory cytokines
from Pneumocystis colonised than non colonised subjects (see table
below). Not signiﬁcant differences have been found among Pneumocystis
colonisation and COPD status evaluated by FEV-1%. As well as no
signiﬁcant differences respect to age, sex or lymphocytes and leucocytes
blood count were found.
Systemic
cytokine levels
(pg/ml)
COPD without
P. jirovecii
(n = 84)
COPD with
P. jirovecii
(n = 42)
P-value
(Student-T)
IL-8 5.3±10 21.9±16.9 0.003
TNF-alpha 19.0±12.2 25.3±17.1 0.069
IL-6 2.5±6.2 9.8±5.4 0.016
MCP-1 505.1±295 802.5±407 0.000
Conclusion: The data suggest a relationship between P. jirovecii
colonisation and high level of systemic inﬂammatory response in patients
with COPD suggesting strongly that P. jirovecii is an infectious agent
thar play a role in COPD physiopathology.
This study was supported by ERA-NET Pneumocystis-PathoGenomics
and FIS CP04/217
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O248 High rate of Pneumocystis jirovecii colonisation in patients
treated with inﬂiximab
C. de la Horra, G. Wissmann, N. Respaldiza, I. Martin-Garrido °,
S. Gutierrez-Rivero, L. Rivero, F.J. Medrano, J.M. Varela, E. Calderon
(Seville, ES)
Background: Inﬂiximab, a monoclonal antibody targeting tumour
necrosis factor alpha (TNF-a), is indicated for the treatment of
rheumatoid arthritis (RA) and other autoimmune diseases. However,
its use has been associated with opportunistic infections, including
Pneumocystis jirovecii pneumonia (PcP). Moreover, P. jirovecii has been
observed colonising to humans with several disorders.
Objectives: To obtain information about P. jirovecii colonisation among
patients with rheumatologic disease treated with inﬂiximab. This
information could be useful for assessing new strategies in the prevention
of PcP in patients at risk.
Methods: 62 consecutive patients treated with inﬂiximab for rheumatic
disorders were included in the study. Oropharyngeal washes (OW)
samples were collected for P. jirovecii detection. Clinical and demo-
graphic data were collected (sex, age, rheumatologic diagnosis, duration
of inﬂiximab use, concomitant use of other drugs for rheumatologic
treatment, use of any other anti-TNF-a agent, use of anti-Pc drugs
in the last six months, smoking, and diagnosis of chronic pulmonary
respiratory disease). P. jirovecii colonisation was identify in OW samples
by PCR at mtLSU-rRNA gene, with primers pAZ102-X and pAZ102-Y.
We adapted a method previously described to a real-time PCR setting,
using a LightCycler 1.5 (Roche, Germany). Individuals in whom the
presence of P. jirovecii was detected at two independent assay in the
absence of respiratory symptoms or radiological ﬁndings suggestive of
PcP were considered to be colonised.
Results: Clinical and demographic data for 62 patients treated with
inﬂiximab are presented in Table 1. jirovecii was detected by real-time
PCR in the OW of 18 (29.0%) out of 62 patients.
Characteristic Colonised patients
(18)
Non-colonised
patients (44)
p-value
Age, mean years ± SD (range) 57.3±12.5 (29−73) 45.7±11.3 (24−74) 0.002*
Male gender, no. (%) 8 (44.4) 26 (59.1) 0.441
Diagnosis rheumatoid arthritis, no. (%) 11 (61.1) 19 (43.2) 0.316
Diagnosis ankylosing spondylitis, no, (%) 5 (27.8) 20 (45.5) 0.316
Diagnosis psoriatic arthritis, no. (%) 2 (11.1) 5 (11.4) 0.999
Duration of inﬂiximab treatment, weeks, median (range) 205 (38–283) 95 (2–192) <0.001*
Corticosteroid use, no. (%) 8 (44.4) 6 (12.8) 0.007*
Corticosteroid dose, deﬂazacort mg/day, median (range) 6.75 (6.0−45.0) 6.0 (6.0−10.0) 0.999
Methotrexate use, no. (%) 16 (88.9) 26 (59.1) 0.048*
Methotrexate dose, mg/week, median (range) 8.75 (7.5−20.0) 7.5 (5.0−20.0) 0.270
*p< 0.05.
Conclusions: P. jirovecii colonisation is associated with inﬂiximab use,
which is mainly demonstrated by the fact that the percentage of colonised
individuals increases with the length of inﬂiximab use. The detection of
P. jirovecii in specimens, such as in OW, may be important to deﬁne
which patients treated with this immunosuppressive drug are at greater
risk of developing PcP.
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O249 Rapid one-step antigen detection method for human
bocavirus
J.O. Koskinen °, M. So¨derlund-Venermo, K. Hedman, R. O¨sterback,
T. Heikkinen, M. Waris, T. Allander, R. Vainionpa¨a¨, A.E. Soini (Turku,
Helsinki, FI; Stockholm, SE)
Objectives: Most research with human bocavirus, a recently found
respiratory pathogen, has been done by molecular biology (polymerase
chain reaction, PCR). The results have been ambiguous because the
virus has often been found in co-infection with other viruses, and also
in clinically healthy subjects. It has been proposed that, for bocavirus,
antigen detection could better indicate the aetiology than qualitative
nucleic acid detection. We have developed a rapid antigen detection test
for the virus.
Methods: The one-step test for bocavirus VP2 antigen is based
on a separation-free two-photon excitation ﬂuorometry (ArcDia TPX
assay technique). The assay protocol is simple; the swab sample
is dissolved in sample buffer, and the solution is dispensed (20 ml)
onto a 384-well microtitre plate (containing the reagents in dry
form) for incubation and automated quantitative measurement. The
immunoassay applies microspheres as solid-phase carriers of puriﬁed
bocavirus-speciﬁc polyclonal antibodies. The virus antigens concentrate
onto the solid-phase which is probed in real-time with ﬂuorescently
labelled antibody reagents. Strong positive samples are reportable in
15 minutes, while low positive and negative samples are reported in
2 hours. The performance of the method was studied with recombinant
human bocavirus-like particles (VP2), and puriﬁed respiratory pathogens
(Group A streptococci, Streptococcus pneumoniae, and inﬂuenza A and
B, respiratory syncytial, metapneumo, adeno, and parainﬂuenza 1−3
viruses).
Results: Analytical detection sensitivity of the method (lowest limit of
detection, 0-control + 3SDs) was 3 ng/ml, dynamic concentration range
was three orders of magnitude, and intra-assay imprecision was 5−10%.
Cross-reactions with the other respiratory pathogens were not found.
Conclusion: The new method enables rapid detection of bocavirus
antigens. The new test is very easy to perform in comparison to
standard ELISAs. The analytical sensitivity of the method is expected
to allow analysis of clinical samples. The sensitivity of the antigen
detection test could be signiﬁcantly increased by the use of monoclonal
antibodies (10–100 fold). Our future objectives include increasing the
detection sensitivity, and analysis of clinical samples in order to study
the correlation of antigen detection and the clinical aetiology.
O250 Mortality and cost-effectiveness of rapid MRSA PCR testing
in hospitalised patients with bacteraemia: a decision model
J. Brown °, J. Paladino (Buffalo, US)
Objective: Patients hospitalised with Staphylococcus aureus bacteraemia
have an unacceptably high mortality rate. Literature available to date has
shown that timely empiric selection of the most appropriate antibiotic
may reduce morality. One tool that may help with this selection is the
Xpert MRSA/SA Blood Culture PCR assay which determines methicillin
resistant S. aureus from methicillin-susceptible S. aureus in less than
1 hour. To date no information is available evaluating the impact of this
PCR technique on mortality and quality of life as compared to traditional
empiric therapy.
Methods: A peer reviewed Europe (EU) and United States (US)
literature search for information regarding the treatment regimens,
outcomes, costs and utilities was performed. Information detailing the
rate of infection, speciﬁcity and sensitivity of the PCR were also
obtained from the peer reviewed literature. Hospital and testing costs
were calculated using direct and indirect hospital costs discounted to
2009 costs. Adjusted life years were determined using US and WHO
life tables. Cost effectiveness ratio (C/E) is deﬁned as the costs per
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life-year for patients who survived. All analyses were performed using
TreeAge Software (2008).
Results: The overall mortality rates for empiric vancomycin (V) and
semi-synthetic-penicillin (SSP) was 30% and 35%, respectively, as
apposed to 24% for those receiving the rapid MRSA PCR testing. These
mortality rates were similar in both the EU and US subsets. Furthermore,
the number needed to test in order to save one life was 20 and 11 for
empiric V and SSP, respectively. Using sensitivity analysis the prevalence
of MRSA was varied from 5% to 80% and yielded an absolute mortality
difference favouring the PCR testing group of 10% and 2%, respectively
as compared to empiric V and 1% and 18% compared to empiric SSP.
In EU the C/E for empiric V and SSP treated patients was €873 and
€949, respectively as compared to €807 for rapid PCR testing. In the
US the C/E for empiric V was $1,049 as compared to $971 for rapid
PCR testing. Using sensitivity analysis the prevalence of MRSA was
varied from 5% to 80% and yielded favourable C/E in both the EU and
US for rapid PCR testing regardless of the empiric treatment regimen.
Conclusion: Rapid MRSA PCR testing using the Xpert MRSA/SA
Blood Culture PCR assay appears to improve mortality rates and is cost
effective in the EU and US across a wide range of MRSA prevalence
rates.
O251 Evaluation of culture-based approaches for rapid detection
of glycopeptide-resistant enterococci: a randomised,
investigator-blinded study
S. Malhotra-Kumar °, J. Cortin˜as Abrahantes, C. Lammens,
G. Molenberghs, M. Aerts, H. Goossens on behalf of the MOSAR
WP2 study group
Background: Rapid detection of gastro-intestinal carriage of
glycopeptide-resistant enterococci (GRE) from screening cultures is
crucial for an efﬁcient control of their spread. We assessed 4 media − 2
chromogenic, ChromID, (bioMe´rieux), and CHROMagar (CHROMagar
Microbiology), and 2 selective, VRE Selective (Oxoid) and ECCV
(BD) − for their ability to detect GRE using well-characterised isolates
and stool samples from hospitalised patients at high risk of GRE
colonisation.
Methods: Twenty-ﬁve isolates consisting of 13 GRE. faecalis/faecium
carrying various van genes and 12 non-VRE at concentrations of 106-
101 CFU/ml and 106 CFU/ml, respectively, and 37 stool samples were
randomised and spiral plated on all media and scored by 5 blinded
investigators for characteristic colonies after 24 hrs incubation. Standard
conﬁrmatory tests were done on 1 putative GRE colony or on 1
characteristically coloured colony each for E. faecalis/faecium from the
selective and chromogenic media, respectively. Detection of van genes,
and ddl or sodA based speciation was done on PCR-sequencing. Mean
sensitivity (SEN) and speciﬁcity (SPEC), and conﬁdence intervals (CIs)
were estimated for each medium by a logistic regression model using a
penalised likelihood approach based on the reader response for the stool
samples and isolates, and additionally on conﬁrmation test results for
the stool samples, both at the aggregated (GRE detected) and penalised
level (correct species–colony colour correlation).
Results: CHROMagar showed the highest SEN based on reader response
at the aggregated and penalised level for both stool samples and isolates
(Table). Using conﬁrmation test results at the aggregated level, SEN for
ECCV was highest while the two chromogenic media showed a decrease
in SEN by at least 11% in comparison to the values obtained based on
reader response. SENs for the 2 chromogenic media were even lower
(<70%) based on conﬁrmation test results at the penalised level. ECCV
and ChromID showed the highest SPECs with both reader response
(stool samples) and conﬁrmation test results at the aggregated level,
and ChromID also at the penalised level, with narrow CIs indicating
a high precision of this parameter estimate. For isolates, SPECs were
highest for CHROMagar at both levels.
Conclusions: CHROMagar showed the best overall performance
considering both SEN and SPEC estimates. ECCV performed well as a
selective medium for GRE detection from stool samples.
Table. Mean sensitivities and speciﬁcities of media for detection of GRE after 24 hrs incubation
Samples Variable Medium for Aggregated Penalised
GRE detection Sensitivity (%) Speciﬁcity (%) Sensitivity (%) Speciﬁcity (%)
Mean 95%CI Mean 95%CI Mean 95%CI Mean 95%CI
Stools Reader ECCVa 86.1 77.6−92.1 98.8 96.0−99.7 NA* NA NA NA
response VRE Selectiveb 57.0 44.6−69.1 93.7 86.6−97.5 NA NA NA NA
ChromIDc 83.3 73.7−90.0 98.9 96.1−99.7 82.9 73.8−89.5 98.6 95.6−99.6
CHROMagard 91.4 85.5−95.2 96.2 91.8−98.4 88.6 82.2−93.2 95.5 90.5−98.0
Conﬁrmation ECCVa 82.9 74.1−89.5 99.1 96.6−99.8 NA NA NA NA
tests VRE Selectiveb 33.5 23.6−44.6 98.4 95.5−99.5 NA NA NA NA
ChromIDc 72.3 61.6−81.3 99.4 97.4−99.9 64.8 53.7−76.8 98.1 94.3−99.4
CHROMagard 72.0 61.7−80.7 98.5 96.2−99.5 67.9 57.6−76.8 94.4 89.4−97.2
Isolates Reader ECCVa 83.4 77.7−87.8 96.3 91.7−98.3 NA NA NA NA
response VRE Selectiveb 65.9 58.3−72.8 94.2 87.8−97.2 NA NA NA NA
ChromIDc 87.3 82.3−91.0 97.4 93.9−98.9 78.2 72.2−83.1 95.1 90.0−97.6
CHROMagard 91.5 87.4−94.2 99.7 98.3−99.9 86.4 81.4−90.1 99.4 97.0−99.9
*Selective media do not differentiate between GRE. faecalis/faecium and thus, the aggregated and penalised
responses are the same.
aBD, BE; bOxoid, UK; cBioMe´rieux, FR; dCHROMagar Microbiology, FR.
O252 Evaluation of a new E-test to detect metallo-beta-lactamases
in Enterobacteriaceae
L. Bylund °, P. Ho, T. Walsh, G. Zambardi, A. Engelhardt (Solna,
SE; Cardiff, UK; La Balme, FR)
Objectives: Metallo-beta-lactamases (MBLs) expressed from Pseudo-
monas are able to confer resistance to all beta-lactams with the exception
of aztreonam. However, Enterobacteriaceae possessing MBLs exhibit
moderate cephalosporin and low carbapenem MICs and thus are often
underestimated. Herein, we describe data from new Etest prototypes
speciﬁcally designed to detect this problematic resistance mechanism.
Methods: 82 MBL-positive (VIM or IMP derivatives) Enterobacte-
riaceae clinical isolates from 8 countries and 27 randomly selected
Enterobacteriaceae negative controls (including the ATCC type strains)
were tested against the 4 different Etest MBL prototypes. Beta-lactam
substrates used were imipenem (IP), meropenem (MP), ceftazidime (TZ)
and cefotaxime (CT) with or without the inhibitors dipicolinic acid
(DPA) and EDTA. The Etest standard procedure for Gram negative
aerobes was used and a reduction of beta-lactam MIC by equal to or
greater than 3 dilutions by EDTA or DPA was interpreted as positive for
MBL. Presence of ESBLs was tested using the Etest CT/CTL, TZ/TZL
and cefepime (PM)/PML strips. AmpC production was detected using
the Etest cefoxitin (FX)/FXI and cefotetan (CN)/CNI strips.
N Etest Combinations
IP/EDTA IP/DPA MP/EDTA MP/DPA TZ/EDTA TZ/DPA CT/EDTA CT/DPA
+ − ND + − ND + − ND + − ND + − ND + − ND + − ND + − ND
MBL-
positive
isolates
82 53 28 1 26 47 9 79 3 0 76 3 3 69 5 8 67 7 8 62 9 11 59 13 10
Negative
controls
27 0 27 0 0 27 0 0 27 0 0 27 0 0 27 0 0 27 0 0 27 0 0 27 0
Total 109
Sensitivity 64.6 31.7 96.3 92.7 84.1 81.7 75.6 72.0
Speciﬁcity 73.4 48.6 97.2 94.5 88.1 86.2 81.7 78.9
Results: The Results are summarised in the Table. The highest level
of detection occurred with MP/EDTA with a sensitivity of 96.3% and
a speciﬁcity of 97.2% even though most MP MICs were below 8mg/l.
ESBLs and AmpC (derepressed native or acquired) were detected in
20/82 and 18/20 strains, respectively. The presence of ESBL and AmpCs
can occlude the presence of MBLs when TZ and/or CT are used as
substrates. Accordingly, the sensitivity increased – 93% and 89% for
TZ/EDTA and CT/EDTA, respectively – when cloxacillin (150mg/l) and
clavulanic acid (4mg/l) was added to the medium on a subset of strains.
Conclusion: Etest with EDTA performed marginally better than
with DPA. Interestingly, the IP/EDTA performed poorly whereas the
MP/EDTA gave the highest rates of detection. When clavulanic acid
and cloxacillin was added to the TZ/EDTA combination, the detection
rates were also acceptable. Such a method could prove invaluable
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for detecting MBLs mediating sub-breakpoint carbapenem MICs in
Enterobacteriaceae.
O253 Evaluation of StrepB Select medium for the detection of
group B Streptococcus
L. Louie °, L. Kotowich, H. Meaney, M. Vearncombe, A. Simor
(Toronto, CA)
Objectives: As group B Streptococcus (GBS) is a signiﬁcant cause
of neonatal morbidity and mortality, antenatal screening for GBS
is recommended. Current methods are time-consuming and labour-
intensive, but newer, chromogenic based media may improve sensitivity
while reducing turn-around time. We compared StrepB Select (Select;
Bio-Rad Laboratories) with conventional culture including broth
enrichment for the detection of GBS from genital specimens submitted
for GBS screening.
Methods: A total of 1025 genital specimens were processed with
direct inoculation of colistin-nalidixic agar with 5% sheep blood
(CNA) and enrichment with Streptococcus Selective Broth (SSB). After
overnight incubation, the CNA plate was examined for the presence
of suspicious colonies. The SSB was subcultured onto CNA (if direct
CNA was negative for GBS) and Select, and incubated overnight at
37ºC. Suspicious colonies, turquoise-blue on Select, and grey colonies
± narrow haemolysis on CNA were worked up by separate, experienced
technologists. Select cultures were incubated and read at both 24 and
48 hours. Identiﬁcation of GBS was performed by conventional tests.
Discrepancies between the two methods were conﬁrmed by PCR for the
cfb gene.
Results: Of the 1025 specimens tested, 243 specimens were positive
(by either method) for GBS, for a positivity of 23.7%. Select detected
241/243 GBS, for a sensitivity of 99.2%, while CNA/SSB detected
224/243, for a sensitivity of 92.2% (P< 0.0001). At 24 hours, direct
culture onto CNA isolated 201 GBS while SSB enrichment with CNA
subculture detected another 23 isolates (224/243 isolates, 92.2%) at
48 hours. All but one GBS was recovered on Select after overnight
incubation following SSB enrichment (240/241, 99.6%). One isolate
required 48 hours. Of the 784 Select specimens that were negative for
GBS, 345 grew turquoise-blue colonies, but the majority that required
further work to rule out GBS grew after 48 hours. Two strains of GBS
that were missed grew as white colonies on Select, and even at 48 h, did
not exhibit the characteristic turquoise-blue colour.
Conclusion: SSB enrichment followed by Select subculture was
extremely sensitive (99.2%) and superior to CNA/SSB for detection of
GBS from genital specimens. However, non-GBS organisms can produce
turquoise-blue colonies on Select and further work must be performed
to rule out the presence of GBS.
O254 Comparison of 5 commercial serological tests for detection
of anti-Chlamydia trachomatis antibodies
D. Baud, L. Regan, G. Greub ° (Lausanne, CH; London, UK)
Objectives: Screening for Chlamydia trachomatis (CT) speciﬁc antibod-
ies is valuable in investigating recurrent cause of miscarriage, pelvic
inﬂammatory disease and tubal damage following repeated episodes
of pelvic inﬂammatory disease. Immunoﬂuorescence (IF) is considered
the gold standard for detection of CT antibodies. The present study
aims to compare the performance of 4 other commercial tests for the
detection of serum IgG antibodies speciﬁc for CT: two CT IgG pELISA
both using major outer membrane protein (MOMP; [“MOMP-Medac”,
CT-IgG-pELISA; Medac, Wedel, Germany and “MOMP-Ruwag”, CT
pELISA; Ruwag, Bettlach, Switzerland), one CT HSP-60 IgG pELISA
(“HSP60-Medac”, cHSP60-IgG-pELISA; Medac, Wedel, Germany), and
a new automated epiﬂuorescence immunoassay (“Inodiag”, “MuST
Chlamydiae; Inodiag, Signes, France).
Methods: A total of 405 patients with (n = 251) and without (n = 154)
miscarriages were tested by all 5 serological tests described above.
Sensitivity and speciﬁcity were calculated using IF as gold standard.
A second standard, deﬁning true positive or negative samples as sera
respectively positive and negative in all 4 others tests, was also used
(see table).
Standard Sensitivity Speciﬁcity
IF 4 tests IF 4 tests
IF – 80 – 94
hSP60-Medac 55.4 90.9 80.9 84.6
MOMP-Medac 50 90.9 91.1 95.8
MOMP-Ruwag 48.1 95.2 93.1 99.5
Inodiag 63.8 100 80.1 86.8
Results: The prevalence of CT-speciﬁc IgG antibodies as determined
by IF, HSP60-Medac, MOMP-Medac, MOMP-Ruwag and Inodiag
was 14.3%, 23.2%, 14.3%, 11.9% and 26.2%, respectively. Inodiag
exhibited the highest sensitivity whereas MOMP-Ruwag and MOMP-
Medac showed the best speciﬁcity (see table). Serological cross-
reactivity with Chlamydia psittaci was observed with all 5 tests
(p< 0.001). Moreover, cross-reactivity with Chlamydia pneumoniae was
also observed with IF, MOMP-Ruwag and Inodiag tests (p< 0.001).
None of the tests appear to cross-react with other Chlamydiales
(Parachlamydia, Neochlamydia, Waddlia), except for HSP60-Medac
which cross-react with Parachlamydia.
Conclusion: Tests in the ELISA format based on peptides from
the MOMP of Chlamydia trachomatis show good sensitivities and
speciﬁcities. The new automated epiﬂuorescence immunoassay from
Inodiag exhibited similar performance than the ELISA tests and
represent an interesting alternative especially when few numbers of
samples have to be processed.
O255 Evaluation of serum Aspergillus galactomannan antigen in
the diagnosis of penicilliosis
Y.T. Huang, C.H. Liao °, P.R. Hsueh, C.C. Hung (Taipei, TW)
Objective: This study aimed to examine the sensitivity, speciﬁcity,
and positive and negative predictive avlue of serum Aspergillus
galactomannan (GM) antigen assay in the diagnosis of penicilliosis in
patients with human immunodeﬁciency virus (HIV).
Methods: From March 2007 to May 2008, patients with HIV infection
who presented with pulmonary infection or suspicious cutaneous lesions
were enrolled for a commercial Aspergillus GM antigen assay (Bio-rad,
Platelia) of the serum samples. Patients receiving amoxicillin/clavulanate
or piperacillin/tazobactam were excluded for analysis.
Cut off value
(O.D. index)
Serum galactomannan
antigen interpretation
Culture
positive
(N= 21)
Culture
negative
(N= 111)
Sensitivity Speciﬁcity Positive
predictive
value
Negative
predictive
value
0.5 Positive (N= 43) 17 26 80.9% 76.6% 39.5% 95.5%
Negative (N= 89) 4 85
0.7 Positive (N= 35) 16 19 76.2% 82.9% 45.7% 94.8%
Negative (N= 97) 5 92
1.0 Positive (N= 27) 16 11 76.2% 90.1% 59.3% 95.2%
Negative (N= 105) 5 100
1.5 Positive (N= 21) 16 5 76.2% 95.5% 76.2% 95.5%
Negative (N= 111) 5 106
Results: During the study period, 132 serum samples were obtained for
analysis, including 21 from patients with culture-conﬁrmed Penicillium
marneffei infection. A cut-off GM optic density index (ODI) of 0.5
yield a sensitivity (SE) of 80.9%, speciﬁcity (SP) of 76.6%, positive
predictive value (PPV) of 39.5% and negative predictive value (NPV)
of 95.5%. The SE, SP, PPV and NPV when different cut off ODI was
used were as follows: 76.2%, 90.1%, 59.3% and 95.2% for ODI=1.0;
and 76.2%, 95.5%, 76.2% and 95.5% when ODI=1.5. Diagnosis of
penicilliosis could be made 2 days earlier by elevated GM ODI than
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by microbiologic cultures (range, 6 days after culture results became
available to 15 days before culture results available). Of the ﬁve patients
who had no penicilliosis but had GM ODI greater than 1.5, one had
Paecilomyces sepsis, one had cryptococcosis and the remaining three
did not have any fungal infection. One patient had follow-up GM
ODI greater than 1.5 despite being asymptomatic after treatment for
penicilliosis. The ﬁtted ROC curve area was 0.903.
Conclusions: Our study indicated that serum Aspergillus GM assays may
assist timely diagnosis of penicilliosis in patients with HIV infection in
endemic regions.
O256 Quality control for diagnostic oral microbiology laboratories
R. Rautemaa-Richardson °, A. Smith, D. Lockhart for the COMB
Network – Clinical Oral Microbiology Network
Objectives: Participation in diagnostic microbiology internal and
external quality control (QC) processes is good laboratory practice, an
essential component of a quality management system and compulsory
in some European countries. Currently, there is no QC scheme for
diagnostic oral microbiology. The aim of this study was to collate
information on current QC needs, and processes undertaken in diagnostic
oral microbiology laboratories.
Method: An on-line questionnaire was devised to ascertain interest
in participating in an oral microbiology QC scheme and sent to oral
microbiology diagnostic laboratories. The laboratories were identiﬁed
from participants attending the European Oral Microbiology Workshop
in Helsinki, 2008. Following this, a pilot round of QC samples was
distributed to all interested laboratories.
Results: We identiﬁed 12 individuals that worked in diagnostic oral
microbiology laboratories and received 7 (58%) positive responses. Of
these 7 laboratories (representing 6 European countries) 71% did not
participate in either internal or external QC. Each laboratory processed
on average a total of 4135 samples annually. 86% of participants
were in favour of a European-wide oral microbiology QC scheme. The
preferred frequency for receiving external QC specimen was once in
3−4 months. The most preferred specimen types were periodontal pocket
and oral pus specimens (both 29%), followed by oral mucosal swabs and
caries activity tests. All participating laboratories were willing to share
and harmonise their specimen processing and interpretation standard
operating procedures. The pilot round specimen was a periodontal pocket
sample. Six laboratories reported their ﬁndings in the speciﬁed time.
The predominant pathogens (Aggregatibacter actinomycetemcomitans,
Porphyromonas gingivalis) were identiﬁed by 5 of 6 laboratories. In
addition to conventional culture, one laboratory used PCR. 5 laboratories
performed antibacterial sensitivity testing primarily by disc diffusion.
Conclusions: This is the ﬁrst attempt to a standardised European-
wide approach to diagnostic oral microbiology. The ﬁndings from this
feasibility study have indicated that a QC scheme for oral microbiology
is of interest and have raised a number a pointers for subsequent rounds
of specimens. Further work to improve the quality, to standardise the
methodology and the interpretation of diagnostic oral microbiology at
the European level is on-going.
O257 Evaluation of MALDI-TOF mass spectrometry for the
identiﬁcation of bacteria under routine conditions in a
clinical laboratory
W. Moussaoui, A. Birgy, G. Pre´vost, Y. Pie´mont, J.M. Scheftel,
M. Kostzrewa, P. Riegel ° (Strasbourg, FR; Leipzig, DE)
Objective: Evaluation of MALDI-TOF mass spectrometry (MT-MS) for
species identiﬁcation of bacteria isolated in a clinical laboratory under
routine conditions.
Methods: For evaluation of different culture conditions and routine
identiﬁcation, measurements were performed with a Microﬂex (Bruker
Daltonik) and spectra were recorded for the mass range of 3,000 to
15,000 Da. Identiﬁcation was obtained by using the BioTyper database
2. 0 (Bruker), giving a log score of similarity with spectra of reference
strains included in the database.
A set of strains belonging to seven relevant species (S. aureus, E. coli,
P. aeruginosa, S. pneumoniae, L. monocytogenes, H. inﬂuenzae, N. sicca)
was used in order to determine the inﬂuence of different cultivation
media (Mueller-Hinton, Sheep blood Columbia agar and chocolate agar)
and different storage conditions (4ºC, 37ºC and room temperature after
to 3 days storage) on the quality of the spectra. To evaluate species
identiﬁcation, all the relevant bacteria isolated over a six-weeks period
from patients specimens were identiﬁed under routine conditions by MT-
MS in parallel with conventional identiﬁcation methods. A total of 531
clinically signiﬁcant strains, consisting of 467 aerobic strains and 64
anaerobic strains was included in this study.
Results and Conclusions: Extraction, preparation of the ground steel
plate, MT-MS of 48 samples, and a search of the database for similarity
for species identiﬁcation took about 2 h with the Microﬂex instrument.
In all cases of culture or storage conditions, MT-MS resulted in usable
spectra and correct identiﬁcation. In total, MT-MS identiﬁed 87% of 531
strains with a concordant identiﬁcation in comparison to the results of the
conventional methods, leading to 93% for aerobic strains. Enterobacteria,
enterococci and staphylococci exhibited more than 95% concordance
whereas streptococci and strictly aerobic Gram-negative bacilli had a
concordant identiﬁcation for 82% and 86% of strains, respectively.
Anaerobic, especially clostridia, showed a high rate of discordant results
(43%). 424 of the 467 (90.1%) aerobic strains had log score values
of >2.0 and were 97% concordant with the conventional identiﬁcations.
Thus, MALDI-TOF provided accurate results for the identiﬁcation of
aerobic bacteria and is a reliable method for the identiﬁcation of such
clinical isolates under routine conditions.
O258 CRP/CD11b RATIO: a novel parameter for detecting
Gram-positive sepsis
J. Nuutila °, P. Jalava-Karvinen, U. Hohenthal, I. Laitinen,
P. Kotilainen, A. Rajama¨ki, J. Nikoskelainen, E.M. Lilius (Turku, FI)
Objectives: Since severe sepsis with acute organ dysfunction can be
fatal within hours, it is customary to start empirical broad-spectrum
antimicrobial therapy in all patients hospitalised for a suspicion of
systemic inﬂammatory response syndrome. However, increased use
of broad-spectrum antimicrobials over the years has contributed to
the emergence of drug resistant strains of bacteria. Especially, drug
resistance among Gram-positive bacteria, the leading cause of sepsis,
is now a serious problem. The objective of this preliminary study was
to develop a method for distinguishing between Gram− and Gram+
bacterial infection.
Methods: In this prospective study, leukocyte and neutrophil counts,
CRP, ESR, and quantitative ﬂow cytometric analysis of neutrophil
complement receptors 1 (CR1/CD35) and 3 (CR3/CD11b), were
obtained from 289 hospitalised febrile patients, of which 89 had bacterial
and 38 viral infection. The patient data were compared to 60 healthy
controls.
Results: It was noticed that in Gram− infection (n = 21) the average
amount of CD11b on neutrophils was signiﬁcantly higher than in Gram+
infection (n = 22). On the contrary, serum CRP level was signiﬁcantly
higher in Gram+ than in Gram− infection. Other measured parameters
did not differ signiﬁcantly between Gram+ and Gram− infections.
We derived a CRP/CD11b RATIO dividing the serum CRP value
by amount of CD11b on neutrophils. In thirteen (76%) out of 17
patients with GRAM+ sepsis had CRP/CD11b RATIO  cutoff value
of 3.1 (Figure 1). Of these 13 patients, 9 (70%) were diagnosed
with Streptococcus pneumoniae, 2 with Staphylococcus aureus, 1 with
Enterococcus faecalis, and 1 with both Streptococcus intermedius and
Streptococcus oralis. Corresponding percentages in patients with local
Gram+ infection, Gram− infection, clinical pneumonia, other clinical
infection, and viral infection were 20%, 14%, 30%, 15%, and 0%,
respectively.
Conclusion: The detection of Gram+ sepsis is possible after combination
of neutrophil CD11b data and serum CRP level. CRP/CD11b RATIO
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displayed 76% sensitivity and 80% speciﬁcity for detection of Gram+
sepsis. The proposed CRP/CD11b RATIO test could, for its part, assist
physicians to decide appropriate antibiotic treatment in patients with
severe bacterial infection.
Figure: CRP/CD11b RATIO in clinical practice. The horizontal line
indicates the optimal cut-off point value of 3.1 in detecting Gram-positive
sepsis.
Failure of antibiotic therapy in the absence
of antibiotic resistance
S279 Bioﬁlms
N. Høiby ° (Copenhagen, DK)
A bacterial bioﬁlm is a structured consortium of bacteria cells
surrounded by a self-produced polymer matrix. Bioﬁlms may be
monospecies or polyspecies bioﬁlms. Bioﬁlm growing bacteria give rise
to chronic infections, which persist in spite of therapy and in spite of
the host’s immune- and inﬂammatory responses. Bioﬁlm infections are
characterised by persisting pathology and immune response (in contrast
to colonisation). Bacterial bioﬁlms use both bioﬁlm speciﬁc (B) and
conventional (planktonic) resistance mechanisms (P) when they are
exposed to antibiotics. The following resistance mechanisms have been
described in bacterial bioﬁlms:
1. Stationary phase physiology (B), low oxygen tension (B) and slow
growth (B) especially inside bioﬁlms whereas the surface of bioﬁlms
is more similar to planktonic growth.
2. Penetration barriers (B), binding to the polymer matrix (B).
3. Mutations, hypermutators (B, P).
4. Chromosomal betalactamase is upregulated (B, P).
5. Antibiotic tolerance/adaptive resistance (B).
6. Efﬂux pumps (B, P).
7. Alginate production (B).
8. High cell density and quorum sensing (B, P).
9. PBP 3 − SOS response ? (B).
The knowledge of these resistance mechanisms can, however, be used
to design new therapeutica approaches especially as regards quorum
sensing inhibitors.
Reference(s)
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S280 Antibiotic treatment failure in the absence of resistance: the
contributions of bacterial density and physiology
B. Levin °, K. Udekwu, F. Baquero (Atlanta, US; Madrid, ES)
We consider two factors that contribute to treatment failure in the absence
of inherited resistance, the density of the population being treated and
the physiological state of the bacteria. We also explore how these factors
might contribute to the evolution of inherited resistance during the course
of treatment. We conclude with a computer- and chemostat-assisted
consideration of the potential clinical implication of these density and
physiology effects and make suggestions for treatment protocols to deal
with them.
Using in vitro cultures of Staphylococcus aureus ATCC25923 or the
clinical isolate ps80 and antibiotics of six different classes we determined
the functional relationship between the inoculum density and the efﬁcacy
of the antibiotics. As measured by the rates and extent of kill and/or the
minimum inhibitory concentration (MIC), the efﬁcacy of all of these
antibiotics declined with increases in the density of bacteria, albeit
to different extents. For daptomycin and vancomycin, much of this
density effect can be attributed to bacteria-associated declines in the
effective concentration of the antibiotic in the medium. For gentamicin,
vancomycin, ciproﬂoxacin and oxacillin, our bioassays failed to reveal
signiﬁcant reductions in their effective concentration in the medium.
The effects of the physiological state of S. aureus on the efﬁcacy of
these antibiotics were examined for bacteria from cultures in “stationary
phase” for different times and from chemostats run at different generation
times. These experiments are currently under way but by the time of the
symposium we will have the full (and true) story. It is, however, clear that
the efﬁcacy of all of these antibiotics declines with the time in stationary
phase (its “age”). And, even slowly dividing cultures from chemostats
are more susceptible to antibiotic-mediated killing that early stationary
phase batch cultures. The efﬁcacy in killing non-growing bacteria varies
among the bactericidal antibiotics examined.
To ascertain the potential clinical implications of these density and
physiological effects, we use both computer and in vitro simulations of
antibiotic treatment. The results of these simulations provide compelling
support for the proposition that antibiotic treatment regimes, including
those designed to prevent the ascent of resistance, should take into
account the anticipated density and physiological state of the target
population of susceptible bacteria.
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S282 Modern molecular methods of diagnosis of viral encephalitis
H.G.M. Niesters ° (Groningen, NL)
There have been an increasing number of neurotrophic viral infections
playing an important role in the World over the last decade. The list
includes West Nile Virus, Nipah and Hendra virus (both paramyx-
oviruses), as well as Chikungunya virus which suddenly emerged.
Furthermore, the relation between JC virus in Progressive Multifocal
Leukoencephalopathy (PML) in patients with multiple sclerosis treated
with a new immunosuppressive drug, has triggered our attention.
The development and implementation of molecular based ampliﬁcation
method has assisted us to detect these viruses more efﬁciently.
These technologies have been used now routinely in a large number
of laboratories to enable the detection of more commonly known
neurotrophic viruses, like HSV, VZV and the neurotrophic picornaviruses
like enterovirus and parechovirus. The pitfalls of these molecular
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methods have been generally solved by implementing regular quality
control testing schemes, like organised by QCMD (quality control of
molecular diagnostics) and the introduction of internal controls during
the whole diagnostic process. Finally, with the ability to quantify
the amount of nucleic acid present in CSF, more information on the
pathogenesis of these viral infections, as well as signiﬁcant tool to
monitor the antiviral effect of treatment options for these viruses, has
become available.
S284 Changing epidemiology of viral encephalitis in the Old World
T. Avsic Zupanc ° (Ljubljana, SI)
Encephalitis can be caused by wide variety of infectious agents,
including viruses, bacteria, fungi and parasites. In addition to common
viral pathogens, arthropod-borne viruses (transmitted through insect
or tick-bite) can cause arboviral encephalitis. In Europe, the most
important pathogens responsible for arboviral encephalitis are tick-
borne encephalitis virus (TBEV), West Nile virus (WNV) and Sandﬂy
fever virus (SFV). Tick-borne encephalitis (TBE) is the most important
ﬂavivirus infection of the central nervous system (CNS) in Europe and
Russia. The epidemiology of TBE is closely related to the ecology
and biology of ticks. In nature, TBE virus is propagated in a cycle
involving permanently infected ticks and wild vertebrate hosts. Virus
transmission occurs horizontally between tick vectors and vertebrates,
with small mammals serving as virus reservoirs. TBE is distributed in
an endemic pattern of natural foci over a wide geographical area focused
on central Europe, the Baltic States and Russia. During the past two
decades, both new endemic foci and an increase in cases have been
reported in many European countries, with the major exception being
Austria, which has a high vaccine coverage (>86%). The disease has also
been considered outside the traditional endemic areas. Some reports of
new endemic areas are attributed to a previous under diagnosis of cases.
However, the true nature of this rise is supported by an increase in areas
with high awareness of the disease and with well established diagnostic
routines. Environmental factors important for sustaining natural foci for
tick-borne encephalitis can be modeled with satellite data. These models
suggest that climate change is partly responsible for increased incidence
in Europe. But, existing methods for risk assessment have limitations.
Thus, risk assessment should combine human habits and socioeconomic
variables with functional variables in natural foci. West Nile virus
(WNV) is a ﬂavivirus that is maintained in a bird-mosquito transmission
cycle. Humans and horses are usually incidental hosts. Historically,
WNV has been associated with asymptomatic infections and sporadic
disease outbreaks in humans and horses in Africa, Europe, and Asia.
Although, WN fever was a minor arbovirosis, some cases of encephalitis
associated with fatalities were reported in Israel in the 1950 s. However,
after few silent decades, the virus has caused frequent outbreaks of
severe neuroinvasive disease in humans and horses in Europe and the
Mediterranean Basin. Even more, new modes of transmission through
blood donations, organ transplants, and the intrauterine route have
been reported. In Europe, an enhanced surveillance of WN infection
in humans, horses, birds, and vectors may reveal the presence of
the virus in different locations. Nevertheless, outbreaks of WN virus
remain unpredictable. Further coordinated studies are needed for a better
understanding of the ecology and the pathogenicity of the WN virus.
Autochthonous European parasites
S287 Tumours from the centre: Echinococcus multilocularis
P. Kern ° (Ulm, DE)
Alveolar echinococcosis (AE) was ﬁrst described by Rudolf Virchow. In
his article “Die multilokula¨re, ulcerirende Echinokokkengeschwulst der
Leber” (1855) he clariﬁed that the disease is caused by the larval stage
of Echinococcus, and is not a form of cancer. It took another 100 years
until the natural cycle involving foxes as deﬁnitive hosts and rodents as
intermediate hosts was described. For many years, AE has been assigned
to as a rare disease in Europe restricted to some endemic foci. However,
current data suggest that the incidence of AE has signiﬁcantly increased,
and the disease is spreading to the North, West, and East. AE has become
an emerging disease in the Baltic countries. Thus, human infections with
E. multilocularis have arrived in the “centre” of Europe. AE is a life-
threatening disease, and is characterised by a tumour-like lesion in the
liver. The larva can inﬁltrate the surrounding tissues and metastasize to
distant organs. In an attempt to classify the large variety of anatomical
ﬁndings in AE, the PNM-classiﬁcation system was developed and serves
as a benchmark for standardised evaluation of diagnostic and therapeutic
measures. Modern imaging techniques, such as ultrasound, CT or MRI
and PET/CT contributed not only to a much better description of the
lesions, but also to a judgment upon the activity of the metacestode.
The differential diagnosis of AE varies from haemangioma-like lesion
of the liver or cancer. The diagnostic skills are limited, and are the
reason for frequent misdiagnosis in geographic areas where AE is rather
unknown. Continuous treatment with benzimidazoles is the backbone
of a lifelong management of AE. However, radical resection is the
procedure of choice and should always be strived for. AE is still a
rare disease in Europe, but where it occurs, it is often diagnosed too
late. Patients are misdiagnosed for months and years, before receiving
the correct treatment. At that late stage the disease has progressed, and
radical cure of the liver lesion(s) is not anymore possible. Recent reports
provided hints for an accelerated larval growth of Echinococcus spp.
in the immunodeﬁcient host. A careful monitoring of patients receiving
immune-modifying drugs is warranted. The modern clinical management
and long-term parasitostatic treatment with benzimidazoles are highly
effective. Thus, a higher alertness for the “tumours from the centre”
would increase the prognosis of this hepatic disease resembling liver
cancer.
S288 Stage-speciﬁc approach and percutaneous treatment in the
management of cystic echinococcosis
O. Akhan ° (Ankara, TR)
The percutaneous treatment of liver hydatid cysts were considered
to be contraindicated due to two main potential risks: anaphylactic
shock and abdominal dissemination of the disease. Since the ﬁrst
case percutaneously treated was published, several series of successful
percutaneous treatment of the liver and the other abdominal organs,
peritoneum, thorax, soft tissue and orbital cavity hydatid cysts have
appeared in the literature.
The main indication for percutaneous treatment of hydatid cyst
includes “viable cysts”. Different types according to Gharbi or
WHO classiﬁcations are treated by different percutaneous techniques.
According to WHO classiﬁcation, CE 1 and 3A are considered to be most
appropriate for PAIR; CE 2 for Catheterisation technique or Modiﬁed
catheterisation technique (MoCaT or PEVAC); CE 3B for MoCaT. No
treatment is necessary in patients with CE 4 and 5 which are managed by
“Wait and Watch approach”. Although surgery is a traditional method of
treatment, the indication for surgery is now limited by the hydatid cysts
ruptured into biliary system, pleura or peritoneum.
Three different techniques are used in percutaneous treatment of liver
hydatid cysts. The ﬁrst one is; the PAIR technique described by
Ben-Amour et al. in 1986. PAIR is the abbreviation of Puncture,
Aspiration of cyst content, Injection of hypertonic saline solution, and
Reaspiration of all ﬂuid. The second one is the Catheterisation technique
with hypertonic saline and alcohol described by Akhan et al. in an
experimental study in sheep in 1993. The third one is called as modiﬁed
catheterisation techniques such as MoCaT or PEVAC. After standard
steps of catheterisation techniques a 14F catheter is inserted into the
cavity to evacuate all the content. Aggressive irrigation with isotonic
NaCl is employed via the catheter to have the cavity emptied.
Considering the number of percutaneously treated patients, it is
reasonable to conclude that the mortality rate is about 0.047%.
Dissemination after percutaneous treatment of the liver hydatid disease
was never reported in any of the published series. Other major
complications need to be addressed are superinfection of the cavity,
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cystobiliary communication and severe anaphylactic reaction with a
reported overall rate of about 10%. Minor complications such as
urticaria, severe itching and hypotension can easily be treated with
antihistaminic. In some patients fever, not exceeding 38.5ºC, may also
be observed and generally does not necessitate any medication.
Recurrence rate varies among 0−4%. Recurrent cysts are also managed
by percutaneous approach. Considering the overall data in the literature
regarding hospital stay is about 2.5−4.2 days.
Percutaneous treatment of hydatid liver disease is an effective and safe
procedure with its unique advantages (e.g., shorter hospital stay, low
complication rate). Today, the percutaneous approach has an important
role in treatment of hydatid cysts not only in the liver but also in the other
organs and tissue. Therefore it must be ﬁrst treatment option whenever
it is indicated.
S289 Frequent heart disease in dogs, emerging cutaneous disease
in humans: diroﬁlariasis
P. Marty ° (Nice, FR)
In Europe, Diroﬁlaria immitis and Diroﬁlaria repens are responsible of
autochthonous ﬁlariases in dogs. Adults of D. immitis kills the dogs
with an heart location and D. repens is often found in subcutaneous
nodules in dogs and cats. The microﬁlariae are present in the blood of
these animals. Diroﬁlariasis is due to the transmission of microﬁlariae by
some mosquito bites (Aedes, Culex, Anopheles, Mansonia, Psorophora
and Taeniorhynchus). Usually non pathogenic to humans, these parasites
are particularly present around the Mediterranean basin. D. immitis
is very rare in humans in Europe, sometimes found in a pulmonary
nodule and the heart location is not described. D. repens is more
frequent and emerging in humans. Usually, only one larva develops,
producing an immature adult worm inside a subcutaneous nodule.
Ultrasound examination may suggest the parasitic origin of the lesion
before an extraction and a parasitological diagnosis of the worm. More
often, a fortuitous diagnosis is made on histological examination. Very
rarely, an adult worm may mature and produce systemic diffusion of
microﬁlariae. Diroﬁlariasis due to D. repens can present problems in
diagnosis and treatment. An ocular and subconjunctival location of
the worm and a subcutaneous nodule enclosing an immature adult
are the commonest clinical forms. Exceptional pulmonary locations are
described. The subcutaneous locations described are: skull, cheek, breast,
inguinal area, buttocks, arms and legs. Cases of testicular location with
painful symptoms have been observed. Blood hypereosinophilia was
exceptionally observed in human. It is treated surgically, by excision,
without chemotherapy.
Current and future trends in rapid
diagnostics for detection of nosocomial
superbugs
S292 Current methods for rapid detection of ESBL
T. Naas ° (Paris, FR)
While the majority of ESBLs, isolated in clinically-relevant Gram
negative bacteria (GNB) (mostly Enterobacteriaceae, P. aeruginosa,
A. baumannii) are TEM-, SHV- or CTX-M-types, a few others have been
reported (SFO, BES, BEL, TLA, GES, BEL, PER, VEB-types, and some
OXA-ESBLs). Laboratory detection of ESBL-producers is important to
avoid clinical failure due to inappropriate antimicrobial therapy and to
prevent nosocomial outbreaks.
Selective culture media (MacConkey and Drigalski agar supplemented
with cefotaxime and/or ceftazidime) have been proposed for detection
of GNB resistant to expanded-spectrum cephalosporins (ESC). Media
using chromogenic based substrates and selective antibiotics have been
developed recently for the detection and presumptive identiﬁcation of
ESBL-producing Enterobacteriaceae directly from clinical specimens.
Detection of ESBLs based only on susceptibility testing is not easy
due to the variety of b-lactamases and their variable expression of b-
lactam resistance. Commercially available ESBL detection methods yield
at most 90% accurate ESBL identiﬁcation, since some ESBL-producers
may appear susceptible to some ESCs. Therefore, any organism showing
reduced susceptibility to ESC should be investigated using ESBL
conﬁrmatory tests. These tests should be able to discriminate between
ESBL-producers and those with other mechanisms conferring ESC
resistance. These phenotypic tests (double-disk synergy test, ESBL Etest,
and the combination disk method) are based on clavulanate inhibition
and ESC susceptibility testing. They often need slight changes by either
reducing the distance between the disks of ESC and clavulanate, the
use of cefepime (not hydrolysed by AmpCs), the use of cloxacillin-
containing plates (that inhibits AmpC), or by double inhibition by EDTA
and clavulanate (masking metallo-enzymes). Enzymatic tests have also
been proposed for identiﬁcation of ESBL-producers.
Several PCR-based techniques (end-point or real time) have been
developed on clinical samples or on colonies. Several ESBL genes
have been detected using PCR coupled to either pyrosequencing, inverse
hybridisation, to dHPLC, or to ﬂuorescent probes. These techniques even
though more speciﬁc require technical knowledge, special equipment, are
costly and detect only known genes, regardless of their expression.
Detection of ESBL-producer remains a challenge for the microbiology
laboratory and one shall be aware that ESBL screening media are now
available.
S293 Future trends for rapid detection of antibiotic resistant
pathogens
F. Tenover ° (Sunnyvale, US)
Resistance to antimicrobial agents has become common in many
bacterial species, particularly those that cause human infections. The
rapid detection of resistant organisms directly in clinical samples
by real-time PCR coupled with molecular beacons, or of potentially
resistant bacteria and yeast in blood culture bottles by peptide nucleic
acid-ﬂuorescence in situ hybridisation (PNA-FISH) is already having
a positive impact on antimicrobial therapy. The direct detection of
Mycobacterium tuberculosis in sputum in approximately 2 hours
with concomitant detection of mutations in rpoB indicating rifampin
resistance (as a surrogate for multidrug resistance) in the near future will
likely improve the outcomes for tuberculosis patients in many developing
and developed countries. Several molecular technologies, including
microarrays, bacterial tag encoded FLX amplicon pyrosequencing
(bTEFAP), and ultra deep sequencing, have not yet transitioned to
clinical laboratories but will likely provide even greater information
about antimicrobial resistance not in just a single species, but in a
whole community of microorganisms. Complex wounds, like diabetic
foot ulcers, containing multiple resistance genotypes are amenable to
analysis by bTEFAP. The implementation of these technologies in the
clinical laboratory will be expensive but the potential to dramatically
improve therapeutic outcomes especially for life-threatening diseases is
unprecedented.
Antibiotic use in hospitals
O294 The ESAC Point Prevalence Survey of patterns of antibiotic
use in 50 European hospitals in 2008
A. Muller °, B. Amadeo, E. Hendrickx, V. Vankerckhoven, P. Davey,
H. Goossens on behalf of the ESAC Hospital Care Sub-project Group
Objectives: To perform a Point Prevalence Study (PPS) on antimicrobial
prescription in a larger sample of European hospitals, as compared to
the PPS-2006 study.
Methods: Data was collected during two subsequent calendar weeks
in May-July 2008 in 50 hospitals in 26 European countries. The study
protocol was a simpliﬁed version of the 2006 one. An internal web-based
application was developed and PDA was used in a subset of hospitals.
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Antimicrobial prescriptions were recorded using the ATC classiﬁcation.
Demographic data on treated patients, indications, diagnoses, culture
pre-therapy and reasons for treatment recorded in notes were collected.
Results: Among the 25,710 admitted patients, 8,126 (31%) received
antimicrobials for a total of 11,208 therapies of which 5,601 (69%,
68% in 2006) were monotherapy. Antibiotics represented 90% of
the prescriptions (range: 74−96). The most commonly prescribed
antibiotics were penicillins with beta-lactamase inhibitor (22%, range:
0−55), cephalosporins (20%, range: 3−60), and ﬂuoroquinolones (13%,
range: 0−40). In intensive care wards, glycopeptides represented the
third class (7%, range 0−25), followed by the ﬂuoroquinolones. The
proportions of parenteral use within the total antibiotic prescriptions, the
penicillins and the ﬂuoroquinolones were 74% (64% in 2006), 32% and
6% respectively, however wide variations occurred between hospitals.
Infections represented 74% (78% in 2006) of all the indications. Among
the curative treatments, 66% (62% in 2006) were for community-
acquired infections. Pneumonia and skin and soft tissue infections were
the predominating diagnoses representing respectively, 25% and 16%.
Surgical prophylaxis represented 72% (68% in 2006) of all prophylactic
treatments. The >1 day course for surgical prophylaxis that was already
high in 2006 (56%) increased to 65% (range: 57–100 depending of the
site) in 2008. The use of single dose pre-operative prophylaxis ranged
from 0% to 91% within the hospitals.
Conclusion: The PPS 2008 results, based on a larger sample of
hospitals and countries are in accordance with the 2006 PPS data. The
survey conﬁrmed the too long duration of surgical prophylaxis and the
predominance of the parenteral route. ESAC successfully developed
a web-based and PDA tool for surveying antibiotic use and quality
assessment in European hospitals, which will be rolled out in 2009 to
many European hospitals.
O295 Appropriateness of antimicrobial use in 11 Dutch hospitals
I. Willemsen °, J. Mannie¨n, B. Benthem, J. Wille, J. Kluytmans (Breda,
Bilthoven, Utrecht, Amsterdam, NL)
Objective: To determine the appropriateness of antimicrobial therapy
(AMT) in 11 Dutch hospitals.
Method: Data were obtained from a prevalence survey performed within
the Dutch surveillance network for nosocomial infections (PREZIES).
AMT administrated on the day of the survey was registered. Antiviral
and antifungal drugs, tuberculostatics, cements containing AMT and
prophylaxis administrated in the operation-theatre were excluded. The
appropriateness of AMT was assessed according to a standardised
algorithm based on the local antimicrobial prescription guidelines.
Per patient a classiﬁcation in appropriate use, inappropriate use and
insufﬁcient information was made.
Figure: Relative risk of IA use of AMT against largest hospital
(hospital C).
Results: A total of 3,546 patients were included of which 1,075 (30%,
range per centre (RPC): 23−37%) received AMT. In the latter group,
AMT was considered appropriate in 70% (RPC: 57−84%), inappropriate
in 17% (RPC: 3−32%) and was not judged because of insufﬁcient
information in 13% (RPC: 1−30%). There was considerable variation in
inappropriate use among the participating centres (ﬁgure). In univariate
analysis older age, the use of quinolones, being on the urology ward
and presence of a suprapubical catheter were associated signiﬁcantly
with inappropriate use. Admission on the ICU and presence of an
intravascular catheter were associated signiﬁcantly with appropriate use.
In a multivariate analyses the presence of suprapubical catheter, being
on the urology ward and the use of quinolones were determinants for
inappropriate use.
Conclusion: This study showed large differences in overall use and
appropriateness of use of AMT between hospitals. Based on these results
it is possible to deﬁne targets for intervention to improve the prudent use
of AMT. The high fraction of patients with insufﬁcient information in
several centres may have inﬂuenced the analyses and should be addressed
in future studies.
O296 Validation of quality indicators for hospital antibiotic use
by the ABS International − Quality Indicators (QI) Project
M. Struelens °, S. Metz-Gercek, R. Mechtler, F. Buyle, A. Lechner,
H. Mittermayer, F. Allerberger, W. Kern and the ABS QI Team &
Feasibility Study Participants
Objectives: The EU-Project Antibiotic Strategy International (ABS)
QI team developed process QIs for auditing the performance of key
treatment and prophylactic practices. An international network of pilot
hospitals tested these tools for feasibility, reliability and sensitivity to
improvement.
Methods: QIs included:
1. surgical prophylaxis (indication, drug choice, timing and duration of
administration);
2. management of community-acquired pneumonia (CAP) (blood
culture and Legionella antigen tests and drug choice for empirical
treatment);
3. management of S. aureus bacteraemia (echocardiography, IV catheter
removal and duration of therapy); and
4. iv-po switch for bio-available antibiotics.
A minimum of 40 consecutive cases per centre and QI were
retrospectively reviewed from clinical, laboratory and administrative
records and assessed for data availability, inter-observer reliability, data
collection workload and performance score.
Results: A total of 1240 patients were evaluated in 11 acute care
hospitals from 5 countries, with a range of 80 to 500 cases and 2 to 9
centres per indicator. Seven centres had already implemented antibiotic
quality improvement and audit programmes. Availability of data was
>85% of cases and ranged between 87% (catheter removal in S. aureus
bacteraemia) and 100% (diagnostic tests for CAP). 13/14 indicators were
found to be reliable with kappa  0.60 (good to excellent agreement).
The workload per case ranged from a median time of 16 (CAP) to
35min (iv-po switch). The intention to treat QI scores showed high
levels of adherence to the surgical prophylaxis QI bundle, with median
values of 81 to 97% for hip prosthesis and 65 to 92% for colo-rectal
surgery. For CAP management, diagnostic testing appeared sub-optimal
(<56% compliance with IDSA guidelines). For S. aureus bacteraemia
management, indicator results ranged from 60 to 65%. For use of bio
available antibiotics, a median of 45% iv administrations were avoidable.
There were marked differences of scores between centres for all QIs.
Conclusions: The ABS QIs are reliable and broadly applicable tools for
auditing antibiotic treatment and prophylactic practices. Inter-hospital
variation in adherence to recommended practice indicates substantial
potential for improvement with different local priorities. These QIs can
be recommended for assessing the effect of quality of care interventions
at either local or multi-centre level.
O297 Does a laminated hand-held card describing antibiotic
policy inﬂuence the junior doctor prescribing in a geriatric
medicine department? A controlled interrupted time-series
D.J. Noimark °, E. Charani, S. Smith, B. Cooper, I. Balakrishnan,
S.P. Stone (London, UK)
Introduction: Reduction of Clostridium difﬁcile infection (CDI), which
often follows use of third generation cephalosporins, is a national
priority. Over a three year period, antibiotic policies were reviewed
and changed in an elderly medicine department according to local
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sensitivities of common pathogens and levels of CDI. A laminated
pocket-sized card describing antibiotic policies was given to all doctors
in the department on induction with instructions not to depart from
these without microbiologists’ approval. This prospective controlled
interrupted time series examines whether this intervention increased
compliance with antibiotic policy and decreased CDI incidence.
Methods: The department’s “narrow-spectrum, no cephalosporin” antibi-
otic policy was changed on 1st August 2006 to replace Trimethoprim
with Cephradine (1st generation cephalopsporin) as empiric treatment
for urinary tract infection, reﬂecting local Escheriscia Coli sensitivities.
In October 2007, all cephalosporins and quinolones were removed from
the policy as CDI levels had increased. Notional 7 day antibiotic usage
was calculated from prospective pharmacy generated data with aspirin,
calcium, bisphosphonate & laxative prescription use as a non-antibiotic
control, and analysed by segmented regression with a robust variance
estimator. CDI rates were prospectively collected separately & analysed
by a Poisson regression model.
Results: An immediate response to change in antibiotic guidelines was
observed (Figure). From August 06-Sep 07 there was a highly signiﬁcant
increase in cephalosporins (85–100% of which was Cephradine alone)
(p< 0.001), a signiﬁcant fall in trimethoprim (p< 0.004) and a signiﬁcant
increasing trend in CDI (incidence rate ratio [95% CI]) for monthly
increase: 1.07 [1.00, 1.14], p = 0.04). From Oct 07-Sep 08 there
was a signiﬁcant decrease in cephalosporins (p< 0.01), quinolones
(p< 0.001) & CDI (IRR 0.78 [0.65, 0.94], p = 0.01) & a signiﬁcant rise
in trimethoprim (p< 0.001). There were no signiﬁcant changes in other
antibiotics including amino & benzyl penicillins & gentamicin. Control
drug usage did not change except for laxatives.
Conclusion: This study, which used a strong prospective quasi-
experimental design, showed that a pocket-sized laminated card appeared
to be an effective way to reinforce antibiotic policy and help control CDI.
This is the ﬁrst report to associate high CDI levels with 1st generation
cephalosporins.
O298 When is a hospital ready to introduce electronic antimicrobial
stewardship? The use of a Readiness Assessment Tool
S. Luu, K. Buising, M. Robertson, K. Thursky ° (Melbourne, AU)
Background: A multidisciplinary team from The Royal Melbourne
Hospital developed an electronic antimicrobial stewardship system called
Guidance DS in 2005. Since then, this system has been successfully
implemented at two other Melbourne hospitals. The impact of the system
on antimicrobial usage and resistance has previously been reported [1].
Recently, the Victorian Government ‘Infection Control Strategy’ funded
the introduction of electronic antimicrobial stewardship to all major
public hospitals in the state. These hospitals had widely variable existing
infectious diseases support, IT infrastructure and prescribing cultures.
No tools existed to assess the readiness of public hospitals to receive
this technology, and therefore guide resource allocation to facilitate
implementation.
Aim: To assess the readiness of Victorian public hospitals to introduce
electronic antimicrobial stewardship.
Method: Literature on readiness for change, organisational culture and
information technology acceptance were reviewed. Group interviews
with project teams at site initiation meetings, one on one interviews
with project ofﬁcers at subsequent meetings, and observation where
appropriate were all used to determine potential barriers and enablers.
This information was recorded using a ‘Readiness Assessment Tool’ and
analysed to identify a number of key domains. To triangulate the data,
questionnaires were distributed to project ofﬁcers asking them to assess
their sites’ readiness to implement the system.
Results: A novel ‘Readiness Assessment Tool’ was developed. It
covered the domains of technical readiness, skills readiness, process
readiness, administrative support readiness, resource readiness and
hospital organisational characteristics. Assessments at several hospitals
highlighted a variety of issues at different sites and allowed early efforts
to address these.
Conclusion: A formative readiness assessment can be used to identify
systematic problems that might facilitate or hinder uptake of electronic
antimicrobial stewardship and to inform the adopters of potential
resources required.
Reference(s)
[1] Buising, K, Thursky, K, Robertson, M, Black, J, Street, A, Richards,
M & Brown, G (2008). Electronic antibiotic stewardship–reduced
consumption of broad-spectrum antibiotics using a computerised
antimicrobial approval system in a hospital setting. J Antimicrob
Chemother.
O299 Fluoroquinolone prophylaxis in haematology-oncology
patients − is it still useful?
W.V. Kern °, M. Steib-Bauert, A. Pritzkow, G. Peyerl-Hoffmann, H. von
Baum, U. Frank, M. Dettenkofer, C. Schneider, K. de With, H. Bertz
(Freiburg, Ulm, DE)
Objectives: Fluoroquinolone prophylaxis (FQPx) may reduce morbidity
and mortality in cancer patients (pts) with neutropenia, but the
development of ﬂuoroquinolone resistance (FQR) in Escherichia coli and
other target organisms limits its usefulness. We evaluated changes in the
incidence density of Gram-negative bloodstream infection (GNB) and in
the in vitro FQR rates after the introduction of FQPx (with levoﬂoxacin)
as a standard of care for pts with high risk neutropenia in a university
hospital.
Methods: We collected individual data for 357 pts admitted during
baseline and during the ﬁrst months following the intervention to assess
clinical outcomes. Individual pt data were compared with aggregate
data (3-month periods). Aggregate data analysis (unit-wide antibiotic
consumption, GNB and numbers of in vitro FQR bloodstream isolates)
was continued for a total of eight 3-month periods for both the
haematology-oncology service and for general internal medicine.
Results: The new policy was introduced in the second half of the year
2005 when unit-wide baseline FQR of E. coli and of coagulase-negative
staphylococcal (CoNS) bloodstream isolates had been 15% and 80% in
the haematology-oncology unit, and 8% and 60% in general internal
medicine, respectively. The individual pt data analysis revealed that pts
not given FQPx had a much higher incidence of GNB than those given
FQPx (22/254 [9%] vs 2/103 [2%], p = 0.01) following the policy change,
and this difference remained signiﬁcant after adjustment for potentially
confounding variables. Aggregate data also demonstrated this reduction
in GNB incidence density, but only until the second quarter of 2007 after
which the GNB incidence density rose to preintervention level. This was
associated with increased FQR rates among E. coli bloodstream isolates
from pts admitted to haematology-oncology (25% in 2006 vs 72% in
2007), but increased FQR rates among E. coli bloodstream isolates were
also observed in general internal medicine pts (12% in 2006 vs 21% in
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2007) although the FQ consumption had remained fairly stable in both
services.
Conclusion: The efﬁcacy of FQPx in cancer pts with neutropenia
appears to diminish as FQR rates in E. coli isolates from pts in general
internal medicine increase, possibly reﬂecting community trends relevant
to the cancer pt setting. Based on aggregate data analysis, a resistance
rate in general medicine exceeding 20% was associated with a virtually
complete loss of FQPx efﬁcacy.
O300 Improving antimicrobial use in the hospital: targeting
quinolones using multiple interventions
I. Willemsen °, B. Cooper, C. Buitenen, M. Winter, J. Kluytmans
(Breda, NL; London, UK; Amsterdam, NL)
Objectives: To determine the effects of interventions on the use of
Quinolones (QUIN) in a hospital.
Methods: During a prospective study, from 2005 through 2007, 4
interventions to improve the use of QUIN were executed. First,
promotion of a switch from IV to oral medication (01–2006); second,
education programs for interns/residents and physicians and the release
of a new antimicrobial formulary (06–2006); third, a restriction note was
printed on all laboratory reports (10–2006); and fourth, active monitoring
and feedback on prescriptions (01–2007). The monthly use of iv and
oral QUIN was calculated based on data from the pharmacy department.
Statistical analyses were performed using segmented linear regression
analysis. Bayesian Model Averaging was used to account for model
uncertainty.
Results: Before the interventions the use of QUIN (both iv and total)
was stable. The best ﬁtting models indicated that the ﬁrst intervention
was associated with a stepwise reduction in IV use of 71 prescribed daily
doses (PDD) (95% CI: 47, 95 (p< 0.001)). There was also an indication
of smaller reduction in IV use associated with intervention 4, but only
the intervention 1 effect was robust to model uncertainty.
The overall use of QUIN was also signiﬁcantly reduced (ﬁgure) with a
large stepwise reduction of 107 PDD (95% CI: 58, 156) associated with
intervention 2.
Conclusions: This study showed that the hospital-wide use of QUIN can
be signiﬁcantly improved (and decreased) by an active policy consisting
of multiple interventions.
O301 Cohort study of adult patients with complicated skin and
soft-tissue infections
C. Marwick °, J. Broomhall, C. McCowan, S. Gonzalez-McQuire,
K. Akhras, S. Merchant, P. Davey (Dundee, High Wycombe, UK;
Raritan, US)
Aim and Objectives: to describe the antibiotic treatment and outcomes
stratiﬁed by severity in a representative sample of adult patients aged 18
or older who were treated in hospital for skin and soft tissue infections.
Background: Skin and soft tissue infection (SSTI) is one of the common
indications for antimicrobial therapy in hospital. In the ESAC (European
Surveillance of Antimicrobial Chemotherapy) point prevalence survey
of 19 European hospitals in 2006 SSTI was the second most common
infection after respiratory infection and accounted for 13% of all
treatments. However, in comparison with respiratory infections there is
little information about the outcomes of treatment for SSTI or about the
validity of clinical severity scores.
Results: We identiﬁed 341 patients aged 18 or over in 2005 who
had a new admission to Ninewells Hospital, Scotland between 1st
January and 31st December 2005 and were discharged with one or
more ICD10 codes for SSTI. There were 187 valid cases of SSTI.
Microbiology samples (n = 480) were taken from 75% of patients. The
most common isolates were Staphylococcus aureus (50% of positive
cultures, of which 47% were MRSA) and Pseudomonas aeruginosa (17%
of positive cultures). Death in hospital or within 30 days of treatment
occurred in 19 (10%) patients. The patients received a total of 80
different empirical antimicrobial regimens. We stratiﬁed patients by Eron
classiﬁcation. We deﬁned sepsis as presence of Systemic Inﬂammatory
Response Syndrome (SIRS) and severe sepsis as a Standardised Early
Warning Score >4. Two Infectious Diseases Physicians (CM and PD)
independently judged empirical antimicrobial therapy as inadequate if it
did not cover the most likely pathogens for any Eron Grade or if it was
oral for Grades 2 to 4. Agreement between raters was 88%. Mortality
and inadequate therapy both increased with Eron grade:
1. No SIRS or co-morbidity: 45% patients, 4% mortality, 10% therapy
inadequate.
2. Signiﬁcant co-morbidity but no SIRS: 33% patients, 7% mortality,
41% therapy inadequate.
3. Sepsis, with SIRS: 17% of patients, 22% mortality, 40% therapy
inadequate
4. Severe sepsis: 5% of patients, 50% mortality, 100% therapy
inadequate.
We also judged that 43% of patients received unnecessarily broad
spectrum therapy.
Conclusions: SSTI is common and is associated with signiﬁcant
mortality. However, choice of empirical therapy is not evidence based,
with signiﬁcant under treatment of high risk patients.
O302 Formal infectious disease consultation is associated with
decreased mortality in Staphylococcus aureus bacteraemia
J.O. Robinson °, S. Pozzi Langhi, M. Phillips, J. Pearson,
K. Christiansen, G. Coombs, R. Murray (Perth, AU)
Objective: Staphylococcus aureus Bacteraemia (SAB) is associated with
considerable mortality. We conducted a study to see if the direct input
of an infectious disease specialist was associated with outcome.
Methods: A retrospective analysis on all methicillin resistant (MRSA)
and a random subset of methicillin susceptible (MSSA) SAB over
10 years comparing those with to those without an infectious disease
consultation (IDC). All blood cultures were phoned to the treating team
by a microbiologist, but only formal clinical review of that patient was
considered as IDC.
Results: Of 599 SAB episodes, 162 (27%) had an IDC. Patients with
an IDC were younger (median 57 vs 65, p = 0.001), and more likely to
be intravenous drug users (16.7% vs 4.1%, p< 0.001) but less likely
to be resident in a long term care facility (6.8% vs 15.1%, p = 0.007)
or indigenous (6.8% vs 12.8%, p = 0.038). Bone/joint infection and
intravenous drug use were more frequently identiﬁed as the source
of bacteraemia in the IDC group, whereas pneumonia or primary
bacteraemia were less frequent. The proportion of SAB due to MRSA
was similar between groups (33.2% vs 32.1%, p = 0.802). Length of
stay was longer in the IDC group (29.5 vs 17 days, p< 0.001) and
endocarditis (19.1% vs 7.3%, p< 0.001) and metastatic seeding (22.2%
vs 10.1%, p< 0.001) were more frequent in the IDC group. However,
SAPS scores were lower in IDC group (27 vs 37, p< 0.001), whilst
ICU admission rates were similar between groups. The S. aureus isolate
tested susceptible against initial therapy more frequently in the IDC
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group (88.9% vs 78.0%, p = 0.003). 7-day (3.1 vs 16.5%), 30-day (8.0%
vs 27.0%) and 1-year mortality (22.2% vs 44.9%) were all lower in the
IDC group (p< 0.001). Multivariate analysis showed that effective initial
therapy was the only variable associated the protective effect of IDC.
Conclusion: All cause mortality was signiﬁcantly lower in patient with
SAB who had an infectious disease consult as a result of a higher
proportion of effective initial antibiotic therapy.
O303 Determinants of antibiotic use in nursing homes in 18 Euro-
pean countries: results of the European Surveillance of An-
timicrobial Consumption (ESAC) Nursing Homes subproject
B. Jans °, L. Fontaine, E. Hendrickx, A. Muller, V. Vankerckhoven,
H. Goossens on behalf of the ESAC Nursing Home Subproject group
Objectives: In the framework of the nursing home (NH) subproject of the
European Surveillance of Antimicrobial Consumption (ESAC) project,
structural, functional and regulatory determinants of antibiotic (AB) use
in NHs in Europe were explored.
Methods: A standardised questionnaire collected national data in
2008 on structural and functional features, characteristics of resident
population, organisation of medical and nursing home care, and
national/regional regulations on infection prevention and AB policy in
NHs in 18 European countries.
Results: Eighteen countries returned the questionnaire. Important
structural NH differences were observed between Member States (MS),
especially regarding mean NH size, resident age and length of stay. Also,
there was no unique scale/score measuring the NH case mix. Medical
care, often provided by individual general practitioners (GP), was co-
ordinated by a co-ordinating physician (CP) in 7 countries. The CPs
were ofﬁcially charged to develop the AB policy and to set up infection
prevention in the NH in only 4 MS.
AB were mostly (16/17) prescribed by GPs and delivered by public
(n = 14) or hospital pharmacies (n = 3). Surveillance of AB use in NHs
was organised in only 4 MS. In 3 countries a NH speciﬁc pharmaceutical
formulary was available. Prescription proﬁles by prescriber were
available in 5 countries. Other quality improvement initiatives in NHs
such as regular training of prescribers, promoting microbiological
sampling, collection of antimicrobial resistance proﬁles or pharmacist
advice on AB prescription were scarce. Guidelines for AB treatment
of most frequent infections were available in many countries but were
focussing on ambulatory care and did not consider the speciﬁc NH
situation. Only in 1 country the presence of an infection control
practitioner was compulsory and partnership with hospital infection
control teams was legally imposed in 3 MS.
Conclusion: Important structural, functional and regulatory NH
differences exist between EU countries. Speciﬁc tools to improve
infection prevention and AB therapy in NHs should take into account
these differences. A European NH network was created in the framework
of the ESAC NH subproject, which will organise point prevalence
surveys on AB use in 2009.
CTX-Ms for ever
O304 Emergence of CTX-M type ESBLs among urinary tract
Escherichia coli in south-western Finland
J. Jalava °, O. Meurman, H. Marttila, A. Hakanen, M. Lindgren,
K. Rantakokko-Jalava (Turku, FI)
Objectives: Extended-spectrum betalactamases (ESBLs), especially
enzymes of the CTX-M group, are spreading rapidly in Europe.
Enterobacteriaceae with reduced susceptibility to third generation
cephalosporins and a positive ESBL conﬁrmatory test are also increasing
in Southwest Finland. The purpose of this work was to study the
resistance genetics of these ESBL-positive Enterobacteriaceae.
Methods: The study comprises a total of 271 clinical Enterobacteriaceae
strains isolated from both inpatient and outpatient specimens. All
Enterobacteriaceae strains that were ESBL conﬁrmatory test positive
between January 2004 and December 2008 were included in this study
(263 Escherichia coli, 8 Klebsiella pneumoniae, one isolate per patient).
Of these strains, 225 (83%) were urine isolates.
Resistance determinations were done using disk diffusion method (CLSI)
or Vitek 2 and ESBL conﬁrmations by the double disk method using
cefotaxime and ceftatzidime with and without clavulanate. Thus far, 219
strains (those collected by end of June 2008) have been analysed for the
presence of the most important ESBL genes (TEM, SHV and CTX-M)
using PCR and pyrosequencing as described before (Haanpera et al.
AAC, 52:2632; 2008).
Results: In 2004 only 10 ESBL-positive strains were found. All of them
harboured a CTX-M type ESBL gene. Since then, the number ESBL-
producing Enterobacteriaceae strains has increased signiﬁcantly being
tenfold in 2008 compared to year 2004 (Figure). A high majority, 197
(90%) of the 219 strains analysed thus far had a CTX-M-type ESBL
gene. Most of those (79%) belonged to the CTX-M-1 group according
to the pyrosequencing results. CTX-M-9 group was the next common,
with 20% of the CTX-M genes belonging to this group. Only two strains
with CTX-M group 2 enzyme were found.
Conclusions: Enterobacteriaceae strains which produce ESBL are
increasing rapidly in Southwest Finland. This is especially true with
E. coli strains isolated from urine. Towards the end of the study period,
the ESBL enzymes were almost exclusively CTX-M, CTX-M-1 group
being the most common. Further research is needed to characterise
genetic elements that carry these ESBL genes.
ESBL strains and the proportion of CTX-M genes in 2004–2008.
O305 International dissemination of extended-spectrum
beta-lactamase CTX-M-14 in Enterobacteriaceae isolates is
mainly associated with the spread of IncK and IncF plasmids
A. Valverde °, R. Canton, P. Hawkey, J.D. Pitout, P. Nordmann,
L. Peixe, F. Baquero, T.M. Coque (Madrid, ES; Birmingham, UK;
Calgary, CA; Paris, FR; Porto, PT)
Objectives: CTX-M-14 constitutes a widely spread extended-spectrum-
beta-lactamase (ESBL), mainly in the community setting. Diversity
of CTX-M-14-carrying plasmids of Enterobacteriaceae isolates from 8
countries is analyzed.
Methods: 52 Enterobacterial isolates [47 Escherichia coli (EC),
4 Klebsiella pneumoniae (KP) and 1 Citrobacter freundii (CF)]
recovered (2000–2006) in France (n = 6), Spain (n = 4), Portugal (n = 6),
UK (n = 11), Kuwait (n = 2), Canada (n = 13) and China (n = 10),
including Hong Kong (n = 3) were studied. Clonality was established
by PFGE and phylogenetic groups of EC and KP were determined
as reported. Susceptibility testing (CLSI), blaCTX-M-14 transferability
and location (I-Ceu-I/S1 nuclease) were investigated. Plasmid analysis
included determination of Inc group (PCR-replicon typing, hybridisation,
sequencing) and comparison of RFLP patterns. Association of blaCTX-
M-14 with ISEcp1, ISEcp1-IS10 or ISCR1 was established by PCR and
sequencing.
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Results: We identiﬁed 42 PFGE types among 52 isolates: 38/47 EC,
3/4 KP and 1/1 CF. Distribution among phylogroups were as follows:
i) EC: A (n = 7), B1 (n = 3), B2 (n = 5) and D (n = 23), and ii) KP:
KpI (n = 2) and KpII (n = 1). Resistance to tetracycline (76%), nalidixic
(74%), streptomycin (67%), sulfonamides (67%), ciproﬂoxacin (60%)
and trimetroprim (43%) was common. Transfer of blaCTX-M-14 was
achieved in 62% of the isolates. Analysis of plasmids showed 6 RFLP
(Rx) patterns: i) types Ra, Rb, and Rc correspond to IncK plasmids
(80 kb) found among different EC phylogroups, being Ra found among
isolates of Spain, Portugal and Canada and Rb among those from UK
and China; ii) types Rd, Re and Rf correspond to IncF plasmids (80 and
100 kb) of CF, EC-D and Kp respectively, being Re pattern identiﬁed
in different clones of EC-D from Canada, and Rf from China and UK;
iii) two IncHI2 plasmids of 242 kb from Spain were isolated from EC
clones. blaCTX-M-14 was mainly identiﬁed downstream ISEcp1 in IncK
or IncF plasmids or downstream ISEcp1 truncated by IS10 in an IncF
plasmid (Re) from Canada (n = 5 isolates/2 clones). Association with
ISCR1 was detected among IncHI2 plasmids.
Conclusions: International dissemination of blaCTX-M-14 is mainly
associated to epidemic IncK and IncF plasmids. The association
with speciﬁc EC clonal groups might have also contributed to its
dissemination and maintenance.
O306 Diversity of conjugative blaCTX-M-carrying plasmids from
Klebsiella pneumoniae strains in Slovenian hospitals
K. Mesko Meglic °, S. Koren, D.M. Livermore, A. Andlovic, S. Jeverica,
V. Krizan-Hergouth, M. Mueller-Premru, K. Seme, N. Woodford on
behalf of the Slovenian ESBL Study Group
Objectives: Diverse strains of K. pneumoniae with blaCTX-M were
noted during a nationwide survey in Slovenia in 2005 and 2006. All
had group 1 CTX-M genes, with blaCTX-M-15 identiﬁed by sequencing.
Efﬁcient in vitro transfer suggested that plasmids carrying blaCTX-M-15
were spreading horizontally in our hospitals and, here, we characterised
the plasmids responsible in the major K. pneumoniae strains identiﬁed
during the survey.
Methods: Plasmids from representative K. pneumoniae strains with
CTX-M-15 enzyme were extracted by alkaline lysis and compared
by ApaI, PstI and EcoRI restriction analysis. They were transferred
into E. coli DH5a by electroporation. Transformants were selected
on cefotaxime-containing agar and were screened by PCR for
beta-lactamase genes, the aminoglycoside resistance genes aac(6′)-Ib
and aac3-IIb, and the plasmid-mediated quinolone resistance genes
qnrA/B/S.
Results: Twelve isolates were characterised, representing 5 major strains
(A-D, and F) found in the most-affected hospitals. Restriction analysis
divided their plasmids into several groups. Representatives of strain
A (n = 4) had essentially the same plasmid (group 1), as did the two
representatives of strain D (group 2a). One strain F isolate had a
plasmid (group 2b) very similar to plasmid 2a from strain D, indicating
possible horizontal transfer. Plasmids of group 3 were retrieved from
representatives of strains B and C, again indicating probable transfer.
Plasmids from three other strains differed substantially from each other
and from plasmids 1, 2a, 2b and 3. Nevertheless, on all plasmids,
blaCTX-M genes were linked to an upstream ISEcp1 element, known to
be involved in their mobilisation. All encoded multi-resistance: all but
one group 1 and one ungrouped plasmid carried aac(6′)-Ib; blaOXA-1
and aac(3)-IIa were detected on all except group 1 plasmids; blaTEM
was found on group 1, 2b, one group 3 and two ungrouped plasmids.
blaSHV and qnrA/B/S genes were not detected.
Conclusion: The considerable diversity of plasmids encoding CTX-M-
15 enzyme in major Slovenian K. pneumoniae strains suggested only
limited transfer, even when multiple strains were present in the same
hospital. Evidence of plasmid transfer was between strains B and C,
and possibly between strains D and F, although these plasmids were not
strictly identical. Analysis of resistance genes encoded by the plasmids
revealed diversity, with groupings coinciding largely with those based
on restriction proﬁles.
O307 Regional study of the genetic context of class 1 integron
harbouring blaCTX-M-2 linked to ISCR1 in nosocomial Kleb-
siella pneumoniae isolates from Uruguay, Argentina and Chile
A. Ingold, G. Borthagaray, A.K. Merkier, D. Centro´n, H. Bello,
C.M. Ma´rquez ° (Montevideo, UY; Buenos Aires, AR; Concepcio´n, CL)
Objectives: To examine the genetic context of class 1 integron
harbouring blaCTX-M-2 in ﬁfteen nosocomial K. pneumoniae isolates
from South America in order to enhance the understanding of the
antibiotic resistance spread among the region.
Methods: DNA was extracted with the use of AxyPrepTM Bacterial
Genomic DNA Miniprep Kit. The analysis of the cassette array was
carried out with the use of primers HS458/HS459 targeting adjacent
conserved regions.
The examination of the surroundings were performed using two
PCR primer pairs, HS817/HS818 and HS825/HS826, to amplify the
initial(IRi) and the terminal(IRt), inverted repeat boundary, respectively.
The primer pair HS825/HS911 was used whenever a negative result
was obtained with HS825/HS826. All PCR products were puriﬁed and
sequenced and the data was analyzed with NCBI Blast Tool.
Results: The sequence obtained with primers HS817/HS818 revealed the
presence of three different transposons backbones at the IRi end. The
Tn5036-like module and the Tn21-like module were present in 4 isolates,
the Tn1696-like module was present in 7 isolates. No amplicons were
obtained with the use of primers HS825/HS826 that amplify a Tn21-like
insertion. Two Uruguayan isolates with a Tn5036 boundary at the IRi
end were tested with HS825/HS911 that target a Tn5036-like backbone
and one generated a product consistent with a Tn5036-like mer region.
Uruguayan isolates carried a single aadA1 cassette (4/5) and the other
one contained a dfrA17-aadA5 array, while the four Argentinian isolates
carried the combination aacA4-aadA1-orfD. Chilean isolates arrays are
in process.
Conclusions: Among the extended-spectrum beta-lactamases, the
cefotaximases constitute a rapidly growing cluster of enzymes that have
disseminated geographically. There is a high frequency of isolation of
CTX-M-2 producing K. pneumoniae associated with a class 1 integron
in the region. Despite being common the presence of ISCR1 linked
to blaCTX-M-2 in K. pneumoniae isolates, this study provides new
and relevant information in the sequence context at the IRi. Here we
report about the cassette array diversity and the diversity of elements in
which the class 1 integron are embedded. Different integron/transposons
carrying the blaCTX-M-2 gene seem to be circulating and different
regional patterns could be emerging, this study highlights the ability of
different genetic elements to act cooperatively to spread and rearrange
antibiotic resistance.
O308 Escherichia coli clones and plasmid-mediated later transfer
disseminate CTX-M-1 and CTX-M-32 among animals and
humans
L. Vinue´, A. Garcı´a-Ferna´ndez, D. Fortini, P. Poeta, M.A. Moreno,
C. Torres, A. Carattoli ° (Logron˜o, ES; Rome, IT; Vila Real, PT;
Madrid, ES)
Objectives: CTX-M enzymes are frequently detected in Europe. In
particular, CTX-M-1 and CTX-M-32-producing strains have been
recovered from both humans and farm animals in Spain, Italy, Greece,
and Portugal, suggesting the existence of community reservoirs for these
enzymes. The aim of this study was to compare Escherichia coli strains
and plasmids harbouring blaCTX-M-1 and blaCTX-M-32 genes isolated
from human and animals.
Methods: Four E. coli CTX-M-1 and eight CTX-M-32 epidemiologi-
cally unrelated producers from sick or healthy animals (pig, dog, cow
and chickens) and from humans (urine, blood and faecal samples) were
analysed by XbaI-PFGE, plasmid transferability, PCR-based replicon
typing, plasmid restriction analysis and Southern blot hybridisation. All
isolates were from Spain but the dog isolate was from Portugal. The
genetic context of the blaCTX-M genes was previously investigated for
all the strains.
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Results: three CTX-M-32 strains (one from healthy chicken and
two from hospitalised patients) showed the same PFGE pattern. A
chromosomal localisation of the blaCTX-M-32 gene was suspected in
these strains. The ﬁve remaining CTX-M-32 producers showed the
blaCTX-M-32 gene on plasmids belonging to the IncN (4 strains) or
untypable groups (1 strain). Two IncN plasmids showed identical PvuII-
restriction patterns: one was identiﬁed in a strain from a healthy chicken
and one was from a hospitalised human patient; these two strains were
isolated in 2002 and 2004, respectively and showed different PFGE
patterns.
CTX-M-1 producers (three from animal strains and one a healthy human)
did not show clonality by PFGE and the blaCTX-M-1 gene was always
located on plasmids, three belonging to the IncN and one to the IncI1
groups. Two of the IncN plasmids carrying the blaCTX-M-1 gene showed
highly related restriction patterns: one was from a healthy dog and one
from a healthy human.
Conclusion: This study demonstrated the presence of clonal E. coli
CTX-M-32 producers in animal and human sources and also detected
epidemic IncN plasmids disseminating among unrelated isolates from
humans and animals, clearly suggesting a potential animal reservoir for
the blaCTX-M-1/32 genes.
Wide spectrum beta-lactamases in
Pseudomonas
O309 Characterisation of blaDIM-1, a novel integron-located
metallo-beta-lactamase gene from a Pseudomonas stutzeri
clinical isolate in the Netherlands
L. Poirel °, J. Rodriguez-Martinez, N. Al Naiemi, Y. Debets-Ossenkopp,
P. Nordmann (K.-Bicetre, FR; Amsterdam, NL)
Objectives: Characterisation of the mechanism involved in the
uncommon resistance to carbapenems observed from a Pseudomonas
stutzeri isolate recovered from a patient hospitalised in the Netherlands
with a chronic tibia osteomyelitis. That strain was resistant to ticarcillin,
piperacillin-tazobactam, imipenem and meropenem, of intermediate
susceptibility to ceftazidime and cefepime, and susceptible to aztreonam.
Methods: Screening for metallo-beta-lactamase (MBL) production was
performed using the E-test method with a strip combining imipenem
and EDTA. Shotgun cloning was performed with XbaI-digested DNA of
P. stutzeri and pBK-CMV cloning vector. Selection was performed on
amoxicillin and kanamycin-containing plates.
Results: E. coli TOP10 (pDIM-1) recombinant strains were obtained,
displaying resistance to penicillins and ceftazidime, reduced suscepti-
bility to cefepime, imipenem and meropenem, and full susceptibility to
aztreonam. Sequence analysis identiﬁed a novel Ambler class B beta-
lactamase DIM-1 for “Dutch IMipenemase” (pI 6.1) weakly related to
all other MBLs. DIM-1 shared 52% amino acid identity with the most
closely related MBL GIM-1, and 45 and 30% identity with the IMP
and VIM subgroups, respectively. DIM-1 hydrolyzes very efﬁciently
imipenem and meropenem, expanded-spectrum cephalosporins, but
spares aztreonam. The blaDIM-1 gene was as a form of a gene cassette
located at the ﬁrst position in a class 1 integron, but the 59be of that
gene cassette was truncated giving rise to a fusion with an aadB gene
cassette encoding an aminoglycoside adenylyltransferase. The third and
last gene cassette corresponded to the qacH cassette encoding resistance
to disinfectants.
Conclusion: A novel MBL gene was identiﬁed in P. stutzeri further
underlining (i) the diversity of acquired MBL genes, especially among
non-fermenters, (ii) that Pseudomonas sp. may be a reservoir of
these genes and (iii) the possibility of spread of important resistance
determinants in Northern part of Europe.
O310 Metallo-beta-lactamases in Pseudomonas aeruginosa clinical
isolates in Greece
P. Giakkoupi, O. Pappa, M. Polemis, A. Bakosi, A. Vatopoulos °
(Athens, GR)
Objectives: Metallo-beta-lactamases of the VIM family are the main
mechanism of carbapenem resistance in P. aeruginosa in Greece. In this
preliminary report we attempted to survey the subtypes of VIM beta-
lactamase currently prevailing in P. aeruginosa clinical isolates in Greek
hospitals, the genetic relatedness of the respective isolates, as well as
the genetic environment of the blaVIM gene.
Methods: Fifteen MBL producing and epidemiologically unrelated
P. aeruginosa clinical isolates were collected in September 2006 from
ﬁfteen different hospitals around Greece. MBL production was initially
identiﬁed by an EDTA synergy test. Identiﬁcation of blaVIM gene,
as well as mapping of the blaVIM cassette carrying integrons were
performed by PCR and sequencing of the products. The O serotypes
of the isolates were determined by a slide agglutination test using
P. aeruginosa antisera (Biorad). Molecular typing was performed by
pulse-ﬁeld gel electrophoresis of SpeI-restricted genomic DNA.
Results: blaVIM-2 gene was detected in nine isolates, blaVIM-4 in ﬁve
and blaVIM-1 in only one isolate. The blaVIM-2 cassette of all nine
isolates was located on the 1600 bp variable region of a class I integron,
preceded by aacA29 gene cassette. blaVIM-4 cassette of all ﬁve isolates
was the ﬁrst cassette of the 3200 bp variable region of a class I integron,
followed by the aacA4 and blaPSE-1 gene cassettes. blaVIM-1 was
the unique cassette of a class I integron. VIM-2 producers belonged
to O8, O11 and O12 serotypes, whereas four isolates were non-typeable.
VIM-4 producers belonged to the same three serotypes, whereas only one
was non-typeable. The VIM-1 producer belonged to O12 serotype. The
nine VIM-2 producing P. aeruginosa isolates revealed a great degree of
variability in PFGE molecular typing, belonging to seven types. Contrary,
the ﬁve VIM-4 producing P. aeruginosa isolates displayed higher genetic
similarity and fell into one major type with 85% homology, which also
included the VIM-1 producing isolate. There was no correlation between
the results of serotyping and molecular typing.
Conclusions: MBL production in P. aeruginosa in Greece seems to be
mainly due to speciﬁc class I integrons harbouring either blaVIM-2 or
blaVIM-4 genes. Genetic variability was higher among bacteria carrying
VIM-2 beta-lactamase, a fact indicating wider intraclonar spread of the
respective integron.
O311 Extended-spectrum cephalosporinases hydrolysing
carbapenems in Pseudomonas aeruginosa
J.M. Rodriguez-Martinez, L. Poirel °, P. Nordmann (K.-Bicetre, FR)
Objectives: Extended-spectrum beta-lactamases of AmpC-type (ESACs)
contributing to reduced susceptibility to imipenem have been recently
reported from Enterobacteriaceae. The aim of the study was to evaluate
the putative role of natural AmpC-type beta-lactamases of P. aeruginosa
in a similar resistance proﬁle.
Methods: Thirty-two non-repetitive P. aeruginosa clinical isolates
recovered in our hospital in 2007 were included. They were selected
on the basis of criteria of intermediate susceptibility or resistance to
ceftazidime and intermediate susceptibility or resistance to imipenem.
MICs were determined by agar dilution and E-test techniques. The level
of expression of the AmpC beta-lactamases was evaluated by measuring
speciﬁc activities. PCR, sequencing, and cloning allowed to characterise
the different bla(ampC) genes. Identiﬁed ESACs were puriﬁed and their
Km and kcat values for beta-lactams determined by spectrophotometry.
Results: Using cloxacillin-containing (an AmpC beta-lactamase in-
hibitor) plates, the susceptibility to ceftazidime was restored for 25 out
of 32 isolates, suggesting overproduction of the AmpC. In addition, in
presence of cloxacillin, reduced MIC values were also observed with
ceftazidime, cefepime and imipenem for 21 out of those 25 isolates.
Cloning and sequencing identiﬁed 10 distinct AmpC b-lactamase variants
among the 32 isolates. Recombinant plasmids expressing the AmpCs
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were transformed into reference P. aeruginosa strain and reduced
susceptibility to cefepime and imipenem was observed only with
recombinant P. aeruginosa strains expressing AmpC beta-lactamases
that had an arginine residue at position 105. The catalytic efﬁciencies
(kcat/Km) of the AmpC variants possessing this arginine residue were
increased against oxyiminocephalosporins and imipenem. In addition,
in-vitro assays demonstrated that those AmpC variants constituted a
favourable background for selection of additional degree of carbapenem
resistance.
Conclusions: Some AmpCs of P. aeruginosa possessing extended
activity torward carbapenems may contribute to carbapenem resistance.
O312 Two novel OXA-type extended-spectrum b-lactamase
in Pseudomonas aeruginosa in Hunan province, China:
blaOXA-128 and blaOXA-129
W.E. Liu °, X.Y. Liu, Y.L. Zhang, X.H. Liang, H.L. Li, J.Z. Liao,
Z.J. Jian (Changsha, CN)
Background: Most OXA-type ESBLs are OXA-10, OXA-2 or OXA-1
derivatives. They display a very low homology, the percentage of
which is between 20% and 30%. OXA-type ESBLs are divided into
ﬁve groups according to the different homology by Frederic Bert, etc.
Group 1 includes OXA-5, OXA-7, OXA-10 and its derivants;Group
2 includes OXA-2, OXA-3, OXA-15 and OXA-20;Group 3 includes
OXA-1, OXA-4, OXA-30 and OXA-31; Group 4 is named after OXA-9;
Group 5 only includes a single enzyme called LCR-1. OXA-type ESBLs
has been reported widespread in the world since the ﬁrst report in 1987,
such as Turkey, France, England and so on. But there is few report about
it in China.
Objective: To investigate the prevalence and genotype distribution
of OXA-type extended-spectrum beta-lactamases (ESBLs) in clinical
Pseudomonas aeruginosa strains isolated from Xiangya Hospital of
Central South University in Changsha city, Hunan Province, China.
Methods: Ninety-seven non-repetitive clinical isolates of P. aeruginosa
were collected between October 2006 and January 2007 from the
hospital. They were screened for OXA-type ESBLS production by
polymerase chain reaction PCR with ﬁve pairs of primes speciﬁc for
blaOXA genes, respectively. Then ampliﬁcation of OXA-type ESBLS
production was performed by PCR with speciﬁc primers. The puriﬁed
and ampliﬁed products were sequenced to conﬁrm the genotype of the
OXA-type ESBLS.
Results: The sequences of the three OXA-type ESBLS PCR products
were then compared in GenBank database and there were no the
completely same ribonucleotide and amino acid sequence with them.
They were two novel OXA-type ESBLS, named as blaOXA-128 and
blaOXA-129, which have been registered in GenBank database under
accession numbers EU573214 and EU573215, respectively.
Conclusions: There have occurred infections caused by P. aeruginosa
producing OXA-type ESBLs in Xiangya Hospital of Central South
University. Two novel OXA-type ESBLS in P. aeruginosa strains have
been discovered in our study, which are named blaOXA-128 and
blaOXA-129, respectively.
Nosocomial pneumonia: the role of
multidrug-resistant Gram-positive infections
(Symposium organised by Astellas)
S314 Nosocomial pneumonia: the role of multidrug-resistant
Gram-positive infections
E. Bouza (Madrid, ES) A.P. MacGowan (Bristol, UK); R. Read
(Shefﬁeld, UK)
Pneumonia is one of the most common nosocomial infections and
is associated with high mortality. In the last 15 years, Gram-positive
bacterial pathogens have risen in prevalence as a cause of hospital-
acquired pneumonia (HAP), including that occurring during mechan-
ical ventilation (ventilator-associated pneumonia; VAP). In particular,
Staphylococcus aureus is a major cause of HAP, including VAP. The rise
of multidrug-resistant infections is a source of concern, with methicillin-
resistant S. aureus (MRSA) accounting for >40% of S. aureus isolates
in some European hospitals. This symposium will take the format of
a question-and-answer roundtable session in which experts will answer
questions and initiate discussion surrounding emerging concerns and
appropriate therapeutic strategies in nosocomial pneumonia, including
that caused by multidrug-resistant Gram-positive pathogens.
Recently, shifts in the susceptibility of S. aureus to established
therapeutic agents for nosocomial pneumonia have added to the
challenge of selecting appropriate empiric therapy. In patients with
suspected multidrug-resistant infections or those who are mechanically
ventilated, prompt initiation of therapy, often before the pathogen has
been conﬁrmed, is critical. Vancomycin is the gold-standard treatment
for multidrug-resistant infections and resistance has been remarkably
slow to emerge. However, clinical reports in Europe of ‘MIC creep’ and
the emergence of vancomycin-intermediate S. aureus (VISA), hVISA
and linezolid-resistant MRSA have presented new clinical dilemmas.
Elevated vancomycin MICs are linked to treatment failure and increased
mortality. Hence, while vancomycin remains a useful therapeutic tool,
treatment decisions present an increasing challenge, especially in groups
of patients in whom rapid eradication of infection with appropriate agents
is critical.
Telavancin is a novel lipoglycopeptide under investigation for treatment
of nosocomial pneumonia. A number of key features suggest telavancin
as a potentially attractive option for nosocomial pneumonia. Telavancin
has a unique dual mechanism of action that disrupts both bacterial
cell wall biosynthesis and cell membrane integrity. The agent is
rapidly bactericidal against a broad range of clinically relevant Gram-
positive bacteria, including MRSA. Two pivotal Phase III studies have
demonstrated telavancin efﬁcacy equivalent to vancomycin in HAP,
including VAP, including in seriously ill patient subgroups and in that
caused by MRSA.
Hantavirus infections in Europe
K328 Hantavirus infections in Europe
A. Vaheri ° (Helsinki, FI)
Hantaviruses are enveloped RNA viruses, each carried primarily by
rodents or insectivores of speciﬁc host species. They have coevolved
with the hosts in which they cause almost asymptomatic and persistent
infections. In humans some hantaviruses cause disease: haemorrhagic
fever with renal syndrome (HFRS) in Eurasia. In Europe Puumala
(PUUV) from bank voles and Saaremaa (SAAV) from ﬁeld mice cause
mild HFRS and Dobrava (DOBV) from yellow-necked mice severe
HFRS. In Asia HFRS is caused mainly by Hantaan and Seoul viruses. In
Americas some viruses cause hantavirus cardiopulmonary syndrome: Sin
Nombre, Andes and other viruses carried by sigmodontine rodents, not
found in Eurasia. In addition, in Europe the common vole carries Tula
and rats Seoul virus. However, they have not been deﬁnitely associated
with disease in Europe, although both can infect humans. We discuss the
epidemiology, molecular genetics, detection of infection in carrier hosts
and humans (including RT-PCR and 5-min serological tests), functions
of hantaviral proteins, risk factors for humans to catch hantavirus
infection (including smoking) and disease (including risk and protective
HLA haplotypes), role and mapping of epitopes of cytotoxic T-cells,
mechanisms of hantavirus-induced apoptosis, newly discovered clinical
features (including hypophyseal haemorrhages in PUUV infection),
and long-term consequences and pathogenesis of HFRS (endothelial
permeability, thrombocytopenia, TNF-alpha and IL-6).
PUUV occurs widely in Europe except in the far north and
Mediterranean regions, SAAV in northern, eastern and central Europe
and DOBV mainly in the Balkans. The epidemiological patterns
differ: in western and central Europe HFRS epidemics follow mast
years with increased oak and beech seed production promoting rodent
breeding. In the north, hantavirus infections and HFRS epidemics
occur in 3−4 year cycles, driven by prey-predator interactions. The
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infections and HFRS are on the increase in Europe, partly because of
better diagnostics and partly perhaps due to environmental changes. In
several European countries hantavirus infections are notiﬁable and in
some countries (e.g. Belgium, Finland, France, Germany, Scandinavian
countries, Slovenia) their epidemiology is relatively well studied. In large
areas of Europe, however, hantavirus infections and HFRS have not been
studied systematically and they are still heavily under-diagnosed.
MRSA screening − will we ever agree?
S330 MRSA: universal screening!
L. Peterson °, A. Robicsek (Evanston, US)
The successful control of any outbreak or epidemic relies on detection
of those harbouring the pathogen (infected and colonised persons)
combined with eliminating spread to new individuals. The approach to
containment and reduction of the global MRSA pandemic is now being
discussed. A challenge for this infection is that most persons harbouring
MRSA do not exhibit signs of disease and thus in order to detect all
potential spreaders of this organism some surveillance must be done.
The required level of detection (surveillance through screening) is not
known and likely varies with the prevalence of colonisation and disease.
For a given MRSA prevalence, the factor that seems most crucial in
reducing spread is the percentage of potential isolation days captured.
The operational processes that highly inﬂuence this are 1) the sensitivity
of screening detection (including sites tested and laboratory methods
used), 2) the speed at which results of newly detected positive patients
are reported from the laboratory (assuming pre-emptive isolation is not
employed), and 3) the selection of patient populations who are to undergo
screening. Laboratory testing has a major impact on detecting MRSA
colonised patients with real-time PCR having a sensitivity of 98% and
a possible 2 hour reporting time compared to direct chromogenic agar
cultures with a sensitivity of 80% and >24 hour reporting and enriched
chromogenic agar testing with a sensitivity of 90% and >48 hour
reporting (Am J Clin Pathol, 2009); both reduced sensitivity and
prolonged reporting time negatively impacting the success of MRSA
timely isolation. We have shown that capturing 33% of MRSA isolation
days in a modest MRSA prevalence setting (9 infections/10,000 patient
days) with a high sensitivity test having a >24 hour result reporting
time did not reduce hospital-wide MRSA disease (Ann Int Med 148:209,
2008). Others have demonstrated that surveillance in an ICU with similar
MRSA prevalence, again with a high sensitivity test having 1 day
result reporting, did not reduce ICU disease until preemptive isolation
was initiated (Crit Care 10:R25, 2006). Finally, we demonstrated that
universal admission surveillance and decolonisation capturing 85% of
possible MRSA isolation days had a dramatic impact by reducing 70%
of all in-hospital infections from MRSA. Future research in this area
should focus on better deﬁning those patients that beneﬁt from MRSA
screening and the role of decolonisation in these programs.
Update on Clostridium difﬁcile
S334 Update on Clostridium difﬁcile pathogenesis
M. Rupnik ° (Maribor, SI)
Clostridium difﬁcile infection (CDI) is a toxin-mediated intestinal
disease and extraintestinal manifestations are exceptional. Clinical
outcomes can range from asymptomatic colonisation to mild diarrhoea
and more severe disease characterised by inﬂammatory lesions and
pseudomembranes in the colon, toxic megacolon or bowel perforation,
sepsis, shock, and death.
The main clinical symptoms, secretory diarrhoea and inﬂammation
of colonic mucosa, can be in great part explained by the actions of
two large protein toxins, toxin A (TcdA) and toxin B (TcdB). Both
toxins are cytotoxic, destroy the intestinal epithelium and decrease
colonic barrier function by disruption of the actin cytoskeleton and tight
junctions resulting in a decreased transepithelial resistance allowing ﬂuid
accumulation. In addition, C. difﬁcile toxins also cause release of various
inﬂammatory mediators which affect enteric nerves, sensory neurons and
promote inﬂammatory cells, adding to the ﬂuid secretion, inﬂammation
and transmigration of neutrophils.
Some experimental evidence points also to possible extraintestinal action
of C. difﬁcile toxin B. In zebraﬁsh embryos TcdB caused damage and
edema in cardiac tissue and in hamsters the same toxin caused lung
damage.
Only recently efﬁcient systems have been developed to genetically
manipulate C. difﬁcile. Comparison of knock-out mutants producing
only one of both toxins have shown that TcdB-positive-only mutants
retain the ability to kill hamsters, whereas TcdA-positive-only mutants
were not virulent for hamsters. These results are in concordance with
epidemiological ﬁndings that naturally occurring A-B+ strains still cause
the entire spectrum of CDI, but are not in concordance with effects
observed after intragastric challenge of hamsters with puriﬁed toxins
TcdA and TcdB.
The role of the third toxin produced by C. difﬁcile, binary toxin CDT
in the development of human disease is not well understood. CDT was
shown to have enterotoxic effect in rabbit ileal loop assay, but natural
strains producing CDT but neither TcdA nor TcdB colonised animals
but were not lethal in hamsters.
Comparative genomic analysis will most likely reveal additional
factors involved in pathogenesis and in increased virulence (including
cell surface layer proteins, sporulation characteristics and antibiotic
resistance). Additionally, the role of the host immune response in CDI
has just started to be better understood.
S335 New developments in the laboratory diagnosis and
epidemiology of Clostridium difﬁcile infection
T. Riley ° (Perth, AU)
Since 2002, there has been an escalation in rates of Clostridium difﬁcile
infection (CDI) with epidemic C. difﬁcile (PCR ribotype 027/North
American pulsed-ﬁeld type 1 [NAP1]) responsible for outbreaks of
severe infection in North America and Europe. While ﬂuoroqinolone
resistance and over-use are thought to be driving the epidemic, the
ageing population and improved case ascertainment are contributing to
the dramatic increase in cases. Other factors may also be important,
such as the increase in prescription of proton pump inhibitors. In
The Netherlands, since 2005, there has been an increase in prevalence
of human CDI with ribotype 078 strains usually found in animals.
These infections were in a younger population and more frequently
community acquired. There was alarm when it was reported that 20%
of retail beef samples in Canada contained C. difﬁcile. The ﬁgure is
higher in the USA where more than 40% of packaged meats (beef,
pork and turkey) from 3 Arizona stores contained C. difﬁcile. Most
animal isolates of C. difﬁcile produce binary toxin, and both pigs and
cattle harbour PCR ribotype 078 a strain that, like ribotype 027, also
produces more toxins A and B, and binary toxin. In the eastern part
of The Netherlands where >90% of pig farms are located, >20% of
human isolates are now ribotype 078, and human and pig strains of
C. difﬁcile are highly genetically related. It has been suggested that
the overlap between the location of pig farms in The Netherlands
and the occurrence of human ribotype 078 infections involves a
common source. That source is likely to be the environment. The
upsurge in CDI has prompted diagnostic companies to try to either
improve current tests or develop new ones. Laboratory diagnostic
methods can be divided into 3 groups; traditional faecal cytotoxin
detection (with or without culture), enzyme immunoassays (EIAs) and
molecular methods. Faecal cytotoxin detection is speciﬁc but lacks
sensitivity, culture is sensitive but lacks speciﬁcity. New EIAs should
ﬁnd a niche in medium sized laboratories. Current in-house PCR
methods have the potential for great sensitivity and speciﬁcity but
have been available only in larger laboratories. New commercially-
available platforms will make this methodology more accessible to
smaller laboratories. Whatever method is chosen, it is necessary for the
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laboratory to have as fast a turn-around-time as possible, particularly in
an outbreak situation.
HPV vaccine
S336 Why did France introduce the anti-HPV vaccine?
D. Le´vy-Bruhl ° (Saint-Maurice, FR)
In 2005, the Advisory Board on Immunisation (ABI) has been asked to
make recommendations to the Ministry of Health regarding the inclusion
or not in the French immunisation schedule of the soon to be licensed
ﬁrst HPV vaccine. The main elements considered in the establishment
of the beneﬁt-risk balance of routine HPV vaccination were:
On the beneﬁt side:
– the very signiﬁcant potentially preventable burden of diseases;
– the very high efﬁcacy of the vaccine against persistent HPV 16/18
infections in naive subjects;
– the expected additional impact on other HPV16/18 related lesions and
cancers;
– the fact that vaccination, by preventing the pre-cancerous lesions, has
the advantage over screening to reduce the cost and anxiety related to
their detection and management;
– the available data in favour of a satisfactory safety proﬁle;
– the beneﬁt of vaccination for the women not covered by the
opportunistic screening program.
On the “risk” side:
– the high cost of vaccination;
– the unknown duration of protection;
– the need for continuation of screening, even for vaccinated women;
– the fact that the majority of residual cervical cancers could be
prevented by the organisation of the screening program;
– the risk of a decrease in compliance to screening for vaccinated
women;
– the low beneﬁt if vaccinated and screened women were the same.
A cost effectiveness analysis, carried out on a multi cohort Markov
model, showed that, over a 70 years period, the impact of vaccinating
80% of 14 years old girls or of organising the screening were
comparable (reduction of cancer deaths close to 20%). However, the
cost-effectiveness ratio of the vaccination was higher than that of the
screening organisation, resp. 45,200 and 22,700 € per life year saved
(at a 3% discount rate). On the basis of the economical analysis, the
screening organisation was therefore the ﬁrst priority. However, if both
interventions were implemented, the overall reduction in cervical cancer
deaths was estimated at 32%. The cost-effectiveness of the addition of
vaccination on the top of the organisation of the screening appeared
acceptable (55,000 € per life year saved).
Based on those results, the ABI issued in March 2007 a recommendation
to include the HPV vaccination in the immunisation schedule for 14 years
old girls, together with a catch up for 15 to 23 years old women not
having started their sexual life more than one year ago. The vaccine cost
has been reimbursed since July 2007.
Clinical microbiology − is outsourcing the
way to go?
S338 The (r)evolution of clinical microbiology in Europe − is it
good or bad?
G. Kahlmeter ° (Va¨xjo¨, SE)
Laboratory medicine in general and clinical microbiology in particular
is presently subject to rapid (r)evolution. Are we aware? Are we in
command? Do we know where we are going? Should we oppose or
cooperate? Do we have a choice? Do we recognise a driving force other
than money? Is it good, bad or just plain necessary? And are we gaining
or losing?
It is not one evolutionary process – it is several parallel processes with
varying emphasis in different areas. There are at least four distinctive
major trends over the last 15 years; the gradual formation of bigger
and bigger units (concentration), the amalgamation of many different
laboratory services into one (Laboratory medicine), accreditation and
an explosion of professional proﬁciencies and backgrounds of staff in
microbiological laboratories. Personally I have withstood the ﬁrst two,
with pleasure succumbed to the latter. A recent 5th trend, outsourcing
microbiology services to large private consortiums, is splitting clinical
microbiology into a purely analytical high-throughput money-saving
activity, often leaving the consultative, clinical part of microbiology and
health care infection control adrift.
What is driving the evolution? Not only cost-saving but also our
inability to recruit medically trained microbiologists, the need to
broaden the knowledge base of microbiology laboratories, automation,
the development of new techniques and apparatus common to many
laboratory disciplines, computerised medicine, political trendiness,
power struggles, and much more.
There is much to be gained by both concentration and amalgamation but
much to be lost as well and many consider the heart and soul of clinical
microbiology at risk.
Over a period of years, rational high-throughput production has won
over consultation and personalised microbiology. That may be ﬁne
for the production of negative HIV-antibody/antigen analysis as for
the screening of blood-donors but certainly not for the bacteriological
cultures taken in conjunction with a hip replacement. Or when it comes
to understand and advise on the intricacies of antimicrobial resistance
development. In other cases “outsourcing” and/or “amalgamation” mean
that blood cultures are sent to X-town, CMV-antibodies to Y-town and
everything else to Z-ville. When that happens clinical microbiology is
lost.
There are several instances where concentration, amalgamation and/or
outsourcing of clinical microbiological services, alone or with other
services, have meant that the tie between clinical microbiology and
infection control has been severed and that many, both small and
large hospitals have lost the personalised service so necessary to
control outbreaks of multi-resistant bacteria and other health care related
infections.
A good service requires a strong knowledgeable and enthusiastic
champion. A service which encompasses too many branches of
laboratory medicine cannot be expected to champion each and every
one with equal strength and fervour. And when outsourced to “big
companies”, there is no “clinical”, only “microbiology”.
In 2008 “medical microbiology” broke out from “laboratory medicine”
in UEMS. We are now striving towards a strong “medical microbiology”
service in Europe. It will have many facets, much strength, some
weakness, great opportunities, but many threats. ESCMID certainly
intends to help shape microbiology in Europe.
S339 One central laboratory is the best
M. Drancourt ° (Marseille, FR)
The optimal organisation of microbiology laboratories in European
metropolis is an evolutionary task, driven by the evolution in laboratory
tasks, laboratory technologies, communication technologies, regulations
and ﬁnancial issues. In the past ﬁve-ten years, medical and societal
query for a more rapid and reﬁned detection and identiﬁcation of
pathogens and antimicrobial resistance determinants coincided with the
expansion of internet-based and remote tools for communication, an
unprecedented revolution in laboratory technologies and new ﬁnancial
constraints. The concentration of laboratory workforces into one unique
laboratory is one way to address these apparently contradictory issues.
The tertiary medical school hospital system in Marseille, a 2-million
metropolitan area in France, comprises four hospitals for a total
of 3,500 beds. The system had once four microbiology laboratories
which have been progressively embedded into a unique, 600,000
acts per year, laboratory which deals with bacteriology, virology and
environmental microbiology and hygiene. The medical staff comprises
of 17, the ingenior staff of 11, technical staff of 88 and support staff
of 13 persons for a total of 129 persons. This organisation allowed
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reducing labour time for routine microbiology, to develop prospective
and sophisticated time-consuming diagnostic methods and to develop
advanced diagnostic methods such as molecular methods (real-time
PCR-based tests, sequencing, and mass spectrometry identiﬁcation)
and new generation serology. New, sophisticated technologies such
as automated serology and mass spectrometry were corner-stones on
which to base the constant diminution of routine labour time and the
development of time-consuming tasks such as fastidious organisms’
isolation. These evolutions paralleled the exponential increase in the
ratio of ingeniors in the laboratory. This paradigm allowed for the
constitution of large collections of biological specimens for retrospective
analyses, the specialisation of every medical senior in one particular ﬁeld
of internationally recognized expertise and the increase in knowledge
output in terms of peer-reviewed papers, patents and grants. Implantation
of point-of-care in the emergency department, in permanent internet-
based connection with the central laboratory, was the last, but not least,
evolution of this system.
Update on tuberculosis
S342 Update on tuberculosis − epidemiology
S. Hoffner ° (Stockholm, SE)
When tuberculosis epidemiology is seen in a global perspective, and
the Millennium Development Goals are considered, it is clear that two
regions of the world, Africa and Europe, are severely behind in the
control of the disease. In Africa, especially sub-Saharan Africa, the
TB problem is closely related to the endemic HIV/AIDS situation. In
Europe, especially the eastern part and in parts of the former Soviet
Union, the main obstacle to an effective TB control is related to drug
resistant forms of M. tuberculosis. The prevalence of the most severe
forms of resistance, MDR- and XDR-TB, is so high that it makes control
efforts both extremely complicated and very expensive. Unfortunately,
increasing levels of drug resistant TB are today also seen in many African
countries, and HIV infection is spreading in Eastern Europe.
During the last ten-year period new tools, based on molecular
ﬁngerprinting of M. tuberculosis strains, have been increasingly adapted
to study TB transmission. With such molecular methods to characterise
clinical isolates of M. tuberculosis it is now possible to study the spread
of individual strains of the bacteria in detail. The laboratory tools used,
RFLP, MIRU/VNTR, spoligotyping and others, will be presented and
their use exempliﬁed. How molecular epidemiology contributed to the
detection and characterisation of a major outbreak of drug resistant TB
in the Stockholm area will be discussed.
Molecular characterisation of clinical isolates from different parts of the
world has led to an increased recognition of the differences between
different families of M. tuberculosis strains. To further describe and
understand the role of these differences in the clinical ﬁeld as well as
for TB epidemiology is an ongoing and interesting ﬁeld of research. An
increased understanding of how TB is transmitted will hopefully help in
the efforts to control this global health threat both on the local level and
in a global perspective.
S343 Diagnosis and treatment
J.S. Friedland ° (London, UK)
Living in the era of increasing tuberculosis drug resistance, the
importance of making an early and accurate diagnosis with drug
sensitivities has never been greater. The epidemiology of tuberculosis
deﬁnes the extent of latent disease and the proportion which becomes
active. Accurate diagnosis is vital if patients are to be treated in a
timely manner and to reduce the amount of time infectious individuals
go untreated in the community disseminating disease. In many areas
of the world, DOTS programmes are at the forefront of tuberculosis
control. However, as a diagnostic this currently relies on sputum smear
microscopy which is known to miss 50% of cases of tuberculosis and
provides no data on drug sensitivity. The second major issue around
TB is the lack of worldwide diagnostic facilities. There is a need for a
simple, low cost, easily implemented diagnostic test.
This talk will brieﬂy consider the issues around the diagnosis of
latent and active disease which are quite distinct. The focus will be
on the diagnosis of active infection. In particular, the use of MODS
(microscopic observation drug-susceptibility) assay in diagnosis of
tuberculosis will be discussed. The potential for using this in resource
poor countries will be reviewed as well as the way sophisticated
technology maybe harnessed to improve reporting and allow translation
to all parts of the world. The important issue of how to distinguish
patients with latent and active disease will also be considered. Key issues
and principles in diagnosis both now and in the future will be reviewed.
In terms of treatment, there are 2 main issues. The ﬁrst is that even
short-course therapy is prolonged being a minimum of 6 months leading
to issue of compliance. This may result in drug resistance. The massive
rise of multi-drug resistant tuberculosis to approximately 500,000 cases
world-wide with around 50 countries reporting extensively drug-resistant
disease means that the need for new approaches to therapy are urgent.
The second part of this talk will review different approaches to using
current anti-mycobacterial drugs, the emergence of a small number of
new drugs such as the diarylquinolones and entirely novel approaches
to control and treat tuberculosis.
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S345 The year in infectious diseases
V. Valtonen ° (Helsinki, FI)
There has been great success and also many threats in the ﬁeld of
infectious diseases during the previous year.
The antimicrobial resistance, especially increasing carbapenem resis-
tance among aerobic Gram-negative rods and XDR Mycobacterial
tuberculosis strains are already big threats in some countries and they
will probably spread to many other areas all over the world in the future
and we will need new drugs for these indications but unfortunately very
few new promising drugs seem to be in the pipeline at the moment for
these purposes.
The virulent Clostridium difﬁcile 027 strain spreads rapidly to many
new countries and e.g. in Finland it killed many times more people
compared with MRSA and ESBL strains in 2008. However, it is possible
to stop its spreading but it needs new thinking in antibiotic use policy and
infection control policy in hospitals. Clostridium difﬁcile 027 infection
has a high relapse rate after metronidazole or vancomycin therapy, but an
experimental “stool exchange treatment” is a promising therapy although
controlled studies are needed to prove this assumption.
An interesting research area during the last years has been the role
of infections in the etiopathogenesis of chronic diseases like cancer,
atherosclerosis, cardiovascular diseases and many autoimmune diseases.
We can ﬁght against many cancers like liver cancer and cervix cancer
with virus vaccines and gastric cancer with antimicrobial drugs. Also
the high incidence of malignant tumours seems to decrease during Haart
treatment in HIV patients. The role of infections in the etiopathogenesis
of cardiovascular diseases and atherosclerosis is complex. It is obvious
that infections play a role in the etiopathogenesis of atherosclerosis,
stroke and myocardial infarction but the undirected routine antimicrobial
treatment is not recommended for these patients but there seems to be
subgroups in patients with various cardiovascular diseases which may
beneﬁt from antimicrobial treatment. Recent studies seem to suggest
that there are HLA types which protect or make people susceptible for
coronary heart disease. The HLA type HLA-B*35 seems to be a risk
factor for coronary heart disease but it is also a risk factor for chronic
Chlamydia pneumoniae infection.
The feared pandemia due to H5N1 inﬂuenza A did not appear during
the recent year and the world is now much more prepared to meet the
next pandemia which, however, hopefully does not come during the next
year.
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Further spread of KPC-type carbapenemases
O348 Emergence of KPC-producing Klebsiella pneumoniae in
Norway is associated with hospitalisation abroad, nosocomial
transmission and sporadic urinary tract infections in
outpatients without recent hospitalisation
Ø. Samuelsen °, C. Giske, U. Naseer, S. Tofteland, D.H. Skutlaberg,
A. Onken, R. Hjetland, A. Sundsfjord (Tromsø, NO; Stockholm, SE;
Kristiansand, Bergen, Oslo, Førde, NO)
Objectives: The worldwide dissemination of KPC-producing multidrug-
resistant Enterobacteriaceae is worrisome. The ﬁrst KPC-producing
Klebsiella pneumoniae in Norway was isolated late 2007 from a patient
after hospitalisation in Greece. Throughout the following year seven
additional KPC-producing K. pneumoniae isolates have been detected
in clinical samples from six new patients. The aim of this study was
to perform molecular characterisation of the strains and examine their
epidemiological relatedness.
Materials and Methods: Antimicrobial susceptibility was examined
by Etest. Molecular characterisation was performed by MLST, PFGE
and sequencing of the blaKPC genetic structure. Plasmid analysis was
carried out by PFGE of S1 nuclease-digested total DNA and Southern
blot hybridisation using a blaKPC probe. Relevant epidemiological data
were collected retrospectively.
Results: Eight KPC-producing clinical isolates of K. pneumoniae have
been identiﬁed from seven patients in two different regions of Norway
from the following specimens: blood culture (n = 3), urine (n = 2),
expectorate (n = 1), perineal swab (n = 1) and wound secretion (n = 1).
Two blood culture isolates with clonally related but different PFGE-
proﬁles were observed in one patient. The detection of KPC-producing
K. pneumoniae isolates in Norwegian patients was associated with import
in four cases after hospitalisation in Greece. Two patients had been
hospitalised at the same hospital in Greece. Isolation of a KPC-producing
isolate in a ﬁfth patient was epidemiologically linked to one of these
imported cases and was a case of nosocomial transmission in Norway.
For the latter two cases no risk factors were identiﬁed with respect to
recent hospitalisation or travel abroad. Molecular analysis of six isolates
has shown genetically related PFGE-patterns and a common sequence
type (ST258). ST258 has been associated with dissemination of CTX-M-
15 in Hungary. The blaKPC gene was localised in Tn4401 on a ~97 kb
plasmid. The two most recent isolates are currently undergoing similar
analysis.
Conclusion: The ﬁrst seven cases of KPC-producing K. pneumoniae
in Norway are associated with hospitalisation abroad, nosocomial
transmission in Norway, or urinary tract infections in outpatients
without obvious risk factors. The clonal relationship between isolates
underlines the existence a biological ﬁt genetic lineage of KPC-
producing K. pneumoniae with an epidemic potential.
O349 Emerging infections due to KPC-2 producing Klebsiella
pneumoniae in hospitals in Greece
P. Giakkoupi, H. Maltezou, M. Polemis, O. Pappa, G. Saroglou,
A. Vatopoulos ° on behalf of the National Surveillance System for
Antimicrobial Resistance
Objectives: Two recent publications have reported the isolation of KPC
producing K. pneumoniae from infections in two patients, one in France
and one in Sweden, who originally had been hospitalised in Greece.
Since this resistant mechanism had not been identiﬁed before in this
country, the purpose of this report was to conﬁrm the presence of blaKPC
producing K. pneumoniae in Greece, to assess the extent of its spread
and to study the genetic relatedness of the respective bacterial strains
and the transferability of the blaKPC harbouring plasmids.
Methods: For a three month period (February to April 2008) 40
hospitals participating in the Greek System for Surveillance of
Antibiotic Resistance (www.mednet.gr/whonet) were asked to seek
for possible KPC producers among K pneumoniae isolates displaying
reduced susceptibility to imipenem (equal or higher than 1mg/L),
a positive Hodge test for the presence of carbapenemase and a
negative EDTA synergy test for the presence of metalloenzymes. The
presence of blaKPC gene in these strains was conﬁrmed by PCR and
sequencing. MICs to carbapenems were determined by etest. Conjugation
experiments were carried out both in broth and on agar. The possible
absence of OmpK36 porin was detected by PCR. Molecular typing was
performed by pulse-ﬁeld gel electrophoresis of XbaI-restricted genomic
DNA.
Results: Ninety two K. pneumoniae clinical isolates (one per patient)
from 13 Hospitals all over Greece were found to harbour blaKPC-2
gene. Although colonies present in the inhibition zone made the exact
determination of imipenem MIC difﬁcult, the absence of OmpK36 porin
was always associated with MIC of imipenem higher than 32mg/L. All
isolates exhibited resistance to all other drug classes except colistin,
tetracycline and tigecycline. PFGE analysis revealed that 85 isolates from
12 Hospitals displayed more than 95% similarity and were classiﬁed
into one pulsotype, whereas the remaining seven isolates belonged into
four different pulsotypes. blaKPC-2 gene could not be transferred by
conjugation from strains belonging to the main pulsotype. However, it
was transferred from strains belonging to three out of the four remaining
pulsotypes.
Conclusion: Production of KPC-2 betalactamase seems to be a new
emerging resistance mechanism in Klebsiella pneumoniae in Greece.
blaKPC-2 gene’s possible clonal spread imposes the urgent need of
implication of infection control practices in the affected hospitals.
O350 An outbreak of Klebsiella pneumoniae producing KPC-2
carbapenemase in a Greek universtity hospital
I. Galani, M. Souli, E. Papadomichelakis, F. Panayea, N. Mitchell,
A. Antoniadou, G. Poulakou, F. Kontopidou, H. Giamarellou ° (Athens,
GR)
Background: Until now, carbapenem resistance among Klebsiella
pneumoniae (Kp) clinical isolates in Greek hospitals has been attributed
to the dissemination of VIM-1 metallo-beta-lactamase. We describe the
ﬁrst outbreak of KPC-producing Kp in Greece; the ﬁrst to occur outside
the USA or Israel. Setting: 21-bed ICU of Attikon University Hospital,
Athens.
Methods: Kp isolates with an imipenem MIC> 1mg/L and a negative
EDTA-imipenem disk synergy test were submitted to boronic acid disk
test, to PCR for a KPC gene with speciﬁc primers and sequencing.
Records from patients colonised or infected with a KPC-producing
Kp were retrospectively reviewed for clinical and epidemiological data.
Environmental cultures for KPC-producers were performed. Clinical
isolates were submitted to molecular typing using PFGE.
Results: From February to November 2008, 552 Kp were isolated
from 95 patients, 132 (23.9%) of which were boronic acid positive
and produced KPC-2. Most of them (126/132, 95.5%) were isolated
since August. A total of 24 patients were identiﬁed as colonised or
infected by a KPC producer which in 22 of them belonged to the same
genetic clone. The source was faeces (73), bronchial secretions (26),
blood (7), CVC tip (5), urine (15), pus (4) and throat (2). Among
patients whose medical records were available, median age was 74,
APACHE II score; 21, length of preceding hospital stay; 28 days,
total length of stay; 50 days, immunosuppresion was identiﬁed in
one and crude mortality was 71%. The KPC-producing Kp was more
frequently ICU acquired whereas in a minority of patients it was
already present on ICU admission. Seventy percent of the patients
had previously received a carbapenem for a median of 15 days.
Environmental colonisation was not identiﬁed. Ten (7.6%) of the KPC-
producers from 8 (33.3%) patients were identiﬁed as the cause of
an infection: bacteraemia (7), ventilator-associated pneumonia (2) and
surgical site infection (1) and exhibited MIC90 (mg/L) for imipenem, >8;
meropenem, >8; gentamicin, 4; ciproﬂoxacin, >2; fosfomycin, >128;
colistin, 0.5 and tigecycline, 4. Most patients were successfully treated
with a colistin-containing combination mostly with a beta-lactam. There
was no attributed mortality.
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Conclusions: The acquisition of KPC carbapenemase by Kp is an
emerging threat for public health in Greek hospitals, which should be
promptly recognized and confronted.
O351 Genetic evidence for KPC-encoding resistance among six
Enterobacteriaceae species other than K. pneumoniae
M. Castanheira °, L. Deshpande, R. Mendes, R. Jones (North Liberty, US)
Objectives: To evaluate the genetic context and location of KPC-
encoding genes among a large collection of Enterobacteriaceae isolates
not K. pneumoniae.
Methods: 61 isolates belonging to six Enterobacteriaceae species (table)
recovered in the USA and Israel from 2000 through 2007 were evaluated.
Isolates from the same bacterial species were typed by PFGE or
automated ribotyping. KPC-encoding gene was fully sequenced. Plasmid
preparations and I-Ceu digestion of total DNA were resolved in agarose
gels, blotted and hybridised with a blaKPC probe. The blaKPC-carrying
element (Tn4401) was ampliﬁed with various primer pairs, digested with
Eag I and sequenced.
Results: 30 strains each carried KPC-2 and KPC-3. One E. cloacae car-
ried KPC-4. 13 K. oxytoca were KPC-2-producers and 2 S. marcescens
harboured blaKPC-3, all from USA. Great genetic diversity was observed
among the isolates (41 different types). One clone of 10 E. cloacae was
detected in New York state (2006–2007). Small clusters of 2 and 3 strains
were detected among E. coli, E. cloacae, K. oxytoca. Plasmids were
present in all but 3 isolates. Persistence of clones throughout the years
was not observed. In 35 isolates the KPC-encoding gene was located
in high molecular weight plasmids (>54Kb). blaKPC was located in
the chromosome of 11 strains (E. cloacae, E. coli and K. oxytoca) and
the location of this gene could not be determined in 15 strains. Small
plasmids were present in several strains, but did not harbour blaKPC.
Tn4401 carried blaKPC in 46 isolates, and the transposon element was
conserved. This structure was not detected in 12 strains.
Conclusions: KPC-encoding genes were most often located in Tn4401
among several Enterobacteriaceae species collected in USA and Israel.
This blaKPC-carrying element was located in plasmids and on the
chromosome. This study highlights the importance of Tn4401 in the
dissemination of blaKPC genes in several genetically diverse bacterial
species. blaKPC was not associated with Tn4401 in only 12 of 61 strains.
These strains are under further investigation.
Bacterial species (no.) Location KPC-types Typing
patterns/clones*
Enterobacter cloacae (25) USA, Israel KPC-2, KPC-3, KPC-4 11/4
Klebsiella oxytoca (13) USA KPC-2 11/2
Escherichia coli (10) USA, Israel KPC-2, KPC-3 8/1
Citrobacter freundii (9) USA KPC-2, KPC-3 8/1
Enterobacter gergoviae (2) USA KPC-2, KPC-3 2/0
Serratia marcescens (2) USA KPC-3 2/0
*Two or more isolates showing identical genotyping proﬁles.
O352 First description of KPC-2 in Raoultella planticola: report
from the SENTRY Antimicrobial Surveillance Program
M. Castanheira °, L. Deshpande, J. Dipersio, R. Mendes, R. Jones
(North Liberty, Akron, US)
Objective: To evaluate the carbapenem resistance mechanism in a
Raoultella planticola bacteraemia isolate recovered from a patient
hospitalised in Ohio, USA.
Methods: Species identiﬁcation was performed by VITEK 2 and
conﬁrmed by 16S rRNA sequencing. Susceptibility testing used CLSI
broth microdilution method. blaKPC was ampliﬁed and sequenced. The
blaKPC genetic element (Tn4401) was ampliﬁed and sequenced. Plasmid
extractions and conjugation experiments were carried out and the isolate
was screened for ESBL-encoding genes, qnr and qepA.
Results: A 83 year old female patient was admitted to a hospital
located in Akron with a diagnosis of CAP in May/2008. Sputum,
paracentesis and blood cultures were negative. Urine culture grew E. coli
and patient received courses of moxiﬂoxacin, ceftriaxone, azithromycin
and meropenem. The patient was discharged and returned after three
weeks with respiratory problems. Tracheal aspirate grew a multidrug
resistant A. baumannii and the blood culture grew the enteric-like Gram-
negative bacillus. The isolate was identiﬁed as R. planticola by the
VITEK 2, which was conﬁrmed by 16S sequencing. R. planticola strain
demonstrated resistance against most b-lactams, including carbapenems.
Screening for KPC-encoding genes was positive and this strain carried
blaKPC-2. Fluoroquinolone and aminoglycoside MIC values were
elevated. KPC-2-encoding gene was located in Tn4401, but conjugation
experiments failed. ESBL and qnr/qepA genes were not detected.
Conclusions: KPC serine-carbapenemases have been detected in several
Gram-negative species commonly isolated from clinical specimens. KPC
genes are embedded in transposon-like structure usually harboured
in conjugative plasmids carrying multiple antimicrobial resistance
mechanisms.
This is the ﬁrst report of KPC-producing R. planticola that is
an environmental organism related to Klebsiella spp. The similarity
between these organisms could facilitate the transfer of genetic
material. KPC-producing isolates appear to be prevalent among different
Enterobacteriaceae species in USA hospitals and was detected in an
isolates of apparent environmental origin.
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O353 Polymorphisms in the promoter region of TANK-binding
kinase-1 are associated with Gram-positive bloodstream
infections
P. Wolffs °, E. Beuken, S. Ouburg, S. Morre´, F. Stassen (Maastricht, NL)
Objectives: It is long known that not all individuals with a speciﬁc
disease present with the same clinical manifestations, nor do they have
identical prognoses or responses to treatments. It has become clear that
variations in the human genome are likely to have an impact on these
aspects. TANK-binding kinase 1 (TBK1) is a central molecule in the
induction of a.o. the type I interferon response to pathogens. Our goals
for this study were 1) to investigate the frequency of single nucleotide
polymorphisms (SNPs) in the promoter and coding region of TBK1 in a
Dutch Caucasian population and 2) to search for potential associations
between these SNPs and bloodstream infections.
Methods: Whole blood samples or samples of positive blood cultures
were collected and after genomic DNA was isolated, PCR and
sequencing were performed for SNP identiﬁcation. Functional studies
included promoter activity measurements using a luciferase assay as
well as electrophoretic mobility shift assays (EMSA) to study binding
of the transcription factor USF1 to the wt and mutant promoter. SNP
incidences were studied in a case control study.
Results: In samples from Dutch Caucasian healthy volunteers, 4 SNPs
were found with allele frequencies higher than 5% whereas 6 other
known SNPs had frequencies lower than 5% in our cohort. Two
SNPs (rs89208169 and rs89208163) located in the promoter region
were studied in a larger cohort of 350 anonymised patients from
the Maastricht University Medical Center with either Gram-positive
or Gram-negative blood cultures. We found that the prevalence of
rs89208169 was signiﬁcantly increased in patients with positive blood
cultures in comparison with those with negative blood cultures or healthy
volunteers. Further investigation of this SNP showed that it is located
just outside a USF1-binding site. Measuring the promoter activity using
luciferase assays, the mutant promoter exhibited a decreased activity of
<35%. This observation was conﬁrmed by EMSA which showed that
recombinant USF1 protein had a reduced binding afﬁnity to the mutant
promoter.
Conclusions: SNP rs89208169 in the promoter region of TBK1 has
a signiﬁcant association with Gram-positive infections. Our results
demonstrate that this is likely due to a decreased expression of TBK1
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due to reduced binding of the transcription factor USF1 to the mutant
promoter. Our results support recent ﬁndings that TBK1 plays also an
important role in the host response to Gram-positive infections.
O354 Evaluation of a novel small molecule caspase inhibitor,
VX-166, as a potential therapy for sepsis
P. Weber °, P. Wang, P.S.H. Wang, R. Wu, M. Miksa, W. Dong, G. Ku,
J.M.C. Golec, D. Dawson, P. Charlton (Abingdon, UK; Manhasset,
Cambridge, US)
Objective: Lymphocyte apoptosis has been recognized as an important
factor contributing to both the onset of sepsis post infection and
to the progression into septic shock. Animal data suggest that
prevention of lymphocyte apoptosis by caspase inhibition stabilises the
immune system, improves bacterial clearance and decreases mortality in
experimental sepsis. The present study evaluated the potential of VX-
166, a novel broad caspase inhibitor, as a therapy for sepsis.
Methods and Results: Initial characterisation of VX-166 in a
number of enzymatic and cellular assays clearly demonstrated that
the compound is a broad caspase inhibitor with potent anti-apoptotic
activity in vitro. In vivo, VX-166 was tested in a murine model
of endotoxic shock and a clinically relevant model of peritonitis.
In the endotoxic shock model, male CD-1 mice (n = 28 per group)
were administered LPS (20mg/kg IV) and survival was monitored
for 96 h. VX-166 administered by repeat IV bolus (0, 4, 8 and 12 h
post-LPS) signiﬁcantly improved survival in a dose-dependent fashion
(p< 0.0001). In the rat peritonitis model, adult male Sprague-Dawley
rats (n = 12 per group) underwent caecal ligation and puncture (CLP)
and survival was monitored over 10d. Continuous administration of VX-
166 by mini-osmotic pump (0.9mg/kg/h) immediately following surgery
signiﬁcantly improved survival (p< 0.01) from 38% in the control group
to 88% in the compound-treated group. Mode of action studies in the
rat CLP model conﬁrmed that VX-166 reduced thymic atrophy and
lymphocyte apoptosis (p< 0.01), supporting the anti-apoptotic activity
of the compound in vivo. In addition, VX-166 reduced plasma endotoxin
levels (p< 0.05), strongly suggesting an improved clearance of bacteria
from the bloodstream.
Most importantly, we demonstrated that VX-166 fully retained its
efﬁcacy when dosed 3 hours after insult (p< 0.01) by improving survival
to 92% versus 42% in control animals, further highlighting the potential
of anti-apoptotic therapy in sepsis.
Conclusion: Overall these data demonstrate that VX-166 inhibits
lymphocyte apoptosis, improves the clearance of bacterial endotoxin and
improves survival in experimental sepsis. Importantly VX-166 improves
survival in the CLP model when dosed post insult, and therefore
represents signiﬁcant progress in the development of therapeutically
viable broad caspase inhibitors for the treatment of this disease.
O355 Activation of Toll-like receptor 2 and Toll-like receptor 2/6
by lactobacilli
V. Vankerckhoven °, S. Van Voorden, N. Hens, H. Goossens,
G. Molenberghs, E. Wiertz (Wilrijk, BE; Leiden, NL; Hasselt, BE)
Objectives: Toll-like receptors function as key regulators of both innate
and adaptive immunity. Lactobacilli modulate the immune system in
different ways. The aim of this study was to examine Toll-like receptor
(TLR2, TLR2/6 and TLR4) signalling induced by clinical and probiotic
Lactobacillus strains.
Methods: A total of 45 Lactobacillus strains (19 L. paracasei and
26 L. rhamnosus) of different origin (22 probiotic, 2 faecal, and 21
clinical) were tested for TLR2, TLR2 in combination with TLR6,
and TLR4. TLR signalling was measured as relative IL-8 promotor
activation in transfected human embryonic kidney (HEK) 293 cells. IL-8
concentrations were measured using an enzyme-linked immunosorbent
assay. Heat-killed Listeria monocytogenes (HKLM) was used as positive
control in all assays, whereas PAM3, PAM2, and LPS were used as
positive controls for, respectively, TLR2, TLR2/6, and TLR4. All assays
were performed at least in duplicate. Linear mixed model analyses and
stepwise model selection were used to identify the statistically signiﬁcant
effects. Random effects were used to account for heterogeneity across
and homogeneity within isolates. P< 0.05 was considered statistically
signiﬁcant.
Results: HEK-TLR2 and HEK-TLR2/6, but not HEK-TLR4, cells
released IL-8 upon stimulation with UV-inactivated lactobacilli, which
was enhanced by co-transfection with CD-14. Interestingly, the produc-
tion of IL-8 was shown to be variable for the different Lactobacillus
isolates. Although similar results were seen for all isolates for TLR2
and TLR2/6, IL-8 production was signiﬁcantly higher for TLR2 (8.4 log
pg/ml) compared to TLR2/6 (6.05 log pg/ml) (P< 0.0001). No signiﬁcant
differences in IL-8 production were seen between clinical and probiotic
isolates. However, L. rhamnosus isolates induced a signiﬁcantly higher
IL-8 production compared to L. paracasei isolates in both cell lines, 7.88
and 6.84 log pg/ml, respectively (P = 0.0004). Intra-isolate correlation
was found signiﬁcant (P< 0.0022).
Conclusions: Our study shows that lactobacilli activate both TLR2
and TLR2 in combination with TLR6. Our results also indicate that
heterodimerisation of TLR2 with TLR6 does not lead to an improved
recognition of lactobacilli. Furthermore, taking intra-isolate correlation
into consideration proved to be important. Finally, our results suggest
that differences in immunomodulation by lactobacilli may be related to
differential signalling through TLRs, including TLR2 and TLR2/6.
O356 Mycobacteria affect group I CD1 expression and lipid-antigen
presentation via p38 signalling in human DC precursor
M.C. Gagliardi, V. Sargentini, R. Teloni, M.E. Remoli, G. Federico,
M. Videtta, G. De Libero, E. Coccia, R. Nisini ° (Rome, IT; Basel, CH)
Objective: To gain insights into the mechanisms used byMycobacterium
tuberculosis and Bacillus Calmette Gue´rin to cause human monocytes
differentiation into CD1 negative dendritic cells (My-MoDC), unable to
present lipid antigens to speciﬁc T cells.
Methods: Human monocytes infected or not with mycobacteria were
induced to differentiate into DC with GM-CSF and IL-4 in the presence
or absence of p38 or ERK speciﬁc inhibitors. Kinases activation was
detected by western blot using antibodies speciﬁc for phosphorylated
and non phosphorylated isoforms. Differentiation of monocytes into
DC and the CD1a, CD1b and CD1c expression was evaluated by ﬂow
cytometry and by real time PCR at different time points from infection.
Functional expression of CD1 molecules was assessed by recognition of
lipid antigens by CD1 restricted T cell clones.
Results: We show that mycobacteria trigger phosphorylation of ERK
and p38 mitogen-activated protein kinase in human monocytes as well
as of activating transcription factor (ATF)-2. Mycobacteria-infected
monocytes treated with a speciﬁc p38 inhibitor, but not with a speciﬁc
ERK inhibitor become insensitive to mycobacterial subversion and
differentiate into CD1 positive My-MoDC, which are fully capable of
presenting lipid antigens. Data indicate that phosphorylation of p38 is
directly involved in CD1 inhibition.
Conclusions: We propose p38 signaling as a pathway exploited by
mycobacteria to affect CD1 expression, thus representing a novel
target of possible pharmacological intervention in the treatment of
mycobacterial infections.
O357 Pro-inﬂammatory effect of activin A on microglial cells
S. Ebert °, S. Ribes, R. Nau, U. Michel (Gottingen, DE)
Objective: Activin A (Act A) is a multifunctional cytokine with roles
in the immune system and the inﬂammatory response. Act A levels
are elevated in the cerebrospinal ﬂuid of patients with meningitis.
Microglial cells, the major constituents of innate immunity within the
brain, express Toll-like receptors (TLRs) recognising exogenous and
endogenous ligands. Upon stimulation with TLR agonists, primary
mouse microglial cells become activated and release nitric oxide (NO),
cytokines, and also Act A, suggesting that they are a source of elevated
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Act A levels during central nervous system (CNS) infections. Both pro-
and anti-inﬂammatory effects of Act A have been observed in vitro. We
investigated whether Act A inﬂuences NO release from microglial cells
stimulated with agonists of TLR2, 4, and 9.
Methods: Primary mouse microglial cells were kept in DMEM
(+FCS+PS) either in presence or absence of Act A (1mM). 24 hours
after addition of Act A, cells were stimulated with the TLR2 agonist
Pam3CSK4 (P3C), the TLR4 agonist endotoxin (LPS), and the TLR9
agonist cytosin-guanosin ODN 1668 (CpG) in the presence of interferon-
gamma (IFN; 100 U/ml) for 48 hours. Control cultures were treated with
IFN only. Concentrations of the TLR agonists evoking about 50% of the
maximum NO release were used. NO release was quantiﬁed using the
Griess reaction. Viability of microglial cells was determined using the
WST-1 assay. Means+SD of NO release in % of maximum NO release
are presented (n = 9). Data were analysed by one-way ANOVA followed
by Bonferroni’s multiple comparison test (p< 0.05 signiﬁcant).
Results: Act A did not inﬂuence NO release from control microglial cells
[10.03+2.90% (IFN), 9.13+2.69% (IFN+Act A); p> 0.05]. However, pre-
treatment with 1mM Act A signiﬁcantly enhanced NO release from
microglial cells upon stimulation with 0.01mg/ml P3C [60.16+4.54%
(P3C), 76.84+5.58% (P3C+Act A); p< 0.001], 0.0003mg/ml LPS
[50.60+4.59% (LPS), 64.15+11.07% (LPS+Act A); p< 0.001], and
0.1mg/ml CpG [44.48+4.14% (CpG), 57.17+8.90% (CpG+Act A);
p< 0.001]. In none of the groups, cell viability was affected.
Conclusions: Pre-treatment with Act A enhances NO release from
microglial cells activated by agonists of the principal TLRs involved in
the recognition of bacteria. These ﬁndings provide further evidence for a
role of Act A in the innate immune response and suggest that Act A acts
as an pro-inﬂammatory modulator during infection and inﬂammatory
processes in the CNS.
Bacterial genome plasticity − new insights
into bacterial adaptation to the clinical
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S361 Role of insertion sequences in the mobility and expression
of antibiotic resistance genes
L. Poirel ° (Kremlin Bicetre, FR)
Insertion sequences (IS) are genetic tools that can mediate expression
of previously silent genes or be responsible for the overexpression
of certain genes (in each case by providing promoter sequences).
In addition to be involved in gene transcription levels, IS elements
also play a very important role for gene acquisition/mobilisation.
An IS is usually made of of two inverted-repeat sequences (IRs)
bracketing a gene encoding the transposase which activity enables
this entity to replicate and target another sequence. The IS-related
mechanisms at the origin of antibiotic resistance gene acquisition are
diverse, including composite-transposition, rolling-circle transposition,
one-ended transposition. IS elements may be also involved in gene
acquisition by mediating co-integration processes, or recombination
events as hypothetized for IS26 in relation with blaSHV extended-
spectrum b-lactamase (ESBL) genes originating from the chromosome
of Klebsiella pneumoniae. The blaCTX-M ESBL genes known to
be extremely widespread worldwide are encoded on plasmids, and
have been found in association with ISEcp1 (acting by one-ended
transposition) or ISCR1 (acting by rolling-circle transposition). In that
case, ISs have played a role in the mobilisation from the chromosome
of Kluyvera spp. being the blaCTX-M progenitors and then in their
expression. Also, genes encoding acquired AmpC b-lactamases, being of
the blaACC, blaDHA, and blaCMY-types, are mostly found in association
with ISCR1 or ISEcp1.
Sometimes antibiotic resistance genes are mobilised by composite
transposons which are made of two copies of a given IS bracketing
the mobilised fragment. In Acinetobacter baumannii, the worldwide
disseminated blaOXA-23 carbapenemase gene is part of a composite
transposon structure made of two copies of ISAba1, forming transposon
Tn2006 which had mobilised a chromosomal fragment from Acinetobac-
ter radioresistens that actually corresponds to the progenitor of blaOXA-
23. Another possibility can be the forming of composite transposon
structure bracketed by two different IS (sharing similar IRs) as observed
with the blaPER-1 ESBL gene in Pseudomonas aeruginosa.
This diversity of ISs elements at the origin of mobilisation/acquisition of
antibiotic resistance genes is therefore responsible for the very efﬁcient
dissemination of many of them.
S362 Resistance islands − their role in the accumulation and
spread of antimicrobial resistance genes
K. Rajakumar ° (Leicester, UK)
Historically, multi-antibiotic resistance in many bacterial species was
largely attributed to the acquisition of resistance (R)-plasmids encoding
one or more resistance determinants. However, over the last decade
the R-plasmid paradigm has begun to be challenged. ‘Resistance
islands’ comprising large, chromosomally-integrated spans of alien DNA
harbouring multiple antibiotic resistance genes have been identiﬁed in
the major hospital pathogens methicillin-resistant Staphylococcus aureus
(MRSA) and multi-resistant Acinetobacter baumannii, and the food-
and water-borne diarrhoeal pathogens Shigella, Salmonella and Vibrio
cholerae. In addition, comparative genomics analysis of the archetypal
Haemophilus inﬂuenzae conjugative resistance element that had spread
worldwide revealed that it belonged to a large syntenic family of
integrative islands, members of which could be found in at least 15 other
b-and g-Proteobacteria. With the exception of the A. baumannii island,
these elements can be described as classic self-excising, -circularising
and -integrative elements. All three functions are mediated by short
island-ﬂanking direct repeats and cognate integrase proteins encoded
by the islands. In 2006 Fournier et al. described an 86 kb A. baumannii
island (AbaR1) which harboured 45 resistance genes packaged within a
highly mosaic, integron-rich element that had almost certainly evolved
via recombination, transposition and integron-mediated cassette capture
from an ‘empty’ ancestral prototype. AbaR1 probably represents a new
class of resistance island as it exhibits several features reminiscent
of complex nested transposons, suggesting a distinct functional natute.
However, despite the widespread distribution of resistance and genomic
islands only a minority are known to code for part or all of the
conjugative machinery necessary for their dissemination; others have
been mobilised by helper plasmids or bacteriophages. Regardless, data
on the mechanisms of mobilisation of the vast majority of similar non-
resistance islands remain sparse. Importantly, resistance islands may
not consists merely of packages of resistance genes. On the contrary,
these diverse and frequently hybrid entities could potentially confer
upon their hosts other advantageous traits relating to host-pathogen
interaction, virulence, survival in the environment and/or transmissibility,
truly justifying the label ‘selﬁsh islands’ and further explaining their
evolutionary success.
S363 Identiﬁcation and characterisation of pathogenicity islands
L. Guy ° (Uppsala, SE)
Due to the availability of new techniques, genome sequencing of bacteria
has become fast and inexpensive. Furthermore, recent methods using
paired-end reads located several kb apart in the genome eases the
assembling process, even though no reference sequence is available.
In a reasonably close future, it should be possible to obtain the fully
assembled sequence of a bacterial isolate overnight.
The new sequencing techniques generate enormous amounts of genomic
data and, thereby, a need for new tools. These should able to quickly
analyze genomes and point to zones of interest, prompting further
analysis on a reduced number of regions or genes, such as genomic
islands.
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Pathogenicity islands, a subset of genomic islands, carry genes such
as toxins or resistance genes and have the particularity to be mobile,
i.e. they may transfer to other species or strains. Thereby, they confer
their new hosts a more resistant or infectious phenotype, making this
phenomenon particularly important to study.
Nucleotide composition of genomes is fairly homogeneous inside
bacterial genomes. In general, horizontally transferred regions can be
spotted due to their particular nucleotide content, because they tend to
retain the composition of their original host and don’t share the one
of their new hosts. To do an analogy with languages, genomes speak
dialects, and as one would easily spot a paragraph in Finnish in an
English text while not knowing Finnish, one can spot genomic and
pathogenicity islands transfers in a given genome.
Several techniques relying on various compositional aspects and on
different algorithmic methods have been recently developed to detect
pathogenicity islands in bacterial genomes. Even very simple measures
of the genome composition, such as the variation in T vs. A bias
(TA skew) can lead to the identiﬁcation of all known prophages in
Streptococcus pyogenes. It can even trigger the discovery of a putative
ancient genomic island carrying a large number of genes related to
pathogenicity in all strains of that species.
In conclusion, with the rise of fast and inexpensive genome sequencing,
new quick and simple methods are being developed. They take the
advantage of the homogeneous nucleotide composition of bacterial
genomes to uncover mobile genetic elements carrying genes involved
in pathogenicity.
HBV resistance: a new frontier for antiviral
therapy
S364 The new drugs and their resistance mechanisms
F. Zoulim ° (Lyon, FR)
In the past 10 years, signiﬁcant progress has been achieved in the
management of chronic hepatitis B with the successive development
of six potent antiviral medications (lamivudine, adefovir dipivoxil,
pegylated interferon alpha, entecavir, telbivudine and tenofovir).
However, the clinical results of antiviral therapy have been limited
by the emergence of antiviral drug resistance especially with the ﬁrst
generation of nucleoside analogs (lamivudine, adefovir and telbivudine).
Furthermore, the unique mechanism of viral genome replication and
persistence within infected cells is responsible for viral persistence
even after prolonged therapy with the newer antivirals (entecavir and
tenofovir). This is the major reason why life-long treatment is envisaged
in the majority of patients, which may expose them to long-term risk of
developing resistance.
The use of in vitro phenotypic assays has been crucial for the
characterisation of newly identiﬁed resistant mutants and determine
their cross-resistance proﬁle. Results allowed to understand the different
mechanism of viral resistance to lamivudine and adefovir, the mechanism
of primary failure to adefovir therapy, the unique mechanism of entecavir
resistance, and to characterise the emergence of multi-drug-resistant
strains in patients receiving sequential antiviral therapy. The cross-
resistance proﬁle for the main resistant mutants was determined which
allowed to provide recommendation to clinicians for treatment adaptation
based on molecular virology data.
The understanding of the development of HBV drug resistance has
allowed to signiﬁcantly improve the management of antiviral resistance
and to design better treatment strategies to prevent resistance. The
current standard of care relies on treatment initiation with antivirals
combining a strong antiviral potency and a high barrier to resistance.
A precise virologic monitoring is required to measure antiviral efﬁcacy,
and to diagnose partial response or viral breathrough at an early stage.
This allows to adapt antiviral treatment preferrably using an add-on
strategy with a drug having a complementary cross-resistance proﬁle.
This strategy has been shown to be efﬁcient in controling viral replication
and preventing liver disease progression in the majority of patients.
S366 Correlation between resistance and clinical progression
A. Dofferhoff ° (Nijmegen, NL)
Treatment of chronic hepatitis B virus (HBV) infection is aimed at
suppressing viral replication to the lowest possible level. In many
prospective clinical trials it has been shown that a sustained HBV
DNA response was correlated with serologic, histologic, or biochemical
responses. Despite the recent progress in hepatitis B antiviral treatment,
it is shown that antiviral drug resistance is inevitable against many of the
nucleoside analogs. The emergence of antiviral-resistant strains of HBV
leads to viral and subsequently biochemical breakthrough and may lead
to disease progression and increased death. Most of the data on the
clinical impact of antiviral resistant HBV came from the data derived
from studies of lamivudine therapy. There is limited data on other HBV
antiviral drugs like adefovir. It is shown in several studies that treatment
of HBeAg-negative chronic hepatitis B with lamivudine effectively
suppresses HBV replication and results in biochemical remission and
histologic improvement in more than two thirds of patients. However,
relapse has occurred in the majority of HBeAg-negative patients after
the cessation of therapy. There are several studies to support the
occurrence of severe hepatic ﬂares, and liver failure after the emergence
of lamivudine resistance. Several studies, where liver biopsies were
taken, demonstrated that histological improvement was reduced in those
patients experiencing lamivudine resistance. The clinical outcome for
patients with antiviral resistance is related to their age, the severity of
the underlying liver disease and the severity of the hepatic ﬂares. On the
other hand in a different study it was found that long-term lamuvidine
treatment was associated with a reduced chance of developing cirrhosis
and HCC in patients without advanced disease but, although resistant
mutants reduced the beneﬁts from lamivudine therapy, the outcome of
these patients was still better than untreated patients. Results of several
clinical trials have shown that the addition or substitution of newer
antiviral agents can restore suppression of viral replication, normalisation
of liver function and reverse histological progression in patients with
antiviral resistance. Consequently, well-tolerated, potent therapies that
offer a strong genetic barrier against the development of resistance
are desirable, since antiviral resistance and poor adherence are key
risk factors for treatment failure and subsequent reversal of clinical
improvement.
Emerging resistances in Gram-negatives:
update for 2009
S369 Salmonella and Campylobacter
T. Pa´l ° (Al Ain, AE)
Resistance of enteric fever-causing and non-typhoid salmonella serovars
to agents traditionally used to treat these infections in the past
shows extensive geographical variation. Decreased susceptibility to
ciproﬂoxacin is rapidly increasing all over the world with target alteration
and increased efﬂux being the most important mechanisms behind.
Infections with such strains often result in extended hospitalisation or
even in therapeutic failures. Furthermore, it is likely that moderately
increased MIC values facilitate the development of strains with higher
level of resistance, i.e. a pattern described at various locations. Screening
methods based on quinolone sensitivity testing may fail to indentify
decreased ﬂuoroquinolone susceptibility both in typhoid, as well as in
non-typhoid salmonella. Plasmid mediated quinolone resistance genes
are detected increasingly all around the world although neither the
frequency nor the variety of genes identiﬁed has approached that
seen in some other members of Enterobacteriaceae. Treatment with
gatiﬂoxacin or azithromycin are alternative options for invasive and
systemic infections caused by strains with decreased susceptibility to
ciproﬂoxacin.
At some parts of the World resistance to extended spectrum
cephalosporins reached such incidence that may have therapeutic
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implications particularly when initial, empiric treatment of invasive
infections is concerned. Resistance is due to plasmid coded AmpC type
beta lactamases (particularly to CMY-2), and most often to ESBLs of
which usually some of CTX-M types are the frequently encountered
ones. Carbapenem resistance is still rare, albeit does occur, among
salmonella isolates. The recent description of a non-typhoid salmonella
strain with the blaIMP-4 gene co-located on a class-1 integron with
several other resistance determinants on a conjugative plasmid is of
particular concern.
Campylobacters exhibit natural resistance to a variety of antimicrobials.
The drugs of choice used to be ﬂuoroqunolones or macrolides. However,
the current incidence of ciproﬂoxacin resistance made the former drugs
already obsolete or seriously limited their use at several parts of the
World. With the exception of few locations the incidence of macrolide
resistance is still relatively low and is seen more frequently in C. coli
than in C. jejuni. However, strains exhibiting resistance against both
groups of drugs have been emerging, particularly in South-East Asia.
S371 Neisseria meningitidis and Neisseria gonorrhoeae
P. Mastrantonio °, P. Stefanelli (Rome, IT)
Neisseria meningitidis, the meningococcus, is a major cause of
meningitis and septicaemia worldwide while Neisseria gonorrhoeae, the
gonococcus, is responsible for one of the most widespread sexually
trasmitted disease. The behaviour of these two species towards antibiotics
is very different: resistance in N. gonorrhoeae is now widespread
occuring as both chromosomally and plasmid mediated to a variety of
drugs, whereas, besides resistance to sulphonamides, N. meningitidis
remains largely susceptible to antibiotics used both for therapy and
prophylaxis. However, as in the gonococcus, the resistance to antibiotics
of N. meningitidis is also evolving, as documented by the ever higher
frequency of strains with intermediate resistance to penicillin in many
countries. Transformation has apparently provided both species with
a mechanism by which they can increase resistance to penicillin by
replacing part of their penA gene, which encodes PBP2, with part of
the penA gene of related species that fortuitously produces forms of
PBP2 less susceptible to the antibiotic. N. meningitidis is still at this
step, whereas N. gonorrhoeae has acquired also mutation in the ponA
gene that encodes PBP1, mutation in porin IB, increased expression of
efﬂux pump and the TEM-1 b-lactamase plasmid. The emergence and
the spread of gonococci fully resistant to penicillin since the second
half of the 1980 s years led to the recommended use of ﬂuoroquinolones
as primary therapy. However, this class of antibiotics became rapidly
unefﬁcacious, mainly in Asia, due to the emergence of mutations in gyrA
and parC which are able to block the activity of the quinolones on gyrase
and topoisomerase IV. Since 2006, CDC no longer recommends their
use for treatment of gonococcal diseases. Fortunately, the occurrence of
quinolone resistant meningococci, due to mutations in gyrA, is still rare
but even if cases are still few they are of great concern for the epidemic
potential of this pathogen and the required prophylaxis of contacts.
Also for the other antibiotic, frequently used to this aim, rifampicin,
some meningococci have showed to be resistant, again for the presence
of mutations, in this case in the rpoB gene coding for the b-subunit of
the meningococcal RNA polymerase.
The molecular epidemiological identiﬁcation of clonal clusters for both
Neisseria species with distinct resistance proﬁles is required to monitor
ongoing trends that may pose problems both in therapy and prophylaxis.
Antibiotic use in primary care: new insights,
better results? (Symposium arranged with
ESPRIT)
S374 Attitudes and perceptions of doctors and patients to
antibiotic use for LRTI in Europe
L. Brookes-Howell °, C. Butler, K. Hood, L. Cooper, H. Goossens
(Cardiff, UK; Antwerp, BE)
Introduction: GRACE is a European Network of Excellence established
to focus on antibiotic use for community-acquired lower respiratory tract
infection (LRTI) and antimicrobial resistance across Europe. GRACE-
02, the second study to begin within GRACE, is a large qualitative study
that explores the attitudes of clinicians and patients to antibiotic use for
LRTI and antibiotic resistance.
Aims: This presentation will focus on clinicians’ accounts of the factors
that contribute to variation in management of LRTI and patient views
on when antibiotics are necessary.
Methods: Semi-structured interviews with 81 clinicians and 121 patients
were conducted in primary care networks in nine European countries.
Interviews were audio-recorded, transcribed and, where necessary,
translated into English for analysis. Themes were identiﬁed, organised
and compared using a Framework Approach.
Results: Analysis of clinician interviews shows that, beside clinical
ﬁndings, factors which inﬂuence the management decision for patients
can be divided into two main areas. Firstly, within each European
network there is a group of country speciﬁc factors imposed by
the system in which consultations take place. These factors include:
near patient test usage, self-medication, patients’ ﬁnances and lack of
consistent, local prescribing guidelines. Secondly, there is a group of
factors, similar across all networks, that relate to personal characteristics
of certain groups of clinicians. These include clinicians’ professional
ethos, self-belief in decision making and attitude towards the doctor-
patient relationship.
Analysis of patient interviews shows that beliefs about antibiotic use tend
to draw on clinical factors, namely the severity of speciﬁc symptoms
(fever and/or coughing). Many patients also implied a period of waiting
or alternative action required before antibiotics are used − to identify
whether the immune system would ﬁght the infection or whether non-
antibiotic management was effective before turning to antibiotics.
Discussion and Conclusion: With a greater understanding of the
factors that contribute to the decision to prescribe, we discuss ideas
to enhance appropriate prescribing. This analysis highlights the need
for interventions to be sensitive to factors relating to the systems in
which different European networks operate, to target the individual
characteristics of speciﬁc groups of clinicians and to build on the clinical
beliefs already held by patients.
Infectious diseases in animal models
O377 Pre-treatment with low-dose endotoxin prolongs survival
from experimental lethal endotoxic shock
K. Kopanakis, I. Tzepi, E.J. Giamarellos-Bourboulis °, A. Macheras
(Athens, GR)
Objective: Clinical trials of immunointervention with anti-endotoxin
antibodies in patients with severe sepsis have failed to disclose survival
beneﬁt. These failures led us to the assumption that the opposite
approach with a low endotoxin stimulus may result to low level
immunoaralysis and subsequent survival beneﬁt. This approach was
tested in an experimental setting.
Methods: A total of 36 male C57B6 mice were studied divided
into two groups: group A stimulated with the ip injection of sodium
saline followed after one day by the ip injection of 30mg/kg of
lipopolysaccharide (LPS) of Escherichia coli O155:H5; and group B
stimulated with the ip injection of 3mg/kg of LPS of the same isolate
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followed after one day by the ip injection of 30mg/kg LPS. LPS was
diluted in sodium saline and the volume of each injection was 0.2ml.
Survival was recorded at six hour time intervals.
Results: Survival of group B was considerable prolonged compared with
group A (log-rank: 5.435, p: 0.020) as shown in Figure 1. Thirteen mice
of group A died (72.2%) compared with seven mice of group B (38.9%,
p: 0.044 between group).
Conclusions: Administration of low doses of LPS prolongs survival after
lethal endotoxic shock. This approach opens a promising novel pathway
for immunointervention in sepsis.
O378 Efﬁcacy of quinolones, mono versus combination therapy,
in difﬁcult-to-treat mixed infections caused by Escherichia
coli and Bacteroides fragilis
M. Glenschek-Sieberth °, K. Merfort, S. Obertegger, R. Endermann
(Wuppertal, DE)
Objective: Complicated intra-abdominal infections (cIAIs) are mostly
polymicrobial infections caused by aerobic and anaerobic bacteria.
A majority of these infections are dominated by Escherichia coli
and Bacteroides fragilis. In this study, the antimicrobial efﬁcacy of
quinolones was evaluated using the murine pouch model infected
concomitantly with E. coli and B. fragilis. This study tests the efﬁcacy
of moxiﬂoxacin (MXF) monotherapy versus levoﬂoxacin (LFX) and
ciproﬂoxacin (CIP) monotherapies and LFX/metronidazole (MET) and
CIP/MET combination therapies.
Methods: Clinical E. coli (n = 2) and B. fragilis (n = 2) isolates
were used. MICs were determined by the broth microdilution method
according to CLSI guidelines. Pouches for the murine model were
created by injecting 5mL of air and 0.5mL of 0.1% croton oil in olive oil
under the skin of the back. On day 3 the air was replaced with 1mL soft
agar. On day 5, the pouches were infected with a bacterial suspension of
E. coli and B. fragilis. Mixed infected mice (n = 5/group) were treated
for 2 days IV, b.i.d. with either MXF (100mg/kg), or LFX (80mg/kg) or
CIP (90mg/kg) alone or in combination with MET (100mg/kg). These
dosages simulate the AUC of the corresponding human IV therapy. Efﬁ-
cacy was assessed as the reduction in colony forming units (CFU) per mL
pouch exudate 48 h post-infection compared with the infection control.
Results: According to CLSI breakpoints, the two B. fragilis isolates
were categorised as intermediate susceptible (MIC=4mg/L) to MXF.
One E. coli isolate was categorised as resistant (MIC=8−16mg/L) to
MXF and one E. coli was categorised as susceptible (MIC=0.016mg/L)
to MXF. In the murine pouch model mixed infected with the
four different strains MXF, LFX/MET and CIP/MET demonstrated
comparable activity. MXF monotherapy and LFX/MET or CIP/MET
combination therapies achieved signiﬁcant reductions in CFUs compared
with the infection controls. LFX and CIP monotherapy failed to achieve
signiﬁcant CFU reductions compared with the infection control.
Conclusions: In the mixed infected murine pouch model, a model for
cIAI abscess formation, LFX and CIP monotherapies exhibited only
low efﬁcacy. In contrast, MXF, LFX/MET and CIP/MET showed clear
therapeutic efﬁcacy, demonstrating the necessity of adequate anaerobic
coverage when choosing antimicrobial treatment. MXF appears to be
suitable for use as monotherapy in cIAIs.
O379 Efﬁcacy of moxiﬂoxacin in a murine granuloma pouch model
caused by clinical Bacteroides fragilis isolates belonging to
different breakpoint categories
M. Glenschek-Sieberth °, K. Merfort, S. Obertegger, R. Endermann
(Wuppertal, DE)
Objectives: Moxiﬂoxacin (MXF) is the only marketed ﬂuoroquinolone
with FDA approval for the monotherapy of complicated intra-abdominal
infections (cIAIs). The obligate anaerobic bacterium Bacteroides fragilis
is implicated in such infections. In this study, the antimicrobial efﬁcacy
of MXF against susceptible, intermediate and resistant clinical B. fragilis
isolates was evaluated using the murine granuloma pouch (MGP) model,
an animal model for infected intra-abdominal abscesses.
Methods:MXFMICs for clinical B. fragilis isolates were determined ac-
cording to CLSI guidelines. FDA/CLSI MXF breakpoints for B. fragilis
were deﬁned as: susceptible 2mg/mL, intermediate =4mg/mL, resistant
8mg/mL. B. fragilis isolates with an MXF MIC of 2mg/mL (n = 5),
4mg/mL (n = 20) and 8mg/mL (n = 8), which were virulent in the MGP
model, were used to determine the efﬁcacy of MXF. For the MGP model,
pouches were created by injecting 5mL of air and 0.5mL of 0.1% croton
oil in olive oil under the skin of the back. On day 3, the air was withdrawn
and replaced by 1mL soft agar. On day 5, a bacterial suspension was
injected into the pouch. Infected mice (n = 6 mice/group) were treated
with MXF 100mg/kg IV, b.i.d. for 2 days. This dose simulates the AUC
of the human 400mg once-daily MXF IV dosage. Efﬁcacy was assessed
by the reduction in colony forming units (CFUs) in pouch exudates
48 hours post-infection compared with the untreated infection control.
Results: In the MGP model, MXF, 100mg/kg b.i.d., displayed good
efﬁcacy in term of CFU reduction against all used strains in this study.
There were no non-responders in terms of CFU reductions.
Table: Efﬁcacy distribution of strains (percent)
Breakpoint categories CFU reduction/mL pouch exudates
of strains 3 log10 <3 log10 to
2 log10
<2 log10 to
1 log10
<1 log10 to
0 log10
<0 log10
Susceptible (n = 5; MIC 2mg/mL) 100% 0% 0% 0% 0%
Intermediate (n = 20; MIC= 4mg/mL) 75% 15% 5% 5% 0%
Resistant (n = 8; MIC 8mg/mL) 50% 25% 12.5% 12.5% 0%
Conclusions:
• In a murine model of cIAIs, MXF demonstrated a high efﬁcacy against
clinical B. fragilis isolates with a MXF MIC 8mg/mL.
• MXF achieved a CFU reduction of 3 log10 against 100% of
susceptible clinical B. fragilis isolates.
• 75% of the intermediate and 50% of the resistant clinical B. fragilis
isolates displayed a 3 log10 CFU reduction by MXF.
O380 Impact of loss of major autolysin AtlE on activity
of cloxacillin and vancomycin against Staphylococcus
epidermidis
M. Hello, N. Caroff, C. Jacqueline, J. Caillon, G. Potel, E. Batard °
(Nantes, FR)
Objective: To study the impact of the loss of major autolysin AtlE
on the activity of cloxacillin and vancomycin against Staphylococcus
epidermidis.
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Methods: Wild-type (wt) atlE(+) O-47 and mutant atlE(−) O-47mut1
S. epidermidis strains were kind gifts from C Heilmann, Mu¨nster,
Germany. Bactericidal activity in Mueller-Hinton broth was assessed
by counting viable bacteria after a 24-h exposition to growing
concentrations of cloxacillin or vancomycin. A sigmoidal dose-response
model was used to estimate the maximal effect of bacterial killing,
expressed as the decrease in bacterial counts. To compare virulence
of both strains in the mouse peritonitis model, neutropenic mice were
inoculated intraperitoneally with 3 to 8 log CFU. The median lethal
dose (LD50) was assessed at Day 6. The efﬁcacies of cloxacillin and
vancomycin were assessed in the mouse peritonitis model. Mice were
treated using various doses of antibiotics immediately after inoculation,
and 4 and 8 h later. The median effective doses (ED50) were assessed at
Day 6.
Results: MICs of cloxacillin and vancomycin were similar for both
strains. The maximal bactericidal activity of cloxacillin and vancomycin
were lower for the mutant atlE(−) strain in comparison with the wt
atlE(+) strain. In the murine model, the LD50 s for wt atlE(+) and mutant
atlE(−) strains were respectively 4.0 and 4.4 log CFU/mL. The ED50 s of
cloxacillin in the mouse peritonitis model were similar for both strains,
as were ED50 s of vancomycin.
Wild-type
AtIE(+) strain
Mutant
AtIE(−) strain
Cloxacillin
Susceptibility MIC, mg/L 0.25 0.5
Bacterial killing in broth Maximal effect, logCFU/mL
(95%CI)
−3.048
(−3.541, −2.555)
−1.347
(−1.622, −1.072)
Mouse peritonitis model ED50, mg/kg 226 205
Vancomycin
Susceptibility MIC, mg/L 1 1
Bacterial killing in broth Maximal effect, logCFU/mL
(95%CI)
−3.936
(−4.446, −3.427)
−1.283
(−1.647, −0.9196)
Mouse peritonitis model ED50, mg/kg 9 6
Conclusion: The loss of atlE had no impact on the MICs of
cloxacillin and vancomycin. Conversely, the mutant atlE(−) strain was
less susceptible to bactericidal activity of both antibiotics, supporting
the implication of AtlE in the tolerance of S. epidermidis to cell wall
active antibiotics. The loss of AtlE did not alter the virulence of
S. epidermidis in the mouse peritonitis model, whereas it decreased
virulence in previously published experiments using an intravenous
catheter infection model. Therefore, the mouse peritonitis model was
suited to compare antibiotics efﬁcacy against atlE(+) and atlE(−) strains.
Our results showed that the loss of atlE did not alter signiﬁcantly the
activity of cloxacillin and vancomycin in the mouse peritonitis model.
This study shows that the loss of atlE results in decreased susceptibility
to bactericidal activity of cell wall active antibiotics, with no apparent
impact on the activity of these antibiotics in the mouse peritonitis model.
O381 In infant rat pneumococcal meningitis, ceftriaxone plus
daptomycin versus ceftriaxone attenuates brain damage
and hearing loss while ceftriaxone plus rifampicin versus
ceftriaxone does not
D. Grandgirard, M. Burri, K. Oberson, A. Bu¨hlmann, F. Simon,
S.L. Leib ° (Berne, CH)
Objectives: Lytic antibiotics for therapy of bacterial meningitis (BM)
increase the release of pro-inﬂammatory bacterial compounds which,
in turns, induce inﬂammation. Exacerbation of the inﬂammatory
response in cerebrospinal ﬂuid (CSF) contributes to the development
of neurological sequelae in survivors of BM. Daptomycin, a non-
lytic antibiotic acting on Gram-positive bacteria has been shown to
decrease inﬂammation and brain injury vs. ceftriaxone in experimental
pneumococcal meningitis. With a view on the clinical application
for empiric therapy of paediatric bacterial meningitis we investigated,
whether therapies combining daptomycin or rifampicin with ceftriaxone
are beneﬁcial when compared to ceftriaxone monotherapy in infant rat
pneumococcal meningitis.
Methods: Eleven day old Wistar rats were infected by intracisternal
injection of S. pneumoniae and animals were treated with daptomycin
(10mg/kg, s.c., daily) plus ceftriaxone (100mg/kg, s.c., bid), rifampicin
(20mg/kg, i.p., bid) plus ceftriaxone or ceftriaxone alone. CSF was
sampled at 6 h and 22 h after the initiation of therapy and assessed for
concentrations of chemo- and cytokines (MCP-1, MIP-1a, IL-1b, IL-6,
IL-10; IL-18 and TNF-a). A subset of animals was sacriﬁced 40 h post
infection (h pi) and brain damage quantiﬁed by histomorphometry. The
remaining animals were treated for 3 d and were tested for hearing loss,
by assessing the auditory brainstem response (ABR) at 3 weeks after
infection.
Results: Compared to ceftriaxone alone, daptomycin plus ceftriaxone
signiﬁcantly (p< 0.04) lowered CSF concentrations of MCP-1, MIP-
1alpha and IL-6 at 6 h and MIP-1a and IL-1b at 22 h after initiation of
therapy, led to signiﬁcantly (p< 0.01) less apoptosis assessed at 40 h pi,
and signiﬁcantly (p< 0.01) improved hearing capacity. While rifampicin
plus ceftriaxone also led to lower CSF inﬂammation (p< 0.02 for IL-6
at 6 h), apoptosis and hearing loss were not signiﬁcantly different from
the ceftriaxone group.
Conclusion: Compared to ceftriaxone monotherapy, daptomycin plus
ceftriaxone lowers the level of pro-inﬂammatory mediators in the CSF
and reduces hippocampal apoptosis and hearing loss in infant rat
pneumococcal meningitis.
O382 Ceftaroline vs. ceftriaxone in a highly penicillin-resistant
pneumococcal pneumonia model
D. Croisier-Bertin °, L. Piroth, P.E. Charles, D. Biek, Y. Ge, P. Chavanet
(Dijon, FR; Alameda, US)
Objectives: Ceftaroline (CPT) is a novel, parenteral, broad-spectrum
cephalosporin exhibiting bactericidal activity against Gram-positive
organisms, including methicillin-resistant S. aureus (MRSA) and multi-
drug-resistant S. pneumoniae, as well as common Gram-negative
pathogens. The efﬁcacy of simulated human dosing with CPT or
ceftriaxone (CRO) was evaluated in a rabbit model of penicillin-resistant
pneumococcal pneumonia.
Methods: 3 S. pneumoniae strains were used to induce pneumonia in
rabbits: PSSP, PISP, and PRSP. MICs (mg/L) were 0.06/0.015, 1/0.125,
and 4/0.25 for CRO and CPT, respectively. The animals were randomised
to no treatment (controls), intravenous (IV) CPT human equivalent (HE)
dosage (600mg/12 h), IV CRO HE dosage (1 g/24 h), or intramuscular
(IM) CPT (5 or 20mg/kg) for PRSP-infected rabbits. Serum levels
were measured by microbiological assay and PK data were obtained.
Evaluation of efﬁcacy was based on bacterial counts in lungs and spleen
(per gram tissue).
Results: 5−7 animals/group were tested. For IV CPT/IV CRO, mean
AUC0−24 was 155/938mg.h/L, Cmax was 20/158mg/L and Cmin was
1.3/6mg/L, respectively. Bacterial counts in target tissues are listed in
the Table.
Group Mean bacterial concentration ± SD (log10 CFU/g)
Lung Spleen
PSSP PISP PRSP PSSP PISP PRSP
Controls 8.1±0.5 8.4±0.5 8.31±0.7 4.91±0.6 4±1.4 4.51±1.1
CRO 1±0b 1±0b 6.2±1.4 1±0b 1±0b 2.02±1.02a
CPT IV 1±0b 1±0b 1.1±0.2b,c 1±0b 1±0b 1±0b
CPT IM
5mg/kg – – 2.31±0.9a,d – – 1.4±0.8a
20mg/kg – – 1.08±0.16b,c – – 1±0a
ap< 0.05 vs controls, bp< 0.001 vs controls, cp< 0.01 vs CRO, dp< 0.05 vs CRO.
IV CPT and IV CRO were highly efﬁcacious against PSSP and PISP.
IV and IM CPT were superior to IV CRO against PRSP with a quasi
sterilisation of lungs and spleen. Combined results from the IV and
IM studies indicated that %T>MIC for CPT of 30% and 45% were
associated with 50% and 100% bacterial count reductions, respectively.
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Conclusion: In this rabbit model of penicillin-resistant pneumococcal
pneumonia, CPT administered IV (with HE dosing) or by IM
administration was more effective against PRSP than IV CRO.
O383 In vivo efﬁcacy of humanised doses of moxiﬂoxacin and
piperacillin/tazobactam in animal models of complicated
intra-abdominal infections
R. Endermann °, D. Hoepker, K. Merfort, M. Glenschek-Sieberth
(Wuppertal, DE)
Objective: Moxiﬂoxacin (MXF) is approved in the USA and other
countries for the treatment of complicated intra-abdominal infections
(cIAIs). We compared the efﬁcacy of MXF with piperacillin/tazobactam
(PIP/TAZ), a commonly used treatment for cIAIs, in three different
models: (a) the murine granuloma pouch model with B. fragilis infection;
(b) a chronic uterus infection with B. fragilis; and (c) an endogenous
infection by normal bowel ﬂora in a murine caecal ligation and puncture
(CLP) model. The dosages of antimicrobials used were equivalent to the
AUC of the human 400mg MXF IV q.d. and the time above MIC of
human 3.375 g PIP/TAZ IV q.d.s. therapy. Dosing was based on unbound
concentrations in humans, neglecting higher Cmax values achieved in
animals.
Methods:
a. Granuloma pouch: pouches were formed by injecting air and 0.1%
croton oil under the loose connective tissue on the back of mice (3
groups, n = 4−5/group). On day 3, the air was replaced by 0.25%
agar in saline. On day 5, B. fragilis ATCC 25285 suspension was
injected into the pouch. MXF 100mg/kg or PIP/TAZ 400mg/kg b.i.d.
were given intravenously (IV) for 2 days. The efﬁcacy endpoint was
bacterial load in the pouch.
b. Uterine infection: mice (3 groups, n = 15−28/group) received beta-
estradiol throughout the study. After 4 days the left uterine tube
was surgically prepared and infected with B. fragilis 06688. Mice
received IV treatment (MXF 100mg/kg or PIP/TAZ 400mg/kg b.i.d.)
for 4 days starting on day 21 post-infection. The efﬁcacy endpoint was
bacterial load in the uterus.
c. CLP model: the murine caecum was surgically prepared. A ligation
was set at the proximal end of the caecum and the ligated part
punctured. The caecum was then replaced into the peritoneum. After
surgery, mice (3 groups, n = 8−9/group) were treated IV with MXF
100mg/kg or PIP/TAZ 400mg/kg for 2 days b.i.d. The efﬁcacy
endpoint was survival over 10 days.
Results:
a. Granuloma pouch: MXF provided signiﬁcantly greater reductions in
CFUs than PIP/TAZ (D log CFU: MXF 6.78 units, PIP/TAZ 2.95
units; P = 0.029).
b. Uterine infection: MXF provided signiﬁcantly greater reductions in
CFUs than PIP/TAZ (D log CFU: MXF 4.45 units; PIP/TAZ 1.16
units; P< 0.0001).
c. CLP model: survival over 10 days was signiﬁcantly higher in the
MXF group than in the PIP/TAZ group (P< 0.0001).
Conclusions: Using humanised dosages, MXF had greater antimicrobial
activity and provided higher survival rates that PIP/TAZ in three different
models for cIAI.
O384 The haemochromatosis-associated Hfe mutation protects
mice from Salmonella typhimurium infection via induction
of lipocalin 2
M. Nairz, I. Theurl, A. Schroll, M. Theurl, S. Mair, T. Sonnweber,
G. Fritsche, R. Bellmann-Weiler, G. Weiss ° (Innsbruck, AT)
Mutations in HFE predispose to hereditary haemochromatosis type I,
a frequent genetic disorder characterised by progressive parenchymal
iron deposition and eventual organ failure. Since HFE mutations are
associated with reduced iron levels within mononuclear phagocytes, we
hypothesized that Hfe deﬁciency may be beneﬁcial in infections with
intramacrophage pathogens.
Using Hfe+/+, Hfe+/− and Hfe−/− mice in a model of typhoid fever, we
found that animals lacking one or both Hfe alleles are protected from
systemic infection with Salmonella typhimurium, displaying prolonged
survival and improved bacterial control. This increased resistance can be
referred to an enhanced production of the siderophore-binding peptide
lipocalin 2 and the reduced availability of iron for Salmonella engulfed
by Hfe deﬁcient macrophages. This effect is mediated via stimulation
of lipocalin 2-dependent iron export from infected cells since Hfe−/−
macrophages concurrently knocked out for lipocalin 2 are unable to
efﬁciently control the infection or to withhold iron from intracellular
Salmonella. Correspondingly, infection of Hfe+/+ and Hfe−/− mice with
siderophore deﬁcient Salmonella abolishes the protection conferred by
the Hfe defect.
Thus, by inducing the formation of the iron-capturing peptide lipocalin
2, the Hfe mutation harbours a genetically determined immunological
advantage towards infections with intracellular pathogens such as
Salmonella.
O385 Allogeneic transplantation of mononuclear cells as
successful immunotherapy in experimental sepsis by
multidrug-resistant Pseudomonas aeruginosa
I. Koutelidakis, A. Kotsaki, P.D. Carrer, K. Louis, A. Savva,
E.J. Giamarellos-Bourboulis ° (Thessaloniki, Athens, GR)
Objective: The majority of clinical trials of immunointervention in
severe sepsis have failed to disclose survival beneﬁt. A likely explanation
may be administration of therapy when immunoparalysis of the septic
host supervenes. In an attempt to reverse immunoparalysis, injection of
mononuclear cells was attempted in experimental sepsis by multidrug-
resistant Pseudomonas aeruginosa (MDRPA).
Methods: Peripheral blood mononuclear cells (PBMCs) diluted in
RPMI were isolated from ﬁve healthy human volunteers after gradient
centrifugation over Ficoll. 1×107/kg of one MDRPA live or heat-killed
isolate from one patient with severe sepsis was injected intraperitoneally
for bacterial challenge. A total of 72 male C57B6 mice were studied
divided into four groups: group A (n = 26) pre-treated with RPMI
and challenged after one hour with live isolate; group B (n = 26) pre-
treated with 5×107 PBMCs/kg and challenged after one hour with live
isolate; group C (n = 10) pre-treated with RPMI and challenged after
one hour with heat-killed isolate; group D (n = 10) pre-treated with
5×107 PBMCs/kg and challenged after one hour with heat-killed isolate.
Survival was recorded for 20 mice of groups A and B and for all mice
of groups C and D. Six mice of groups A and B were sacriﬁced six
hours after challenge. Blood was collected from the lower vena cava and
TNFalpha and IL-6 were estimated in serum by an enzyme immunoassay.
Bacterial growth of liver and lung at the same time was assessed.
Results: Median survival of group A was 24 hours and of group B
88 hours (log-rank: 4.524, p: 0.033). Nineteen animals of group A died
(95%) compared with eight animals of group B (40%, p: 0.038). Four
animals of group C died (40%) compared with nil animals of group D
(0%, log-rank: 4.274, p: 0.03). Median serum TNF-a of groups A and B
at sacriﬁce was 31 and 184 pg/ml respectively (p: 0.048). Respective
values for IL-6 were 2084 and 2231 pg/ml (pNS); for liver bacterial
cells 3.63 and 4.99 log10 cfu/g (pNS); and for lung bacterial cells 2.56
and 4.22 log10 cfu/g (pNS).
Conclusions: Allogeneic transplantation with PBMCs prolonged sur-
vival in experimental sepsis by MDRPA. Its mechanism of action was
related with a) blockade of cell wall structures as shown by survival
experiments with heat killed isolate; and b) reversal of immunoparalysis
as evidenced by increase of serum TNF-a. This approach creates a
promising novel perspective for immunointervention in sepsis.
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O386 Small-animal positron emission tomography in the mouse
model of genital Chlamydia infection
A. Marangoni °, C. Nanni, M. Donati, R. Aldini, D. di Pierro,
S. Trespidi, S. Accardo, S. Fanti, R. Cevenini (Bologna, IT)
Objectives: Chlamydia trachomatis is one of the world’s major causes
of sexually transmitted diseases of the cervix and urethra and it is a
major agent of pelvic inﬂammatory disease.
Genital tract infection of female mice with Chlamydia muridarum closely
mimics acute genital tract infection in women. Aim of this study was to
assess the predictivity of 68Ga-chloride Small Animal Positron Emission
Tomography (PET) for the identiﬁcation of reactive animals and the
follow-up of infection at various times after vaginal inoculation.
Methods: Chlamydiae elementary bodies were puriﬁed from LLC-MK2
cells by sucrose-gradients density centrifugation.
Animals used in this study were 23 female Balb/c mice, 6−8 weeks old.
All the animals received 2.5mg of medroxyprogesterone acetate i.m. 9
and 2 days prior the infection.
20 mice were infected by placing 15 ml of SPG containing 107 inclusion
forming units (IFUs) of C. muridarum into the vaginal vault. Infection
was induced under Ketamine anaesthesia. As control, 3 animals were
challenged with 15ml of SPG.
5 infected animals plus 1 control mouse underwent a 68Ga-chloride
Small Animal PET. After 60 minutes of uptake, the animals were
anaesthetized again and whole body images were acquired for 15 minutes
in a single bed position using a Small Animal PET tomography.
Images were reconstructed with iterative algorithm. This procedure was
performed 5, 12 and 19 days after infection.
Infection was monitored by obtaining cervical-vaginal swabs from all the
20 infected animals 6, 13 and 20 days after infection. Moreover, 5 groups
of 3 animals each were sacriﬁced at 6, 13, 20, 27 and 34 days after
infection. Genital tracts were divided into the cervical-vaginal region,
uterine horns, and oviducts. Individual wells of LLC-MK2 monolayers
in 24-well plates were inoculated with 200 ml of the solution from vaginal
swabs or homogenised tissues.
Inclusions were visualised by using ﬂuorescein conjugated monoclonal
antibody against Chlamydia group antigen.
Results: Results are summarised in the ﬁgure.
Conclusion: These preliminary data indicate that 68Ga-chloride PET
is a promising technique to in vivo evaluates inﬂammatory response to
genital C. muridarum infection. Further studies are required to test 68Ga-
chloride PET’s potential in the follow-up of animals with experimental
genital infection after antibiotic treatment.
Nosocomial infections: a major clinical
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O387 Inadequate statistical power of published comparative
cohort studies on ventilator-associated pneumonia to detect
mortality differences between the compared groups
M. Falagas °, V. Kouranos, A. Michalopoulos, S. Rodopoulou,
A. Athanasoulia, D. Karageorgopoulos (Athens, GR)
Objective: Comparative cohort studies are often conducted to identify
novel therapeutic strategies or prognostic factors for ventilator-associated
pneumonia (VAP). We aimed to evaluate the statistical power of such
studies to provide statistically and clinically signiﬁcant conclusions.
Methods: We searched in PubMed and Scopus for comparative cohort
studies evaluating the mortality of patients with VAP. We calculated for
each of the included studies the statistical power to detect the observed
difference in mortality between the compared groups (observed power),
as well as 3 expected, clinically relevant, effect sizes (expected power).
Results:We identiﬁed 39 (20 prospective) comparative cohort studies on
VAP as eligible for inclusion in this analysis. The median observed power
of these studies was 17.9% [interquartile range (IQR), 9.8−52.4%].
The median expected power was 10.0% (IQR, 7.2−13.6%) for a risk
ratio for mortality of 0.85 between the compared groups; 14.7% (IQR,
10.6−21.8%) for a risk ratio of 0.80; and 7.9% (IQR, 6.3−10.2%) for a
reduction in mortality from 30% to 25%. All expected power measures
were signiﬁcantly lower than the observed power.
Conclusion: The statistical power of most cohort studies to detect the
observed difference in mortality between compared groups of patients
with VAP is low. The power is even lower when expected, clinically
relevant, differences in mortality are considered. For a wiser utilisation
of resources allocated to research, we favour the conduction of cohort
studies with larger sample size so that potential differences between the
compared groups are more likely to be shown.
O388 Frequency, prevention, outcome, and treatment of
ventilator-associated tracheobronchitis: systematic review
and meta-analysis
M. Agraﬁotis °, I. Siempos, M. Falagas (Athens, GR)
Objective: To clarify issues regarding the frequency, prevention,
outcome, and treatment of patients with ventilator-associated tracheo-
bronchitis (VAT), which is a lower respiratory tract infection involving
the tracheobronchial tree, while sparing the lung parenchyma.
Methods: We performed a systematic review and meta-analysis of
relevant available data, gathered though searches of PubMed, Scopus,
and reference lists, without time restrictions. A conservative random
effects model was used to calculate pooled odds ratios (OR) and 95%
conﬁdence intervals (CI).
Results: Out of the 564 initially retrieved articles, 30 papers
were included. Frequency of VAT was 10.2%. Selective digestive
decontamination was proved an effective preventive strategy against
VAT. Presence, as opposed to the absence, of VAT was not associated
with higher mortality (OR: 1.18, 95% CI 0.90−1.53). Administration
of systemic antimicrobials (with or without inhaled ones), as opposed
to placebo or no treatment, in patients with VAT was not associated
with lower mortality (OR: 0.56, 95% CI 0.27−1.14). Most of the
studies providing relevant data noted that administration of antimicrobial
agents, as opposed to placebo or no treatment, in patients with VAT
was associated with more ventilator-free days and lower frequency of
subsequent pneumonia, but without shorter length of intensive care unit
stay or shorter duration of mechanical ventilation.
Conclusions: Approximately one tenth of mechanically ventilated
patients suffer from VAT; an infection potentially prevented by the
implementation of selective digestive decontamination. Antimicrobial
treatment of patients with VAT may protect against the development
of subsequent ventilator-associated pneumonia.
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O389 Characteristics of elbow prosthetic joint infection: a 13-year
retrospective analysis of 358 elbow prostheses
Y. Achermann °, C. Spormann, C. Kolling, C. Remschmidt, J. Wu¨st,
B. Simmen, M. Vogt (Baar, Zurich, CH)
Objectives: Elbow arthroplasty is increasingly used for treatment of
rheumatic or posttraumatic arthritis. Data on epidemiology, character-
istics and treatment outcome of elbow prosthetic joint infection (PJI)
is limited. Furthermore, no validated therapeutic algorithm exist as for
hip or knee PJI. We analyzed all PJI, which occurred in a cohort of
implanted elbow prostheses during a 13-year-period.
Methods: Between 01/1994 and 12/2007, all cases with implanted elbow
prosthesis at our institution were retrospectively included. Elbow PJI was
deﬁned as visible purulence, acute inﬂammation on histopathology, sinus
tract or microbial growth in periprosthetic tissue. Patients were regularly
follow-up at outpatient orthopedic visits and were in addition recently
contacted by phone. A Kaplan-Meier survival analysis was performed.
Results: During the study period, 358 elbow prostheses were implanted.
Overall, 25 of 358 cases (7%) developed elbow PJI (median age 61 y,
range 41−82 y, 40% males). Among them, 14 (56%) had a rheumatic
disorder and 11 (44%) a posttraumatic arthritis. 12 infections were early
( 3 months), 3 were delayed (3−24 months) and 10 were late (
24 months). More infections were acquired intraoperatively (n = 15, 60%)
than haematogenously (n = 10, 40%). The following pathogens were cul-
tured: Staphylococcus aureus (n = 11), coagulase-negative staphylococci
(n = 7), Streptococcus agalactiae (n = 2), Corynebacterium sp. (n = 1),
Enterococcus sp. (n = 1), Enterobacter cloacae (n = 1), mixed infections
(n = 1) and culture-negative (n = 1). Treatment approaches included
de´bridement with implant retention (n = 19), one-stage exchange (n = 2),
two-stage exchange (n = 1), resection arthroplasty (1) and antibiotics
only (n = 2). At follow-up, 16 (64%) patients were free of infection
(median follow-up time 2.6 y, range 0.7−11.3 y) and 9 (36%) had a
relapse (median time to infection 0.4 y, range 0.1−4.0 y). One patient
died due to infectious endocarditis with secondary haematogenous elbow
PJI. The relapse-free survival (95% conﬁdence interval) was 75% (58%-
93%) after 1 year, 70% (52%-89%) after 2 years, 62% (39%-85%) after
3 years and 52% (27%-78%) after 4 years.
Conclusions: The infection incidence after elbow arthroplasty was
higher (7%) than reported after hip (<1%) or knee arthroplasty (<2%).
Most infections (48%) manifested early ( 3 months). Underlying
rheumatic disorder were common in elbow PJI (58%). The relapse-free
survival after elbow PJI was 75%, 70%, 62% and 52% after 1, 2, 3 and
4 years.
O390 Ecological effects of selective digestive tract decontamination
and selective oropharyngeal decontamination on colonisation
with antibiotic resistant Gram-negative bacteria
E.A.N. Oostdijk °, A.M.G.A. De Smet, H.E.M. Blok, E.S. Thieme Groen,
J.A.J.W. Kluytmans, M.J.M. Bonten (Utrecht, Breda, NL)
Introduction: Selective Digestive tract Decontamination (SDD) and
Selective Oropharyngeal Decontamination (SOD) aim to eradicate
Gram-negative bacteria (GNB) from the intestinal en respiratory tract
in intensive-care-unit (ICU) patients. We aimed to quantify effects of
SDD and SOD on bacterial ecology in 13 ICUs that participated in a
clustered group-randomised cross over study in the Netherlands, in which
SDD, SOD or standard care (SC) was used during consecutive periods
of 6 months (NEJM 2009;360:20). The order of periods was randomised
per ICU.
Methods: Point prevalence surveys of rectal and respiratory samples
were performed once monthly in all patients in ICU (receiving or not
receiving SOD/SDD). Selective media were used to detect GNB and
MIC testing was done for ceftazidime (CFT), ciproﬂoxacin (CIP) and
tobramycin (TOB). Effects of SDD on rectal carriage were determined by
comparing data from 6 SDD months in each ICU to data from all months
preceding and following (in which SOD or SC was given). Combined
effects of SDD/SOD on respiratory tract carriage were determined by
comparing data from 12 months SDD/SOD (in any order) to data from
the 6 SC months before and afterwards.
Results: 2583 rectal and 2023 respiratory tract samples were analysed.
During SDD average proportions of patients colonised with GNB
resistant to either CFT, TOB, CIP were 5%, 7% and 7% and these
proportions were 15%, 13% and 13% during the post-intervention
period (p< 0.05 in each case). This effect is most explicit for CFT
with resistance levels increasing from 2.6% in the last month of SDD
to 11.4% in the 1st month after SDD (p< 0.05). During SDD and
SOD resistance levels in respiratory tract samples were <6% for all
three antibiotics, but prevalence increased gradually (for CFT and TOB
resistance; p< 0.05 for trend). After discontinuation of SDD and SOD
average proportions increased to levels >10% for all three antibiotics
(p< 0.05 in each case). CFT resistant isolates in rectal samples mainly
included Enterobacteriaceae not being Escherichia coli and Klebsiella
spp, whereas TOB and CIP resistant isolates mainly included E. Coli.
Conclusion: SOD and SDD have marked effects on the bacterial ecology
in an ICU with a rapid and persistent increase in resistance after
intervention. Antibiotic resistance remains a major concern associated
with these infection control measures.
O391 Throwing caution to the winds? Three cases of anaphylaxis
to chlorhexidine coated central venous catheters from a
regional cardiac centre in northwestern England
A. Guleri °, M. Hartley (Blackpool, UK)
Background: Chlorhexidine, a bactericidal antiseptic chemical, is used
in a wide variety of clinical settings within our institution. We report a
cluster of 3-cases of anaphylaxis to chlorhexidine coated central venous
catheters in patients scheduled for cardiac surgery in the Lancashire
Cardiac Centre in northwest England during 2008.
Chlorhexidine based products include skin prep [2%] prior to
venepuncture/insertion of vascular catheters, shampoo/bodywash [pre-
op and MRSA decolonisation regime]; urinary catheter lubricant; contact
lens solution; mouthwash; topical cream; chlorhexidine bonded medical
devices.
Case study: All 3-patients suffered a severe systemic anaphylactoid
reaction immediately after insertion of a central venous catheter impreg-
nated with chlorhexidine acetate and silver sulfadiazine (ARROWgard
Blue Catheter). Two of the patients responded to standard resuscitation
and the surgery was postponed to a later date. The third patient failed
resuscitation measures requiring cardiac massage until cardiopulmonary
bypass was established and cardiac surgery was performed. In all
3 patients, tryptase levels were acutely elevated indicating mast cell
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degranulation. Subsequently, allergen speciﬁc IgE to chlorhexidine
was demonstrated and skin prick/intradermal testing was positive to
chlorhexidine, conﬁrming the diagnosis of chlorhexidine-precipitated
anaphylaxis in each patient.
A detailed review of the case-notes revealed that each patient had
manifest evidence of minor cutaneous reactions to pre-operative
chlorhexidine use that had not been ascribed to chlorhexidine at the
time.
Discussion: FDA issued a public health notice [1998] following 1st
description of anaphylaxis to chlorhexidine coated central venous
catheter. A recent case cluster has also been reported from another
cardiac centre in the UK [3-cases over a 9-month period]. References to
be presented.
It is interesting that these reports of chlorhexidine anaphylaxis have
all occurred in patients undergoing cardiac surgery. These patients
receive multiple exposures to chlorhexidine during their pre-operative
investigations and preparation. This has increased recently as a result
of the drive to reduce the incidence of hospital-acquired infections. We
wish to postulate that these patients have been sensitised by repeated
topical exposure to chlorhexidine and have exhibited anaphylaxis when
this allergen was presented to the patient in the form of the chlorhexidine
coated central venous catheter.
O392 The effects of closed endotracheal suction systems on cross
transmission with Pseudomonas aeruginosa in intensive care
unit patients
I. Jongerden °, A. Buiting, J. Kesecioglu, S. Zeidler, M. Leverstein-van
Hall, B. Speelberg, M. Bonten (Utrecht, Tilburg, NL)
Objectives: Closed endotracheal Suction Systems (CSS) are increasingly
used in mechanically ventilated intensive care (ICU) patients. As
compared to the traditional – and less expensive – Open Suction Systems
(OSS), CSS are assumed to reduce bacterial cross-transmission, although
this has not been studied extensively. We determined the effects of
CSS, as compared to OSS, on the incidence of cross-transmission with
Pseudomonas aeruginosa (PA) in a cluster-randomised cross-over study
in four ICUs in two hospitals (between January 2007 and March 2008).
Methods: During two 6-month periods, all endotracheal suctioning
procedures (ES) in a single unit were performed with either OSS or
CSS, with the order of systems randomised. All patients with a length
of ICU stay >24 hours were included and respiratory samples were
collected for microbiological analysis on admission, and twice weekly
thereafter. Samples were analyzed for growth of PA and representative
isolates were genotyped with multiple-locus variable-number tandem-
repeats analysis (MLVA). Cross-transmission was deﬁned upon MLVA-
type and overlapping times in ICU.
Results: In all, 1110 patients (11319 patientdays) were included and
68 (6.1%) patients were colonised with PA on admission. 107 Patients
acquired colonisation with PA: 46 (8.4%) and 61 (12.6%) during CSS
and OSS, respectively (p = 0.026). Acquisitions per 1000 patientdays at
risk were 9.7 for CSS and 14.4 for OSS (p = 0.040). Yet, average daily
PA prevalence in the ICUs was 12.4 and 14.5 during CSS and OSS,
respectively (p=NS). In all, 4903 cultures were obtained (completeness
of culture taking 96%). 228 PA strains from 158 patients were genotyped.
During CSS, 38 of 70 patients (54%) carried a strain shared by at least
one other patient, which was 40 of 88 patients (45%) during OSS. Within
overlapping time intervals between positive PA cultures, there were 9
(22.5%) and 8 (14.5%) possible cases of cross-transmission during CSS
and OSS, respectively (p=NS). Taking into account a timeframe of 9 days
between positive PA cultures, 15 (37.5%) possible cases during CSS and
12 (21.4) during OSS were counted (p=NS).
Conclusion: In crude analysis, CSS was associated with a 4% lower
acquisition rate with PA, which could not be explained by a lower
incidence of cross-transmission and which yielded a slightly decreased
average endemic prevalence in the ICU.
O393 Repeated prevalence surveys of healthcare-associated
infections in Finnish neonatal intensive care units –
preliminary results
E. Sarvikivi °, O. Lyytika¨inen on behalf of the NICU Prevalence Survey
Study Group
Objectives: To evaluate the burden of healthcare-associated infections
and the distribution of infection types and causative agents in neonatal
intensive care unit (NICU) patients.
Methods: NICUs of all secondary and tertiary care hospitals in Finland
were invited to the prevalence study consisting of six monthly surveys,
the ﬁrst of which was conducted in November 2008. All infants present
in the unit at the day of the study were included. A one-day training
session for the study teams of the participating units was organised. The
study protocol, a standardised case-record form, written deﬁnitions for all
study variables, and CDC deﬁnitions (in Finnish) as well as practical case
exercises were provided. Variables collected included gestational age,
birth weight, type of delivery, severity of illness, preceding surgery, and
contact isolation. For infections, type, origin and causative microbes were
recorded. Indwelling devices (e.g., urinary catheter, central or peripheral
line, ventilator) and antimicrobial agents were documented on the study
day and retrospectively, for the preceding six days.
Results: All invited NICUs (N= 23) accepted the invitation. The ﬁrst
survey included 209 patients, 95 (45%) of whom from tertiary care
NICUs. In total, 42 (20%) patients with 43 infections were detected.
The most common type of infection was clinical sepsis, 52% of which
had an onset during the ﬁrst day of life. Positive cultures were obtained
from 8 (19%) of the infections. The causative agents identiﬁed were
Staphylococcus aureus, Corynebacterium diphtheriae, Staphylococcus
capitis, Enterococcus faecalis, and coagulase-negative staphylococci.
Table 1 summarises the characteristics of patients and infections stratiﬁed
according to the level of care. Data on ﬁve surveys will be available and
presented in May 2009.
Table 1. Characteristics of patients and infections during the ﬁrst point prevalence
survey of healthcare-associated infections in 23 neonatal intensive care units
(NICUs), Finland, November 2008
NICUs
Tertiary care
(N= 5)
Secondary care
(N = 18)
All
(N = 23)
Patients, N (%) 95 (45) 114 (55) 209 (100)
Birth weight <1500 g 41 (43) 27 (23) 68 (24)
Ventilator 7 (7) 1 (1) 8 (4)
Nasal-CPAP 29 (31) 5 (4) 34 (16)
Total parenteral nutrition 13 (14) 4 (4) 17 (8)
Central venous catheter 17 (18) 1 (1) 18 (16)
Patients with infection(s), N (%) 25 (26) 17 (15) 42 (20)
Bloodstream infection 4 0 4
Clinical sepsis 17 14 31
Pneumonia 4 0 4
Urinary tract infection 0 1 1
Necrotising enterocolitis 1 0 1
Conjunctivitis 0 2 2
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Conclusions: The infection prevalence was high. However, most
infections were classiﬁed as clinical sepsis, and the prevalence of
this type of infection is likely to be overestimated due to the fact
that empiric antimicrobial treatment is routinely started if maternal
risk factors for neonatal infection exist. Repeated surveys can help to
improve collaboration between the infection control team and ward staff,
and thereby lead to improved surveillance and control of healthcare-
associated infections.
O394 NA Antimicrobial prophylaxis in surgery: an international
survey
V. Alexiou °, V. Ierodiakonou, G. Peppas, M. Falagas (Athens, GR)
Background: We sought to investigate current clinical practice of
antimicrobial prophylaxis (AMP) in surgery.
Methods: Survey regarding the administration of AMP to patients,
without comorbidity or allergy, undergoing surgery, among surgeons
indexed as corresponding authors for articles published in general
surgery, orthopedics, gynaecology and cardiac surgery journals.
Results: 1068 surgeons answered (response rate 68%). 26.1% of the
respondents do not begin infusion of the ﬁrst antimicrobial dose within
1 hour from incision, as suggested by guidelines, 27.2% continue
administering AMP for 2 or more days after surgery, including 7.6% that
continues for 4−7 days after surgery. There were signiﬁcant differences
in the selection of AMP regimens between participating surgeons from
Europe and North America. Furthermore, 19% of Europeans order
infusion of the ﬁrst antimicrobial dose during incision compared to
3.9% of North Americans, 74.2% of Europeans discontinue AMP within
24 hours from surgery compared to 86% of North Americans. Finally,
31% of general surgeons originating from the North America administer
supplementary oral prophylaxis for colectomy compared to only 5% of
surgeons from Europe.
Conclusions: Even among experts, certain aspects of AMP are
rather controversial. A uniform, evidenced-based practice is warranted
especially in the era of increasing antimicrobial resistance.
O395 Inhaled colistin as adjunctive to intravenous colistin for the
treatment of microbiologically documented VAP
I. Korbila, A. Michalopoulos, P. Rafailidis, D. Nikita, G. Samonis,
M. Falagas ° (Athens, Heraklion, GR)
Objective: Ventilator-associated pneumonia (VAP) due to multidrug-
resistant Gram-negative bacteria contributed to the revival of intravenous
(IV) colistin. However, the administration of inhaled colistin for VAP is
controversial.
Methods: We performed a retrospective cohort study of patients with
microbiologically documented VAP who received IV with or without
inhaled colistin.
Results: 78 patients with VAP received IV plus inhaled colistin, while 43
patients received IV colistin alone, at an average daily IV colistin dose
of 7.0±2.4 (mean±SD) and 6.4±2.3 million IU, respectively (P = 0.13);
the average daily dose of inhaled colistin was 2.1±0.9 million IU.
The outcome of infection was cure for 62/78 (79.5%) versus 26/43
(60.5%) patients who received IV plus inhaled colistin versus IV
colistin alone, respectively (P = 0.025); all-cause in-hospital mortality
was 31/78 (39.7%) versus 19/43 (44.2%), respectively (P = 0.63);
all-cause ICU mortality was 28/78 (35.9%) versus 17/43 (39.5%),
respectively (P = 0.92). The use of inhaled colistin was the only variable
independently associated with cure of VAP in the multivariable analysis
[odds ratio (OR)=2.53, 95% conﬁdence interval (CI)=1.11−5.76]. The
only independent predictors of mortality were a greater APACHE II score
(OR= 1.12, 95% CI=1.04−1.20), presence of malignancy (OR= 4.11,
95% CI=1.18−14.23) and lower daily dosage of IV colistin (OR= 0.81,
95% CI=0.68−0.96).
Conclusion: The outcome of VAP was better in patients who received
inhaled colistin along with IV colistin than IV colistin alone. There was
no statistically signiﬁcant difference regarding all-cause in hospital and
ICU mortality between the compared groups. Randomised controlled
trials are warranted to further evaluate the role of inhaled colistin in
VAP.
O396 Increased risk of common infections in hospitalised patients
with type 2 diabetes mellitus
A. Zacharof ° (Halandri, GR)
Objectives: Clinical data on the association of Diabetes Mellitus (DM)
with common infections are lacking, are not conclusive, and are often
biased. We try to determine the relative risk of common infections in
patients with type 2 DM.
Methods: In a 21 year’s prospective cohort study conducted as part
of our Hospital epidemiological Survey, we compared 1797 adult
patients who had DM type 2 with 4189 control patients who had
hypertension without diabetes. We measured the number of attended
episodes of infection in the respiratory tract, urinary tract, and skin
and mucous membranes. We applied statistical multivariable and logistic
regression analysis to determine independent risks of infections and their
recurrences in patients with diabetes, compared with control patients.
Results: Upper respiratory infections were equally common among
patients with diabetes and control patients. Patients with diabetes
mellitus had a greater risk of lower respiratory tract infection (adjusted
odds ratio: 1.32 [95% Conﬁdence Interval, 1.13−1.53]), urinary tract
infection (adjusted odds ratio 1.24 [95% CI, 1.10−1.39]), bacterial skin
and mucous membrane infection (adjusted odds ratio 1.33 [95% CI,
1.15−1.54]), and mycotic skin and mucous membrane infection (adjusted
odds ratio 1.44 [95% CI, 1.27−1.63]). Risks increased with recurrences
of common infections.
Conclusion: Patients with Diabetes Mellitus type 2 are at increased risk
for lower respiratory tract infection, urinary tract infection, and skin and
mucous membrane infection. Studies are warranted into management of
such infections in patients with diabetes.
Current management of Helicobacter pylori
infections
S414 Epidemiology of H. pylori infection
H. Rautelin ° (Uppsala, SE)
Helicobacter pylori causes a chronic infection in the human gastric
mucosa (gastritis) worldwide. Man is the natural host of H. pylori.
It has been estimated that about half of the world’s population is
infected. The critical period to obtain the infection is in childhood and
early adolescense, although the precise person-to-person transmission
routes are largely unclear. Low socioeconomic status and crowded living
conditions are risk factors for H. pylori infection. In these conditions
the child may easily obtain the infection from an infected mother or
infected siblings. H. pylori usually causes a life-long infection, which
only rarely disappears unless treated. However, since the early 1900 s,
and particularly during the latter half of the century, the prevalence rates
of H. pylori infection have clearly decreased in developed countries along
with rapidly improving living standars. In elderly people the infection
is still common and reﬂects the high prevalence rates of the infection
in their childhood, whereas in the youngest age groups, the infection is
rare due to a low rate of childhood infections. In developed countries
the rate of new infections in adults is rare, about 1−2% per 10 years and
thus, the low prevalence of H. pylori at present in the young age groups
is not likely to increase during the coming years. In a recent study from
Finland, the seroprevalence of H. pylori was about 3% among teenagers
and among the 45-year-old subjects the seroprevalence was <30%. In
addition to the natural decline of H. pylori infection, the active treatment
of the infection in many developed countries has contributed to the rapid
disappearance of H. pylori. The prevalence of H. pylori is much higher in
developing than developed countries. This is also reﬂected in developed
countries in the higher prevalence rates of H. pylori among children
born to parents of foreign origin. H. pylori causes always gastritis and
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about 15−20% of the infected individuals will develop other sequelae
such as peptic ulcer disease. However, the rapidly declining prevalence
rate of the infection is reﬂected in the decreasing number of H. pylori
positive peptic ulcers in many countries. About one third or even half
of infected individuals develop atrophic gastritis, a risk factor for gastric
cancer, during decades of the infection. The declining prevalence rates
of H. pylori infection have been associated with the declining incidences
of gastric cancer later on.
S415 Diagnosis of H. pylori in a high and low prevalence population
H.I. Maaroos ° (Tartu, EE)
Detection of the H. pylori is based on the direct examination of the
bacteria (bacteriology, morphology, cytology), on the production of
urease by the bacteria (13 C urea breath test, rapid urease test), on
the production of antibodies to H. pylori (several serological tests) or
on the molecular genetics of the bacteria (PCR tests). Some of the
tests require invasive procedures (endoscopy) and some others belong
to group of noninvasive tests. Usually, the diagnosis of H. pylori
infection must be proved at least by two positive tests. The sensitivity
and the speciﬁcity of the tests is variable. The choice of the tests
is dependent not only their invasive or nonivasive character or their
sensitivity and speciﬁcity, but also on the aim of testing (screening
of population, diagnosing of the disease, checkup of the results of
treatment). Additional factor inﬂuencing the results of testing is the
prevalence of H. pylori infection in studied target groups. The accuracy
of the tests is lower in a primary health care setting than in a hospital
setting owing to the lower prevalence of target disorders among patients
consulting the family doctor. Estimation of the pre-test probabilities of
the infection in individual patients is needed to achieve high accuracy
of test results. Also validation of the tests is essential for different
populations as the rate of H. pylori infection varies greatly among
different European countries and different ethnic groups.
S416 Antimicrobial susceptibility and treatment strategies
F. Me´graud ° (Bordeaux, FR)
Helicobacter pylori can become resistant to most of the drugs currently
used for the eradication. As with Mycobacterium tuberculosis, this
resistance occurs essentially via point mutations. Due to selection
pressure the level of resistance is constantly evolving and necessitates
setting up surveillance systems. At the European level, point prevalence
evaluation is made every 10 years.
We will report on the last survey which began in April 2008 and
is scheduled to last until March 2009. Thirty-seven centres from 23
countries supposedly culturing H. pylori routinely have been enrolled.
The same protocol for susceptibility testing using Etest for 5 antibiotics
(clarithromycin, levoﬂoxacin, tetracycline, amoxicillin, rifabutin and
metronidazole) kindly provided by AB BioMerieux are used on a deﬁned
Mueller Hinton blood agar. Only patients not having received previous
H. pylori treatment have been included. An on-line report system has
been designed.
At this stage the results for 1,000 patients and H. pylori strains are
reported and indicate a global resistance rate of 19.9% to clarithromycin,
13.9% to levoﬂoxacin and 35.4% to metronidazole. As expected,
resistance to amoxicillin 2.1%, tetracycline 1.2% and rifabutin 0.7%, is
low. Detailed results will be presented according to age, gender, country
of residence and of birth, and endoscopic features.
According to the European Maastricht 3 guidelines (1995), susceptibility
to clarithromycin should be tested or clarithromycin should not be used,
if its resistance reaches 15−20%, which is the case in most European
countries. An alternative is to use levoﬂoxacin with amoxicillin and a
proton pump inhibitor (PPI) for 10 days but resistance to levoﬂoxacin is
also increasing very quickly. Other possibilities include a combination
of amoxicillin-metronidazole or tetracycline-metronidazole always with
a PPI despite metronidazole resistance which can be overcome in vivo
by increasing the treatment duration. Rifabutin can also be used with
amoxicillin but must be kept as the last option because of its toxicity
and impact on Mycobacteria.
Acknowledgement: The author is grateful to the steering committee of
the European survey of antimicrobiol susceptiblility of H. pylori: Y.
Glupczynski, A. Hirschl, M. Kist, M. Lopez Brea, L. Andersen as well
as to the participants who made this study possible.
S417 CagA of Helicobacter pylori acts at the very early stage of
differentiation of MDCK monolayers
L. Buti, R. Rappuoli, A. Covacci °, H. Ploegh (Siena, IT; Cambridge, US)
Type I strains of Helicobacter pylori possess the cag pathogenicity
island to deliver virulence factors. cag is a specialised Type IV
secretion machinery that is activated during infection and comprises
31 genes originated from a distant event of horizontal transfer. After
translocation the effector protein CagA is phosphorylated on tyrosine
residues restricted to a previously identiﬁed repeated sequence called D1.
This sequence is located in the C-terminal half of the protein and contains
the ﬁve amino acid motif EPIYA, which is ampliﬁed by duplications in
a large fraction of clinical isolates. Tyrosine-phosphorylation of CagA is
essential for the activation process that leads to dramatic changes in the
morphology of cells growing in culture. In addition, we observed that two
members of the Src kinases family, c-Src and Lyn, account for most of
the CagA-speciﬁc kinase activity in AGS cell lysates. Translocated CagA
interacts with the ZO-1 and Jam host-cell proteins causing disruption
of the apical junctional complex. Transfection of the cagA gene into
polarised epithelial cells induces disruption of cell-to-cell contacts and
altered morphology. Strikingly CagA-expressing cells become migratory
and invasive penetrating into collagen gel. The study of different portions
of the molecule revealed the presence of two distinct functional domains
and both are necessary to induce abnormal cell differentiation through
interactions with host cell morphogens. Cell polarity and invasion have
been suggested to contribute to both early and late stages of cancer
formation. These results suggest a mechanism by which CagA may acts
at the early stage of tumorigenic progression causing loss of cell polarity,
increased cell motility and invasiveness of epithelial cells.
European perspective on mosquito- and
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S423 The spread of Chikungunya virus
P. Parola ° (Marseille, FR)
After a period of 50 years of silence, a disease with an unpronouncable
name, “chikungunya” (CHIK), has recently become a medical reality and
reached the public throughout the world. In 2004, a large chikungunya
virus (CHIKV) outbreak emerged in Eastern Africa, spread in West
Indian Ocean islands with an unprecedented devastating outbreak in
2005–2006, then jumped to India and continued expansion into South-
eastern Asia. In 2007, the virus reached Europe. Since the beginning
of this outbreak, several million cases of chikungunya virus disease
have occurred in autochthonous populations and in travelers who were
diagnosed after they returned home from epidemic areas. New clinical
entities, including severe to lethal presentations, were reported in
complement to classical features, a febrile polyarthritis followed by long-
lasting rheumatism. CHIKV which was usually transmitted by Aedes
aegypti mosquitoes, has now been repeatedly associated with a new
vector, Ae. albopictus (the “Asian Tiger Mosquito”) which has spread
in tropical areas previously occupied predominantly by Ae. aegypti, and
has dispersed worldwide. Within one year, a single new mutation (E1-
A226V) was present in the CHIKV isolates in all places, providing
selective advantage for CHIKV transmission by Ae. albopictus. Due to
the globalisation of Ae. albopictus, this mutation increases the potential
for CHIKV to permanently extend its range into Europe, Americas and
other susceptible areas. As CHIKV could spread throughout the world,
all physicians should be prepared to encounter this arboviral infection
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that represent a paradigm for emerging arboviral infections. We present
here the different aspects of this reemerging and fascinating disease,
focusing on the lessons from the recent large scale outbreaks.
Beyond antibiotics: the biologic basis and
clinical utility of adjuvant therapy for severe
pneumonia (Symposium arranged with the
International Sepsis Forum)
S426 Low-monocyte human leucocyte antigen-DR expression is
independently associated with nosocomial infections after
septic shock
C. Landelle °, A. Lepape, N. Voirin, E. Tognet, J. Bohe´, P. Vanhems,
G. Monneret (Lyon, FR)
Objective: Sepsis-induced immunosuppression is hypothesized to
contribute to a heightened risk of secondary nosocomial infection
(NI). The main objective is to assess whether low monocyte human
leucocyte antigen-DR (mHLA-DR) expression, proposed as a marker of
immunosuppression, is associated with an increase of NI after septic
shock.
Methods: A prospective observational study was conducted in 2
intensive care units (ICUs) in a French university hospital. The study
included 209 septic shock patients during the period December 1, 2001
through April 30, 2005. mHLA-DR was measured by standardised ﬂow
cytometry at days 3−4 and 6−9 after the onset of septic shock. All
patients were screened daily for 4 NI sites after septic shock onset
during ICU stay: microbiologically-documented pulmonary, urinary
tract, bloodstream and catheter-related infections. A multivariate Cox
model was used to identify the variable independently associated with
the risk of NI, based on their adjusted hazard ratios (aHR) and their 95%
conﬁdence interval (95% CI).
Results: At days 3−4, we obtained measurements in 153 patients
of whom 42 developed NI. The latter exhibited lower mHLA-DR
values than those without NI (28% vs 39%, p = 0.03). Multivariate
Cox model analysis revealed that mHLA-DR <25% was the sole factor
independently associated with NI occurrence after adjustment for clinical
parameters (age, gender, Simpliﬁed Acute Physiology Score II, Sepsis-
related Organ Failure Assessment, and intubation) with an aHR of 1.92
(95% CI: 1.04−3.57; p = 0.04). Similarly, at days 6−9, mHLA-DR <40%
remained the sole parameter predicting NI with an aHR of 2.28 (95%
CI: 1.19−4.36; p = 0.01).
Conclusion: Low mHLA-DR expression after septic shock indepen-
dently predicts NI. This promising biomarker may be of major interest in
identifying patients at increased NI risk who could beneﬁt from targeted
and tailored therapy aimed at restoring immune functions.
S427 The cytokine response in severe pneumonia: insights from
preclinical studies
T. van der Poll ° (Amsterdam, NL)
Pneumonia, the leading infectious cause of death in the US, kills more
people annually than AIDS, tuberculosis, meningitis and endocarditis
combined. From a wide range of observational studies of community-
acquired pneumonia (CAP), only half of the cases had an aetiologic agent
identiﬁed. Streptococcus pneumoniae was consistently the predominant
bacterial aetiology. This lecture will primarily focus on the innate
immune response to pneumococcal pneumonia.
Toll-like receptors (TLRs) are key molecules that recognize pathogen
associated molecular patterns (PAMPs) and induce an inﬂammatory
response. Pneumolysin, an intracellular toxin found in all S. pneumoniae
clinical isolates, is an important virulence factor of the pneumococcus
that is recognized by TLR4. Although TLR2 is considered the most
important receptor for Gram-positive bacteria, TLR2 does not play
a decisive role in host defence against S. pneumoniae pneumonia;
likely, pneumolysin-induced TLR4 signalling can compensate for TLR2
deﬁciency during respiratory tract infection with S. pneumoniae. Besides
TLR2 and TLR4, TLR9 contributes to an effective host defence against
S. pneumoniae in the airways. The importance of TLR signaling for
host defence against pneumococcal pneumonia is illustrated by the fact
that mice lacking the common TLR adaptor protein MyD88 are highly
susceptible to this infection.
Activation of TLRs results in the production of proinﬂammatory
cytokines. There is ample evidence that underlines the importance
of tumour necrosis factor (TNF) and interleukin (IL)-1 in host
defence in bacterial pneumonia: In a murine S. pneumoniae pneumonia
model, treatment with a neutralising anti-TNF mAb strongly impaired
antibacterial defence. In addition, IL-1a receptor type I deﬁcient mice
infected with S. pneumoniae displayed an increased bacterial outgrowth.
Of considerable interest, treating IL-1 receptor deﬁcient mice with a
neutralising anti-TNF antibody made them extremely susceptible to
pneumococcal pneumonia.
Infection of the lower airways by S. pneumoniae is associated with
complex interaction between the pathogen (e.g. cell wall components,
pneumolysin) and the host (e.g. TLRs, cytokines). These interactions
play a crucial role in the outcome of this clinically important infection.
S428 The role of microbial virulence factors in the pathogenesis
of bacterial pneumonia
S. Opal ° (Pawtucket, US)
Severe bacterial pneumonia remains uncommon unless speciﬁc con-
ditions exist that tip the balance between the host and pathogen in
favour of the microorganism. Such conditions include: persons at the
extremes of age; exposure to especially virulent organisms; patients
with concomitant illness impairing pulmonary clearance mechanisms;
and immunocompromised hosts. Pathogens overcome an array of innate
and acquired host defences to successfully invade the host. The known
virulence traits of three common respiratory pathogens (Streptococcus
pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa)
will be brieﬂy reviewed. The capsular polysaccharide of pneumococci
is the major anti-phagocytic virulence trait but many other factors
contribute to disease pathogenesis including the critically important
exotoxin known as pneumolysin, bacteriocins, adherence factors, choline
binding proteins, lipoteichoic acid, iron, manganese and magnesium
transporters, pili, competence and bioﬁlm capacity, and virulence genes
that promote invasion and impair clearance once the organism has
entered the blood stream. S. aureus is notorious for the numerous A/B
type toxins, cytotoxins, and superantigens it generates during the course
of invasion. Staphylococci deploy a complex series of quorum sensing
signals that coordinate adhesin and invasion genes within bioﬁlms or
between planktonic organisms and likely contribute to the success of
this pathogen. P. aeruginosa produces an array of extracellular exotoxins
and cytotoxins delivered by type III secretion systems. These include
elastase, phospholipases C, a series of apoptotic and anti-phagocytic
exotoxins, along with an alginate capsule and an unusual and variable
LPS structure that participate in microbial invasion. The pathogen
expresses at least three interacting, quorum sensing systems to coordinate
virulence and bioﬁlm formation. A detailed understanding of these
virulence factors is now providing therapeutic options to control these
respiratory pathogens. Surface expressed and extracellular toxins of
pneumococci have been selected as new vaccine targets. Inhibitory
peptides and small molecule inhibitors of quorum sensing and bioﬁlm
formation are under investigation for staphylococcal and P. aeruginosa
infections. These innovative and non-antibiotic treatment strategies are
gaining greater importance as progressive antibiotic resistance threatens
the management of these severe bacterial infections in the future.
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An update on infections you would be
surprised to see
S431 Brucellosis
G. Pappas ° (Ioannina, GR)
Brucellosis, possibly the commonest zoonotic infection worldwide, has
troubled humans since antiquity. Recent years have seen the expansion of
the animal reservoir of the disease to a wide spectrum of wildlife species,
extending to marine mammals, and the recognition of novel Brucella
species. Furthermore, animal and human disease has re-emerged in
numerous countries which were brucellosis-free, and currently the most
important endemic foci include Near East and Central Asia. Complex
socioeconomic and political factors may be incriminated for these
alterations in endemicity. The complex mechanisms by which Brucella
evades immune response and survives intracellularly are progressively
clariﬁed. Novel diagnostic techniques as real time PCR may shed light
in the life cycle of Brucella inside the human host; preliminary studies
have indicated that the pathogen may persist in latent form for years after
apparent clinical cure, in asymptomatic individuals. Treatment principles
have not evolved signiﬁcantly. The expert guidelines issued recently
under the name of “Ioannina Recommendations” support the need for
a six-week combined treatment that includes traditional antibacterials
and is modiﬁed accordingly in serious complications as spondylitis and
central nervous system involvement. The road to the development of a
vaccine for humans seems long though.
S433 Anthrax
M. Doganay ° (Kayseri, TR)
Anthrax is ancient diseases and relatively a forgotten disease in western
world until 2001 when spores were mailed in USA causing ﬁve deaths.
Currently, human anthrax is seen most commonly in agricultural regions
of the world where anthrax in animals is prevalent, in which countries
of Middle East, in Africa, Central Asia and South America. It is also an
endemic disease in Turkey.
Human cases may occur in an agricultural or an industrial environment.
The infection is an occupational hazard of workers who process hides,
hair, bone and bone products, and wool and of veterinarians and
agricultural workers who handle infected animals. The main route of
transmission is contact with or ingestion of contaminated meal with or
inhalation of Bacillus anthracis spores. The aim of the present study was
to review human anthrax in Turkey during the last decade.
Papers on anthrax published from Turkey between 1990 and 2007 were
collected and reviewed. Most cases were recorded from the central and
eastern parts of Turkey. Three of the reports appeared in international
journals prior to 1990, 10 reports appeared in the 1990 s, and 24 reports
appeared after the anthrax events of 2001 in the USA. These reports
included 926 cases, 426 of which could be reviewed: 413 (96.9%) cases
of cutaneous anthrax, 8 (1.9%) cases of gastrointestinal anthrax, and 5
(1.2%) cases of anthrax meningitis. Of all the affected patients, 95.2%
had contact with contaminated materials. A Nosocomial spread from
a 20 day-old baby who developed a cutaneous anthrax lesion on the
periumbilical region to two nurses and one cleaner was reported. Most
of the patients (88.7%) had received penicillin G. Total mortality was
2.8%.
A total of 138 clinical isolates from human cases were evaluated in
ﬁve studies. All isolates tested against Penicillin G were susceptible.
None of the strains produced beta-lactamase. Doxcycline, tetracycline,
erythromycin, aminoglycosides and ciproﬂoxacin were highly active
against all strains.
Anthrax is an endemic disease in Turkey, and acquisition of infection is
generally through contact with ill or dying animals or animal products.
Sheep and cattle are generally involved. Most clinical disease in humans
is cutaneous anthrax, although other clinical forms are seen and have
a greater mortality. Penicillin remains the drug of choice in treating
the disease. Controlling anthrax in humans depends on controlling the
infection in animals.
S434 Leptospirosis
P.A. Tambyah ° (Singapore, SG)
Leptospirosis is a very old disease that has been known for more
than a hundred years and possibly even longer since the time of
Hippocrates. It remains a major cause of illness in many tropical and
subtropical countries and thus in travellers. It has also been identiﬁed
as a zoonosis in Europe and North America. It is a disease that can
surprise us because the clinical presentations are not always typical. In
recent years, pulmonary and other atypical presentations have been more
widely recognised. There is no effective vaccine but chemoprophylaxis is
effective in selected populations. Prompt recognition and early institution
of appropriate treatment as with most other infectious diseases appear
to be critical in ensuring a good outcome for our patients. There are
interesting new developments in diagnostics and molecular epidemiology
but clearly there are many challenges remaining in this ﬁeld.
Acinetobacter baumannii antibiotic resistance
and virulence genes
O435 Worldwide dissemination of the blaOXA-23 carbapenemase
gene associated to different genetic structures in
Acinetobacter baumannii
P. Mugnier °, L. Poirel, T. Naas, P. Nordmann (Le Kremlin-Biceˆtre, FR)
Objectives: Carbapenem-resistant Acinetobacter baumannii are increas-
ingly reported worldwide. One of the main carbapenem resistance
determinant corresponds to the carbapenem-hydrolysing oxacillinase
OXA-23. The blaOXA-23 gene had been previously reported to be
located in a composite transposon structure Tn2006 (ﬂanked by two
copies of insertion sequence ISAba1), or in the transposon structure
Tn2007 made of one copy of ISAba4. Our objective was to determine
the genetics associated with the blaOXA-23 gene among A. baumannii
isolates from worldwide origin.
Methods: Twenty carbapenem-resistant clinical A. baumannii isolates
harbouring the blaOXA-23 gene were collected from different sources
worldwide. Detection of the blaOXA-23 gene was performed by PCR
followed by sequence analysis. The plasmid/chromosomal location of
the blaOXA-23 gene was determined by using the I-CeuI technique.
Genetic structures surrounding the blaOXA-23 gene in A. baumannii
were investigated by cloning and sequencing. Genotyping of the isolates
was performed by PFGE and MLST.
Results: The collection was made of isolates recovered from France,
Belgium, Vietnam, Saoudi Arabia, New Caledonia, South Africa,
Australia, Lybia, Egypt, Kingdom of Bahrain. Among these 20 isolates,
15 clones were identiﬁed. Several isolates recovered from very different
locations were corresponded to a same clone (i.e. South Africa and
New Caledonia). Ten isolates possessed the blaOXA-23 gene on a
chromosomal location and the 10 others on a plasmid location. The 10
isolates in which the blaOXA-23 gene was chromosome-borne harboured
the entire Tn2006 composite transposon that was always bracketed by a
9-bp long target site duplication (differing among the different clones),
as a signature of transposition events. Among the 10 isolates in which the
blaOXA-23 gene was plasmid-borne, different structures were identiﬁed.
One isolate harboured the entire Tn2006 transposon. The blaOXA-23
gene was associated to an upstream-located ISAba1 element (like with
Tn2006), but lacked the second downstream-located ISAba1 copy for 6
isolates, and was located inside transposon Tn2007 for 3 isolates.
Conclusion: This study shows that dissemination of blaOXA-23 is
related to diverse genetic structures. However, transposon Tn2006 corre-
sponds to the main structure disseminating blaOXA-23 in A. baumannii.
The blaOXA-23 gene was either plasmid- or chromosome-located, that
may suggest frequent mobilisation events of those structures.
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O436 blaOXA-58-carrying Acinetobacter baumannii in Portugal:
more ancient and prevalent than initially imagined
S. Quinteira °, F. Grosso, A. Gomes, H. Ramos, L. Peixe (Famalica˜o,
Porto, PT)
Objectives: Although OXA-58 has been reported from many countries,
in Portugal only a previous description of a single isolate was made till
now. We aimed to analyse the spread of blaOXA-58 among imipenem-
resistant A. baumannii (IRAb), within a university hospital, throughout
a period of 6 years.
Methods: From 2001–2006, 181 IRAb were collected from several
specimens and different wards. Isolates were identiﬁed by API32GN and
16SrDNA sequencing. MICs were determined for b-lactam antibiotics by
the Etest and for colistin and tigecycline by the agar dilution method.
Susceptibility to aminoglycosides and ciproﬂoxacin was tested by disk
diffusion method. Carbapenemase activity was detected by a bioassay.
PFGE (ApaI) was done in representative isolates. blaOXA-23-like,
blaOXA-24-like, blaOXA-51-like and blaOXA-58 genes were sought by
multiplex PCR. The presence of ISAba2 and ISASba3 surrounding the
blaOXA-58 gene was investigated. Hybridisation assays were performed
using blaOXA-58 probe after ICeuI digestion to ascertain the genetic
location of the gene. Sequencing of blaOXA-58 ﬂanking regions was
conducted in plamidic extract from a representative strain.
Results: blaOXA-58, found in 22 A. baumannii isolates, all belonging
to the same pulsotype, was ﬁrst recovered in 2001, thus preceding the
original description from Poirel et al. (2005). The remaining positive
isolates were collected during the 2001–2004 period and were found not
to be clonally related to the endemic OXA-40 carrying Iberian clone.
This blaOXA-58-producing clone showed resistance to several b-lactams
(including imipemem), susceptibility to ceftazidime, netilmicin and
minocycline, and variable susceptibility to meropenem, cefepime, and
aztreonam.
MICs for colistin and tigecycline ranged from >16mg/L and from
0.25−4mg/L, respectively.
All OXA-58-producing isolates presented the ISAba3 downstream of
the blaOXA-58 gene. Hybridisation assays revealed a plasmidic location
for the blaOXA-58 gene with ca 90Kb. Plasmid sequencing showed an
ISAba3-like truncated at the 3′ end upstream of the blaOXA-58 gene, a
fact that may explain the observed negative carbapenemase-production
bioassay.
Conclusion: blaOXA-58-carrying A. baumannii is, apparently, more
ancient than initially imagined. Although undetected from 2004 onwards,
the fact that it possessed a non-expressible gene, due to alterations in
the promoter region, suggests that this information might have been
incorporated from a still unidentiﬁed source.
O437 Outbreak of OXA-23-producing carbapenem-resistant
Acinetobacter baumannii/calcoaceticus in an intensive care
unit in Brazil
C.G. Prates, A.F. Martins, S.V. Superti, L. Lutz, F.S. Lopes, F. Ramos,
A.P. Zavascki ° (Porto Alegre, BR)
Objective: To describe an outbreak caused by OXA-23-producing
Acinetobacter baumannii/calcoaceticus (AB) in an intensive care unit
(ICU) from a tertiary-care hospital from Brazil.
Methods: All patients admitted to the 22-bed ICU of Hospital Ernesto
Dornelles from March 2006 (detection of the index case) up to November
2008 were assessed. Univariate analysis of potential predictors of 30-day
mortality was performed. Variables with a p0.10 were included in a
Cox regression model. A p0.05 was signiﬁcant.
A sample of 25 CRAB was submitted to PCR for blaoxa-23 gene.
Susceptibility tests were performed by disc-diffusion method (CLSI
guidelines). MICs for polymyxin B were determined by agar dilution
and for tigecycline by E-test in isolates submitted to PCR.
Results: A total of 2879 patients were admitted to ICU during the study
period, 60 (2.1%) presented the recovered of at least one CRAB. The
incidence rate of CRAB was 3.2 per 1000-patient/day: 1.3 per 1000-
patient/day in 2006, 3.2 in 2007 and 5.4 in 2008. The prevalence of
CRAB among all AB isolates was 29.0% in 2006, 70.0% in 2007 and
88.1% in 2008. The mean±SD age of patients was 69.4±14.3 years.
Twenty-seven (45%) were male. Isolates were recovered from respiratory
secretions (33 isolates, 55.0%), blood (11, 18.3%), urine (7, 11.7%),
catheter (5, 8.3%) and other secretions (4, 6.7%). Only 24 (40.0%) of 60
patients received appropriate antimicrobial therapy either with polymyxin
B (79.2%), ampicillin-sulbactam (12.5%) or tigecycline (8.3%). Overall
30-day mortality of patients with CRAB was 50%. Mortality rates
were 3.2 per 1000-patient/day. These rates were signiﬁcantly higher
among patients who have not received appropriate therapy (1.2 per
1000-patient/day) compared with those who have received it (0.3 per
1000-patient/day; p = 0.001; ﬁgure 1). In the Cox regression model only
receiving appropriate treatment (hazard ratio [HR] 3.29; 95% Conﬁdence
Interval [CI] 1.35−8.02); p = 0.009) was independently associated with
30-mortality. Positive blood culture for CRAB remained in the ﬁnal
model (HR 1.85; 95% CI 0.86−4.00; p = 0.12). All 25 isolates submitted
to PCR were positive for blaoxa-23. All these isolates were susceptible
to polymyxin B and tigecycline.
Conclusion: High 30-day mortality occurred in this ICU outbreak. Many
patients did not receive appropriate therapy, which signiﬁcantly increased
mortality. Other clinical risk factors for mortality in this outbreak are
currently under investigation.
O438 Molecular identiﬁcation and characterisation of
Acinetobacter baumannii in Norwegian strain collections
reveal major discrepancies to phenotypic identiﬁcation and
the presence of carbapenemase-producing clonal lineages
N. Karah °, B. Haldorsen, K. Hegstad, A. Sundsfjord, Ø. Samuelsen
on behalf of the Norwegian Study Group on Acinetobacter
Objectives: Acinetobacter baumannii is an important opportunistic
pathogen that mainly affects critically ill patients in intensive care units.
The aim of this project was to analyse two national strain collections
of Acinetobacter spp. from Norway with respect to precise species
identiﬁcation of A. baumannii and further characterisation of conﬁrmed
A. baumannii isolates with regard to antimicrobial susceptibility,
presence of carbapenemases and clonal lineages.
Materials and Methods: A total of 31 multidrug-resistant isolates
of Acinetobacter spp. submitted to the Reference Centre year 2003–
2008 from various clinical specimens and 118 blood culture isolates of
Acinetobacter spp. from all Norwegian clinical laboratories year 2005
to 2007 were included. Identiﬁcation of A. baumannii was performed by
VITEK2, blaOXA-51 PCR, and 16S-23S rRNA intergenic spacer PCR.
Sequencing of 16S rRNA and rpoB was used to conﬁrm the results.
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Susceptibility testing was examined by Etest. The presence of deﬁned
blaOXA-enzymes related to carbapenem resistance and epidemic clonal
lineages were examined by multiplex PCRs.
Results: In total 100 out of 149 isolates were identiﬁed as A. baumannii
by VITEK2. However, only 17 isolates were conﬁrmed as A. baumannii
by molecular methods. Molecular identiﬁcation methods showed
consistent results with only one exception: one isolate was identiﬁed
as A. baumannii by the 16S-23S rRNA intergenic spacer PCR and
A. radioresistens by sequencing of 16S rRNA/rpoB. Among the 17
isolates identiﬁed as A. baumannii, 7 isolates were from the multidrug-
resistant strain collection and 10 from the national blood culture
collection. Five of the A. baumannii isolates detected were intermediate
susceptible or resistant to carbapenems and were PCR-positive for
blaOXA-23-like (n = 4) and blaOXA-58-like (n = 1). BlaOXA-24-like
was not identiﬁed. Six isolates were found to belong to European clones
I (n = 3) and II (n = 3).
Conclusion: Automated phenotypic identiﬁcation of A. baumannii show
major discrepancies compared to molecular methods which showed
consistent results. A. baumannii represents only 8.5% of the blood culture
isolates phenotypically identiﬁed as Acinetobacter spp. indicating that
other Acinetobacter species are important causes of bacteraemia. The
presence of blaOXA-23-like and blaOXA-58-like genes was related to
carbapenem resistance and isolates belonging to European clones I and II
have emerged in Norway.
O439 Novel genetic context of multiple blaOXA-58-like genes in
Acinetobacter genospecies 3
B. Evans °, A. Hamouda, K. Towner, S. Amyes (Edinburgh, Nottingham,
UK)
Objectives: The spread of carbapenemase genes within Gram negative
bacteria is of great cause for concern. In 2008, the ﬁrst report of
a blaOXA-58 gene outwith Acinetobacter baumannii was reported in
Acinetobacter genospecies 3. We had also identiﬁed a genospecies 3
isolate encoding a blaOXA-58-like gene, and the aim of this study
was to examine the genetic environment of the gene to investigate the
mobilisation between species.
Methods: Restriction analysis of rRNA was used to conﬁrm identity
to the species level. Susceptibility to imipenem and meropenem was
determined through the plate doubling dilution method. Screening
by PCR for blaOXA-51-like, blaOXA-23-like, blaOXA-40-like and
blaOXA-58-like genes was carried out. Analysis of the genetic
environment surrounding the blaOXA-58-like gene was conducted by
sequencing inverse PCR products and gene-walking fragments. The
structure of the surrounding sequence was conﬁrmed using internal
primers, which were also used to screen other blaOXA-58-like positive
isolates in our collection.
Results: Restriction analysis conﬁrmed the isolate belonged to Acine-
tobacter genospecies 3. The isolate showed reduced susceptibility to
imipenem and meropenem with MICs of 2mg/L for both antibiotics. The
isolate was negative for a blaOXA-51-like, blaOXA-23-like or blaOXA-
40-like gene, but positive for a blaOXA-58-like gene. Analysis of the
genetic environment of the blaOXA-58-like gene revealed the gene was
within a novel genetic structure. Upstream of the blaOXA-58-like gene
was the left-hand end of an ISAba3 element, interrupted by an ISAba125
element. The elements contained putative promoter sequences. Down-
stream was an araC1 and a lysE gene, followed by a sequence similar
to the Re27 element described previously. Following this was a complex
region containing the right-hand end of an ISAba3 tnpA gene, interrupted
by an incomplete tnpA gene with 99% similarity to ISAba3, itself
interrupted by an ISAba125 sequence. This region was followed by a
second blaOXA-58-like gene. All other blaOXA-58-like positive isolates
in our collection were negative for ISAba125 upstream of blaOXA-58.
Conclusion: This study is the ﬁrst to report multiple copies of a
blaOXA-58-like gene in an Acinetobacter genospecies 3 isolate, and has
identiﬁed a novel structure containing two blaOXA-58-like genes and
two ISAba125 sequences. The ISAba125 elements may be responsible
for the duplication of the blaOXA-58-like gene.
O440 Three major A. baumannii clones account for all
carbapenem-resistant strains
M.L. Mezzatesta °, M. D’Andrea, R. Migliavacca, T. Giani, F. Gona,
G. Marchese, E. Nucleo, L. Pagani, G. Rossolini, S. Stefani (Catania,
Siena, Pavia, IT)
Objective: Acinetobacter baumannii is a signiﬁcant nosocomial
pathogen that has the potential to spread among hospitalised patients
especially in intensive care units. Clinical isolates of A. baumannii are
often characterised by a multiple antimicrobial resistance phenotype,
including major therapeutic options such as carbapenems.
To trace the diffusion of carbapenem-resistant A. baumannii in Italy,
a Sequence Typing (ST) scheme was compared with typing results
generated by PFGE.
Methods: 119 A. baumannii isolates were collected during 2004–2005
in 8 Italian regions. All strains were non susceptible to carbapenems
and antibiotic resistance determinants were investigated by PCR. PFGE
was routinely performed and the MLST scheme used was based on
fragments of the six genes as published in the MLST Pasteur web site
http://www.pasteur.fr/recherche/genopole/PF8/mlst/, while primers used
for the ampliﬁcation of rpoB were designed using Vector NTI on the
basis of the published sequence (CU459141).
Representatives of major European clones I (RUH875) and II (RUH134)
were used as controls.
Results: Our results conﬁrm the particular propensity of A. baumannii
for nosocomial cross-transmission in vast geographical areas.
All isolates, belonging to three MDR clones, were characterised by the
presence of blaOXA-58 determinant. Six isolates, belonging to PFGE
type C, were also positive for the blaOXA-23 allele. No isolates were
positive for the blaOXA-24 allele.
Conclusions: PFGE and MLST possess the same discriminatory power,
the same reproducibility, and are epidemiologically concordant in
deﬁning the three clones circulating in Italy, two of them belonging to
the 2 pan European clones; the third clone was isolated only in 1 centre.
N. strains PFGE ST Allelic proﬁle OXAs content
type subtype cpn60 fusA gltA pyrG recA rplB rpoB
109 A 3 2 2 2 2 2 2 2 2 OXA51-like, 58
4 B 0 1 1 1 1 1 5 1 1 OXA51-like, 58
6 C 2 20 3 1 1 1 5 1 1 OXA51-like, 58, 23
RUH 134 A – 2 2 2 2 2 2 2 2 –
RUH 875 B – 1 1 1 1 1 5 1 1 –
O441 Detection of extended-spectrum beta-lactamase type PER-1
in Acinetobacter baumannii species isolated from bloodstream
infections and investigation of clonal relationship
M. Cosar, I. Tuncer, U. Arslan °, A. Mansur, B. Otlu, R. Durmaz,
D. Findik (Konya, Malatya, TR)
Objective: Acinetobacter baumannii is an important nosocomial
pathogen with wide intrinsic resistance. However, due to the dissemina-
tion of the acquired resistance mechanisms; such as extended-spectrum
beta-lactamase (ESBL) and metallo betalactamase (MBL) production,
multidrug resistant strains have been isolated more often. PER-1 was ﬁrst
detected in Turkey and was found to be widespread among Acinetobacter
spp. and P. aeruginosa. Since then, PER-1 has been discovered in other
countries, and most recently found in northern Italy and in Korea. In this
study, the presence of PER-1 type ESBL was investigated in caftazidime
resistant A. baumannii strains isolated from bloodstream infections by
PCR and also the clonal relatedness of the isolates were investigated
by Random Ampliﬁed Polymorphic DNA (RAPD) and Pulsed Field Gel
Electrophoresis (PFGE) in all PER-1 producing A. baumannii strains.
Methods: A. baumannii strains isolated from bloodstream infections was
included in this study. The isolates were identiﬁed as A. baumannii
by conventional methods and Phoenix 100 BD automated System
system (Becton Dickinson Diagnostic Systems, Sparks). Ceftazidime
resistance was determined by E-test. PER-1 genes were screened by
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PCR. The clonal relationship of PER producing A. baumannii isolates
were analyzed by RAPD and PFGE. Data analyses were performed using
Gel Compar II (Applied Maths, Sint-Martens-Latem, Belgium).
Results: Of the 100 A. baumannii isolates; 78 (78%) were determined
as ceftazidime-resistant by E-test. Among the 78 ceftazidime-resistant
A. baumannii isolates the PER-1 gene was identiﬁed in 18 (23%). The
similarity of the bands were calculated according to “dice smilarity
coefﬁcients” and all PER-1 positive isolates were found as clonally
related.
Conclusion: In our study the prevalence of PER-1 was lower than the
previous studies. But the presence of high ceftazidime resistance rates
among these isolates may indicate the presence of other beta-lactamases.
DNA analysis by PFGE and RAPD revealed an outbreak caused by
a unique clone. Detection of clonal related isolates among different
services may be because of the treatment of these patients at the same
services before and this may explain the spread of PER-1 positive strains.
O442 Resistance genomic islands related to AbaR1 are common
in Acinetobacter baumannii strains belonging to European
clone I
L. Krizova °, M. Maixnerova, L. Dijkshoorn, A. Nemec (Prague, CZ;
Leiden, NL)
Objective: Acinetobacter baumannii strains belonging to European (EU)
clone I are commonly resistant to multiple antimicrobial agents. A
number of resistance genes were recently detected on an 86-kb genomic
resistance island (AbaR1) inserted in the ATPase gene of EU clone I
strain AYE. The aim of this study was to assess the presence of AbaR1-
related structures in epidemiologically unrelated strains of EU clone I.
Methods: The study set included 25 multi-drug resistant (MDR) strains
of EU clone I collected in 19 European countries in 1978–2004 and 10
genotypically unique, fully susceptible strains. Using PCR, all strains
were investigated for the presence of the ATPase gene and for nine
genes found to be associated with AbaR1. Furthermore, the strains were
tested for the disruption of the ATPase gene using PCR primers directed
against the 3′ and 5′ ends of this gene. Strains with the disrupted gene
were investigated for the presence and structure of the ATPase gene-
AbaR1 connecting regions using PCR mapping and RFLP. PCR primers
were derived from the known sequence of strain AYE.
Results: All strains were positive for the ATPase gene. The 10
susceptible strains had an intact ATPase gene whereas all MDR strains
failed to produce the expected amplicon in the ATPase disruption test. All
EU clone I strains yielded positive results for the ATPase gene-AbaR1
connecting regions, the structure of which corresponded to those of AYE.
These ﬁndings suggest the presence of ATPase integrated elements in
clone I strains, the integration of which had invariably taken place at the
same locus site. None of the AbaR1-associated resistance genes were
found in any of the susceptible strains. In contrast, the MDR strains
harboured the following AbaR1-associated genes (% positive strains):
aacC1 (21), aadA1 (21), aadB (4), aphA1 (21) strA (3), merA (20), tetA
(18), cat (23), the gene encoding heavy metal detoxiﬁcation protein (25).
Individual MDR strains carried from one to nine AbaR1-associated genes
in 11 different combinations. There was a good correlation between the
content of resistance genes and resistance phenotypes.
Conclusion: Genetic structures related to AbaR1 are common in strains
belonging to EU clone I. The heterogeneity of resistance patterns in this
clone is likely to result from the variations in the content of AbaR1-
related structures.
Supported by grant 310/08/1747 of the Grant Agency of the Czech
Republic.
O443 Mutation frequency of rifampicin resistance in Acinetobacter
baumannii clinical isolates
P. Komp Lindgren °, H. Seifert, O. Cars (Uppsala, SE; Cologne, DE)
Objectives: To study the differences in mutation frequency and evaluate
the possible correlations between drug resistance development and
mutation rate in Acinetobacter baumannii (AB).
Methods: The mutation frequency (MF) of rifampicin (RIF) resistance
was used as a surrogate measure of differences in mutation rate and
for detection of the presence of mutator phenotype. The MF of RIF
resistance was measured in 100 clinical isolates collected from different
AB infections over a 20 year period in Europe and USA and two
reference strains (AB ATCC 19606 and 17978). MF of RIF in AB
isolates was compared with E. coli control strains with altered mutation
rates. 10−20 cultures of each isolate were grown over night and plated
onto RIF containing Mueller-Hinton agar plates and non RIF containing
plates to determine the MF of rifampicin resistance. After 24 hour
incubation colonies were counted and the frequency was calculated. The
MF was compared to each individual strain’s resistance proﬁle (resistant
vs multidrug resistant, MDR) and infection speciﬁc history (sporadic vs
outbreak isolate).
Results: The MF of RIF resistance ranged between ~2.2×10−10 to
7.8×10−8. None of the isolates displayed any MF near the mismatch-
(mutS, 3.0×10−6) or dam-mutant (3.9×10−7) of E. coli. Still, many of the
AB isolates, 66 of 102, displayed a MF of rifampicin lower (<10−9) then
wild type E. coli. There were no signiﬁcant mean differences between
sporadic (1.3×10−8) and outbreak (1.2×10−8) isolates. In the comparison
of resistance proﬁle and MF, the MIC values of 5 different antibiotic
classes were used. The isolates were classiﬁed as resistant (resistant to
<2 antibiotics) and MDR (resistant to 3) by the MIC values according
to EUCAST breakpoints. The mean MF of resistant versus MDR isolates
were 8.8×10−9 and 1.2×10−8, respectively.
Conclusion: Although no A. baumannii isolates displayed a strong
mutator phenotype, the diverse mutation frequencies reﬂect the past
evolutionary history of these isolates. The existence of a signiﬁcant
number of possible ‘weak-mutators’ (10 times increased MF) among
clinical isolates presents a hidden potential for the rapid evolution of
resistant isolates. It was previously shown in E. coli that a slightly
increased mutation rate (4−20 fold) can drive the evolution of antibiotic
resistance. Our ﬁnding that MDR A. baumannii isolates had increased
mutation rates can have an impact on future development of resistance
in these isolates.
O444 Genome comparison of Acinetobacter baumannii: evaluation
of drug resistance, adherence, haemolysis and other
potential virulence factors
F. Imperi, M. Iacono, L. Antunes, L. Villa, P. Visca, G. De Bellis,
A. Cassone, A. Carattoli ° (Rome, Segrate, IT)
Objectives: despite the importance of Acinetobacter baumannii as
emerging pathogen worldwide, studies on the mechanisms underlying
its pathogenesis are lacking. Multidrug resistant strains are emerging
throughout many geographic areas and two pan-epidemic European
clones (I and II) have been documented, endowed with a broad range
of antibiotic resistance. In this study, the genome sequences of the
multidrug resistant A. baumannii ACICU (European clone II; Iacono
et al. AAC 2008) and AYE (European clone I, Vallenet et al. PLOS
One 2008) strains were compared with the genome of the antibiotic
susceptible, not pathogenic SDF strain, and with that one of the reference
ATCC17978 strain (Smith et al. Genes Dev 2007) with the aim of
identifying genomic regions implied in pathogenesis and drug resistance.
Methods: protein similarities were searched by the BLASTp algorithm.
Pathogenicity studies were performed using the Galleria mellonella
model of infection. Haemolysis was evaluated on deﬁbrinated horse
blood.
Results: in this study, we used larvae of the insect G. mellonella
(greater wax moth) as infection model to compare the virulence of the
A. baumannii strains ATCC17978, AYE, ACICU and SDF. The 50%
lethal dose (LD50) was comparable for AYE and ACICU, while it was ca.
10- and 100-fold higher when larvae were infected with ATCC17978 and
SDF, respectively. Thus, the SDF genome was used as reference genome
to identify functions acquired by pathogenic strains with a possible
role in antibiotic resistance and pathogenicity. Sixty-two clusters,
corresponding to almost 870 CDSs, were identiﬁed in the ACICU and
AYE genomes (and partially in ATCC17978) that were absent in SDF.
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These clusters encode: (i) resistance genes and transporters plausibly
involved in drug efﬂux (30 transporters of the MFS, DMT, ABC, RND,
MOP and ACR3 families were unique of drug resistant strains and absent
in the susceptible SDF strain); (ii) pili and ﬁmbriae systems related to
bioﬁlm formation and motility; (iii) haemolysin- and haemagglutinin-
related proteins differently distributed among the four genomes, (iv) iron
uptake and other metabolic genes.
Conclusion: Genome comparison identiﬁed unique features of A. bau-
mannii epidemic clones and provided novel insights into the genetic
basis of multidrug resistance and pathogenesis in this species. This study
may contribute to understand the concept of infection, invasiveness and
colonisation in the emergent pathogen A. baumannii.
Hard to swallow − emerging and re-emerging
issues in food-borne infection (Symposium
arranged with EFWISG)
S460 MRSA in food products: cause for concern or case for
complacency?
J. Kluytmans ° (Breda, NL)
In 2003 a new MRSA strain was found in The Netherlands that could
not be typed with Sma1 Pulsed Field Gel Electrophoresis due to the
presence of a novel methylation enzyme. The initial observations on this
strain were related to persons, who had contact with pigs. Using MLST
analysis it was shown that all non-typable strains belonged to one clonal
compex, ST-398. Subsequently a study was performed which conﬁrmed
the association of ST-398 in humans and a reservoir in pigs and veal
calves. Meanwhile, this clone has been found in horses and chicken as
well. In geographic areas with a high density of pig- or cattle-farming the
prevalence of MRSA has increased dramatically since an active screening
was recommended by the Dutch Working Party on Infection Control
(WIP) in June 2006 (WWW.WIP.NL). At present, approximatelty 30% of
ll new cases of MRSA in The Netherlands are ST-398.Some case reports
show that this strain can cause serious infections. On the other hand there
are indications that ST-398 is less virulent and less transmissible among
humans than other MRSA strains. At this time ST-398 has been found
all over the world, nearly always in relation to animal husbandry.
The ﬁndings above prompted investigations into the presence of MRSA
in food. A large survey in The Netherlands showed that 145 out of
1293 pieces of retail meat harboured MRSA (11.2%). The quantity of
MRSA per piece of meat was low. This raises concern over the potential
spread of MRSA or the resistance genes into the general population.
The presence of low amounts of ST-398 is not considered to be a risk if
the meat is prepared properly. There is a theoratical risk for tansmission
related to handling of meat. At present there are no indications that the
presence of ST-398 in food is causing further spread into the community.
Interventions in the use of antimicrobials:
do they affect antimicrobial resistance?
O463 Reduction of the use of macrolides does not decrease
macrolide resistance in Streptococcus pneumoniae
M. Bergman °, S.T. Nyberg, P. Huovinen, A.J. Hakanen and The Finnish
Study Group for Antimicrobial Resistance (FiRe Network)
Objectives: Macrolide resistance in Streptococcus pneumoniae and
marolide usage in Finland was evaluated.
Methods: 29,535 S. pneumoniae isolates were tested during 2001 −
2007 for macrolide resistance in the laboratories of 20 central
hospital districts, covering the whole of Finland. The susceptibility
testing was performed according to the guidelines of CLSI. Data
concerning outpatient macrolide sales were obtained from the National
Agency of Medicines. The macrolide (erythromycin) resistance trends
were statistically evaluated, as well as the consumption ﬁgures of
azithromycin, roxithromycin, clarithromycin, and all macrolides pooled.
The effect of age was also evaluated.
Results: Results show that in spite of a notable decrease in total
macrolide usage from 2.06 to 1.43 Deﬁned Daily Doses/1000 inhab-
itants/day (p = 0.008), macrolide resistance in S. pneumoniae increased
signiﬁcantly (p< 0.001). The result was similar when different macrolide
compounds were analysed separately. The increase in resistance could
especially be seen in the age group of children under 5 years old. In 2007,
macrolide resistance in this age group was 29.2%, whereas patients over
5 years old had a resistance rate of only 17.2%.
Conclusion: In conclusion, despite a reduction in macrolide usage,
macrolide resistance in S. pneumoniae in Finland did not decrease.
Instead, macrolide resistance increased statistically signiﬁcantly during
the study period. The increase was the most striking among isolates from
children under 5 years old. This implies that antimicrobial usage is not
the only factor that affects resistance.
O464 Effect of reduced use of quinolones on the observed
resistance rates in E. coli
I. Willemsen °, B. Cooper, C. van Buitenen, M. Winter, J. Kluytmans
(Breda, Amsterdam, NL; London, UK)
Objectives: To determine the effects of multiple interventions that
reduced the use of Quinolones, on the observed resistance of E. coli
in a teaching hospital.
Methods: During a prospective study, from 2005 through 2007, 4
interventions to improve the use of quinolones (QUIN) were executed.
First, a switch from intravenous- to oral medication (01–2006); second,
education programs for interns/residents and physicians and the release
of a new antimicrobial formulary (05–2006); third, a restriction
note was printed on all laboratory rapports (10–2006) and fourth,
active monitoring and giving feedback on prescriptions (01–2007).
Susceptibility patterns for E. coli including ciproﬂoxacin, cefuroxim,
ceftazidim, co-trimoxazole and tobramycin from hospitalised patients
were analyzed starting in 2004. Statistical analyses were performed using
segmented Poisson regression models to look at effect of interventions
on resistance (both sudden stepwise changes and changes in trends).
Bayesian model averaging was used to account for model uncertainty.
Results: Before the start of the interventions the resistance rate was
increasing by an average of 2.6% per year. The interventions resulted
in a signiﬁcant reduction of QUIN use from on average 550 Prescribed
Daily Doses to 350 PDD per month. In the best ﬁtting Poisson model
for the resistance data, a signiﬁcant stepwise decrease was found to be
associated with interventions 2 and 4. However, there was substantial
uncertainty in the model choice, and after accounting for this there
was no conclusive evidence in support of any particular intervention,
although there was evidence that at least one of the interventions was
associated with the observed reduction in resistance. There were no
stepwise decreases or decreasing trends in resistance rates to other
antimicrobials during the study period.
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Conclusions: This study found that targeted interventions that reduce the
use of QUIN were associated with a decrease of the QUIN resistance
rate in E. coli.
O465 Antibiotic therapy and resistance in Germany: inﬂuence and
intervention
E. Velasco °, W. Espelage, I. Noll, A. Barger, T. Eckmanns (Berlin, DE)
Objectives: Growing populations of older and immunocompromised
patients, changes in epidemiology and unchecked use of antibiotics
can led to a rise in consumption as well as resistance to certain
treatments. Medical doctors (MDs) often have an important role
alongside contributing factors. We conducted a national survey of MDs
in Germany on their behaviours and expectations for intervention.
We aimed to assess MD behaviours with and inﬂuences on antibiotic
prescribing and the potential for related interventions that address
antibiotic resistance.
Methods: A representative sample comprised 10,610 MDs with differing
practice specialties, from both stationary and ambulatory settings
(respectively: 36% and 0% internists, 0% and 54% general practitioners,
32% and 11% surgery, 3% and 4% ear/nose/throat, 10% and 10%
paediatrics, 5% and 3% urology, 9% and 13% gynaecology, 2% and 4%
dermatology, 3% and <1% other) in 15 federal states. We developed
study questions to capture baseline information on MDs and their
practice with antibiotics. Questions also focused on selected inﬂuences
that may affect behaviour in practice. Other questions solicited opinions
about interventions that may improve practice. Mailed questionnaires
were distributed to participants via state medical associations.
Results: Among survey respondents (n = 3,613; response rate = 34%),
66% reported that they prescribe antibiotics daily, and 90% indicated
they do so at least weekly. Of all surveyed MDs, 60% reported that
they think their own prescribing practice has an inﬂuence on antibiotic
resistance in their region. Of all MDs, 83% found it “important” to
continually improve use of antibiotics through industry independent
experts providing consultation, audits and feedback. Of all MDs, 96%
found it “important” to have provision of regional coverage of antibiotic
resistance with appropriate feedback for practicing MDs, and 82% found
it “important” to have provision of antibiotic regulations of prescriptions
with appropriate feedback for practicing MDs. (Results in Table 1.)
Table 1. Selected questions from survey
Question n = Responsesa
% Stationary % Ambulatory % Combined
Do you use some form of guidelines for antibiotic
therapy?
3442 84 yes
13 no
78 yes
16 no
81 yes
15 no
How often do you consult other colleagues about
starting a patient on antibiotic therapy?
3547 49 daily
2 never
5 daily
30 never
26 daily
16 never
Do you think your own prescribing practice has an
inﬂuence on antibiotic resistance in your region?
3529 70 yes
21 no
51 yes
36 no
60 yes
29 no
Do you think antibiotic resistance is a relevant
problem in your work position?
3527 88 yes
11 no
67 yes
29 no
77 yes
21 no
“I would rather prescribe antibiotics than not when
a patient wants to work”
1839 – 18 agree
35 disagree
25 disagree strongly
–
“I would rather prescribe antibiotics than not when
treating immunosuppressed patients”
1702 25 agree strongly
60 agree
3 disagree
– –
Do you ﬁnd guidelines for diagnostics and therapy
for antibiotic infections for MDs in ambulatory
settings important?
1844 – 48 “very important”
92 “important”
–
Do you ﬁnd clinic-internal guidelines for
diagnostics and therapy for antibiotic infections
with consideration of local resistance data
important?
1690 65 “very important”
95 “important”
– –
aNot all results shown and remaining percentages are as follows: A closed three category scale was used for options
“yes”, “no”, “do not know”. A closed four category scale was used with options “very important”, “important”, “less
important” and “not important”. A closed ﬁve category scale was used for options “daily”, “weekly”, “monthly”,
“seldom” and “never”. A closed ﬁve category scale was used for options “strongly agree”, “agree”, “neutral”,
“disagree” and “strongly disagree”.
Conclusion: Many MDs prescribe antibiotics often and believe their
practice may have an effect on antibiotic resistance. Results indicate
that MDs value information, interventions and surveillance in order to
support responsible use of antibiotics. There is an ongoing effort in Ger-
many to address these ﬁndings at the national level e.g. by establishing
a surveillance system for antibiotic resistance and antibiotic usage.
O466 Two years after introduction of ertapenem in the antibiotic
formulary of an intensive therapy unit in a large teaching
hospital: effect on antibiotic resistance patterns of
Pseudomonas species and Enterobacteriaceae
P. Lal °, T. Neal (Liverpool, UK)
Objectives: Ertapenem, a parenteral carbapenem licensed for once daily
use in April 2002 in Europe is increasingly being used as monotherapy
for treatment of serious infection caused by Enterobacteriaceae. In two
international randomised trials its use was not associated with increase
in bowel colonisation of extended-spectrum b-lactamase/Amp C b-
lactamase (Amp C) producing Enterobacteriacae or imipenem-resistant
Pseudomonas species, a major issue in infection control. Ertapenem was
introduced in our intensive therapy unit in January 2007.We carried out
this study to determine changes in antibiotic resistance patterns amongst
Pseudomonas species and Enterobacteriaceae between the periods before
[January 2005 to December 2006] and after [January 2007 to December
2008] its introduction.
Methods: The antimicrobial susceptibility data was collected from an
online database maintained in the department and percentage resistance
(% resistance) for all antimicrobials was compared between the two
periods separately for Pseudomonas species and Enterobacteriaceae. The
p values were calculated using Fisher’s exact test.
Results: The % resistance amongst Pseudomonas species in the two peri-
ods was: amikacin (3%, 0.6% *), ciproﬂoxacin (23%, 22%), ceftazidime
(6%,7%), gentamicin (4%, 0.8%*), piperacillin/tazobactam (4%, 3%),
carbapenems (19%, 20%) respectively. That for Enterobacteriaceae
was: co-amoxiclav (44%, 39%), amoxicillin (85%, 89%), 2nd & 3rd
generation cephalosporins combined (40%, 38%), cefpodoxime (46%,
42%), ceftazidime (30%, 32%), cefoxitin (42%, 36%*), ciproﬂoxacin
(32%, 34%), gentamicin (15%, 11.5%*), amikacin (1.9%, 1.7%),
piperacillin/tazobactam (23%, 22%), trimethoprim (45%,43%) and
carbapenems (0.6%, 2.2%*) respectively. (* denotes signiﬁcant p values
<0.05, see Table).
Table: The percentage antibiotic resistance amongst Pseudomonas species and
Enterobacteriaceae between the periods 01/05–12/06 and 01/07−12/08
Antimicrobials % Resistance p value
01/05–12/06 01/07–12/08 (Fisher’s
exact
test)
Enterobacteriaceae
Co-amoxiclav 44 39 0.018
Amoxicillin 85 89 0.740
2nd &3rd cepahalosporins (total) 40 38 0.07
Cefpodoxime 46 42 0.14
Ceftazidime 30 32 0.26
Cefoxitin 42 36 0.004
Ciproﬂoxacin 32 34 0.18
Gentamicin 15 11.5 0.0094
Amikacin 1.9 1.7 0.10
Trimethoprim 45 43 0.31
Piperacillin/tazobactam 23 22 0.64
Carbapenems (imipenem, meropenem) 0.6 2.2 0.0042
Pseudomonas species
Amikacin 3 0.6 0.02
Ciproﬂoxacin 23 22 0.74
Ceftazidime 6 7 0.77
Gentamicin 4 0.8 0.005
Piperacillin/tazobactam 4 3 0.43
Carbapenems (imipenem, meropenem) 18.7 19.7 0.26
Conclusions: This study shows signiﬁcant increases in resistance of
Enterobacteriaceae to carbapenems in the period after introduction of
ertapenem. However there was no signiﬁcant change in resistance of
Pseudomonas species to carbapenems. The resistance to co-amoxiclav
and cefoxitin decreased signiﬁcantly in Enterobacteriaceae in the latter
period suggesting a reduction in Amp C producing organisms. The
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aminoglycoside resistance decreased signiﬁcantly in the latter period in
both Enterobacteriaceae and Pseudomonas species. These ﬁndings which
are important for treatment and infection control demonstrate the need
for resistance surveillance after introduction of a new antimicrobial to
detect any collateral changes.
O467 Survey of antibiotic resistance in Streptococcus pneumoniae
collected in Belgium during winter 2008. Follow-up of resis-
tance since 1995 and possible effect of antibiotic campaigns
R.L.M. Vanhoof °, E. Van Bossuyt, S. De Craeye, J. Van Eldere,
J. Verhaegen, L. Kaufman on behalf of the Belgian SP Study Group
Objectives: S. pneumoniae remains an important pathogen with high
rates of antibiotic non-susceptibility being reported worldwide. There
remains a need for continuous national surveillance of resistance. Here,
we compare the 2008 data with those obtained since 1995.
Methods: Strains were collected by 15 centres. MIC to Penicillin (PN),
Amoxicillin (AM), Cefuroxime (CR), Cefotaxime (CT), Ciproﬂoxacin
(CI), Levoﬂoxacin (LV), Moxiﬂoxacin (MO), Erythromycin (ER),
Telithromycin (TL) and Tetracycline (TT) was determined by the NCCLS
microdilution test. Data on antibiotic use were obtained from ESAC.
Results: In the 2008 survey, 448 strains were tested. Non-susceptibility
rates (%I+R) were as follows: PN: 11.6, AM: 0, CR: 9.2, CT: 2.0, CI:
5.1, LV: 0.7, MO: 0.4, ER: 29.7, TL: 0 and TT: 21.9. ER-TT (12.7%)
was the commonest IR proﬁle. MDR was 22.5%. In the period 1995–
2008, 3262 strains were collected. PN-IR increased signiﬁcantly from
12.5 (1995) to 21.0 (2001) and decreased to 11.6 in 2008. AM, CR and
CT had a similar evolution. AM peaked at 3.1 in 2003 and decreased
to 0 in 2008. CP-IR decreased signiﬁcantly from 1999 (15.1) to 2008
(5.1). ER-NS (21.6−37.7) increased over the years and TT-IR (22.8−38.5)
stayed high. IR for LV, MO and TL were always low (0.5−3.3; 0−0.6;
0−1 resp.). B-lactam distributions were bimodal. PN MIC50 shifted to
the right from 1995 (0.008) to 2003 (0.06) and returned to 0.015 (2008).
FQs had one-modal distributions; MIC50 remained stable (CP, LV: 0.5−1,
MO 0.06). IR for PN, ER and TT were always higher in children (CH)
than in adults (AD). Signiﬁcant differences were found for PN (1995),
ER (1997, 2004, 2006, 2007, 2008), TT (2004, 2006). Generally, CP-
IR was higher in AD than in CH. IR was lower in the North (N) than
in the South (S). Signiﬁcant differences: PN (2005, 2006), ER (2003,
2004, 2005), TT (2005). Both N and S knew a deceasing IR tendency:
PN= N (12.1−8.1), S (18.8−13.2); CP= N (11.6−5.9), S (18.9−5.9);
TT= N (27.4−21.5), S (35.9−23.5). ER increased in the N (20.9−29.7).
Total outpatient antibiotic use (DID) decreased from 26.2 (1999) to 22.7
(2004) and increased to 24.2 (2006). DID for PN and FQ increased,
MLS stabilised and TT decreased.
Conclusions: Since 2001–2003 an IR decrease was noted for PN, CP
and TT. ER-IR increased further over the years. The decrease paralleled
the start of public campaigns on antibiotic use. IR rates remain higher
in CH than in AD. The N/S difference became less marked.
Paediatric infections: new bugs and emerging
roles for the older ones
O468 Parachlamydia and Rhabdochlamydia in respiratory secre-
tions of premature newborns: prevalence and clinical impact
F. Lamoth °, A. Schneider, S. Aeby, K. Jaton, B. Vaudaux, G. Greub
(Lausanne, CH)
Objectives: Parachlamydia acanthamoebae is a new recognized member
of the order Chlamydiales. Growing evidences suggest that this bacteria
may have a pathogenic role in humans causing respiratory diseases. It
has also been recently identiﬁed as an agent of bovine abortion and
may be a cause of miscarriage in women. In contrast, little is known
about the pathogenic role of Rhabdochlamydia crassiﬁcans, another
related Chlamydiales. Molecular diagnostic tools are useful to detect
these obligate intracellular bacteria because of their inability to grow
on conventional culture media. The aim of this work was (i) to develop
a real-time PCR for the diagnosis of Rhabdochlamydia infection and
(ii) to study respiratory secretions of newborns for the presence of
Parachlamydia and Rhabdochlamydia DNA.
Methods: A new quantitative real-time TaqMan PCR (q-PCR) to
be used on ABI Prism 7900 was developed. The q-PCR was then
blindly applied to 41 consecutive respiratory samples (endotracheal
or nasopharyngeal secretions) taken from 29 critically-ill newborns
admitted in the neonatology ward of our university hospital. These
samples were also tested using a previously developed Parachlamydia-
speciﬁc PCR.
Results: Most newborns (28/29) were premature (median gestational
age: 28.6 weeks; range: 24.6−41.2). Initial respiratory distress syndrome
was present in 86% of them. Positive PCR results were obtained in
12/29 (41%) patients (8 Parachlamydia, 3 Rhabdochlamydia, 1 both
species) at a median of 17.5 days (range: 2–230) after birth. When
compared to the control group (17 patients with negative PCR), these
12 newborns had a signiﬁcantly worse primary adaptation and a higher
incidence of resuscitation maneuvers at birth (Table). Duration of non-
invasive mechanical ventilation and stay in neonatology ward were also
signiﬁcantly longer. A fatal issue was observed in 3 infected cases, as
compared to no death in controls (p = 0.06). Gestational age at birth as
well as the incidence of pulmonary or systemic infections did not differ
between cases and controls.
Conclusion: A high prevalence of Parachlamydia and Rhabdochlamydia
DNA was observed in respiratory secretions of premature critically-ill
newborns. The presence of DNA of these microorganisms was associated
with a worse primary adaptation, a more severe respiratory distress
syndrome and a trend towards a higher mortality. Their pathogenic role
should be further investigated.
Table. Newborns with positive PCR for Parachlamydia and/or Rhabdochlamydia
in respiratory secretions compared with control group
Positive
results
(n = 12)
Negative
results
(n = 17)
P value
Primary adaptation (Apgar score)
First score (1min)* 2.5 (0−7) 8 (2−9) 0.002
Sum of 3 scores (1, 5, 10min)* 18.5 (8−27) 27 (17−29) 0.002
Cardiac resuscitation (ﬁrst 48 h)** 6 (50) 0 (0) 0.002
Invasive mechanical ventilation (ﬁrst 48 h)** 11 (92) 8 (47) 0.019
*median (range); **total number (percent).
O469 Superior detection of Kingella kingae and Staphylococcus
aureus in paediatric osteoarticular infections using
molecular assays
S. Juretschko °, T. Beavers-May, C. Hemphill, J. Romero, S. Stovall
(Little Rock, US)
Objectives: Delayed diagnosis and treatment may worsen the outcome
of paediatric osteoarticular infections. Epidemiological data show
Staphylococcus aureus as the predominant pathogen. Recently increased
prevalence of Kingella kingae infections has been reported in young
children.
The genus Kingella consists of 3 species, K. kingae, K. oralis and
K. denitriﬁcans. All are Gram negative, sometimes difﬁcult to stain,
rod shaped bacteria that are normal respiratory and genitourinary ﬂora.
They are slow-growing and fastidious. Although improved recovery was
shown when using Fan or PEDs-F blood culture bottles, the majority of
these infections remain undetected, especially in pre-treated patients. We
report the use of real time polymerase chain reaction (rt-PCR) assays
for detection of K. kingae and S. aureus in paediatric osteoarticular
infections.
Methods: 116 synovial ﬂuid samples from 97 patients, 1 month and
17 years of age, were collected over 19 months (03/2006 to 10/2007). The
samples were from 54 knees, 39 hips, 9 ankles, 6 elbows, 4 shoulders,
2 wrists and 2 femur abscesses. After automated DNA/RNA extraction,
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specimens were subjected to 4 hour pathogen-speciﬁc rt-PCR. Samples
were inoculated onto sheep blood and chocolate agar as well as a Peds-F
bottle. Final species identiﬁcation and antimicrobial susceptibilities were
determined by Phoenix (TM).
Results: 45 patients (56 specimens) had positive culture and/or rt-
PCR, resulting in an overall positivity rate of 46%. S. aureus was the
predominant pathogen accounting for 31 specimens of 23 patients (12
MRSA, 11 MSSA) and. 37% of positive specimens (18 patients) were
due to K. kingae (n = 21). Among children 0−2 years (n = 35), K. kingae
was the predominant pathogen accounting for 16 positive patients (46%),
followed by MSSA in 4 patients (11%). The positivity rate for this
age group was 57%. Only 2 children >2 years (5 and 9 years) were
positive for K. kingae. MRSA was the predominant pathogen in 6−12
year olds, and MSSA was evenly distributed among children 3−17 years
old. Culture detected only 5 of 21 specimens positive for K. kingae and
25 of 31 S. aureus. 4 other pathogens were detected by culture only.
Conclusion: The use of these molecular assays enhances detection
of organisms, especially for K. kingae (19% vs. 5% for culture).
Additionally, faster identiﬁcation (TAT 4 hrs) allows for rapid targeted
therapy. This improvement in TAT could lead to shorter hospital stays
in about 54% of cases.
O470 Population dynamics and geographical diversity of Moraxella
catarrhalis in the Generation R study
S.J.C. Verhaegh °, M.L. Snippe, H.A. Moll, A. van Belkum, J.P. Hays
(Rotterdam, NL)
Objectives: Moraxella catarrhalis is often found in the nasopharynx
of children having the capacity to cause respiratory infections. Several
virulence-associated genes have been identiﬁed inM. catarrhalis, though
relatively little is known about the frequency of these genes. In this
study, genotyping, virulence gene screening, and virulence gene PCR-
RFLP studies were used to investigate isolate variation in chronologically
distinct, and serial, isolates of M. catarrhalis colonising young children.
Methods: Nasopharyngeal swabs were taken from children enrolled in
the Generation R focus cohort group, a study based in Rotterdam, The
Netherlands, comprising 1,079 children, born between February 2003
and August 2005. Nasopharyngeal swabs were taken at 1.5, 6 and
14 months of age. Of the 732 M. catarrhalis isolates cultured, 48 single
and 82 serial isolates were further investigated for genotype (PFGE or
MLST), virulence gene frequency (PCR screening), and virulence gene
diversity (PCR-RFLP).
Results: Genotyping revealed a high degree of diversity, indicative of a
panmictic bacterial population. Further, there was no association between
genotype and colonisation frequency, or year of isolation. PCR screening
for virulence genes revealed an incidence of 98% for uspA1, 81% for
hag, 82% for uspA2 and 18% for uspA2H. No signiﬁcant difference
was observed in the prevalence of virulence-associated genes between
isolates originating from children who were colonised only once or
children colonised on all 3 occasions (P = 1). PCR-RFLP analysis of
uspA1, hag and uspA2 showed many gene variants, with no association
between PCR-RFLP patterns and colonisation frequency, or year of
isolation.
Conclusion: Even in relatively localised geographical settings, the
genotypic diversity of M. catarrhalis isolates colonising children is
large, with no yearly pattern of genotype predominance. Children
serially colonised with M. catarrhalis isolates appear to clear a
particular genotype only to become subsequently colonised with a
different genotype. The incidence of virulence genes in this relatively
localised study group is remarkably similar to that reported in global
M. catarrhalis isolates, possibly indicating that similar selection pressure
exists forM. catarrhalis at both the local and global level. Virulence gene
variation appears to be high, even in this relatively restricted geographical
group. These results could have consequences for vaccines designed
against virulence genes.
O471 Epidemiology of cytomegalovirus in pregnancy and risk eval-
uation for delivering a child with congenital CMV infection
A. Naessens °, I. Foulon, A. Casteels, W. Foulon (Brussels, BE)
Objectives: To evaluate the epidemiology of cytomegalovirus in
pregnancy and to evaluate the risk for delivering a child with congenital
CMV (cCMV).
Methods: Between 1996–2006, 11825 unselected mother-infant pairs
were included. In the mother a serological screening was performed
consisting in the detection of CMV IgG and IgM antibodies at the
ﬁrst prenatal visit and at birth. In the neonate CMV urine culture was
performed to diagnose congenital infection. When a pregnant woman
was found to have a second trimester spontaneous abortion or a death
in utero, an investigation for possible congenital CMV infection was
carried out.
Results: Serological screening at the ﬁrst prenatal visit showed no
immunity in 4701 women, evidence of past infection (IgG positive
IgM negative) in 6877 women (58.2%) and in 250 women (2.0%) both
IgG and IgM antibodies were detected. After investigation of stored
and follow up samples from these 250 patients, 14 could be classiﬁed
as having a primary CMV infection during pregnancy, 99 patients had
previous immunity before the current pregnancy and from 137 patients
the type of the maternal CMV infection could not be determined.
Follow-up serology of the 4701 women without immunity revealed a
seroconversion in 58 of them (1.2%).
A total of 61 (0.52%) congenital infections (cCMV) were diagnosed.
The incidence of the cCMV among the different groups of women are
summarised in the table.
Conclusion: cCMV infection occurs in 0.52% of our population of
pregnant women. cCMV was considered to be due to a primary maternal
CMV infection in 54% of the infants; 33% due to a recurrent maternal
CMV infection and in 13% the type of maternal infection could not be
determined.
The risk for a seronegative pregnant woman of acquiring CMV during
pregnancy is 1.2%. The transmission risk after a maternal primary
infection is 45%. Women with prior immunity have a very low risk
(0.20%) for cCMV, this risk increases to 3% when IgM are ﬁnd in women
with know prior immunity. The risk for women with undetermined
infectious status in early pregnancy to give birth to a congenitally
infected neonate is 5.8%.
Pregnant women N N cCMV risk of cCMV
IgG pos/IgM neg. at ﬁrst prenatal visit 6877 17 0.20%
Seroconversion during pregnancy 58 26 45%
IgM positive at ﬁrst prenatal visit 250 18 7.2%
Primary infection 14 7 50%
Prior immunity 99 3 3%
Undetermined maternal infection 137 8 5.8%
Total population 11825 61 0.52%
O472 Rotavirus gastroenteritis in Norway: analysis of prospective
surveillance and hospital registry data
E. Flem °, K. Vainio, H. Døllner, C. Midgaard, F.J. Bosse,
A.G. Wesenberg Rognlien, A. Rojahn, S. Nordbo, G. Størvold,
G. Njølstad, K.O. Wathne, K. Konsmo, P. Aavitsland (Oslo, Trondheim,
Bergen, NO)
Objectives: We examined the epidemiology and burden of rotavirus
gastroenteritis in Norway to inform the national decision on introducing
new rotavirus vaccines into routine immunisation.
Methods: We reviewed the national hospital registry data on children
<5 years of age hospitalised with acute gastroenteritis (AGE) during
January 1995–December 2004. We also conducted sentinel rotavirus
surveillance among children <5 years of age admitted with AGE to
three large hospitals during 2006–2008, and examined the numbers of
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rotavirus-positive tests reported to the national laboratory surveillance
system in 1995–2004.
Results: During 1995–2004, 14973 gastroenteritis hospitalisations were
reported for an annual rate of 4.9 (95% conﬁdence interval (CI)
4.6−5.3) hospitalisations per 1000 children. The proportion of AGE
hospitalisations with rotavirus-speciﬁc code on the discharge records
was 14%. However, sentinel surveillance determined that 63% (95%
CI 57.4−68.3) of these hospitalisations were associated with rotavirus,
yielding an estimated annual incidence of 3 (95% CI 2.6−3.5) rotavirus
hospitalisations per 1000 children, corresponding to ~906 (range 735–
1092) hospitalisations annually. Children aged 6−23 months accounted
for 61% of all conﬁrmed rotavirus cases. Rotavirus hospitalisations
demonstrated distinct spring seasonality. No rotavirus-associated deaths
were reported during sentinel surveillance or in the hospital registry data.
Conclusions: Estimated two thirds of all gastroenteritis hospitalisations
in children <5 years of age in Norway are attributable to rotavirus.
This report provides the ﬁrst data on rotavirus epidemiology and disease
burden in Norway. Further studies are needed to assess the economic
impact of rotavirus disease and the cost-effectiveness of vaccination to
inform decisions on introduction of rotavirus vaccines into the national
program of childhood immunisation.
Pseudomonas aeruginosa and its relatives
S473 Dynamics of antibiotic resistance and virulence in
Pseudomonas aeruginosa
T. Ko¨hler ° (Geneva, CH)
Pseudomonas aeruginosa may colonise the lungs of cystic ﬁbrosis
patients over years but may also cause acute infections in mechanically
ventilated patients and immuno-compromised hosts within a matter
of days. Despite aggressive antibiotic treatments the organism is
rarely eradicated. Instead P. aeruginosa adapts to its host environment
by developing resistance mechanisms and changing its lifestyle and
virulence properties. Focusing on mechanically ventilated patients, we
will detail the dynamics of resistance emergence and persistence of
P. aeruginosa lung populations during antibiotic therapy. We further
discuss how P. aeruginosa populations evolve naturally in the absence
of any antimicrobial treatment within the lungs of intubated patients by
changing their virulence properties. The relevance of these ﬁndings both
with respect to concepts of social evolution and the development of novel
anti-infective strategies will be highlighted.
S474 Drug efﬂux in intrinsic and acquired resistance in
P. aeruginosa
C. Llanes, K. Jeannot, D. Hocquet, L. Vettoretti, P. Ple´siat ° (Besanc¸on,
FR)
The genome of P. aeruginosa encodes many potential efﬂux systems.
However, only a few of them appear to play a signiﬁcant role in antibiotic
resistance. In this respect, the Mex (for Multiple efﬂux) systems are of
particular interest because of their ability to extrude a wide range of
antimicrobials. These polyspeciﬁc machineries result from the assembly
of (i) a drug/proton antiporter, (ii) a periplasmic adaptor protein, and
(iii) an outer membrane gated channel. It is now well established that
the constitutive expression of the tripartite pump MexAB-OprM provides
P. aeruginosa with a relatively high intrinsic resistance to quinolones, b-
lactams (except imipenem), tetracyclines, macrolides, chloramphenicol,
trimethoprim, and novobiocin. This protective mechanism is potentiated
by the poor permeability of the outer membrane and activity of
another pump, MexXY/OprM, whose expression is induced by substrates
targeting the ribosome (e.g., tetracyclines, macrolides, aminoglycosides).
Accumulating reports indicate that multidrug resistant mutants up-
regulating one or both of these systems are quite common in the
clinical setting. Such mutants, which are readily selected by sub-optimal
treatments with ﬂuoroquinolones, b-lactams or aminoglycosides, tend
to accumulate various resistance mechanisms without loosing the wild-
type pathogenicity of P. aeruginosa. Whether the low resistance levels
(MIC x 2- to 8-fold) conferred by efﬂux may promote second-step
mutants with altered drug targets (GyrA, GyrB, ParC) or derepressed
AmpC b-lactamase has not been conﬁrmed in vitro. In the speciﬁc
context of cystic ﬁbrosis (CF), a recent study from our laboratory
showed that the MexXY/OprM pump can be responsible for much higher
resistance levels to aminoglycosides (64- to 128-fold). This increased
efﬁcacy of the system partially results from adaptive mutations in the
mexY gene. In contrast, subpopulations deﬁcient in MexAB-OprM tend
to emerge during long-term colonisation of CF airways. While easily
selected in vitro on selective media, mutants overexpressing other Mex
systems (MexCD-OprJ, MexEF-OprN, MexGHI-OpmD, MexJK/OprM,
MexVW/OprM) have been rarely described in CF and non-CF patients.
Some data support the notion that up-regulation of MexCD-OprJ or
MexEF-OprN might be detrimental to the virulence of P. aeruginosa. In
conclusion, therapeutic strategies based on efﬂux inhibitors should target
the MexAB-OprM and the MexXY/OprM systems in priority.
European aspects of malaria
S478 Rapid diagnostic tests for malaria: twenty years to
convince . . .
B. Genton ° (Lausanne, CH)
Prompt diagnosis and treatment of malaria are critical factors in reducing
morbidity and mortality. Microscopy has long been the gold standard
for malaria diagnosis, but the newer rapid diagnostic tests (RDTs) now
offer considerable advantages, especially so in endemic countries. After
close to twenty years of development and operational research, the
diagnostic performance of RDTs is now established in all settings.
Meta-analyses have clearly demonstrated equivalence of RDTs over
expert microscopy to detect parasites, and clear superiority over routine
microscopy. Actually, one of the major reasons that have delayed
successful implementation of RDT in endemic areas was the use of poor
quality microscopy that has impeded reliable measurement of sensitivity
and speciﬁcity and undermined conﬁdence of health workers in RDTs.
Other factors were poor product performance, inadequate methods to
determine the quality of products and a lack of emphasis and capacity
to deal with these issues. For the potential of RDTs to be realised, it
is crucial that high-quality products that perform reliably and accurately
under ﬁeld conditions are made available and that quality insurance is
performed on all steps of the procedure. In achieving this goal, the
shift from symptom-based diagnosis to parasite-based management of
malaria can bring signiﬁcant improvement for the management of fever
in endemic areas.
For travelers returning in temperate climates with fever, RDTs have
also the potential to improve diagnostic procedures, especially so in
hospitals where reliable microscopy is not available out of hours. In
patients with no danger sign or signiﬁcant thrombopenia, a negative
RDT is sufﬁcient to exclude malaria and allows waiting 12−24 hours for
performing or reading the microscopy slide. RDTs should be repeated
every 12−24 hours for three consecutive days if fever persists and in the
absence of alternative diagnosis.
RDTs represent a revolution in the ﬁght against malaria and will
tremendously help to manage appropriately patients with fever, especially
so when malaria is declining and hence other causes of fever increasing.
The ambitious deployment that is foreseen in the coming years in Africa
through large grants from the Global Fund should contribute to achieving
the millennium goals.
S479 Clinical aspects of imported malaria
C. Hatz ° (Basel, CH)
Fever is the key symptom of malaria among returning travellers (97%).
Headache, chills, myalgia, sweating and lack of a focus are frequently
recorded, but non-speciﬁc. Nausea and vomiting are often seen in
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children. The differential diagnosis of other infections, mainly of viral
origin, is further difﬁcult because (dry) cough and (mild) diarrhoea are
often present. Laboratory ﬁndings (thrombocytopenia, low or normal
leucocyte count) can be helpful in the assessment of mild to moderate
malaria.
Clinical signs and symptoms, e.g. fever, may be mitigated in semi-
immune patients (visiting friends and relatives, foreign visitors) seen in
non-endemic countries who represent the majority of cases diagnosed in
industrialised countries. Caution is warranted in assessing such patients
as many of them may no longer be exposed to malaria in their countries
of origin, thus no longer partially protected and also at risk of suffering
from severe complications.
Up to 10% of all imported malaria cases may be severe, presenting with
jaundice, impaired consciousness to coma, acute renal failure, and, in
the course of events, acute respiratory failure. Delay in diagnosis and
start of treatment is partly responsible for fatality rates of 1% and more
in some countries.
If you don’t look for them, you won’t ﬁnd
them: anaerobes revisited
S481 Anaerobic microbiota of the mouth − friend or foe?
E. Ko¨no¨nen ° (Turku, FI)
Anaerobes form a major part of the commensal microbiota in the
digestive tract where they constitute an integral component of the
function on mucosal surfaces. In the mouth, teeth create a unique,
non-shedding environment for bacteria to attach and to form bioﬁlms.
There is an age-related succession order of species in bacterial
colonisation of the mouth, and once established, individual anaerobic
species tend to remain as members of the oral microbiota. The age-
related pattern of the colonisation of anaerobic bacteria is partly
connected with the development (or loss) of the dentition. Interactions
between different bacteria residing in the same microenvironment
inﬂuence the composition of the microbiota − or the development
of pathologic conditions. Although commensal bacteria are regarded
beneﬁcial to the host, some anaerobic members of the oral microbiota
contain characteristics potentially detrimental for the health status of
an individual. Molecular means of characterisation have resulted in
increased knowledge about the “normal” microbiota of the mouth and
in detection of new species and genera as well as phylotypes, which can
be associated with infectious situations in the mouth. Oral infections are
multifactorial and polymicrobial in nature, and their aetiologic organisms
originate mainly from the oral resident microbiota. The involvement
of anaerobes is most obvious in infections of root canals, periodontal
tissues, and tissues surrounding erupting wisdom teeth where typical
anaerobic ﬁndings are Gram-negative rods. In addition, Gram-positive
anaerobic cocci and non-spore-forming Gram-positive anaerobic rods
are common in odontogenic infections. On some occasions, anaerobes
of localised dentoalveolar infections can spread to adjacent tissues and
even to the bloodstream, resulting in severe complications in extraoral
sites. Interestingly, a relatively limited number of anaerobic species
are involved in clinically severe infections, however, microbial ﬁndings
seem to vary depending on geography. Concomitant with the increase in
the number of immunosuppressed patients, the number of opportunistic
infections caused by commensal anaerobes may increase. Identiﬁcation
to the species level will help to establish associations between individual
anaerobic species and speciﬁc disease states.
S482 The hidden villains in severe diabetic foot infections
D.M. Citron ° (Culver City, US)
Studies on the bacteriology of diabetic foot infections (DFI) have
yielded varied and often contradictory results. The role of anaerobes
is particularly unclear, often because the type and severity of the
infection is poorly deﬁned, recent antibiotic therapy is unknown, and
specimen collection and culture techniques are inadequate. When optimal
collection, transport, and culture techniques are used, multiple organisms
including aerobes and anaerobes are usually recovered from severe
DFI. Interactions within these polymicrobial soups lead to production
of virulence factors, such as haemolysins, proteases, collagenases, and
short chain fatty acids, which promote inﬂammation, impede healing
and contribute to the chronicity of the infection. To better deﬁne the
bacteriology of diabetic foot infections, we analyzed our data from a
large prospective U.S. multicentre trial of patients with moderate to
severe infection that required initial parenteral antibiotic therapy and
used optimal post-debridement sample collection, transport and culture
procedures. Of the 427 culture-positive specimens (of 454 total), only
16.2% were pure cultures while 30.4% yielded 5 or more organisms.
A total of 462 anaerobes (range 0−9, average 2.3, per specimen)
were recovered from 49% of patients, with Gram-positive cocci (GPC)
accounting for 45.5% of all anaerobic strains. Finegoldia magna was
the predominant species, recovered from 24.4% of patients (99/406)
with Prevotella spp. the second most common (12.3% of patients),
followed closely by Porphyromonas spp. (10.3%) and the Bacteroides
fragilis group (10.2%). B. fragilis was the predominant species (40.4%,
19 of 47) within the group. A greater proportion of anaerobes were
cultured from tissue than from ‘deep swab’ specimens (5.5 vs. 2.1),
especially for Porphyromonas spp. (70% vs. 23%), and Prevotella spp.
(72% vs. 23%). GPC and B. fragilis group species appeared more evenly
distributed among the 4 specimen types. GPC were present in 37.4% of
patients, but are often under-reported in studies, possibly because of the
selective media used. LKV agar grows B. fragilis group and Prevotella
spp, but not Gram-positive anaerobes or Porphyromonas spp., which
could explain why many studies ﬁnd the B. fragilis group to be the
predominant anaerobe. Clostridia were present in 4.9% of our patients. If
you look closely, the hidden villains are lurking just beneath the inﬂamed
surface and are not so difﬁcult to ﬁnd.
Shifting from cultures to direct detection of
bacterial components
S485 Is culture still the gold standard, really?
M. Struelens ° (Brussels, BE)
Tremendous technological advances are made in culture-independent
methods of detection and identiﬁcation of human bacterial pathogens,
such as PCR or hybridisation of their genomic DNA. Yet, time honoured
Pastorian bacterial culture in liquid and solid nutritive media still remains
the gold standard for the laboratory diagnosis of a majority of bacterial
infections. This unusual robustness of a 19th century technology stems
from its unmatched operational characteristics:
1. broad range of detected agents, depending on adequate combination
of media/incubation conditions;
2. unlimited source of clonal population for individual isolate, allowing
versatile characterisation of antibiotic susceptibility and/or pathogenic
factor production and/or epidemiological subtyping;
3. possibility of storage/bio-banking of cells for complementary clinical
testing, research and diseases surveillance collections;
4. proof of pathogenic role of agent at the time of viable cell isolation
from the site of infection, in contrast to false-positive results with
molecular tests (tissue translocation or persistence of bacterial DNA,
soluble antigen,. . . ).
Major drawbacks of bacteriological culture include long turn-around
time, cost and labour/skill intensity. These are partly alleviated by new
technologies, including automated processing, physical/chemical growth
detection and rapid molecular ﬁngerprinting (MALDI-TOF, Raman
spectrometry, 16S rDNA SNP detection). It is likely that the next
decade will see a complete redeﬁnition of the place of direct detection
methods and culture-based conﬁrmation methods in clinical bacteriology,
enabling a rejuvenation rather than elimination of culture as a daily
diagnostic tool.
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S486 Detection of nucleic acids, is there a future after PCR?
J. Schrenzel ° (Geneva, CH)
The advent of real-time PCR revealed instrumental to the successful
implementation of molecular methods in routine clinical microbiology
laboratories. Automated nucleic extraction platforms can now be coupled
to robotic handling for large-scale detection and quantiﬁcation purposes,
mostly in virology. I will review here the attempts of implementing
home-brew and commercial nucleic-acid based detection methods
directly from blood samples and highlight hopes and pitfalls. I will
then expand on two promising nucleic acid ampliﬁcation methods:
LAMP (loop mediated isothermal ampliﬁcation) and a protein-free
method called DNAzyme. These isothermal ampliﬁcation methods share
several strengths: robustness across highly diversiﬁed physico-chemical
conditions, versatility in assay development and minimal requirements
(if any) for sample preparation. They will deﬁnitely compete against
current real-time PCR assays and might become a novel standard, due
to lower costs and improved performances.
S487 Single-cell identiﬁcation by improved ﬂuorescence in situ
hybridisation techniques
R.I. Amann °, B.M. Fuchs (Bremen, DE)
The ribosomal RNA (rRNA) approach to microbial evolution and
ecology has become an integral part of microbiology. Rapidly growing
databases exist that encompass besides the 16S rRNA sequences of
almost all validly described Bacteria and Archaea also numerous 16S
rRNA sequences of so far uncultivated microbes, directly retrieved
from the environment by PCR or metagenomics. Based on the patchy
evolutionary conservation of rRNA genes oligonucleotide probes can be
designed in a directed way with speciﬁcities ranging from species up to
large evolutionary entities like phyla or even domains.
When such probes are labeled with ﬂuorescent dyes or the enzyme
horseradish peroxidase they can be used to identify single microbial
cells by ﬂuorescence in situ hybridisation (FISH) directly in complex
environmental samples. An update on recent applications and method-
ological improvements will be given which includes the identiﬁcation
of small bacterial cells by catalyzed reporter deposition (CARD)-FISH.
With optimised methods and proper controls FISH yields exact cell
numbers and spatial distributions for deﬁned bacterial populations also
in highly complex mixed microbial communities.
Reference(s)
R. Amann & B.M. Fuchs (2008) Nature Reviews Microbiology 6:339–
348.
S488 Protein pattern matching − identiﬁcation of microorganisms
using matrix-assisted laser desorption/ionisation time-of-ﬂight
(MALDI-TOF) mass spectrometry
A. Mellmann ° (Mu¨nster, DE)
Quick and reliable species identiﬁcation of microorganisms is of great
importance in medical microbiology. Several bacterial and fungal species
can be identiﬁed only using laborious and time-consuming methods.
Furthermore, in many cases misidentiﬁcation occurs due to e.g. limited
biochemical reactivity, different morphotypes or limited information in
reference panels. In this talk, matrix-assisted laser desorption/ionisation
time-of-ﬂight (MALDI-TOF) mass spectrometry will be presented as
a method for species identiﬁcation. This technology applies protein
pattern matching based on mass spectrometry. During the identiﬁcation
process, a mass pattern is generated for each organism. The subsequent
comparison of this pattern with a database comprising reference
patterns derived from well-characterised reference strains leads to species
identiﬁcation. As examples, the identiﬁcation of various nonfermenting
bacterial strains isolated from clinical specimens in comparison to
partial 16S rDNA sequencing will be shown. Moreover, speed, accuracy
in comparison to other methods, and inter- and intra-laboratory
reproducibility of MALDI-TOF MS-based species identiﬁcation will be
discussed.
Streptococci: mechanisms of resistance and
epidemiology
O489 Trends in invasive Streptococcus pneumoniae serogroup 1
sequence types in Belgium
T. Goegebuer, K. Van Pelt, J. Verhaegen, J. Van Eldere ° (Leuven, BE)
Objectives: S. pneumoniae serogroup 1 (SG1) isolates frequently cause
invasive pneumococcal disease, particularly in children. From 2003
onwards a marked increase in SG1 isolates was observed; overall
prevalence increased from 8.2% (1998–2002) to 13.6% (2003–2006).
We determined the sequence types (ST) in SG1 isolates in order to
better understand trends in SG1 resistance and spread.
Methods: As national reference centre, we receive all invasive isolates
from more than 100 of 182 laboratories in Belgium. 124 randomly
chosen SG1 isolates from all ages from 1998 to 2006 were analysed
via multi-locus sequence typing (MLST) as described by Enright &
Spratt (Microbiol. 1998; 144: 3049−60). We also included data on strain
characteristics and patient characteristics.
Results: 10 different sequence types (ST) were identiﬁed: ST350
(n = 66), ST306 (n = 24), ST304 (n = 13), ST227 (n = 10), ST228 (n = 5),
ST2915 (n = 2), ST305 (n = 2), ST612 (n = 1), and ST217 (n = 1). All ST
are known to circulate in Europe, US and Canada, but not in South-
America or Asia. During 1998–2002 the predominant ST’s were ST350
(46%), ST227 (17%) and ST304 (15%). For 2003–2006, ST350 (59%)
and ST306 (33%) were most prevalent.
The prevalence of ST350 has stabilised around 60% of SG1 isolates
since 2000. It was observed in all Belgian provinces, but it was
signiﬁcantly more prevalent in the Northern part of Belgium. Only
22% of ST350 strains were susceptible to macrolides, tetracycline and
b-lactams. Resistance to macrolide and/or tetracycline increased from
33% in 2000 to 86% in 2006. This increase was almost entirely due to
multi-drug resistance (macrolides plus tetracycline).
ST306 is known to be highly invasive and was not present in Belgium
before 2001, but increased to 30% of SG1 isolates in 2006. All ST306
isolates have remained drug-susceptible.
ST227 is the most common ST in England, the US and Canada and was
present during the period 1998–2002, but wasn’t observed after 2003.
Conclusion: The increase in SG1 invasive S. pneumoniae in the period
1998–2006 was predominantly linked to the increase in ST350 and
ST306. While ST350 was already present in 1998, ST306 emerged only
recently. Resistance development was very prominent in ST350 but was
not yet observed in ST306.
O490 Clonal diversity of penicillin non-susceptible Streptococcus
pneumoniae isolates in Moscow, Russia
T. Savinova, E. Ilina, A. Borovskaya, S. Sidorenko ° (Moscow, RU)
Objectives: Russia is in a favourable position regarding prevalence of
penicillin-resistance among Streptococcus pneumoniae, not more than
15−20% of isolates demonstrated reduced susceptibility during last
10 years. Since epidemiological studies of pneumococcal resistance have
revealed the worldwide dissemination of epidemic clones, the aim of the
present study was to evaluate genetic heterogeneity of Russian isolates.
Methods: Thirty nine penicillin non-susceptible isolates of S. pneumo-
niae collected in 2005 − 2007 during nationwide survey were included
in the study. Multilocus sequence typing (MLST) was performed as
described by Enright, M. C., et al. The sequence types (STs) were
obtained by using the MLST database (http://www.mlst.net). Clonal
relationships in the strain collection were visualised using eBURST
(http://eburst.mlst.net). Groups of isolates sharing six of seven alleles
were assigned to clonal complexes (CCs).
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Results: A total 17 different ST and 16 different CC were detected. Only
ﬁve CC were represented by multiple isolates. CC81 was predominant
and represented by 12 isolates (30.8%), all of them were ST81. These
isolates demonstrated similar multidrug resistance phenotypes; besides
non-susceptibility to penicillin all of them were resistant to macrolides,
tetracycline and chloramphenicol, six isolates were also resistant to
levoﬂoxacin. Four isolates belongs to CC271 (three ST236 and one
ST651) and demonstrated different resistance phenotypes. Three isolates
belongs to CC315 (all ST315) and demonstrated resistance to macrolides
and chloramphenicol. Each of CC280 (all ST239) and CC414 (all
ST1500) were represented by two isolates and were susceptible to all
antibiotics except penicillin. 16 different ST (ﬁve of them new) were
represented by a single isolate
Conclusion: Penicillin non-susceptible S. pneumoniae in Russia are
represented by multidrug resistant CC81 isolates related to international
Spain23F-1 clone and heterogeneous group of isolates of different CC
with low level of associated resistance to other antimicrobials.
O491 Macrolide resistance of invasive Streptococcus pneumoniae
in Slovenia, 1998 – 2007
T. Kastrin °, M. Paragi, J. Kolman, M. Cizman, M. Bezensˇek,
M. Culaﬁc, V. Mioc (Ljubljana, SI)
Objectives: The surveillance of invasive pneumococcal diseases is a part
of slovene National Public Health program since 1993. In the present
study we investigated the genetic basis of macrolide resistance.
Methods: Isolates of Streptococcus pneumoniae (SP), isolated from
sterile body sites were nationally collected. All isolates were typed with
capsular swelling reaction. Antibiotic susceptibility was determined by
disc diffusion test and E-test following the CLSI recommendations. The
presence of erm(B), mef(E), mef(A) and erm(TR) genes were determined
by PCR. Clonality of the selected isolates was studied by PFGE of SmaI-
digested bacterial DNA.
Results: A total of 1448 invasive isolates of SP were collected in
Slovenia from 1998 to 2007. Of these, 156 isolates (10.8%) were resistant
to erithromycin. We observed a rise of macrolide resistance in invasive
S. pneumoniae from 4.7% in 1998 to 16.8% in 2007. The most prevalent
determinant of macrolide resistance in the observed period was the
erm(B) gene (55%), followed by the mef(E) (27%) and mef(A) gene
(12%). The erm(TR) gene was not found. The most prevalent serotypes
among macrolide resistant isolates were 14 (35%), 6B (18%), 19F (9%),
9V (9%), 19A (8%) and 6A (4%). Multiple antimicrobial resistance
was demonstrated in 53.8% of macrolide-resistant clinical isolates. The
strains carrying the erm(B) gene were multiple resistant in 72.1% of
cases, whereas the strains with the mef(E) gene were associated with
multiple resistance in 52.3% of cases. Strains with mef(A) gene were
susceptible to all other antibiotics. During the observed period the
number of isolates with erm(B) gene was constantly increasing, on the
other hand the number of isolates with mef(E) gene was constant for
the last four years. The ﬁrst isolate with mef(A) was demonstrated
in 2002 and in 2007 they were more common than isolates with
mef(E) gene. We demonstrated that all except two isolates with mef(A)
gene were genetically closely related and belonged to international
clone England14−9. In conclusion, the main reason for the increase of
serotype 14, mef(A) positive isolates was the spread of the England14−9
clonal cluster.
Conclusions: Due to the increase of the incidence and resistance
of pneumococcal isolates the epidemiological surveillance, sero- and
molecular typing of invasive pneumococci is an important issue of Public
Health institutions.
O492 Resistance among invasive Streptococcus pyogenes in France,
2006–2008
A. Ergani °, A. Doloy, C. Plainvert, G. Collobert, C. Poyart, A. Bouvet
(Paris, FR)
Objectives: To investigate the MLSB and tetracycline resistance and
the emm gene distribution among the invasive Streptococcus pyogenes
(GAS) strains.
Methods: Between January 2006 and December 2008, a total of
991 strains responsible for invasive infections for adult patients were
sent to the French National Reference Center for Streptococci to be
studied. Antibiotic susceptibility testing was done by disk diffusion
method according to the CA-SFM guidelines. MICs were determined
by E-test method. Streptococcal emm sequence was done according to
the CDC protocol. Detection of macrolide and tetracycline resistance
genes: erm(B), erm(TR), mef(A), tet(M), tet(O), tet(K), and tet(L) was
performed by PCR.
Results: Among the 991 Streptococcus pyogenes invasive strains; more
than ten different emm-types were identiﬁed. The most frequent emm
sequence types were emm1, emm28 and emm89. A total of 80 strains
(8%) were resistant to erythromycin. Erythromycin resistance prevalence
had decreased during the three years period (12.2%-2006, 7.6%-2007,
5.5%-2008). 69 had an MLSB constitutive (65 strains) or inducible (4
strains) phenotype due to erm(B) or erm(TR) resistance gene. 11 with the
M phenotype and mef(A) gene were susceptible to clindamycin. Among
the 132 (13.3%) tetracycline resistant isolates tet(M), tet(O) and tet(L)
genes were detected in 86, 27 and 19 strains, respectively. Tetracycline
resistance prevalence had also decreased during the three years period
(16.8%-2006, 14%-2007, 8.7%-2008).
Conclusion: Most of the invasive French GAS isolates remained
erythromycin and tetracycline susceptiple during three years. Nontheless,
the resistance rates have had the tendency to decrease slightly. Taking
into account the resistance trends helps to guide the therapy for
penicillin-allergic patients.
O493 Molecular characterisation of macrolide resistance in Strep-
tococcus dysgalactiae subsp. equisimilis isolates from Portugal
M.D. Pinho °, J. Melo-Cristino, M. Ramirez on behalf of the Portuguese
Group for the Study of Streptococcal Infections
Objectives: During a survey on antimicrobial susceptibility in beta-
haemolytic group C and G streptococci (GCGS) from Portugal, a
macrolide resistance rate higher than previously reported in other
European countries was found (22%) among S. dysgalactiae subsp.
equisimilis isolates. To gain further insights into the resistance mech-
anisms involved and the clonal structure of the resistant population, we
undertook the phenotypic and molecular characterisation of macrolide
resistant S. dysgalactiae subsp. equisimilis isolates and compared it with
the susceptible population.
Methods: Antimicrobial susceptibility testing and macrolide resistance
phenotype were determined by disk diffusion. All the macrolide-
resistant isolates were further characterised by MIC testing and genotype
determination by PCR. A combination of emm typing and pulsed-ﬁeld
gel electrophoresis (PFGE) was used to type the population and the
Simpson’s index of diversity (SID) with 95% conﬁdence intervals was
calculated as previously described.
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Results: A total of 69 isolates were resistant to erythromycin (MIC
range, 4 to >256 ug/ml). The vast majority of isolates presented a MLSB
phenotype (n = 64) and carried the erm(A) gene (n = 55), while the mef-
encoded M-phenotype was expressed by only 5 isolates. Among resistant
isolates, 13 distinct emm types were found distributed by 10 PFGE
clusters that overlapped with the main clusters detected in the susceptible
population. The emm types stG480, stG6, stG485 and stG2078 accounted
for approximately two thirds of the resistant isolates. PFGE did not
always separate neither macrolide-resistant from susceptible isolates nor
erm(B) and mef(A) from the prevailing erm(A) isolates. The SIDs of
emm and PFGE calculated for resistant isolates were not statistical
different from the overall population. The two most prominent MLS
resistant lineages were one with stG480/erm(A) isolates (n = 8) and
stG485/mef(A) (n = 3), and another including stG2078/erm(A) (n = 8).
Conclusion: Although most of the resistant isolates presented a MLSB
phenotype and carried an erm(A) gene, molecular typing revealed
extensive diversity in both emm types and PFGE clones. Macrolide
resistance had a polyclonal origin, with resistance emerging among
most susceptible clones. Monitoring of macrolide resistance patterns
in S. dysgalactiae subsp. equisimilis is essential as this pathogen is
increasingly recognised as an important human pathogen.
O494 Penicillin resistance caused by dissemination of serotype
14 – clone Spain9V ST156 in the vaccine era
A.S. Simo˜es °, R. Sa´-Lea˜o, S. Nunes, N. Fraza˜o, A. Tavares, H. de
Lencastre (Oeiras, PT)
While performing pneumococcal nasopharyngeal colonisation surveil-
lance studies among children attending day care centres (DCC) in
Portugal, we observed that the rate of strains with penicillin MIC 
2 ug/mL more than tripled from 1.8% in 2006 to 6% in 2007 (p = 0.002).
The aim of this study was to characterise the 20 isolates recovered in
2007 which had a MIC to penicillin  2 ug/mL.
Methods: Pneumococci were isolated and identiﬁed on the basis of
selective growth on gentamycin blood agar plates, optochin susceptibility,
colony morphology, and alfa-haemolysis. Susceptibility to antimicrobials
agents was performed according to the CLSI recommendations and
deﬁnitions. Strains were serotyped by the Quellung reaction and/or
multiplex PCR using speciﬁc primers for each serotype. Pulsed-Field Gel
Electrophoresis (PFGE), after restriction of the total DNA with SmaI,
was performed to compare genetic backgrounds.
Results: Sixteen of the 20 isolates belonged to serotype 14, three were
serotype 19A and one was of serotype 15A. Strains of serotype 14
were also resistant to sulfamethoxazole-trimethoprim and belonged to
a single PFGE cluster identiﬁed as clone Spain9V ST156. The penicillin
resistant serotype 14 strains were isolated in two DCC, from nine
children vaccinated with the 7-valent pneumococcal conjugate vaccine
(PCV7), four non-vaccinated children and three children with unknown
vaccination status. Five of these carriers had received antibiotics recently.
In these two DCC the overall proportion of children vaccinated with
PCV7 was 64%; 27% of the children had received antibiotics within
the previous month and 16% had received three or more courses of
antibiotics in the last six months.
Conclusions: Since the introduction of the PCV7 in Portugal, in June
2001, the proportion of penicillin resistant pneumococci recovered from
colonisation has been stable (c.a. 2%). The sudden increase in the levels
of penicillin resistance observed in the 2007 surveillance study was
found to be largely due to the dissemination of clone Spain9V ST156
serotype 14 variant in two DCC with high consumption of antibiotics.
The observations suggest a combination of high antibiotic selective
pressure and transmission rates resulting in an outbreak-like situation
with a penicillin resistant vaccine type clone being disseminated among
children in day care despite use of PCV7.
O495 Inducibility of PatA/PatB efﬂux pumps by ﬂuoroquinolones
in Streptococcus pneumoniae
F. El Garch, A. Lismond, F. Van Bambeke °, P.M. Tulkens (Brussels, BE)
Background: Beside target mutation, active efﬂux is another common
resistance mechanism to ﬂuoroquinolones (FQ) in S. pneumoniae. Two
main efﬂux systems have been described so far, namely PmrA (member
of the MFS superfamily) and the two ABC transporters PatA/PatB. We
have studied the inducibility of pmrA, patA and patB genes expression
when bacteria are exposed to subinhibitory concentrations of FQ.
Methods: We used a wild-type sensitive strain (ATCC49619), two
clinical strains resistant to FQ (SP13 and SP295), and two efﬂux mutants
(SP334 and SP335; selected in vitro after exposure to ciproﬂoxacin [JAC
2007, 60:965–972]). MIC were determined according to CLSI. Induction
was obtained by growing bacteria in Todd-Hewitt broth added by half
the MIC of each FQ (CIP, NOR, LVX, MXF, GMF) for 4 h at 37ºC in
5% CO2 atmosphere. Expression levels of pmrA, patA and patB genes
were determined by real-time PCR. Reversibility of induction was tested
by re-cultivating bacteria for 4 h in drug-free medium.
Results: Antimicrobial susceptibilities for CIP and MXF and gene
expression at basal level and after exposure to these FQ are shown in
the Table. At the basal level, the 4 resistant strains harboured efﬂux
mechanisms (MIC of NOR [not shown] and CIP reduced of at least 2
dilutions by reserpine) that did not affect MXF, LVX and GMF. PmrA
gene was not or only modestly overexpressed in all strains, with no
overexpression after induction. In contrast, PatA/B genes were markedly
overexpressed in the 4 resistant strains and were further induced to higher
levels after exposure to CIP or MXF. Similar results were obtained with
LVX, NOR and GMF [not shown]. Induction was however reversible
upon drug removal.
Conclusion: The ABC efﬂux system PatA/PatB is reversibly induced
upon exposure of S. pneumoniae to sub-MIC concentrations of FQ,
whether good substrates (CIP, NOR) or not (MXF, LVX, GMF). This
effect is particularly marked in strains showing a high basal expression
level, suggesting it contributes to resistance.
Strains and MIC (mg/L)a Inducer Gene expression levelsb,c
antibiotics pmrA patA patB
ATCC 49619 Basal 1 1 1
CIP: 1/0.5 + CIP 1.24±0.03 3.46±0.02 3.14±0.01
MXF: 0.25/0.25 + MXF 1.03±0.01 3.05±0.03 3.07±0.32
SP13 Basal 1.90±0.16 12.66±0.24 11.98±0.58
CIP: 16/2 + CIP 1.65±0.02 22.11±0.32 20.51±2.81
MXF: 0.25/0.25 + MXF 1.52±0.03 20.74±3.54 22.4±3.06
SP295 Basal 1.24±0.05 4.90±1.11 4.83±0.65
CIP: 2/0.5 + CIP 1.16±0.07 25.78±2.71 13.86±4.18
MXF: 0.125/0.125 + MXF 1.10±0.03 27.03±0.67 19.21±1.50
SP334 Basal 0.84±0.06 3.54±0.16 4.40±0.17
CIP: 4/1 + CIP 1.25±0.01 14.47±1.22 13.82±0.93
MXF: 0.5/0.5 + MXF 1.14±0.04 10.56±0.43 10.97±0.57
SP335 Basal 2.33±0.31 10.71±1.75 7.44±0.71
CIP: 32/2 + CIP 1.95±0.05 113.80±48.8 97.94±9.35
MXF: 0.5/0.25 + MXF 2.56±0.03 145.88±1.75 81.62±6.57
aMIC determined without/with the efﬂux pump inhibitor reserpine (10mg/L);
bexpressed as the ratio to the basal expression level measured in ATCC 49619;
cgene expression level in boldface indicates an increase compared to the basal
level without inducers.
O496 Efﬂux increases QRDR (quinolone resistance determining
region) mutation frequency in ﬂuoroquinolone-susceptible
pneumococci
N. Mihaylov, C.B. Duesberg °, D. Rudolf, T. Fuehner, T. Welte,
M.W. Pletz (Hanover, DE)
Objectives: Resistance to ﬂuoroquinolones requires sequential mutations
in both target enzymes DNA gyrase and topoisomerase IV. Single
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mutations usually increase the MIC slightly, but enhance the probability
of further mutations. Efﬂux pumps like PmrA reduce antibiotic
concentrations in the bacterial cell, enabling longer survival. We
hypothesised that efﬂux positive bacteria are more likely to develop
resistance than efﬂux negative bacteria.
The following questions were addressed:
1. Do the efﬂux pump inhibitors reserpine and verapamil reduce the
mutation frequency?
2. Do ﬂuoroquinolone-susceptible efﬂux positive pneumococci exhibit
higher parC or gyrA QRDR mutation frequencies than efﬂux negative
isolates?
3. Does efﬂux phenotype impose a ﬁtness cost?
Methods: Matched efﬂux positive and negative pneumococcal isolates
with identical or similar genotype according to multi-locus sequence
typing collected by the German community acquired pneumonia network
CAPNETZ were analysed (n = 17). Strains TIGR4 and R6 were included
as efﬂux negative controls.
Ciproﬂoxacin (CIP) MICs and efﬂux phenotype were measured by agar
dilution method, for efﬂux detection reserpine (10mg/l) was added and
a fourfold decrease in MIC was considered as efﬂux positive.
Mutation frequencies were determined by plating bacterial suspensions
onto agar with and without CIP. After incubation colonies were counted
and the ratio of CFU/ml yielded the mutation frequency. Equally, the
mutation frequency was determined adding different concentrations of
verapamil (10, 25, 50, 100, 500mg/l) or reserpine (0.01, 0.1, 1, 5,
10mg/l).
Biological ﬁtness was calculated as the maximum slope of growth curves
recorded in a microtitre plate reader.
Results: 1) Even at low concentrations, reserpine clearly reduced the
mutation frequency of efﬂux positive and, to a lesser extent, efﬂux
negative pneumococci when exposed to CIP (ﬁgure 1); verapamil
exhibited this effect merely at high concentrations. 2) Efﬂux positive
isolates produced more frequently mutants (8/9) than efﬂux negative
isolates (2/10) (p = 0.005, Fisher’s exact test). 3) Efﬂux phenotype had
no measurable impact on the biological ﬁtness.
Conclusion: A positive efﬂux phenotype increases the QRDR mutation
frequencies in the presence of ﬂuoroquinolones and this effect can be
inhibited by very low concentrations of reserpine. As a matter of concern,
efﬂux is not associated with decreased biological ﬁtness.
Figure 1. Effect of reserpine on the mutation frequency of pneumococcal
isolates with identical MLST sequence type.
O497 Lack of emergence of ﬂuoroquinolone resistance and gyrA
mutatios in S. pneumoniae despite increased ﬂuoroquinolone
use
R. Melano, S.N. Patel, A. McGeer °, K.A. Green, D.R. Pillai,
S.M. Poutanen, D. Low on behalf of the Canadian Bacterial
Surveillance Network (CBSN)
Background: Use of ﬂuoroquinolone (FQ) has been associated with
increasing FQ resistance in S. pneumoniae. Because respiratory FQs
(levoﬂoxacin (Levo) and moxiﬂoxacin (Moxi)) are ﬁrst line therapy for
serious respiratory infections, increasing FQ resistance (FQR) in SP is
a concern. Levo targets parC, and Moxi targets gyrA, which may permit
differentiation of degree of selective pressure. We examined FQ use, and
changes in the prevalence of FQR and QRDR mutations in Canadian
isolates of SP.
Methods: CBSN is a Canadian collaborative network of microbiology
laboratories that has performed surveillance for antibiotic resistance in
SP since 1988. Antimicrobial resistance is performed in a central lab to
CLSI standards. We sequenced QRDR regions of all FQR isolates and
a stratiﬁed sample of FQ susceptible isolates. Population FQ use was
obtained from IMS Canada.
Results: From 1995 to 2007, FQ use increased from 53 to 97 Rx/
1000pop/yr; Levo use from 0 to 10 Rx/1000pop/yr, and Moxi use from
0 to 17 Rx/1000pop/yr. 31081 isolates were available for testing. Levo
R rates increased from 0 in 1993 to 1.8% in 2002 then remained stable
until 2008 (1.6% in 2008). Moxi R rates increased to 0.6% in 2004, then
stabilised (0.7% in 2008). The prevalence of parC only mutations has not
increased signiﬁcantly in the last decade (see Table). The prevalence of
isolates with both parC and gyrA mutations increased until 2002, but has
decreased in 2008. The ﬁrst gyrA only mutant was detected in 2000; the
prevalence of gyrA only mutants since then has increased, but remains
very low (7/2044, 0.34% in 2007).
Conclusion: Despite increasing use of respiratory FQs, FQR in
pneumococci is very low and not increasing in Canada. The prevalence
of isolates with parC mutations is decreasing. Isolates with mutations in
gyrA alone remain extremely rare, suggesting that Moxi exerts minimal
selective pressure for resistance.
Year Rates of mutations in QRDR regions
N parC only parC&gyrA gyrA only
1997 1409 1.72 0.40 0
1998 1426 1.89 0.21 0
1999 2086 1.52 0.28 0
2000 2191 1.46 0.64 0.14
2001 2240 1.74 0.85 0.04
2002 2504 1.11 1.55 0.04
2003 2419 0.83 0.87 0.12
2004 2548 0.63 1.35 0.12
2005 2662 1.05 1.24 0.08
2006 2224 1.88 1.27 0.39
2007 2044 1.03 0.68 0.34
O498 Characterisation of a chimeric mosaic structure carrying
erm(B) and tet(O) genes in S. agalactiae
A. Lupo °, M. Scillato, O. Tomasello, T. Triscari Barberi, S. Stefani,
J. Blackman Northwood, D.J. Farrell, M. Santagati (Catania, IT;
Cambridgeshire, UK)
In Streptococci, two well characterised macrolide resistance have
been described: target modiﬁcation and active drug efﬂux. Target site
modiﬁcation is mediated by the erm genes – erm(B), erm(A), erm(C) –
which confers the MLSB phenotype. Target modiﬁcation by mutations
in 23S rRNA as well as mutation in L4 and L22 ribosomal proteins
have also been reported. Expression of mef(A) genes activate an efﬂux
mechanism responsible for M-type resistance
We characterised a clinical isolate of S. agalactiae MB56GBS022
exhibiting the MLSB phenotype and tetracycline resistance. In this
study, we determined the resistance genes, their association, and their
localisation and mobility by conjugation.
Methods: The macrolide and tetracycline resistance genes were
conﬁrmed by PCR. The association between macrolide and tetracycline
genes was investigated by Long-PCR and sequencing. Conjugation
experiments were performed by ﬁlter matings. The genetic localisation
of resistance genes was determined by endonuclease I CeuI – followed
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by PFGE and Southern blot. The hybridisation study was performed
using three speciﬁc probes for the 16S and 23S rRNA genes, for erm(B)
and tet(O) genes.
Results: S. agalactiae MB56GBS022 carried erm(B) and tet(O) genes
on the same amplicon of 7 kb in size. The nucleotide sequence analysis
of the entire product was identical to the pEOC01 of 11 kb from
Pediococcus acidilactici that contains four orfs, of which orf2 and orf3
encode a putative resolvase and topoisomerase type I, respectively.
The endonuclease I CeuI method, that easily distinguishes between
plasmid and chromosomal localisations as I-CeuI only cuts chromosomal
DNA, revealed the localisation of resistance genes on the plasmid.
All attempts to transfer erm(B)-tet(O) structure by conjugation from
S. agalactiae MB56GBS022 to OG1SS E. faecalis as recipient failed.
Conclusion: Our results show the ﬁrst case of the association between
erm(B) and tet(O) genes on the unique mosaic structure in S. agalactiae,
probably on the plasmid, as demonstrated by the I CeuI-assay. Further
studies are on going to characterise the entire genetic element carrying
resistance genes.
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O499 Improving inﬂuenza pre-analytic collection systems:
alternative collection systems to inactivate, preserve, or
extract inﬂuenza for rapid testing
S. Castriciano °, K. Luinstra, M. Ackerman, A. Petrich, M. Smieja
(Brescia, IT; Hamilton, CA)
Objectives: In this study, 3 alternative inﬂuenza sample collection
systems were evaluated for potential use in a pandemic situation.
The objectives were to develop: 1) a non-temperature dependent
swab collection and transport system, that inactivates inﬂuenza virus
infectivity but preserves cell morphology and nucleic acid (NA) for the
detection of suspected inﬂuenza infections and/or 2) a system compatible
with direct NA testing without the need for puriﬁcation prior to detection
by a rapid real-time RT-PCR.
Methods: Flocked nasopharyngeal swabs (NPS) collected in UTM (U)
were compared to NPS collected in a CyMol (C), M-swab (M) or Dry (D)
Flocked Swab collection system (Copan, Italia). CyMol is an alcohol-
based medium that preserves cells for DFA testing. The M-swab contains
600 uL of medium and 150 uL of glass beads, and requires no NA
puriﬁcation step. Shell vial culture was used to assess inﬂuenza virus
inactivation after 30 minutes exposure to the collection media. A mock-
infected Inﬂuenza A virus sample was absorbed to duplicate swabs then
placed into the 4 collection systems. The infected collection media were
held at RT for 30 minutes and then inoculated in duplicate into shell vial
culture and stained after 48 hours. Inﬂuenza A stability and NA recovery
after mock infection of each collection system was assessed after 1, 7,
14 and 21 days (d) at 4ºC, −20ºC, room temperature (RT) and 37ºC.
Aliquots of infected collection media were extracted by easyMag and 5
uL of puriﬁed NA tested by a quantitative inﬂuenza A RT-PCR on the
Roche LightCycler. M-Swab collected samples were also tested directly
or after boiling, without NA puriﬁcation.
Results: Shell vial culture found that Inﬂuenza A virus was inactivated
after 30 minutes exposure to the C medium but not when exposed to the
U and M media. Inﬂuenza A was detected by DFA from the U and C
cell smears. Quantitation of Inﬂuenza A RNA was constant after 1, 7
and 14 d in U, C, M and D collection systems at −20, 4ºC and RT. The
quantity of RNA recovered declined signiﬁcantly after 14 d at 37ºC in
all 4 collection systems. M with boiling yielded data comparable to the
easyMag extraction.
Conclusions: The Copan CyMol medium inactivates inﬂuenza infectiv-
ity, preserves cells and stabilises RNA up to 14 days at −20, 4ºC and
RT. CyMol medium is a potential alternative for safe sample collection
during a pandemic inﬂuenza situation. The M-swab presents a rapid
testing alternative.
O500 Molecular detection of 12 viruses and subtypes by Luminex
respiratory viral panel in respiratory specimens from
children
R. Selvarangan °, S. Selvaraju, D. Baker, K. Estes, L. Hays, D. Abel,
S. Hiraki (Kansas City, US)
Objective: Luminex respiratory viral panel (RVP) is a multiplex PCR
capable of detecting and differentiating twelve different respiratory
viruses and their subtypes; inﬂuenza A (Flu A) (subtypes H1 and
H3), inﬂuenza B (Flu B), Respiratory syncytial virus (RSV) (subtypes
A and B), Adenovirus (AdV), Parainﬂuenza 1 (PIV 1), Parainﬂuenza 2
(PIV 2), Parainﬂuenza 3 (PIV 3), human metapneumovirus (hMPV) and
Rhinovirus (RhV). The aim of this study was to evaluate the analytical
performance characteristics of RVP assay and to evaluate its ability to
detect respiratory viruses from nasopharyngeal aspirates obtained from
children.
Method: Analytical sensitivity, speciﬁcity, accuracy and precision of
the Luminex RVP assay were determined using control viral stocks and
respiratory specimens previously tested by Rmix shell vial culture.
Result: Luminex RVP assay reliably detected ATCC viral stocks of
Flu A, Flu B, RSVB, RhV and PIV3 in the range of 10e-2 to 10e-4
TCID50/ml. No cross reactivity was noted with CMV, HSV, HHV6,
EBV, VZV, PIV4, cornoavirus 229E and OC43. Among 146 respiratory
specimens previously characterised by culture 138 specimens were
accurately detected with overall accuracy of 95%. The median coefﬁcient
of variation in mean ﬂuorescent index values of signals from replicate
analyses of inﬂuenza A, B and RSV was 9% (7% to 25%). The 146
clinical specimens tested by RVP assay included 109 culture positive
and 37 culture negative specimens. Respiratory viruses isolated from
the culture positive specimens include the following; 19 AdV, 11 Flu
A, 10 Flu B, 19 RSV, 9 PIV1, 6 PIV2, 5 PIV3, 19 hMPV and 14 RhV.
RVP assay detected all of the respiratory viruses except one each of RSV,
PIV1 and PIV2 virus with overall sensitivity ranging from 88% to 100%
for the different respiratory viral groups. Among the 37 culture negative
specimens 20 respiratory viruses were detected by RVP of which 15
were subsequently conﬁrmed by repeat analyses.
Conclusion: Luminex RVP assay is a highly sensitive and speciﬁc test
useful in the detection of commonly encountered respiratory viruses in
respiratory specimens. The addition of RVP assay to the viral testing
algorithm of respiratory infections in children provides rapid results,
improves diagnostic yield and may result in decreased antibiotic usage,
reduced diagnostic testing and reduced hospital stay.
O501 Aetiological role of viruses in hospitalised patients with
acute gastroenteritis in Greece
M. Savvala, I. Daniil, I. Berberidou, A. Koutsibiri, A. Stambolidi,
M. Papachristodoulou, N. Spanakis, D. Petropoulou °, A. Tsakris
(Athens, GR)
Objective: In developed countries, viruses, particularly noroviruses,
are recognized as the leading cause of acute gastroenteritis. We
determined the aetiology, prevalence and seasonal distribution of viral
gastrointestinal infections in hospitalised patients with acute diarrhoea.
Methods: During one-year period (November 2007-November 2008),
a total of 201 faecal specimens were collected from 165 children,
21 premature neonates and 15 adults who were hospitalised with
symptoms and signs of acute gastroenteritis. Stool samples were tested
for the presence of rotavirus, adenovirus, astrovirus and norovirus.
Rotavirus, adenovirus and astrovirus antigen detection was performed by
chromatographic immunoassays (Rotavirus and Adenovirus, VIKIA®-
bioMerieux, France; H&R Astrovirus-Vegal Farmaceutica, Spain).
Noroviruses were detected by an enzyme immunoassay (Ridascreen®r-
biopharm, Germany) and conﬁrmed by reverse transcription-PCR. Data
were analyzed for seasonality of infection and possible transmission
mode.
Results: The overall incidence of viral identiﬁcation in acute diarrhoeal
stool was 24% (48 of 201 patients). Fifty one viral antigens were detected
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and the overall prevalence rates for rotavirus, adenovirus, norovirus and
astrovirus were 14.9% (30/201), 7.0% (14/201), 3.0% (6/201) and 0.5%
(1/201), respectively. Noroviruses were detected in 3 patients during an
epidemic in December 2007, in one patient while he was in cruise
and in 2 premature neonates hospitalised in the neonatal unit. Mixed
viral infection by norovirus and astrovirus was detected in an adult
and by rotavirus and adenovirus in 2 adults. The majority of cases of
viral gastroenteritis occurred in spring (37.5%) and in summer (27.1%),
caused mainly by rotavirus, while norovirus infections occurred during
early autumn and winter.
Conclusions: Rotaviruses followed by adenoviruses were the main
causative agents of viral gastrointestinal infections in our hospitalised
population, which was mostly consisted of infants and young children.
The aetiological diagnosis of gastroenteritis allows the isolation of
infected patients, the prevention of epidemics and the avoidance of
unnecessary use of antibiotics.
O502 Presence of oncogenic human papillomavirus infections in
female population from southern Italy, correlation with
cyto-histological abnormalities and implications in vaccine
campaign
L. Tagliaferro °, P. Menegazzi, E. Reho, L. Barzon, G. Palu` (Lecce,
Padua, IT)
Objectives: The advent of some HPV prophylactic vaccines increased
the necessity to improve the knowledge of local viral type distribution to
survey the impact of vaccination on HPV-related diseases. Actually, few
epidemiological data are available in Italy, so we evaluated the presence
of oncogenic HPVs in female population from South of Italy and their
correlation with cervical cyto-histological abnormalities.
Methods: 654 genital samples, collected from 2003 to 2008, were
investigated for HPV presence and matched with PAP test results and
histological data, when available.
HPV typing was performed by a commercial assay, able to detect up to
28 genotypes.
Results: HPV DNA was detected in 45.9% of samples, 41.7% of which
had multiple infection. In women with single infection, the most common
HPV types were HPV-6 and HPV-16, followed by HPV-51, HPV-31,
HPV-53 and HPV-66, whereas in women with multiple infections HPV-6
was the most commonly detected type, followed by HPV-66, HPV-31,
HPV-16 and HPV-51.
A different distribution of HPV types and a higher rate of multiple
infections were observed in young vs. older women, suggesting the
existence of a natural selection of HPVs which preserve a better ﬁtness.
High-risk HPVs were detected in all high-grade cervical intraepithelial
lesions, with HPV-16, HPV-18, HPV-31, and HPV-51 as the most
frequent types. However, HR-HPV types were detected also in a high
rate of women with a negative Pap test as well as in women with a
negative cervical biopsy, suggesting the need to improve the accuracy of
available cervical cancer screening tests.
Conclusion: The results of this study, which provide information on the
epidemiology of HPV infection and type distribution in women from
South Italy, should be taken into consideration in the implementation of
local vaccination programs.
O503 HPV infection in HIV-infected men who have sex with men
and correlation with HHV8 shedding
S. Parisi °, C. Boldrin, R. Scaggiante, M. Cruciani, S. Andreis,
A. Barelli, S. Pagni, F. Dal Bello, G. Palu` (Padua, Verona, Venice, IT)
Objectives: To evaluate HPV genotypes circulation and persistence over
time in different sampling sites among HIV(+) men who have sex with
men (MSM) (pts) and correlations with HHV8 oral shedding.
Methods: Samples obtained from rectal mucosa- (RS), pharyngeal-
swabs (PhS) and saliva of 118 pts from December 2007 to December
2008 were studied. After 6mo, samples were collected again.
Ampliﬁcation products were sequenced by in-house method using ABI
PRISM 3130 XL. HHV8 oral shedding was tested by Real-Time in-house
method.
Results: HPV was found in 97 (82%) of RS: 9 pts had multiple
HPV-genotypes, and 82 pts a single genotype or an identiﬁed type
with a co-infection with other not-identiﬁed types [32 (39%) High-Risk
genotypes (HR) − 11 HPV-16, 1 HPV-18, 2 HPV-33, 1 HPV-53, 6 HPV-
58, 11 HPV-66-; 42 Low Risk genotypes (LR) − 12 HPV-6, 6 HPV-11,
1 HPV-40, 7 HPV-61, 5 HPV-70, 2 HPV-72, 4 HPV-81, 5 HPV-83, and
8 other types]. 2 pts had ampliﬁcation products not further analysable,
4 typing are ongoing and 21 pts were negative.
After 6mo, 56/58 RS (+) re-tested were found still positive; 27 pts with
LR/HR-RS still harboured the same genotype; 2 LR became negative;
5/9 RS-negative became positive, 3 with HR-HPV.
Among 71 PhS evaluated, 17 (24%) were positive (5 HR-HPV), 15 with
concurrent RS (+), often with a different genotype.
81% of pts receiving antiretroviral therapy (66% of total) and 90% of
naive pts (34% of total) were found RS(+). No signiﬁcant differences
were observed in HR-HPV prevalence among these groups.
92 pts were evaluated for oral HHV8 shedding. 12 pts were
HHV8(−)/RS-HPV-neg, 55 HHV8(−)/RS-HPV(+) and 25 (27%)
HHV8(+)/RS-HPV(+); 12 associated with HR/LR-HPV. 66% of HHV8-
pos were HIV treated.
Conclusions: A high prevalence of HPV infection was found in RS from
HIV(+) MSM, with HR/LR types in at least 76% of positive RS and in
61% in the entire cohort, irrespective of HAART treatment. Moreover,
the persistence over 6mo of the same HPV-types in RS was commonly
observed, together with HPV infection in pharynx. HHV8 oral shedding
was correlated with HPV infection. These ﬁndings suggest a possible
multiple source of acquisition and spreading of HPV to sexual and non-
sexual contacts. Careful survey for HPV and HHV8 infection should be
carry out in HIV-MSM, a population at high risk of developing HPV-
and HHV8-related cancers. These co-infections suggest repeated sexual
unprotected contacts.
O504 Viral antigen expression in individuals with chromosomal
integrated HHV-6
V. Strenger °, W. Schwinger, W. Zenz, I. Lautenschlager, S.W. Aberle,
T. Popow-Kraupp, E.P. Nacheva, A. Virgili, G. Zobel, C. Urban (Graz,
AT; Helsinki, FI; London, UK)
Objectives: Chromosomal integration of the HHV-6 genome (CIHHV-6)
into the human genome occurs in 1−2% of healthy individuals and leads
to persistently high levels of HHV-6 PCR copy numbers in blood and
tissue. Consequently, this may be interpreted as persistent active HHV-6
infection.
Although HHV-6mRNA has been detected in a few individuals with
CIHHV-6, there is no evidence of replication of viral particles up to
now. Viral cultures have shown negative results. So, CIHHV-6 is thought
not to be linked to any disease.
Methods: We performed HHV-6 antigen detection in PBMCs of 4
individuals with FISH proven CIHHV-6 by means of antibodies directed
against HHV-6 variant A and B (indirect immunoperoxidase staining).
Results: In 2 unrelated female adolescents (both with CIHHV-6 variant
A) we detected HHV-6 antigen. One patient is suffering from recurrent
parotitis since 5 years and from hypoimmunoglobulinaemia. The other
patient (15a) was treated with allogeneic bone marrow transplantation
(BMT) for acute myeloid leukaemia (AML) and acquired CIHHV-6 from
the healthy donor. So, CIHHV-6 is only found in blood cells. In the
latter patient only symptoms attributable to the post BMT course have
been observed (prolonged mixed haematological chimerism, protracted
mucositis, transient hypertension and transient neuropathy). At the time
of antigen detection 5 years after BMT the patient was clinically well.
In 2 individuals (a girl after fatal myocarditis and her healthy father −
both with variant B) no HHV-6 antigen has been detected.
Discussion: Up to now CIHHV-6 is considered not to cause any
disease. For the ﬁrst time we show the expression of HHV-6 antigen,
which indicates the replication of viral particles. This might have a
pathophysiological impact.
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One patient with positive antigen detection is suffering from a disease
of unclear aetiology. So, an association of replication of CIHHV-6 with
the disease might be considered.
In contrast, the other patient did not show any symptoms at the
time of antigen detection. This patient shows a special mode of
acquisition of CIHHV-6 (by BMT) possibly resulting in differences in
the immunological priming and response. In addition, in the latter patient
CIHHV-6 is restricted to blood cells.
Two other patients did not show antigen expression. So, it is unclear how
the transcription and translation of viral genes is inﬂuenced?
Furthermore, is there a pathophysiological impact of viral replication in
individuals with CIHHV-6?
1 2 3 4
Age 5a 43a 15a 18a
Gender female male female female
Underlying
disease, symptoms
at the time of
antigen detection
minimally
conscious
state after
resuscitation
due to severe
myocarditis
healthy,
father of
patient 1
AML, BMT
5 years ago,
transmission
of CIHHV-6
by BMT, no
symptoms
chron.
parotitis
for the last
5 years,
hypoimmuno-
globulinaemia
HHV-6 variant B B A A
Antigen detection neg. neg. pos. pos.
Chromosome site 9p ter 9p ter 17p ter 17p ter
O505 Cellular inﬂammation and viral loads in primary
Epstein-Barr viral meningo-encephalitis
E. Bathoorn °, B.J. Vlaminckx, R. Donders, S.A. Schoondermark-Stolk,
S.F. Thijsen (Utrecht, Nieuwegein, NL)
Objectives: Several case studies have reported on meningo-encephalitis
caused by a primary Epstein-Barr virus (EBV) infection. We aimed to
investigate the viral loads, and the inﬂammatory characteristics of this
thus far poorly deﬁned disease entity.
Methods: We evaluated all cases from 2003–2008, in which an EBV
polymerase chain reaction test (PCR) was requested on a cerebro
spinal ﬂuid (CSF) sample. Primary infection was deﬁned as a clinical
presentation with sore throat/pharyngitis/malaise in combination with
lymphocytosis, and detectable heterophile antibodies or positive EBV
IgM antibodies. Patients with proven neuroborreliosis served as control
group. Leukocyte response and EBV viral loads in CSF, and serum were
compared between primary EBV and neuroborreliosis cases.
Results: We identiﬁed six cases with a primary EBV infection
(median age: 22, male: 4) with neurological symptoms ranging from
meningeal signs to encephalitis. These were compared to 14 patients
with neuroborreliosis (median age: 27, male: 6). In four out of six
patients with a primary EBV infection with neurological symptoms EBV
DNA was detected in CSF and in serum, whereas all neuroborreliosis
cases were EBV PCR negative in both compartments. Viral loads were
lower in CSF as compared to serum. In blood, leukocytes, lymphocyte,
and monocyte counts were signiﬁcantly increased as compared to the
neuroborreliosis cases (see table 1).
Table 1
EBV-meningitis (n = 6) Neuroborreliosis (n = 14)
Leukocytes in blood (×109/L) 13.5 (10.3−18.5)* 7.2 (5.9−10.5)
Neutrophils in blood (×109/L) 5.8 (4.7−10.5) 4.4 (3.4−8.0)
Lymphocytes in blood (×109/L) 7.6 (2.9−12.8)† 1.7 (1.2−2.2)
Monocytes in blood (×109/L) 1.3 (1.2−1.7)† 0.7 (0.6−0.9)
EBV PCR in CSF (DNA copies) 226 (<50–1461)† ; n = 2 <DL All <DL
EBV PCR in serum (DNA copies) 1507 (<50–14127)† ; n = 2 <DL All <DL
Data presented as median (interquartile range). *p< 0.05; †p< 0.01; comparison by Mann-Whitney U-test.
CSF: cerebrospinal ﬂuid. EBV: Epstein-Barr virus. DL: detection limit (50 DNA copies).
Conclusion: Sixty-seven % of cases with EBV meningo-encephalitis
have detectable viral DNA amounts in CSF and serum, whereas
neuroborreliosis patients do not. Cases with primary EBV meningo-
encephalitis have increased systemic leukocytosis, with higher lympho-
cyte, and monocyte levels compared to neuroborreliosis patients.
O506 Incidence of post-herpetic neuralgia in treated and untreated
patients with herpes zoster followed for 1 year in an Italian
prospective cohort: preliminary results
G. Parruti °, F. Sozio, C. Rebuzzi, M. Tontodonati, E. Polilli,
A. Agostinone, A. Manna, F. Di Masi, A. Consorte, G. Congedo,
L. Cosentino, D. D’Antonio, L. Pippa, L. Manzoli, C. Granchelli
(Pescara, Chieti, IT)
Objectives: A large prospective cohort of patients with herpes zoster
(HZ) was enrolled between May 2006 and June 2008 in Pescara, Italy,
with a planned 1-year follow-up after clinically and/or molecularly
assessed diagnosis. Aim of the study was to evaluate predictors of
prolonged acute course and/or incidence of Post-Herpetic Nevralgia
(PHN).
Methods: Data from all enrolled patients were collected by a network of
51 general practitioners. Suspected cases and patients with intense acute
pain were referred to our institution for immediate evaluation. Clinical
and demographic information was mandatory at baseline, as photographs
of enrolled patients. For uncertain cases, varicella-zoster virus (VZV)
antibodies and VZV DNA PCR on plasma and/or vesicular eluates
(whenever available) were performed. Follow-up data were collected at
outpatient control visits or by phone calls at 1, 3, 6 and 12 months after
onset of HZ. PHN was diagnosed when pain persisted or relapsed at least
one month after complete clearing of dermatomeric lesions. Adverse
events other than pain were classiﬁed according to WHO grading scale
and reported if 2. All statistical calculations were performed by Stata
8.0 software package.
Results: 523 patients were enrolled, 306 (58.5%) females, with a mean
age of 57.7 years, 1-year follow-up data being now available for 489. HZ
was localised at thorax in 45.4% and head in 20.7%; pain in the acute
phase was reported as intense or very intense by 127 (25.97%) patients;
54 (11.04%) patients were referred for molecular diagnosis as clinically
uncertain, 37 (68.5%) being conﬁrmed as VZV-related cases. Forty eight
(9.82%) patients were not prescribed any antiviral drug at diagnosis by
referring physicians, in spite of extensive support in the study plan.
During follow-up, 163 (33.3%) patients reported any type of adverse
event (at a mean of 91.2±74.8 days), including 93 (19.02%) patients
reporting PHN. PHN was signiﬁcantly more frequent in untreated vs
treated patients (37.5% vs 17.0%, p = 0.001), as were total adverse events
(54.2% vs 31.1%, p = 0.001). Untreated patients did not signiﬁcantly
differ from those treated by age (56.3% vs 57.7%, p = 0.66) and sex
(females vs males 11.9% vs 6.9%, p = 0.056), whereas they complained
for more intense pain (15.0% vs 8.0%, p = 0.024) at presentation.
Conclusion: Our study conﬁrms the importance of early diagnosis and
prompt antiviral treatment at the onset of HZ in order to minimise the
risk of PHN.
O507 Emergence of an unusual group A rotavirus VP4 genotype
among bovine population in India
A.B. Kolpe, R. Arora, M.M. Yadav, C.G. Raut, S.D. Chitambar ° (Pune,
IN)
Objective: To perform the molecular characterisation and the phyloge-
netic analysis of unusual G8P[14] bovine group A rotavirus (BoRV-A)
strains identiﬁed in Pune, western India, during a 2007–2008 rotavirus
(RV) epidemiological surveillance.
Methods: Faecal specimens (n = 78) from apparently healthy and
diarrheic calves (aged <1 year) were collected per-rectally and
investigated for detection of group A rotavirus by antigen capture
ELISA (Generic Assay, Germany). ELISA positive specimens (n = 3)
were investigated further for molecular characterisation.
Genotyping of BoRV-A strains was carried out on dsRNA extracted from
10% PBS faecal suspensions by a nested and/or heminested RT-PCR
S106 19th ECCMID, Oral presentations
speciﬁc for VP7 and VP4 genes, using pools of G and P type speciﬁc
primers. All strains (NIV/BRV/68, NIV/BRV/79, and NIV/BRV/86) were
not typeable for the VP4 and VP7 genes.
After puriﬁcation by “Qiaquick Gel Extraction Kit” (QIAGEN,
Germany), the VP4, VP6, VP7, and NSP4 ﬁrst amplicons of the BoRV-A
strains were subjected to sequence analysis with automated sequencer
ABI 3130 XL DNA Analyzer (Applied Biosystems, USA). Phylogenetic
analysis was performed using MEGA version 4.0.
Results: The NIV/BRV/68, NIV/BRV/79, and NIV/BRV/86 strains
exhibited long e-type, G8 and P[14] speciﬁcities for VP7 and VP4
genes respectively. By sequence analysis, the VP7 genes displayed high
nucleotide (nt) and amino acid (aa) identities to Indian bovine B17 (nt-
94.5−98.2% and aa-97.5−99.2%) and Egyptian human EGY2295 (nt-
94.2−95.1% and aa-96.8−97.9%) strains, while the VP4 sequences were
closely related to the Hungarian human Hun5 strain (nt-94.7−95.4% and
aa-97.8−98.2%). The VP6 sequences were found to contain subgroup-I
speciﬁcity and showed maximum identity with Indian porcine HP140
strain, while NSP4 belonged to genotype-A.
Phylogenetic analysis revealed human and porcine origin of VP4 and
VP6 genes respectively, while bovine origin was conﬁrmed by VP7 and
NSP4 sequence analysis.
Conclusion: The Indian NIV/BRV/68, NIV/BRV/79, and NIV/BRV/86
strains could be the result of a reassortment between a Hun5-like
human strain with P[14] speciﬁcity, long e-type and subgroup I, already
circulating in Hungary, Italy, and a G8 bovine strain. The genetic
relatedness of NIV/BRV strains to Hun5 provides direct evidence for
the bovine origin of the VP4 and VP7 genes of human G8P[14] strains.
O508 Prolonged survival of dengue virus in blood and excretion
in urine after clinical recovery
C. Laosakul °, M. Sriprapun, K. Chaiyo, S. Krajiw, D. Chansinghakul,
G. Suwanpimolkul, J. Pupaibool, K. Arunyingmongkol, C. Pancharoen,
U. Thisyakorn, W. Kulwichit (Bangkok, TH)
Objectives: Dengue is a ﬂavivirus and is among the most widely-spread
viral diseases. Our previous report demonstrates existence of live dengue
virus in blood and urine even in the convalescent postfebrile period. In
some cases, excretion in the patient’s urine can be detected as late as
28 days after the onset of illness. This goes along with the model of
West Nile virus, another type of ﬂavivirus, which can be excreted in the
urine for months after acute infection in both animal studies and human
case report. Here we report a pilot study to address a magnitude of such
ﬁndings.
Methods: Between April 2007 and October 2008, paediatric and adult
febrile patients suspected of dengue infection were enrolled. Diagnosis of
dengue was based on standard speciﬁc serology on paired sera. Patients
with negative serology served as controls. Blood and urine specimens
were collected at several time points. Whole blood was separated into
plasma and peripheral blood mononuclear cells (PBMC). These have
been aliquoted and used for earlier studies and some stored in freezers.
Available plasma, PBMC, and urine were processed and inoculated
into Aedes aegypti. Surviving mosquitoes at 14 days after inoculation
were employed for viral detection by dengue-speciﬁc RT-PCR. Indirect
ﬂuorescence antibody (IFA) staining of mosquito heads was performed
on all positive RT-PCR specimens, except for the one from PBMC
(awaiting IFA result).
Results: 5 and 45 cases of primary and secondary infections,
respectively, and 4 negative controls were included. These translated into
55 and 59 early and late dengue specimens, and 6 and 4 early and late
negative-control counterparts, respectively. Dengue virus were isolated
in some blood and urine specimens as late as 46 days after the onset of
illness. No virus was isolated from control specimens. All but 5 positive
RT-PCR specimens also demonstrated positive IFA. 4 out of 5 negatives
were from early-phase specimens.
Conclusion: Our study demonstrates prolonged survival of dengue virus
after clinical recovery. This ﬁnding has pathologic and epidemiologic
signiﬁcance, adding a potential role of urine in the transmission of the
disease. Spread of the virus to humans might occur through infectious
urine with help from arthropod vectors. This research could provide new
insights into our understanding of the pathogenesis of DENV infection.
Isolation of dengue virus from blood and urine specimens during
early (days 1−7 after onset of illness) and late (days 8−46) phases of
infection (specimens with dengue isolated/total specimens for mosquito
inoculation)
Early phase Late phase
Plasma 16/25 (64%) 0/13 (0%)
PBMC not performed 1/2 (50%)
Urine 8/29 (28%) 12/44 (27%)
All specimens 24/54 (44%) 13/59 (22%)
